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Abstract 
In most inherited retinal degenerations such as age-related macular degeneration, 
death of photoreceptors leads to irreversible vision impairment. As the retina starts to 
degenerate, the retinal environment begins to remodel. While variations in the timing 
and magnitude of retinal response have been reported by various studies looking at 
different initiating insults, there has been no comparative assessment of the diseased 
retinae across time in multiple models of retinal degeneration. Here, the process of 
gliosis, outer nuclear layer cytoarchitecture and integrity of the outer limiting membrane 
(OLM) were examined in seven different mouse models of inherited retinal 
degeneration. Findings from this study demonstrated that each of the examined 
mutants manifests a unique pattern of alterations occurring in the retinal 
microenvironment, including significant changes to OLM junctions. Moreover, these 
animals showed that the type of the Müller glial response and its magnitude are not 
correlated with disease severity. Having identified marked but varied changes in the 
expression of GFAP, Vimentin and chondroitin sulphate proteoglycas (CSPGs) 
between different models, further work investigated whether it is possible to prevent or 
manipulate these changes. By knocking down expression of GFAP and Vimentin by 
with RNA interference (RNAi), the role of these proteins both in the development of 
degeneration-associated glial hypertrophy and in influencing photoreceptor 
transplantation outcome was assessed. Consistent with the idea that CSPGs 
deposition in the subretinal space represents a barrier to therapeutic interventions, an 
enzymatic approach was used to effectively digest these molecules in a diseased 
mouse retina. In the last instance, RNAi-mediated knockdown of CRB1, one of the key 
regulators of AJs, was used to introduce disruption of OLM integrity. The overall aim of 
this thesis was to provide a better understanding of the barriers in a diseased retinal 
environment and how they can be manipulated to ease in a future some of the 
therapeutic strategies to help to restore lost vision. 
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GCAPs - guanylate cyclase activating proteins 
GCL – Ganglion cell layer 
GFAP - Glial fibrillary acidic protein 
GFP- green fluorescence protein  
H2B - Histone 2B 
HRP - Horseradish peroxide 
HSPGs - heparin sulphate proteoglycans  
ICAM-1 - Intercellular Adhesion Molecule 1  
ICH- immunocytochemistry 
IF – intermediate filament  
IHC – immunohistochemistry  
IL - Interleukin  
INL – Inner nuclear layer 
IPL – Inner plexiform layer 
iPSCs - induced pluripotent stem cells 
IS- inner segment 
IS/OS – Inner /outer segment region 
JAMs - junction adhesion molecules   
LB - lysogeny broth 
LCA – Leber's congenital amaurosis 
MD - Macular degeneration 
15"
MG – Müller glia 
mGluR - metabotropic glutamate receptors  
MPP5 - Membrane protein palmitoylated  5 
N - number  
NL-68 – neurofilament-68 
NSC – neuronal stem cell 
OCT - ocular coherence tomography 
OLM – Outer limiting membrane 
OMI - ovomucoid inhibitor albumin 
o/n - overnight 
ONL – Outer nuclear layer 
OPL – Outer plexiform layer 
OS – outer segment 
P – postnatal 
PAR - portioning defective complex 
PBS – phosphate buffer saline 
PBST - phosphate buffer saline with Tween-20 
PFA – paraformaldehyde 
PG - Proteoglycan 
PR – photoreceptor 
PALS1- Protein associated with Lin Seven 1 
PATJ - PALS1-associated tight junction protein 
PDE - phosphodiesterase 
R - Rhodopsin molecule 
RCS – Royal College of Surgeons rat strain 
RFP – red fluorescence protein 
RNA - Ribonucleic acid 
ROI – region of interest 
ROS - reactive oxygen species 
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RP – Retinitis pigmentosa  
RPC - retinal progenitor cells 
RPE – Retinal pigmented epithelium 
RT – room temperature 
QRT-PCR - Real-time quantitative polymerase chain reaction  
SAR – subapical region 
SEM – standard error margin 
Sh – small harpin 
SHH - Sonic hedgehog 
Si – small interfering 
SOC - super optimal catabolite medium 
TJ- tight junction 
TNF-α - Tumor necrosis factor α  
TR – transfection reagent  
U – unit 
VEGF - Vascular endothelial growth factor 
v/v – volume per volume 
WB – Western Blot 
Wnt – wingless signalling pathway 
w/v – weight per volume 
w/w – weight per weight 
ZO-1 – Zonula occludens 1  
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Most people say that it is the intellect which makes a great scientist. They are wrong: it 
is character.   
Albert Einstein 
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Introduction 
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1.1 Thesis overview 
Vision is often considered to be the most important of all the human senses as it 
enables human beings to interact with their surrounding environment. The sense of 
sight is a result of sequential activity, which begins with the reflection of the light from 
an object to the lens, which is embedded within the eye. The lens focuses this light 
onto a layer of tissue that lines the back of the eye, called the retina. The retina is 
packed with neurons, including the light-sensitive cells, the photoreceptors, which 
absorb photons of light and convert them into an electrical signal, which is passed to 
second and third order neurons for further processing, before travelling along the optic 
nerve fibres to the brain where it is decoded. The retina, therefore, is one of the most 
important players in the process of vision as it helps to decode the light stimulus and 
transfer it into a biological message that can be read by our brain. 
Retinal diseases that lead to death of the photosensitive photoreceptor cells within the 
retina leave patients partially or completely blind. Inherited retinal dystrophies, typically 
grouped under the umbrella of retinitis pigmentosa (RP), affect 1 in 3,000 of the 
population, and age-related macular degeneration (AMD) affects 1 in 10 people over 
60 years, a figure that is rising in Western societies as the society ages (Minassian et 
al., 2011; Owen et al., 2012). In the majority of cases, existing treatment options at 
best slow disease progression and do so only in a minority of cases. To restore vision 
in these cases, various alternative therapeutic approaches have been proposed and 
tested, both pre-clinically and clinically (reviewed in (Sabel, 2008; Pearson et al., 2014; 
Lewis et al., 2015)). Intraocular injection of soluble growth factors such as acidic and 
basic fibroblast growth factor (FGF) or brain-derived neurotrophic factor (BDNF) has 
been able to slow down progression of retinal degeneration, by promoting survival of 
remaining retinal cells (Faktorovich et al., 1990; LaVail et al., 1992; Chaum, 2002). 
Clinical and pre-clinical studies on gene replacement therapy with the use of viral 
vectors have shown the proof of concept in reintroduction of a normal gene product 
(Bainbridge et al., 2008; Maguire et al., 2008; Palfi et al., 2010; Mookherjee et al., 
2015) with some patients reporting restoration of vision (Bainbridge et al., 2015; 
Edwards et al., 2016). Rescue of visual function following the transplantation of 
immature photoreceptors has also been reported to be successful with major advances 
in the generation of competent donor cells from different sources including patient 
derived stem cells (Gouras et al., 1994; Gouras and Tanabe, 2003; Seiler and 
Aramant, 2012). However, all of the mentioned strategies have their limitations mainly 
due to environmental and morphological changes that occur in the diseased eye that 
have a significant impact on the outcome of a clinical treatment (reviewed in (Colella 
and Auricchio, 2012; Hippert et al., 2016; Zarbin, 2016)). It is well known that during 
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disease progression, the retina undergoes structural remodelling, such as changes in 
retinal glia (reactive gliosis) or rupture of the outer limiting membrane (OLM) thus 
creating a different environment that can influence the outcome of a cell transplant. For 
these reasons, understanding the retinal remodelling and the processes behind glial 
scar formation may help us to develop more effective strategies to treat a wide range of 
retinal dystrophies. In Chapter 3, a variety of murine models of retinal dystrophies were 
examined to provide a detailed characterisation of the diseased environment at 
different stages of retinal disease. A comprehensive comparison was performed to 
investigate whether the aetiology arising from different underlying genetic causes of 
retinal degeneration leads to a unique pattern of retinal alterations and structural 
remodelling. In Chapter 4, the impact of preventing the upregulation of the intermediate 
filament (IF) proteins, Glial fibrillary acidic protein, GFAP, and Vimentin, which play a 
key role in gliosis, was studied in a model of RP. Specifically, their role with respect to 
glial hypertrophy and its impact on cell replacement therapy was investigated. 
Numerous studies have reported an upregulation of different proteoglycans, a class of 
inhibitory extracellular matrix (ECM) molecules, in a wide range of retinal retinopathies 
(Inatani et al., 2001; Zhang et al., 2003b; Singhal et al., 2008). Chapter 5 assessed the 
expression pattern of one of the main proteoglycans, Aggrecan and its receptor in two 
models of inherited RP. The last two will focus on the OLM integrity during retinal 
degeneration (Hippert et al., 2015) and its role as a third retinal barrier. In Chapter 6, a 
detailed characterisation of the OLM remodelling was performed over a time course of 
disease progression in different models of retinal degeneration. Consistent with the 
idea that OLM may represent a barrier to therapeutic strategies (Pearson et al., 2010; 
Barber et al., 2013), an attempt to disrupt it using RNAi strategy was made to knock 
down one of its junctional proteins, CRB1. The overall aim of this study was to provide 
a better understanding of the diseased environment and how it can be manipulated to 
ease some of therapeutic strategies. 
 
1.2 Gross anatomy and function of the eye 
The eye has evolved as a highly specialized organ with a common structure shared by 
all the vertebrates. It is organised into three distinct layers, which together allow the 
external stimulus encoded in a form of light to travel to the brain resulting in visual 
perception of the external world. 
The eye (Figure 1.1) is protected from the outside by a relatively tough layer, the 
sclera. This layer minimises the risk of trauma and functions as a barrier to 
environmental pathogens. In the area protected by the eyelids, the sclera is covered by 
a thin, transparent membrane (conjunctiva), which runs to the edge of the cornea. The 
22"
cornea, together with the sclera, helps to shield the eye from the outside. This 
avascular structure also aids the light stimulus to be focused on the retina located at 
the back of the eye, therefore making it the first component of the visual process. The 
cornea is divided into specialised layers consisting of the epithelium, the stroma and 
the endothelium. The epithelium is constantly being regenerated by the stem cells 
found at the limbus of the cornea to ensure that the oxygen supply is efficiently 
maintained. The next layer, the stroma is made of collagen fibres, which allow the 
cornea to maintain its transparency. The last layer, the corneal endothelium is 
responsible for hydration of the stroma.  
After passing through the cornea, light travels through the intermediate layer divided 
into the anterior components: the pupil, the iris, the ciliary body, and the lens, and the 
posterior part, the choroid. The pupil, which appears as a black dot in the middle of the 
eye, constantly enlarges and constricts itself like the lens of a photographic camera 
lens depending on the changes in the amount of light in the immediate proximity. The 
size of the pupil is controlled by the action of the pupillary sphincter muscle and dilator 
muscle. A coloured area surrounding the pupil, the iris, controls the amount of light that 
enters the eye allowing more light to enter when the environment is dark and less light 
when it is bright. The iris attaches to the sclera at its outer anterior edge, so-called the 
ciliary margin, which is also connected to the ciliary body. The ciliary body, which 
comprises of the ciliary muscles, is vital to proper functioning of the eye. This two-layer 
structure is divided into two regions, the pars plicata where the ciliary processes extend 
from and produce the aqueous humour in the anterior chamber, and the pars plana 
located more posteriorly, that secretes and releases components of the vitreous into 
the vitreous cavity. The vitrous humour is a watery substance that fills the eye allowing 
the eye to maintain its shape. This liquid is drained through the Schlemm canal so that 
any build-up in the eye can be removed. The ciliary body also extends the zonular 
fibers that act as an anchorage for the lens, allowing it to be positioned. The lens, that 
is located behind the iris, changes its shape and focuses light onto the retina. Through 
the action of the ciliary muscles, the lens is able to fine tune light refraction, a process 
known as accommodation, by becoming thicker to focus on nearby objects and thinner 
to focus on distant objects. 
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Figure 1.1 Gross anatomy of the human eye.  
Copyright note: Image of the eye was taken from http://www.ehealthideas.com/2013/10/eye-diagram-
fovea.html. Accessed online on 20.05.2016.  
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After the light passes through the lens, it is projected onto the retina (Figure 1.2A). The 
retina is made of photosensitive cells, rod and cone photoreceptors, which are 
responsible for converting the light stimulus into chemical and electrical signals. These 
cells are also responsible for ‘seeing’ colours. The electrical pulses generated by the 
photoreceptors, then travel along the fibres of different neuronal cell types connected 
to the optic nerve. It is the optic nerve that transmits these signals along its axons to 
the brain where the retinal images are being interpreted by the visual centres (Figure 
1.2B). At the centre of the retina, there is a region called the optic disc, which serves as 
an exit point for the optic nerve and an entry point for several major incoming blood 
vessels that supply retina. No light sensitive tissue is found in the optic disc, causing a 
break in the visual field, more commonly known as the blind spot. Adjacent to the optic 
disc, in humans, lays a region, which is specialised for high acuity, the macula (Figure 
1.2C). Together with its central part, the fovea, the macula helps to increase the details 
of the images to a perceivable point. The fovea, which is enriched in cone cells, is 
enclosed by the parafovea and in turn by the perifovea. The macula is the only place in 
the retina, where cones dominate over rods, as beyond it, the rod photoreceptor is 
more abundant responsible for highly compressed, low-resolution information.  
Beneath the neurosensory retina, lies a single layer of retinal pigmented epithelium 
(RPE). It is an additional layer lying just underneath the photoreceptors and is 
responsible for creating a barrier between the retina and blood supply coming from the 
choroid (Figure 1.2C). Connected by a series of tight junctions, the RPE offers 
photoreceptors a trophic support, plays essential role in the maintenance of the retinal 
homeostasis and shields the retina from the blood supply coming from the choroid. The 
choroid, located between the retina and the sclera, is often referred to as the vascular 
layer, as it supports a dense network of blood vessels delivering all the vital nutrients 
and oxygen to various parts of the eye.   
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Figure 1.2 From the retina to the brain: the route of the light stimulus.  
A) The light travels through the eye towards the outer part of the neuroretina, composed of photosensitive 
cells, rods and cones. After the light photon is converted into the electrical impulse, it travels to the bipolar 
and ganglion cells, and eventually to the optic nerve. B) In the next instance, the sensory information via 
the optic never fibres is sent to through the thalamus to corresponding areas in the visual cortex. 
Interestingly, the left and right eye sends information to both the left and the right hemisphere, and the 
visual cortex processes each of the cues separately and in parallel. This is an adaptational advantage to 
an organism that loses sight in one eye, because even if only one eye is functional, both hemispheres will 
still receive input from it. C) The macula together with its central region, the fovea, is very dense in cone 
photoreceptors. Below photoreceptors is the RPE, which is separated by a specialised membrane, the 
Bruch’s membrane, from the vascular choroid, which is enriched in resident macrophages and dendritic 
cells.  
Copyright note: Images A and B were copied from Stangor (2012) 
http://2012books.lardbucket.org/books/beginning-psychology/s08-02-seeing.html. Accessed online on 
20.05.2016. Image C was reprinted by permission from Nature Publishing Group: (Forrester, 2003), 
Nature Medicine.  
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1.3 The retina 
The retina is a complex structure generated from the neuroectoderm, which also gives 
rise to other parts of the central nervous system (CNS) during embryogenesis. There 
are six major types of neuronal cells in the retina born at different stages during eye 
development. These cells assemble themselves into three distinct layers that are 
separated by the areas of synaptic contacts (Figure 1.3). This type of laminar 
organisation allows the retina to perform its unique functions including perception, 
integration and transmission of visual information. As in the CNS, the retinal neurons 
are provided with a support by glial cells, with Müller glia playing a major role in 
neuronal function and survival. 
1.3.1 Development of a retina 
In a mouse, development of the retina begins around embryonic day (E) 11 from the 
optic vesicles (Carter-Dawson et al., 1978; Young, 1985). Findings from numerous 
studies have shown that retinogenesis is highly conserved across vertebrates and it 
can be broadly categorised into several phases, including the initial proliferation of 
retinal progenitor cells (RPCs); restriction in the multipotent competence of RPCs; and 
commitment towards specific cell type by expression of cell-specific genes essential for 
maturation, specialisation and function of the differentiated cells. All of these stages are 
tightly regulated by a number of different transcription factors and extrinsic regulators 
(reviewed in (Swaroop et al., 2010)). 
The process of retinogenesis starts when the optic vesicles, and later the optic cup, 
undergo a series of changes due to intrinsic and extrinsic factors (Figure 1.3A). This 
allows for generation of neuroepithelium, made of multipotent RPCs. In the early 
stages of retinogenesis RPCs undergo rapid symmetric proliferation to expand the 
progenitor pool (Figure 1.3.B). Several growth factors, including Sonic hedgehog 
(SHH), FGF and Epithelial growth factor (EGF) are active during the patterning of the 
neural tube to ensure the expansion and maintenance of the progenitor pool (Anchan 
et al., 1991). As development progresses, RPCs start to shift towards asymmetric 
division, allowing a subset of RPCs to exit the cell cycle in a strict order and 
differentiate into subsequent retinal cell types (Turner and Cepko, 1987; Wetts and 
Fraser, 1988). As illustrated in Figure 1.3, one of the first cell types to be generated are 
ganglion and horizontal cells, followed by cone photoreceptors and amacrine cells. In 
the second wave of retinogenesis, RPCs differentiate into rod photoreceptors, bipolar 
cells and finally Müller glia cells (Figure 1.3C). A large array of transcription factors, 
mostly basic Helix-loop-helix (bHLH) and homeodomain factors, expressed by subsets 
of RPCs or their post-mitotic progeny, together with extrinsic factors from the 
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environment induce and regulate the differentiation of the specific cell types within the 
neural retina (Jadhav et al., 2006; Yaron et al., 2006). One of early transcription factors 
involved in the development of different retinal cell types is Orthodenticle homeobox 2 
(Otx2) (Nishida et al., 2003; Akagi et al., 2004). Otx2 was found to be expressed in the 
cells that give rise to the RPE and post-mitotic RPCs that later form ganglion cells, 
bipolar cells and photoreceptors (Bovolenta et al., 1997; Baas et al., 2000). Otx2 gene 
was demonstrated to be one of the key regulators of photoreceptor cell fate as it 
modulates the expression of Cone-rod homeobox protein (Crx) in photoreceptor 
precursor cells (Furukawa et al., 1997). Crx, is the principle transcription factor that 
directs rod and cone photoreceptor cell differentiation. Together with Otx2, Crx 
orchestrates the transcription of many photoreceptor-specific transcription factors 
which direct retinal precursors towards specific cell fate (Furukawa et al., 1999). One of 
the key regulators of the photoreceptor cell fate is a neuronal retina leucine zipper 
transcription factor (Nrl). Nrl is considered as one of the earliest rod-specific 
photoreceptor markers as it is preferentially expressed in rod precursors shortly after 
terminal mitosis (Mears et al., 2001). Nrl mediates a rod lineage through multiple 
mechanisms including activation the Rhodopsin (Rho) promoter as well as regulation of 
Nuclear Receptor Subfamily 2 Group E Member 3 (Nr2e3), which promotes rod 
photoreceptor genesis and, in parallel, represses cone-specific genes (Oh et al., 2008). 
The peak of Nrl expression overlaps with rod differentiation, with a subsequent decline 
in expression in later stages, but with the expression maintained in mature rod 
photoreceptors, suggesting that Nrl is required for both rod differentiation and 
maintenance (reviewed in (Montana et al., 2011)). While the commitment towards a rod 
fate is well characterised, much less is known about cone photoreceptor fate 
specialisation. A number of genes have been implicated in this process, though, 
including the retinoid-related orphan receptor (Rrb), which synergises with Crx 
transcription factor to positively regulate the S-opsin gene expression (reviewed in 
(Mansergh et al., 2015)). 
The formation of synaptic connections between different neuronal cells in the retina 
happens in distinct stages (reviewed in (Reese, 2011)).  First to be established are the 
lateral connections between ganglion and amacrine cells followed by connections 
between photoreceptors. Since bipolar cells are last to differentiate during 
retinogenesis, the vertical networks are not formed until early postnatal stages.  
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1.3.2 Retinal structure  
1.3.2.1 Photoreceptor layer  
There are nine layers in the retina with three distinctive layers of neuronal cells (Figure 
1.3A) (Kolb et al., 2001). First, the photoreceptor layer, which is located directly above 
the RPE and consists of photosensitive rods and cones, designed to capture light 
quanta, or photons, that hit the eye. Photoreceptors are organized in four distinct 
regions: the cell body, which includes the nucleus, located in the outer nuclear layer 
(ONL); the inner segment (IS); the outer segment (OS); and the synaptic region (Figure 
1.3B). The IS region houses the photoreceptor’s metabolic machinery, which provides 
the energy in the form of ATP, which is produced by the numerous mitochondria and is 
required to power the sodium-potassium pumps necessary for stabilizing the resting 
potential. This segment is connected via a non-motile cilium to the photosensitive OS, 
which includes hundreds of stacked membranous discs transporting the proteins 
associated with phototransduction, including the visual pigment (Opsin). It has been 
estimated that each day approximately 10% of the OS discs at the distal end are shed 
and phagocytised by underlying RPE due to the light damage (reviewed in (Kevany 
and Palczewski, 2010)). All the shed discs are replaced with new ones, which are 
added at the proximal end, to allow photoreceptors for carrying the phototransduction 
process. The rate of formation and disposal of the discs are roughly equal so that a 
constant OS length is maintained in the adult retina (Young and Bok, 1969; Jonnal et 
al., 2010).  
Different subtypes of photoreceptors can be classified based on the expression of a 
unique type of Opsin. In the human retina, three subtypes of cone photoreceptors have 
been isolated according to their opsin that defines the cell’s light sensitivity including L-
opsin (long, 564 nm), M-opsin (medium, 533 nm) and S-opsin (short, 437 nm). These 
different cone types help mediate colour vision, as well as high visual acuity under 
brighter light conditions. As mentioned in Section 1.2, the human retina has a region 
called the fovea, which is tightly packed with cones but only of the M and L type. S-
opsin cones account for only 10% of the overall cone population and are absent from 
the fovea (Curcio et al., 1990; Cornish et al., 2004). By contrast, the murine 
dichromatic retina has only two types of cones: M-cones, located mainly in the superior 
region, and S-cones, mostly found in the inferior part of the retina (Applebury et al., 
2000). In contrast to cones, only one type of rod cell has been found in the retina of all 
the vertebrates including both mice and humans. Rod photoreceptors express 
rhodopsin, which is a special type of opsin that enables for a vision in dim light 
conditions. In the retina of most mammals, rods greatly outnumber cones, even in 
species that are largely diurnal. Human retina has approximately six million cones, 
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which accounts for only 3% of the overall number of all the photoreceptor cells present 
in the retina (Sawides et al., 2016).  
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Figure 1.3 The retinal structure. 
A) Histological section of the human retina with a schematic diagram illustrating different layers of the 
retina. The outer nuclear layer (ONL) contains photoreceptor cell bodies, from which the inner segment 
(IS) and outer segment (OS) extend towards the RPE. The inner nuclear layer (INL) includes amacrine, 
bipolar and horizontal neurons, whereas ganglion cells, axons of which form the optic nerve, reside in the 
ganglion cell layer (GCL). Outer and inner plexiform layers (OPL and IPL, respectively) contain synaptic 
regions. B) A schematic diagram illustrating the morphology of the cone and rod cell. The OS is made of 
hundreds of membranous discs that contain components of the phototransduction machinery, whereas the 
IS it contains hundreds of mitochondria and serves as the energy supplier of the photoreceptor cell. The 
visual proteins are transported to the outer segment via a connecting cilium. The nucleus is contained in 
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the cell body, and the presynaptic region includes one or more ribbon-like structures for docking of 
synaptic vesicles.  
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1.3.2.2 Inner nuclear layer 
The inner nuclear layer (INL) comprises of different neuronal cell types, which 
propagate the electric signals received from photoreceptors to the brain. 
1.3.2.2.1 Horizontal cells 
Immediately above the photoreceptor nuclei, at the most apical side of the INL, reside 
the horizontal cells (reviewed in (Jeon et al., 1998)). These cells form synaptic 
connections with rods and cones and take part in a lateral inhibition circuit where they 
modulate multiple photoreceptor inputs projecting towards bipolar cells. One horizontal 
cell is connected to many neighbouring photoreceptors, which helps to modulate the 
magnitude of the bipolar cell activation. This helps the eye regulate the vision under 
different light settings.  
1.3.2.2.2 Bipolar cells 
Also located within the INL are the bipolar cells, which are excitatory glutaminergic 
interneurons and the predominant interneuron of the retina (reviewed in (Lauritzen et 
al., 2016)). The bipolar cells are connected to photoreceptor terminals via their 
dendrites and on the other side their axons form synapses with the ganglion cells. 
These cells are highly specialised and they are assigned only to rods or cones, but not 
to both as in case with the horizontal cells. There is only one type of a bipolar cell 
receiving the electrical inputs from rods, the rod ON-bipolar cell and at least 13 
subtypes of the cone bipolar cells, both ON and OFF. The distinction between ON and 
OFF types depends on the response of the bipolar cell to photoreceptor activation and 
changes in their glutamate release.  
1.3.2.2.3 Amacrine cells 
Amacrine cells are the inhibitory interneurons that are located within the INL and GCL 
whose primary function is thought to moderate signals received from the bipolar cells 
and project them further to the cells located in the GCL (reviewed in (Baden and Euler, 
2016)). There are many different subtypes of amacrine cells that can be distinguished 
based on the neurotransmitter they release and the type of connection they make, with 
type II being the most abundant.  
1.3.2.3 Ganglion cell layer 
Ganglion cells are the last neuronal cell type that is found in the retina. These cells are 
located in the inner most layer, the ganglion cell layer (GCL), where they collect inputs 
from bipolar and amacrine cells and project them to the brain via axonal projections 
that form the optic nerve (reviewed in (Sanes and Masland, 2015)). These cells 
constitute a large family, with different cell subtypes being responsible for encoding a 
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specific type of visual information. These distinctive subclasses can be distinguished 
into five major types due to their morphology, type of projections, and function they 
serve. The first three classes of ganglion cell, Midget, parasol and bistratified ganglion 
cells, project to different regions of the lateral geniculate nucleus (LGN) in the brain. 
The type 4 is unusual in its photosensitive properties, due to its expression of the visual 
photopigment, Melanopsin. Melanopsin enables ganglion cells to respond directly to 
light stimulus in the absence of rods and cones, for example in the pathological 
conditions. The projections of these ganglion cells end up in the suprachiasmatic 
nucleus (SCN) and help to maintain the circadian rhythm. The last class of ganglion 
cells, type 5, extends its fibres to the superior colliculus and accessory optical system 
where they allow for navigation of the eyes towards the regions of interest as well as 
they enable to keep the gaze when we move. 
1.3.2.4 Synaptic layers  
There are two distinct synaptic layers found in the retina, the outer plexiform layer 
(OPL) and the inner plexiform layer (IPL). The OPL is situated between the ONL and 
INL and contains the synaptic connections established between photoreceptor cells 
and the dendrites of the bipolar cells, as well as synaptic formations of the horizontal 
cells with photoreceptors and bipolar cells. The IPL holds synaptic connections 
between bipolar and ganglion cells, the bipolar and amacrine cells, and between the 
amacrine and ganglion cells. 
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1.3.2.5 Retinal glial cells  
In the mouse retina there are two types of the glial cells, macro- and microglia.  
Müller cells are the predominant macroglia type with their nuclei embedded within the 
INL, from where they project one process towards the vitreous surface and the inner 
limiting membrane (ILM), and the second towards the outer edge of the ONL and OLM. 
Müller glia cells surround blood vessels and neuronal cells in the retina providing a 
support for neuronal function and survival (reviewed in (Bringmann et al., 2006)). They 
deliver nutrients and trophic factors to the neurons, as well as removing metabolic 
waste (Bringmann et al., 2009b). By regulating transcellular ion, water and bicarbonate 
transport, Müller glia modulate the extracellular fluid and, in turn, keep the homeostatic 
balance of the retina. These cells are also involved in the regulation of synaptic activity 
in the retina as they are equipped with cellular machineries for the uptake and 
exchange of various neurotransmitters, including glutamate, released by neurons, 
particularly the photoreceptors (reviewed in (Bringmann et al., 2006)). By spanning the 
entire thickness of the retina, Müller glial processes act as optical fibres guiding the 
light towards photoreceptors in order to minimise the amount of photons being 
scattered across the inner retina. Previously, it has been thought that there was only 
one type of Müller glial cell; however recent studies have revealed that this glial 
population is more heterogeneous than previously thought, with individual Müller cells 
responding differently to a pathological insult (Luna et al., 2010). Moreover, it has been 
reported that although Müller glia in all vertebrates share similar morphological 
properties, there are some differences between different species (Dreher et al., 1992; 
Sarthy and Ripps, 2001). For example, in the feline retina, the Müller glia processes 
that lie adjacent to vitreous cavity have a club-like shape; whereas in many other 
species these processes are highly branched (Dreher et al., 1992).  
The other macroglial cells of the retina are retinal astrocytes, which typically exhibit a 
stellate morphology. Astrocytes do not develop from the retinal neuroepithelium, but 
migrate from the outside of the neural retina along the optic nerve (Fernández-Sánchez 
et al., 2015). These cells primarily reside within the GCL, where their processes follow 
the fibres of ganglion cells towards the optic nerve forming rows with vitreal surface.  
There are also two forms of microglia found throughout the retina: resident microglia 
and infiltrating microglia. These cells have a close relationship with neurons, where 
they protect them from the invading microbes, clearing cellular debris and enforcing 
programmed cell death (reviewed in (Rock et al., 2004)). They also release a number 
of factors including brain-derived neurotrophic factor (BDNF), as well as various anti-
inflammatory cytokines that sustain and support neuronal survival. However, these 
cells may also release proinflammatory and pro-angiogenic factors in diseases such as 
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AMD leading to pathological neovascularization and further retinal damage (Lewis et 
al., 2005). 
 
1.3.2.6 Inner and outer membranes  
1.3.2.6.1 Outer limiting membrane 
At the apical edge of the ONL, Müller glia and photoreceptor ISs are connected via a 
series of tightly arranged adherens junctions, which are formed from cadherin-catenin 
transmembrane protein complexes. These junctions contribute to the maintenance of 
the retinal structure, as they are linked to the actin cytoskeleton within the cell 
cytoplasm, via essential adapter proteins (reviewed in (Alves et al., 2014b)). The OLM 
structure, apart from providing mechanical strength, also functions as a permeability 
barrier to any molecules coming from the choroid and the phototransduction process, 
thereby protecting the neuroretina from toxicity.  
1.3.2.6.2 Inner limiting membrane 
On the side of the vitreous, Müller cells, together with astrocytes, form a very thin and 
transparent coating, the ILM. Its primary function is believed to act as a diffusion barrier 
between the neural retina and vitreous humour at the inner surface of the retina. 
1.3.2.7 Interphotoreceptor matrix 
The interphotoreceptor matrix (IPM) is a highly organized structure with interconnected 
domains surrounding cone and rod photoreceptor cells, which extends into the 
subretinal space. This subretinal region, located between the ONL and RPE, is highly 
enriched in proteins belonging to the proteoglycan family, which have an ability to bind 
to many ECM molecules and growth factors. Based on known roles of the ECM in 
other tissues, the IPM is thought to have several prominent functions including serving 
as a cell adhesion and migration substrate, regulating retinoid transport, participating in 
cytoskeletal organization in surrounding cells, and regulation of oxygen and nutrient 
transport (reviewed in (Ishikawa et al., 2015)). In addition, a number of studies suggest 
that the IPM may also play a significant role in the aetiology of retinal degenerative 
disorders (LaVail et al., 1981; Bridges, 1985; Mieziewska et al., 1993).  
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1.4 Process of phototransduction  
The phototransduction cascade refers to a biological process that transforms a light 
stimulus in a form of photon into an electrical signal, with photorecepotors being the 
main players in this process. As previously mentioned, rods and cones possess outer 
segments, which contain the biochemical machinery needed for visual transduction. All 
the necessary components of the phototransduction cascade are packed into discs that 
in rods are surrounded by the plasma membrane of the outer segment (Figure 1.5), 
whereas in cones these discs are an extension of the plasma membrane, arranged into 
a series of infoldings. These open discs in cones allow for faster fluxes of molecules 
between the cell exterior and interior, such as chromophore transfer for pigment 
regeneration and fast calcium dynamics during light adaptation. Rods are able to 
detect single photons hitting the retina, which is attributed to three factors: high 
quantum efficiency of photoactivation, low intrinsic noise, and a powerful signal 
amplification cascade. The dense stack of discs of the OS allows for every photon 
traveling axially to be detected and transmitted to the inner retina.  
1.4.1 Dark condition  
In the inactive state, most neurons maintain a membrane potential of about -60 to -70 
mV. When the neuronal cell becomes activated, the cation channels become open 
which causes influx of sodium (Na+) cations inside the cell making it more positive. This 
results in cell depolarisation and opening of the voltage-gated calcium (Ca2+) channels 
at the synaptic terminal. The influx of the Ca2+ cations stimulates fusion of synaptic 
vesicles with the plasma membrane and the release of neurotransmitter into the 
synaptic cleft. The process is terminated by a hyperpolarisation caused by the efflux of 
the positively charged cations from the cell, leading to restoration of the resting 
membrane potential. In rod and cone cells this process works “backwards”. In the dark, 
or at ‘rest’, the photoreceptors are depolarized to -35 to -45 mV, because the Na+ gated 
channels located at the OS surface are open due to binding of guanosin 3’,5’ cyclic 
monophosphate (cGMP). To maintain this depolarisation state, potassium (K+) 
selective channels in the IS pump out potassium cations K+, which balances the influx 
of cations at the OS, completing an electrical circuit, referred to as the “dark” or 
circulating current. This results in photoreceptors depolarisation, which allows for the 
voltage gated Ca2+ channel located in the photoreceptor synaptic terminals to stay 
open. As Ca2+ ions flow inside the terminals, the synaptic vesicles fuse with the cell 
membrane and release the neurotransmitter glutamate into the extracellular space 
between photoreceptors and terminals of inner- neurons. When rods and cones 
receive light, the channels in the OS close and the membrane hyperpolarises towards 
the equilibrium potential for K+. 
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1.4.2 Light detection  
In a mouse retina, there are two type of cones S- and M-type, and only one type of 
rods. This distinction between different photoreceptor types depends on the expression 
of different Opsins, which belong to the super family of G-protein coupled receptors. 
Mouse retina is unusual in the sense that individual cones express both S- and M-cone 
pigments, but as the levels of the M-pigment start to decrease in a gradient manner 
from dorsal to ventral retina (Applebury et al., 2000). The activation of Opsins is the 
first step in the photodetection cascade with phototransduction occurring in rods being 
one of the best-characterised signalling pathways in the retina (Figure 1.4).  
When the light is being detected, the light photon is being absorbed by the visual 
pigment Rho, which is embedded within the discs of the photoreceptor OS. Rho is a 
divided into two parts: the chromophore 11-cis retinal and one of the opsin molecules. 
First identified by George Wald in 1934, 11-cis-retinal cannot be made de novo by the 
body as it is derived from vitamin A (Wald, 1934). Deficiency of vitamin A in a diet 
lowers sensitivity of rod cells as fewer functional Rho molecules are produced, which 
leads to the development of night blindness (Goodman, 1984; Jacobson et al., 1995). 
The photon absorption results in 11-cis retinal chromophore photoisomerisation and its 
structural change converting it into the all-trans retinal isomer. This change forces the 
Rho molecule (R) to expand resulting in its activation (R*), which leads to activation of 
the next visual component located on the surface of OS disc membrane, transducin. 
Transducin is the most stable G-protein (G) known and it consists of three subunits: α, 
β and γ. Rods and cones have different isoforms of transducin, being Gαt1Gβ1γ1 in rods 
and Gαt2Gβ3γ8 in cones. In the dark, the α-subunit (Gα) normally binds GDP 
nucleotide. Upon Rho activation, the Gα subunit aligns with R* and GDP is being 
replaced with GTP. In turn, transducin becomes activated (G*) with the Gα-GTP 
separating R* molecules as well as the other two subunits (Figure 1.5b). In the next 
instance, the activated Gα-GTP* binds to cGMP phosphodiesterase (PDE) to carry the 
signal forward. Released R* is free to activate additional transducin molecules. 
Transducin is tenfold less abundant than rhodopsin pigment, but its activation by R* 
represents the first amplification step in the phototransduction cascade.  
PDE represents the third component in the phototransduction process and the second 
amplification step with a density at roughly 1-2% of Rho. PDE is a tetrameric protein 
consisting of two equally active catalytic subunits, α and β, and two identical γ subunits. 
In the dark, the two PDEγ subunits bind to the two catalytic subunits. In the light, Gα-
GTP* encounters PDEγ subunits causing a sterical displacement of the PDEα and 
PDEβ subunits and as a consequence PDE activation (PDE*). PDE* then hydrolyses 
the diffusible messenger cGMP present in a cytoplasm to 5’-GMP reducing its 
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concentration and leading to the closure of the cGMP-gated channels on the plasma 
membrane. The cGMP-gated channel belongs to the family of cyclic-nucleotide-gated 
(CNG) channels, which are non-selective cation channels. This channel closure leads 
to localised reduction in the influx of Na+ cations into the OS, which results in 
membrane hyperpolarisation and cessation of glutamate release at the synaptic 
terminals. For the channel to respond to changes in cGMP concentration, it must revert 
to the closed state, thereby allowing cGMP to dissociate from the channel. This 
happens only if the concentration of cGMP reaches a certain level. If the concentration 
of cGMP remains low, the channel will stay closed since there will be fewer nucleotides 
around. Thus ‘channel chatter’ ensures that the response to a decrease in cGMP levels 
will be quick. The rod photoreceptor possesses a vast number of cGMP-gated 
channels, but only a small percentage is normally open in darkness. Here, the activity 
of PDE serves as an important regulator of photoreceptor function, as the rod 
photoreceptor possesses a vast number of cGMP-gated channels but only a small 
percentage is normally opened in darkness. As cGMP is constantly synthesised in the 
cytoplasm, the lack of activated PDE would lead to cGMP cytoplasmic accumulation 
and in turn activation of a greater number of cGMP-gated channels resulting in a 
permanent depolarisation of the photoreceptor. The lowering in the concentration of 
cGMP leads to closure the Na+ channels which in turn causes photoreceptor 
hyperpolarisation and subsequent closure of voltage-gated Ca2+ channels. As the level 
of intracellular Ca 2+ falls, the release of glutamate ceases, leading to depolarization of 
ON-bipolar cells and hyperpolarization of cone OFF- bipolars. The hyperpolarisation of 
the photoreceptor becomes the first step in the termination of phototransduction 
process. 
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Figure 1.4 Phototransduction cascade.  
Activation of rod phototransduction cascade in the OS results in the closure of cGMP-gated channels on 
the plasma membrane (from dark to light state). R, Rho (inactive); R*, Rho (active); T, transducin; PDE, 
phosphodiesterase (inactive); PDE*, phosphodiesterase (active); NCKX, Na/Ca,K exchanger. IPM, 
interphotoreceptor matrix.  
Copyright note: Image taken from http://webvision.med.utah.edu/, and it is a courtesy of Dr Wolfgang 
Baehr. Accessed online on 20.5.2016.  
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Following light activation, a timely recovery of the photoreceptor is essential so that it 
can respond to subsequent light stimulus, hence the efficient inactivation of each of the 
activated components, R*, G*, and PDE*, as well as the efficient regeneration of Rho 
and the rapid restoration of the cGMP concentration, are needed. One hallmark of rod 
phototransduction is the reproducibility of its single-photon response in both amplitude 
and kinetics. First, Rho kinase (GRK1) phosphorylates serine and threonine residues 
at the C-terminus of R*. Phosphorylation of R* alone decreases is activity and allows 
for binding of arrestin. Arrestin is a very large protein, whose sheer bulk prevents any 
transducins from getting close enough to bind to R*. Arrestin remains bound to the Rho 
molecule until the all-trans chromophore is removed, diffused into the cytosol of the OS 
and transported out of the segment into the RPE. In the RPE the chromophore is 
reduced by appropriate enzymes to all-trans retinol, and ultimately converted into 11-
cis retinal. In this form, the chromophore is transported across the IPM enveloped by 
11-cis retinal binding protein back to the photoreceptor OS. Here, phosphatase 
dephosphorylates the deactivated Rho molecule allowing 11-cis retinal to re-bind to the 
opsin thus restore the inactive visual pigment. 
G* is inactivated by hydrolysis of GTP to GDP via activity of GTPase, which is 
accelerated by the GTPase Activating Protein (GAP) complex. Upon hydrolysis of GTP 
to GDP, Gα* subunit releases the PDEγ* subunits allowing them to re-bind to the PDE 
catalytic subunits, α and β. Gα subunit eventually re-joins with the other two subunits to 
reconstitute the inactive transducin heterotrimer. To ensure that Gα* does not 
inactivate before triggering activation of PDE, Gα* transducin and the GAP complex 
have a low affinity for each other, until transducin Gα*-GTP binds to PDEγ.   
Full recovery following the photoresponse requires that the cytoplasmic cGMP levels 
get restored to the dark-adapted concentration. As noted above, cGMP is synthesised 
continuously from GTP by a membrane-associated enzyme, guanylate cyclase (GC). 
Retinal GC is a transmembrane protein that exists as homodimer, whose activity is 
kept low by the action of guanylate cyclase activating proteins (GCAPs), which bind 
calcium ions. As levels of calcium start to fall as a result of Na+/K+, Ca2+ exchanger 
machinery, GCAP dissociates itself from its bound Ca2+ and activates GC leading to 
transformation of GTP back to cGMP. This allows for restoration of the intracellular 
cGMP levels to high concentrations, which cause the Na+ cation channels to re-open 
and restore the cell’s depolarisation state.   
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1.5 Retinal degenerative diseases and their genetics 
Vision is a primary sense that allows for normal interactions with the external 
environment; its loss has tremendous consequences on quality of life, especially for 
humans. The impairment of sight can be caused by an obstruction preventing light 
getting to photosensitive cells, as in the case of cataracts, or by the inability of the 
neuroretina to detect light or to transmit the received stimulus to the visual centres in 
the brain. The latter are usually a consequence of photoreceptor dysfunction or their 
complete loss due to degeneration. During the last decades, studies on retinal 
degenerative diseases identified over 1500 entries of inherited retinal dysfunctions 
associated with over 250 different causative genes (https://sph.uth.edu/retnet/). This 
genetic heterogeneity in retinal degenerations is further complicated by the fact that, 
very often, there is no clear one-to-one genotype-phenotype correlation. For example, 
mutations in the same gene can result in a spectrum of different phenotypes, whereas 
defect in one of many different genes can manifest itself in a similar manner (reviewed 
in (Boon et al., 2008)). As a consequence, hereditary retinal retinopathies are currently 
thought to be the most genetically heterogeneous group of diseases in humans. 
1.5.1 Classification of retinal degeneration phenotypes 
Recent advances in technology and medical equipment facilitated development of 
better methods for non-invasive assessment of the structure, physiology as well as 
function of the eye and the retina. Examination of the ocular fundus by ocular 
coherence tomography (OCT) is commonly used in clinics to examine the structure of 
the retina, whereas electroretinography (ERG) allows for studying of retinal function. 
On the other hand, next-generation sequencing is helping to identify numerous 
defected genes and/or loci associated with loss of vision in patients suffering from a 
retinal degeneration. These assessments allow clinicians for making correct diagnosis 
and classify patients according to different pathological phenotypes (Figure 1.6).  
With regard to inherited disorders, depending on the disease type, rods and cones can 
be differently affected. Commonly, the clinical phenotypes of inherited retinal diseases 
are usually divided into rod degenerative RP and cone or cone-rod dystrophy (CD or 
CRD, respectively). Primary RP comes in many forms and consists of large numbers of 
genetic mutations affecting rods directly. Typically, in the early stages of the disease, 
the rods of the peripheral retina begin to degenerate, leading to gradual development 
of night blindness. As the disease progresses, patients start to lose visual field and 
visual acuity due to subsequent cone impairment. A typical pathological characteristic 
of RP is the occurrence of black pigment in the peripheral retina coupled with thinning 
of blood vessels at the optic nerve head (reviewed in (Parmeggiani, 2011)).   
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In contrast to RP, in primary CD, a dysfunction or loss of cone photoreceptors might 
not necessarily lead to secondary degeneration of rods; however, when rods are 
involved in CD, the disease is referred to as CRD. A typical clinical phenotype of CD 
manifests itself first with the loss of visual acuity, impairment of colour vision and 
photosensitivity (light aversion). In CRD, as the disease progresses and severe retinal 
degeneration has developed, rod photoreceptors start to follow the fate of cones 
(reviewed in (Hamel, 2007)).  
Of all the retinal degenerations, Leber's congenital amaurosis (LCA) is one of the most 
severe, accounting for approximately 5% of all retinal dystrophies and 20% of 
paediatric patients. There are at least 20 known different gene mutations associated 
with this condition causing severe and early visual impairment, sluggish or near- 
absent pupillary responses, and severely subnormal or non-detectable ERG responses 
(reviewed in (Chacon-Camacho and Zenteno, 2015)).   
Since the photoreceptor OS is a modified primary cilia, mutations in genes affecting 
cilia biogenesis or function often result in retinal degeneration, in addition to the 
dysfunction of ciliated cells in other organs. These so-called syndromic ciliopathies 
may affect vision, as well as hearing (Usher syndrome), renal function (Senior-Loken 
syndrome), or proper brain development (Joubert syndrome) (reviewed in (Rachel et 
al., 2012)). 
In addition to primary mutations in photoreceptor genes, genetic defects in RPE, which 
takes part in the maintenance of photoreceptor homeostasis, are also found to be 
associated with retinal degenerations (reviewed in (Travis et al., 2007)). 
Macular degeneration (MD) is a specific form of retinal degeneration where both rods 
and cones are affected but only within the macular region. This condition manifests 
itself by a loss of the central vision enabling us to read or see fine details. The most 
common monogenic MD is Stargardt disease, a condition that has an early age onset. 
AMD is a form of MD, with many genetic and environmental factors being involved, and 
with symptoms not present until affected individuals are much older. In this condition, 
the macular area and fovea become compromised due to the pigment epithelium 
behind the retina degenerating and forming drusen (yellow spots) leading to 'dry' AMD 
or abnormal neovascularisation and eventual leakage of fluid behind the fovea ('wet' 
phenotype) (reviewed in (Fritsche et al., 2014)).  
Another retinal degenerative disease associated with ageing is glaucoma. This 
condition manifests itself by elevation in the intraocular pressure due to dysfunction in 
fluid exchange within the anterior chamber. As the pressure within the vitreous 
chamber gradually rises, the blood vessels of the optic nerve head become 
compromised leading to damage of the ganglion cells axons and their subsequent 
43"
death. Apart from this mechanical dysfunction, glutamate intoxication has also been 
associated with the progression of neuronal degeneration observed in glaucoma 
(reviewed in (Schumer and Podos, 1994)).   
The last retinal condition worth mentioning with respect to the work described in this 
thesis is diabetic retinopathy (DR). In contrast to the previously mentioned diseases, 
loss of vision is a side effect of diabetes where the vital blood vessels of the eye 
become distorted and start to proliferate in uncontrollable manner. Among the 
symptoms experienced by diabetic patients are elevated blood sugar levels, blurred 
vision, dark spots and sudden loss of vision. In more advanced stages of DR, 
development of glaucoma, retinal detachment or macular edema are also accompany 
the above mentioned pathological changes (reviewed in (Cai and McGinnis, 2016)).  
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Figure 1.5 Characterisation of retinal diseases in human patients.   
Fundus images of A) healthy retina, B) RP retina, C) MD retina, D) ‘Dry’ AMD retina, E) ‘wet’ AMD retina, 
F) LCA retina, G) DR retina and H) retina with a glaucoma.  
AMD; age-related macular degeneration; DR, diabetic retinopathy; LCA, Leber's congenital amaurosis; 
MD, macular degeneration; RP, retinitis pigmentosa. 
Copyright note: Images taken from http://webvision.med.utah.edu/. Accessed online 20.05.2016.   
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1.5.2 Genetics of retinopathies 
The majority of our understanding of retinopathies comes from studies on animal 
models. The use of model organisms has not only increased our knowledge of a 
normal retinal function, but has also allowed us to shed some light onto the 
mechanisms underlying retinal pathologies. Although Drosophila and zebrafish have 
been used as classical models for discovering the basic principles of visual pathways, 
it is the mouse that has become the most widely used model in pre-clinical translational 
eye research. Naturally occurring mutants, as well as genetically engineered mice, not 
only provided invaluable insights into disease pathology, and have been key in the 
development of clinically relevant therapies. Here, an evaluation of the most common 
retinopathies is presented with a reference to genetic mutation (Table 1.1), with 
particular reference to those models used in this thesis.  
1.5.2.1 Retinal diseases caused by photoreceptor developmental defects 
Transcription factors including CRX, NRL, and NR2E3 are crucial for the proper 
development of photoreceptors, as they orchestrate the expression of rod and cone-
specific genes (Swaroop et al., 2010). Genetic mutations in the genes encoding for 
these factors have been found in patients with LCA, RP, CD, and CDR and can result 
in photoreceptor dysfunction and, in some cases, photoreceptor death (Berger et al., 
2010; Khateb et al., 2016). 
CRX has a key function in regulation of rod and cone specific genes and because of 
that defects in CRX gene can result in development of a number of different 
phenotypes in humans. Mouse knockout mutants are born blind, have no functional 
photoreceptors and show malformations in OS and synaptic terminals with the 
expression of phototransduction genes being compromised. The mutation ultimately 
leads to photoreceptor degeneration (Furukawa et al., 1999).  
NRL transcription factor was shown to be responsible for determination of rod cell fate 
as Nrl knockout mouse lacks rod photoreceptors and rod specific genes (Mears et al., 
2001). In humans, mutations in Nrl gene are associated with RP with both rods and 
cones being severely affected (DeAngelis et al., 2002). In the Nrl-/- retina, the 
expression of cone specific genes is elevated, however the cone cells that are present 
are more of a hybrid cell type and have been referred to as ‘cods’. A typical 
characteristic of Nrl-/- retina is the development of retinal folds commonly known as 
rosettes (Stuck et al., 2012). Studies of this genetic mutant provided invaluable 
information on rod development and function and helped to understand better the 
photoreceptor fate determination (Mears et al., 2001).  
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Mutations in NR2E3, which is downstream of NRL (Oh et al., 2008), are associated 
with retinal spots, which correlate with presumptive rosette formation, and progressive 
photoreceptor degeneration leading to visual impairment at later stages of disease 
progression (Haider et al., 2009). The retina of individuals with defects in Nr2e3 gene 
lacks rods, but shows an increase in the number of S-cones (Haider et al., 2001). 
Studies on Nr2e3-/- mutant showed that the expression of this transcription factor is 
limited to post-mitotic rod cells indicating that NR2E3 promotes rod cell fate while at the 
same time inhibiting cone specific genes (Cheng et al., 2006). 
A number of mutations are associated with the malformation of photoreceptor OSs, 
especially to their discs. Mutations in Peripherin (Prph), which is essential for the 
formation of the rod and cone OS during development and their postnatal renewal 
(Travis et al., 1991), are linked to a variety of retinal diseases including CRD 
(Nakazawa et al., 1996) and autosomal dominant RP (Keen and Inglehearn, 1996). 
Commonly referred to as the ‘retinal degeneration slow’ (rds) transgenic mouse line 
carries a mutation in Prph gene and has shorter OSs (Travis et al., 1991; McNally et 
al., 2002) and early photoreceptor degeneration (Kedzierski et al., 1997).  
1.5.2.2 Retinal degenerations associated with phototransduction process 
The process of phototransduction depends on many different phototransduction 
proteins. Mutation to any the genes encoding for these molecules frequently results in 
vision impairment. As visual pigment is a major structural component of rods and 
cones, it is not surprising that genetic defects in Rho and cone Opsins not only affect 
the process of phototransduction, but also lead to photoreceptor dysfunction and 
subsequent death. In humans, defects in RHO gene lead to the development of a 
variety of different RP phenotypes depending on the type of mutation, but are usually 
associated with night blindness and progressive photoreceptor deterioration. The Rho 
knockout mutant mouse shows a malformation of rod OSs, with degeneration of rod 
cells starting as early as three weeks of age (Humphries et al., 1997). 
In 1996, a mutation in GNAT1 gene, which encodes α-subunit of G protein transducin 
in rods, was found in patients suffering from congenital stationary night blindness 
(CSNB) (Dryja et al., 1996; Naeem et al., 2012). A transgenic mouse model revealed 
that defects in Gnat1 result in a decrease in activity of GTPase and impaired ability to 
activate PDE6 (Moussaif et al., 2006) leading to slow degeneration of rods over time 
(Calvert et al., 2000). On the other hand, defects in GNAT2, which controls the 
expression of cone α- transducin (Morris and Fong, 1993), result in a lack of 
functioning cones with the majority of individuals developing a complete achromatopsia 
(Kohl et al., 2002). The Gnat2-/- mouse resembles the human phenotype and shows 
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clear dysfunction of cone photoreceptors, mislocalisation of Opsin protein, remodelling 
of a retina and clear signs of progressive cone deterioration (Jobling et al., 2013).  
Null or missense mutations in the gene encoding PDE protein, which is the third major 
component in the phototransduction cascade, can be associated with an autosomal 
recessive form of RP (McLaughlin et al., 1993; Dryja et al., 1999) or autosomal 
dominant CSNB (Gal et al., 1994). The Pde6brd10/rd10 mutant manifests a mild 
degenerative phenotype and is a widely used tool by researchers working on 
therapeutic interventions for RP (Chang et al., 2002). In contrast, Pde6brd1/rd1 mouse, 
commonly referred to as rd1, is the oldest mouse model used in RP research and 
manifests a very fast degeneration of photoreceptors with the majority of cells absent 
by the 2nd month of age (Caley et al., 1972; Sanyal and Bal, 1973). In a recent study by 
Nishiguchi, Carvalho et al., the most commonly used strain of the rd1 mutant, 
(C3H/HeN background), which is often used in preclinical studies, was found to 
harbour a second genetic mutation in the GPR179 gene, expressed in bipolar cells 
(Nishiguchi et al., 2015), which impairs further transmission of detected light stimulus 
towards the visual centres in the brain.  
Mutations in different components of the phototransduction pathway may result in 
abnormal CNG channel activity, triggering photoreceptor cell death. Moreover, over 50 
different genetic defects in the genes that encode CNG gated channels have been 
found in relation to channelopathies (https://sph.uth.edu/retnet/). Depending on the 
cell-type expression of mutant protein, rods and cones are affected differently, leading 
to distinct clinical symptoms. Mutations in CNGA1 or CNGB1 genes that encode CNG 
channels in rod photoreceptors lead to autosomal recessive RP (Dryja et al., 1995; 
Bareil et al., 2001), whereas mutations in the cone CNG channel gene CNGA3 and 
CNGB3 are the major cause of achromatopsia in humans (Kohl et al., 1998; Kaupp 
and Seifert, 2002). In mice, complete knock-out of Cngb1 mimics retinal degeneration 
observed in human RP patients, with the loss of rods at birth followed by progressive 
degeneration of cones (Hüttl et al., 2005). Cnga3-/- mouse mutants lack functional CNG 
channels in the cone OS with progressive loss of cone photoreceptors over time (Biel 
et al., 1999).  
Termination of phototransduction cascade is achieved by R9AP protein and G protein 
β5 deactivating the G*-PDE* complex, and GC with their activators GCAPs that 
transform GTP back to cGMP. R9AP mutations are responsible for a bradyopsia 
condition, where the eyes of affected individual adapt more slowly than usual to 
changing light levels (Nishiguchi et al., 2004). Defects in GC1 gene expression leads to 
permanent closure of cGMP gated cation channels and development of in CD and LCA 
(Hanein et al., 2004); whereas GCAP1 mutations have been linked to CRD (Baehr et 
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al., 2007) as they decrease the sensitivity to detect Ca2+ causing continuous 
stimulation of GC1 protein in dark conditions (Hanein et al., 2004).  
RPE plays a crucial part in the visual cycle as it is responsible for recycling of the rod 
and cone visual pigments and mutations in several RPE specific genes are associated 
with retinal degeneration. Human LCA type 2 is associated with mutations in Retinal 
Pigment Epithelium-specific 65 kDa protein (RPE65) (Cideciyan, 2010). RPE65 is 
almost exclusively expressed in the RPE and functions as the retinoid isomerase 
responsible for converting all-trans retinoid to 11-cis retinal during pigment 
regeneration (Moiseyev et al., 2005). Improper functioning or absence of RPE65 
results in a lack of 11-cis retinal production and an inability to efficiently form the visual 
pigments, Rho and Cone Opsin (Redmond et al., 1998; 2005). Rpe65 mutant mouse 
suffers from severe visual impairment with progressive retinal degeneration probably 
due to constant activation of phototransduction cascade by the large amount of free 
visual pigment. A more mild form of retinal degeneration manifests RPE65-
R91W transgenic mouse where the retina is able to produce some of 11-cis-retinal 
allowing for partial recovery of Rho pigment (Samardzija et al., 2007).  
1.5.2.4 Other retinal degenerations 
Mutations in the Crumbs Homologue Protein 1 (CRB1) gene are associated with 
variable phenotypes of severe retinal dystrophies, ranging from LCA to CRD which 
may be accompanied by specific fundus features including Coats-like vasculopathy 
(reviewed in (Bujakowska et al., 2011). Retinae of CRB1 patients have altered laminar 
organisation and are usually much thicker than that of healthy individuals (Jacobson et 
al., 2003). Moreover, CRB1 mutations seem to present a phenotypic variability in 
patients which leads to differences in clinical diagnoses (for example, LCA, juvenile-
onset RP, or autosomal recessive RP). Patients with CRB1 defects present an 
abnormal hyperreflective lesions of various sizes and retinal depths in regions of 
thickened, non-seeing retina. These hyperreflective lesions show some resemblance to 
the retinal folds observed in the Crb1rd8/rd8 mutant mouse, which suffers from similar 
disruptions to OLM integrity (Mehalow et al., 2003). Previous studies of different Crb1 
mutants (Crb1-/-, Crb1c249wl and Crb1rd8/rd8) have shown the retinal abnormalities 
reported in these animals seem to be light-dependent and usually restricted to the 
inferior quadrant of the retina (van de Pavert et al., 2004). Recently, Alves et al. 
reported that the Crb2 knockout mouse manifests a more similar disease phenotype to 
that observed in CRB1 patients (Alves et al., 2014a) indicating that the role of Crumbs 
proteins may vary between different species.  
Interestingly, a recent study by Zhao, Andrieu-Soler et al., published in The Journal of 
Neuroscience characterized a recessively inherited retinal phenotype of the Brown 
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Norway rat strain from Janvier Breeding Centre (BN-J). A thorough analysis of the BN-
J retinae showed that they display retinal abnormalities such as neuronal and vascular 
changes, focal alternations to retinal lamination and development of retinal cysts, all 
very similar to retinal pathology seen in Macular telangiectasia type 2 (MacTel 2) 
Genetic analysis showed that the BN-J rat has a mutation on the 6th exon of the Crb1 
gene, which results in the ablation of 14 nucleotides and insertion of 8 new one. This 
mutation was shown to lead to dislocalisation of CRB1 from the SAR in glial cells of the 
BN-J retina.  
Stargardt disease is an autosomal recessive form of juvenile MD that severely impairs 
central vision. Mutations in ABCA4 gene were one of the first to be associated with this 
condition (Allikmets et al., 1997). ABCA4 gene encodes an ATP-binding cassette 
transporter (ABC) which actively transports all-trans-retinal (atRAL) from the internal 
membranes of retinal OS discs to the cytoplasm, where it is reduced to retinol (Kiser et 
al., 2012). In the generated Abca4-/-Rdh8--/- transgenic mouse model, this process is 
impaired which results in the accumulation of the retinoid waste in the OS (Maeda et 
al., 2009).  
Usher syndrome belongs to genetically heterogeneous group of RP diseases 
accompanied by a progressive loss of hearing and varying degrees of vestibular 
dysfunction. To date, 11 different genetic mutations have been found linked to three 
distinguished disease phenotypes. The most severe form of Usher condition, Type 1, is 
caused by genetic defects in MYO7A gene that encodes myosin motor protein 
expressed in embryonic RPE, photoreceptors, cochlear and vestibular neural epithelia 
(Weil et al., 1996).  
Following activation by light, photoreceptors propagate the received stimulus towards 
inner retina via a graded decrease in glutamate release at the synaptic terminals. 
Mutations in the genes encoding for the voltage-gated calcium channels have been 
associated with X-linked CSNB (Strom et al., 1998), X-linked CRD (Huang et al., 2013) 
and autosomal recessive form of CRD (Wycisk et al., 2006b). In mouse, spontaneous 
mutation in Cacna2d4 gene results in retinal degeneration with a characteristic 
malformation of a synaptic layer (Wycisk et al., 2006a). 
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Phenotype 
(disease) 
Cell type affected 
Mode of 
inheritance 
Genes 
Non-syndromic monogenic 
CSNB 
Rods more than 
cones 
Dominant GNAT1, PDE6B, RHO 
Recessive GNAT1,CABP4, GRK1, SAG 
X-linked CACNA1F 
LCA Rods and cones 
Dominant CRX 
Recessive 
CRX, APIL1, TULP1, 
CABP4, REP65, CEP290, 
CRB1 
RP 
Rods more than 
cones and/or RPE 
Dominant 
CRX, NRL, NR2E3, PRPH2, 
RHO, ROM1, RPE65 
Recessive 
ABCA4, MERTK, NRL, 
NR2E3, PDE6A, RHO, 
RPE65,SAG, TULP1 
X-linked RPGR, RP2 
CD-CDR 
Cones more than 
rods 
Dominant AIPL1, CRX, PRPH2 
Recessive ABCA4, CNGB3, RAB28 
X-linked CACNA1F, RPGR 
MD Rods and cones 
Dominant PRPH2, ELOV4 
Recessive ABCA4 
X-linked RPGR 
Synaptic 
diseases 
Rods and cones 
Dominant UNC119, RIMS1 
Recessive CACNA2D4 
X-linked CACNA1F, XLRS 
Syndromic 
Joubert 
syndrome 
Rods and cones Recessive CEP290 
Senior-Loken 
syndrome 
Rods and cones Recessive CEP290 
Usher syndrome Rods and cones Recessive MYO7A, USH2A 
 
Table 1.1 Genetics of some common human forms of retinal degenerations. 
CSNB, Congenital stationary night blindness; CD or CRD Cone or Cone-rod; DR, Diabetic retinopathy; 
LCA, Leber's congenital amaurosis; MD, Macular degeneration; RP, Retinitis pigmentosa.  
Copyright note: Table adapted from (Veleri et al., 2015). 
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1.6 Retinal remodelling in degenerative conditions  
In retinal degenerations such as RP, AMD, or Usher Syndrome, death of 
photoreceptors, often triggered by rod degeneration, leads to irreversible vision 
impairment. As the retina starts to degenerate, the retinal structure and the 
environment begin to remodel, with a series of morphological, molecular and functional 
alterations in different retinal cells (Strettoi et al., 2002; Jones et al., 2003a; Jones and 
Marc, 2005; Sethi et al., 2005). This retinal remodelling is a complex 
pathophysiological process, but studying it may help to advance the research towards 
more efficient ocular therapies. 
Retinal remodelling is usually divided into three different phases (Figure 1.6) (reviewed 
in (Cuenca et al., 2014)). Phase I is a pre-degeneration phase, indicated by early 
markers of cellular stress but with no major changes to retinal morphology or function 
(Figure 1.6A). In Phase II, photoreceptors start to deteriorate, with glial and RPE cells 
becoming involved (Figure 1.6B). Phase III is the ultimate phase where the retina 
undergoes major organisational alterations including neuritogenesis, cell migration, 
loss of distinct layer lamination, glial hypertrophy, metabolic changes of neurons and 
glia cells, synaptic rewiring and many more (Figure 1.6C). The progress of the 
remodelling is directly linked to a degree of retinal damage and speed of photoreceptor 
loss and it should be taken into account before any therapeutic intervention.  
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Figure 1.6 Retinal remodelling during degeneration.  
Retinal degeneration leads to significant remodelling which can be classified into three different phases. 
A) Phase I is a pre-degeneration phase as indicated by early markers of cellular stress, but with no major 
changes to retinal morphology or function. B) In Phase II photoreceptors start to deteriorate, with glial and 
RPE cells becoming involved. C) Phase III is the ultimate phase where the retina undergoes major 
organisational alterations including neuritogenesis, cell migration, loss of distinct layer lamination, glial 
hypertrophy, metabolic changes of neurons and glia cells, synaptic rewiring and many more. 
Copyright note: Figures A-C were reprinted by permission from Elsevier: (Cuenca et al., 2014), Progress 
in Retinal and Eye Research. 
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1.6.1 Alterations of photoreceptor cells 
Pathological insult induces photoreceptor stress leading to a cascade of events that 
culminates in molecular changes and eventual photoreceptor apoptosis. Two 
symptoms of photoreceptor malfunction typically occur in stressed rod and cone cells; 
anomalous delocalisation of visual pigments and anomalous restructuring of 
photoreceptor axons by sprouting and/or retraction. The period preceding rod death is 
often associated with a progressive shortening of rod OS and slow changes in the 
distribution of the Rho pigment (Roof et al., 1994). In healthy retina, Rho is mainly 
found in the OS of rods with small traces in the IS. In animal models of RP (Fariss et 
al., 1997; Fernández-Sánchez et al., 2011; Martinez-Navarrete et al., 2011) or in RP 
human retina (Fariss et al., 2000) Rho was found to relocate to rod photoreceptor cell 
bodies, axon processes and axon terminals. These changes are accompanied by 
disorganisation in the OS disc membranes, as reported by Cueneca et al. (Cuenca et 
al., 2013). In retinal diseases where cones degenerate secondarily to rods, the lack of 
trophic factors secreted by rods is thought to be responsible for cone deterioration 
(Léveillard et al., 2004). In this disease scenario, cones start to degenerate similar to 
rod cells, with prominent changes in the cytosolic macromolecule expression, notably 
decreased levels of calbindin and arrestin (John et al., 2000). The morphological profile 
of cone cells also changes, with swelling and shortening of the OS and IS taking place 
(García-Ayuso and Ortín-Martínez, 2013; Cuenca et al., 2014)The retinal changes 
associated with photoreceptor stress are also visible at the rod and cone synaptic 
connectivity. Studies on rd1 mouse mutant (Fei, 2002) and human RP retina (H et al., 
1998; Fariss et al., 2000) showed that in regions where the photoreceptors have 
significantly degenerated, the remaining rod photoreceptors extend their neurites 
beyond the INL and towards the IPL. Gupta et al. also observed these axonal 
extensions into the INL in human ‘dry’ AMD retina (Gupta et al., 2003). Interestingly, 
this pathological elongation of cone neurites was reported to be absent from the 
macula, at least in retinae suffering from LCA (reviewed in (Vugler, 2010)). As retinal 
degeneration progresses and the number of photoreceptor cells drastically falls, the 
ONL becomes noticeably thinner (Hippert et al., 2015). As a consequence, synaptic 
connections become lost and a range of rewiring events in the inner retina starts to 
take place (Sullivan et al., 2007). 
1.6.2 Remodelling of the inner retina and re-wiring of the neuronal 
networks 
Following the death of photoreceptor cells and loss of synaptic contacts with rod and 
cone terminals, the bipolar cells start to retract their unused dendrites from the OPL, 
which leads to remodelling of the synaptic connectivity (Cuenca et al., 2005). With the 
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old synapses disappearing, the functional bipolar cells begin to seek for new input 
contacts with remaining photoreceptor cells indicating that there is some degree of 
synaptic plasticity in the adult retina (Strettoi et al., 2003; Barhoum et al., 2008; 
Martinez-Navarrete et al., 2011). Surprisingly, this bipolar remodelling is not a 
characteristic common to all retinal degenerations. In the study on the Royal College of 
Surgeons (RCS) rat model of RP, no new sprouting of the bipolar dendritic processes 
was observed (Cuenca et al., 2004).  
Alterations in the efferent terminals and morphological changes of the amacrine cells 
also accompany retinal remodelling in disease conditions. In the rd1 mouse mutant, the 
synaptic ribbons, the protein structures surrounded by synaptic vesicles (Dowling and 
Boycott, 1966; Kolb et al., 2001), of the bipolar postsynaptic terminals manifested an 
abnormal shape similar to that observed in the immature retina (Strettoi et al., 2002). 
As degeneration progresses, changes to amacrine cell synaptic connections also 
become more apparent, with some reports showing neuronal sprouting and alterations 
in the signal propagations towards the GCL (Jones et al., 2012). In the animal model of 
DR, the loss of dopaminergic and cholinergic amacrine cells has been observed which 
lead to significant deficits in vision (Gastinger et al., 2006).   
1.6.3 Müller glia reactivity and development of the glial scar 
In the retina, Müller glia are the first indicators of any alterations to the retinal 
environment and almost any pathological insult causes their activation. As these glial 
cells span the entire thickness of the retina, they interact with all retinal cell types 
across all the layers. The number of physiological functions that Müller glia perform is 
countless and ranges from the maintenance of structural integrity of the retina to being 
the light-guiding fibres (reviewed in Bringmann 2006). In a healthy retina, these cells 
are key modulators of neurotransmitter levels preventing toxic accumulation of glycine, 
GABA and glutamate in the retina. Alterations in functioning of the neurotransmitter 
transporters have been found in many different retinopathies including retinal ischemia, 
diabetes and glaucoma (Naskar et al., 2000; Barnett et al., 2001; Holcombe et al., 
2008). Following insult to the retina, these cells undergo activation and change of their 
function including a reduction of the glutamate transport, which results in the rise of 
extracellular glutamate to excitotoxic levels and consequent damage to the retinal 
neurons (Barnett and Pow, 2000). The composition of cytoskeleton of Müller glia also 
changes including the increase in the density of the IFs (Lu et al., 2011) that is 
accompanied by the hypertrophy of the glial processes throughout the retina and 
development of so–call glial scar (Lewis et al., 1989; Lewis and Fisher, 2003). 
Although, the precise role of gliosis is still to be determined, the extend of it is strictly 
driven by the size and nature of the neuronal damage, influencing how much cell 
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replacement is actually needed to fill up the injured space (Ridet et al., 1997; 
Wilhelmsson, 2008). 
1.6.3.1 Upregulation of the intermediate filament proteins and glial hypertrophy 
Glial scar is considered to be a hallmark of any CNS damage (Ridet et al., 1997; 
McGraw et al., 2001; Beattie et al., 2002; Myer et al., 2006). This scar is mainly formed 
by reactive glial cells that migrate to the site of the injury, where they start to proliferate 
and increase the complexity of their processes (Panickar and Norenberg, 2005; Pekny 
and Nilsson, 2005). The final outcome is a tightly packed, hyperfilamentous astrocytic 
tissue with limited extracellular space that is filled with glial processes high in IFs 
levels. This glial scar has been reported to have a negative impact not only on the 
spontaneous neuronal regeneration, but also on the therapeutic interventions including 
gene therapy (Grüter et al., 2005), cell replacement therapies (reviewed in (Pearson et 
al., 2014; Hippert et al., 2016) and the ability of implanted retinal grafts to contact the 
underlying retina (reviewed in (Zhang et al., 2004)). 
Under normal conditions, Müller glial cells in a mouse retina maintain high levels of 
filamentous Vimentin (Kivelä et al., 1986). GFAP is less abundant in Müller cells and is 
usually restricted to inner end feet terminals and astrocytes (Dreher et al., 1992; Sarthy 
and Ripps, 2001; Lewis and Fisher, 2003). Following trauma to the retina such as 
retinal detachment, GFAP undergoes rapid upregulation in Müller glia (Guérin et al., 
1990; Fisher and Lewis, 2003). Increased levels of GFAP have also been found after 
the introduction of retinal ischemia (Kim et al., 1998), hypoxia (Kaur et al., 2007) or 
experimental glaucoma (Xue et al., 2006). Similar response and upregulation of IFs 
were reported in astrocytes that invade the lesion site elsewhere in CNS (Petito et al., 
1990; Schmidt-Kastner et al., 1990; Panickar and Norenberg, 2005). Several 
researchers claimed that this pronounced increase in IF proteins has several 
physiological and pathological functions in the modulation of the CNS damage. The 
Eng group (1998) was one of the first that created a transgenic mouse model that 
carried a full copy of a human GFAP gene. They have shown that GFAP 
overexpression prompted glial hypertrophy in the uninjured CNS which was also more 
severe and complex than that observed in normal wild-types (Eng et al., 1998). Studies 
on the knockout animals reported that following retinal detachment the absence of IFs 
results in fewer morphological alterations in the Müller cells with a marked decrease in 
the extend of reactive gliosis (Kinouchi et al., 2003; Lundkvist et al., 2004), suggesting 
that IFs play an important role in glial hypertrophy. 
In a healthy retina, Müller cells are much softer than any other retinal cell type (Lu et 
al., 2006). This biomechanical property of the glial cells allows the retina to adapt to 
physical forces, such as traumatic injury or raised intraocular pressure. Following 
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retinal degeneration, Müller cells undergo structural changes, which make them much 
stiffer (Lundkvist et al., 2004). This increase in stiffness is a major factor that 
contributes to viscoelastic properties of the glial cells and is coupled with a remodelling 
of the glial network associated with changes in the retinal architecture, such as folding 
and shrinkage (Lu et al., 2011). Although the exact purpose of this rigidness still 
remains unknown, it is believed that stiffer glial cells help to stabilise the delicate retinal 
architecture after loss of photoreceptor cells. Moreover, Lundkvist et al. suggested that 
more rigid Müller cells may modulate neovascularisation with new blood vessels 
growing towards the vitreous rather than within retinal tissue (Lundkvist et al., 2004). 
Interestingly, this increase in stiffness is thought to be associated with the upregulation 
of IF proteins such as Nestin, Vimentin and GFAP (Lu et al., 2011) that also contribute 
to glial associated hypertrophy and formation of a glial scar at the edges of the 
neuroretina (Figure 1.7) (Lewis and Fisher, 2000).  
1.6.3.2 Müller glia activation and neuronal regeneration 
For many years, researchers have debated the role of Müller glia in the diseased 
retina, with both cytoprotective and cytotoxic roles being proposed. For example, 
Pease at al. study showed that in the animal model of glaucoma, these glial cells are 
invaluable producers of neurotrophic factors such as ciliary neurotrophic factor (CNTF), 
which has been shown to have potent neuroprotective effects on neuronal cells (Pease 
et al., 2009). On the other hand, Müller glia have an intimate relationship with cells 
from the immune system (reviewed in (Cuenca et al., 2014)). Molecules from 
inflammatory cells, platelets, and plasma may activate Müller cells, and these cells may 
express a wide variety of inflammation- and immune-response-related factors and 
enzymes such as Tumor necrosis factor α (TNF-α), Interleukins (IL), interferon, and 
Intercellular Adhesion Molecule 1 (ICAM-1) (Bringmann et al., 2009a). Müller cells 
were found to be propagators of neuronal cell death through their interactions with 
microglia and the synthesis and secretion of TNF-α (Lebrun-Julien et al., 2009). Wang 
et al. demonstrated that the cytokinesis released by reactive Müller glia lead to 
activation of the resident immune cells and their migration within the retina (Wang et 
al., 2011). In the healthy retina, microglia are located almost exclusively in the inner 
retinal layers up to the OPL. However, under the injured or diseased circumstances, 
microglial cells become activated and start to migrate in a radial direction across retinal 
lamina. Wang et al. suggested that Müller glia ease the migration of activated microglia 
cells by providing an adhesive cellular scaffold that guides the movement of microglia 
across various retinal layers (Wang et al., 2011).  
In the studies on retinal detachment, the upregulation of IFs in Müller glia and the 
formation of a glial scar at the outer edge of the neuroretina was reported to impede 
tissue regeneration such as outgrowth of photoreceptor OS (Fisher and Lewis, 2003). It 
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has been demonstrated that a single Müller cell process lying between the reattached 
neuroretina and the RPE is sufficient to completely inhibit OS regeneration in that 
region (Anderson et al., 1986). Interestingly, there appears to be a special relationship 
between the formation of the glial scar and cone photoreceptors. Lewis and Fisher 
observed that if a Müller cell process grows beyond the OLM into the segment region 
that process inevitably occurs adjacent to a cone (Lewis and Fisher, 2000).  
Müller cells mediated gliosis was also implicated in the failure of therapeutic 
intervention including cell transplants. Young et al. reported that hippocampus-derived 
neuronal progenitors integrate poorly in the adult retina of dystrophic rats, in 
comparison with a neonatal or mature animals (Young, 2000). Additionally, it has been 
found that reactive gliosis exacerbated the progression of some retinopathies including 
those observed in diabetes (Amin et al., 1997). Studies with transgenic animals lacking 
both GFAP and Vimentin in Müller cells have found that these animals create a more 
permissive environment for the grafted cells as demonstrated by better integration and 
differentiation of transplanted cells as well as a higher neurite outgrowth than in wild-
type recipients (Kinouchi et al., 2003). Interestingly, when either GFAP or Vimentin 
alone was suppressed the migratory capacity of the transplanted cells was reduced 
(Kinouchi et al., 2003). The formation of glial scars was also implicated in the failure of 
visual recovery after subretinal implantation of microphotodiode arrays (Pardue et al., 
2001) indicating that the scar tissue acts as a barrier between the implant and retinal 
neurons. Further support for the negative role of the IF proteins comes from the studies 
with viral vectors. Calame et al. study reported that the lentiviral cell transduction was 
affected by the extent of the reactive gliosis, showing that retinal environment may 
modify the tropism of the viral vectors (Calame et al., 2011). Moreover, glial 
hypertrophy and extension of Müller cell processes are also believed to support the 
immunological response to injury (Wang et al., 2011). 
Although it is widely believed that the glial scar is a hindrance to retinal regeneration, 
some studies have shown a useful role of the glial scar during the acute phase of 
retinopathy. Glial hypertrophy is thought to help maintain the structural integrity of the 
retina by filling the space where photoreceptors die. Lee et al. found that glial 
processes of reactive Müller glia take part in the formation of “rings”, which contribute 
to the survival of remaining cone photoreceptors by releasing tropic factors (Lee et al., 
2011). Additionally, the IFs upregulation could potentially have a beneficial role for the 
therapeutic outcome such as cell transplantation. In regions with increased levels of 
GFAP, the number of survived transplanted stem cells was found to be significantly 
higher in comparison with control, undamaged retinae (Nishida et al., 2000). These 
findings have led to a hypothesis that changes in the properties of Müller glia 
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cytoskeleton after injury may play a beneficial role in the migration and integration of 
transplanted cells. 
1.6.4 Changes in the composition of the extracellular environment 
The ECM is a complex network of scaffolding molecules that plays an important role in 
cell signalling, migration and tissue structure. Following a pathological insult, the 
composition of this matrix adapts to retinal needs, which results in the expression of 
both growth-inhibitory and growth-stimulatory factors (Jones and Marc, 2005).  
Proteoglycans (PGs) are major components of the ECM in the CNS and consist of a 
protein core with one or more glycosaminoglycan (GAG) chains attached. GAGs are 
classified into four families: heparan sulphate (HS), chondroitin sulphate (CS), 
dermatan sulphate (DS) and keratan sulphate (KS). PGs are commonly classified 
according to their associated GAG chains (e.g. CSPGs) and also by the core protein 
properties. Neurocan, Versican, Brevican and Aggrecan, also called hyalectans, are 
the main PG core proteins found in the CNS.  
During development, proteoglycans contribute to guidance of neurons and axonal 
pathfinding. After maturation of the CNS, CSPGs become concentrated in the 
perineuronal nets where they help to maintain the CNS structural organization (Carulli 
et al., 2005; Tsang et al., 2009). It has been hypothesized that these CSPGs -enriched 
perineuronal nets may be responsible for the loss of synaptic plasticity of the neuronal 
cells (reviewed in (Fawcett, 2009)). Following the CNS injury, these proteins are 
markedly upregulated in the reactive astrocytes within the glial scar which makes them 
one of the major contributors to a formation of barrier for regenerating neurons 
(Bradbury et al., 2002; Faulkner, 2004; Silver and Miller, 2004). Numerous studies 
found that CSPGs inhibit growth of sprouting axons, restrict plasticity and cause growth 
cone collapse both in vitro and in vivo. It has been shown that CSPGs inhibit binding of 
adhesive matrix molecules, such as laminin, to their transmembrane receptors which 
results in a blockage of their normal growth promoting function (Muir et al., 1989; Zhou, 
2006). Therefore, it is believed that inhibition of CSPGs at the site of the insult could 
become an effective strategy for the CNS regeneration. 
In the eye, CSPGs predominate in the neural retina, while HSPGs are expressed 
throughout the basement membranes (Inatani and Tanihara, 2002). As CSPGs interact 
with many different ECM proteins and growth factors, it makes them key players in a 
range of cellular and signalling processes. For example, during eye development, both 
CSPGs and HSPGs help to guide navigating axons (Ichijo, 2004). During pathological 
condition, CSPGs deposition changes within the ECM, as the neuronal structures start 
to remodel (Friedlander et al., 1994; Gilbert et al., 2005; Crespo et al., 2007). Currently, 
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our understanding of PG function in the diseased retina is very limited. As described in 
Chapter 3, a recently conducted extensive assessment of different models of retinal 
degenerations showed disease specific changes in the CSPGs expression (Hippert et 
al., 2015), which had previously been reported to correlate with good or poor outcomes 
following photoreceptor transplantation (Barber et al., 2013). Clinically, PGs have been 
implicated in the pathological deposits associated with AMD due to less efficient 
binding of the disease associated 402H variant of complement factor H to sulphated 
PGs in Bruch’s membrane (Clark et al., 2010a; 2010b). In animal study, Chen et al. 
reported a marked increase in the levels of Aggrecan in the IPM in two rat models of 
retinal dystrophy (Chen et al., 2012a). In a recent study by the Cepko’s lab, microarray 
analysis of individual Müller glial cells revealed CSPG5 (Neuroglycan) to be 
significantly upregulated in a mouse model of RP in comparison to wild-type controls 
(Roesch et al., 2012). Alterations in Neurocan expression have also been found to be 
associated with pathological insult to the retina (Inatani et al., 2000) and animal models 
of RP (Tucker et al., 2011). This increase in the CSPGs deposition may have 
detrimental impact on the elongation of neuronal processes, as demonstrated by 
Inatani et al. where the outgrowth of rat RGCs was inhibited on Neurocan-coated 
plates (Inatani et al., 2001). Moreover, they found that this inhibition persists even after 
removal of CS sugar chains from the core protein suggesting that the Neurocan protein 
itself is inhibitory. In a study by Li et al. β1-integrin mediated adhesion was impeded in 
the presence of Neurocan, which may stop the neurite outgrowth from retinal neuronal 
cells (Li et al., 2000). In studies of cell-based therapies, it has been reported that the 
upregulation of CSPGs in the diseased retina prevents the migration and integration of 
transplanted donor cells (Suzuki et al., 2007; Singhal et al., 2008; West et al., 2009; Ma 
et al., 2011; Barber et al., 2013). Moreover, therapeutic approaches such as cell 
transplants may also be impaired by the presence of specific CSPGs, as the increase 
of these molecules in the subretinal space may act as an inhibitory cue for the 
migration of the transplanted rod precursor cells towards the ONL ( Barber et al., 
2013). Indeed, treatment with chondroitinase ABC (ChABC) enzyme, which digests 
sugar chains from the core protein, increased the number of integrated cells in the 
mouse model of RP following transplantation of Nrl rod precursor cells (Barber et al., 
2013).  
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Figure 1.7 Gliosis in a retinal degeneration.  
Retinal degeneration leads to significant changes in the retinal environment including development of 
gliosis. The retinal gliosis is associated with an increase in intermediate filament proteins, proliferation of 
Müller glia and hypertrophy of their processes, and upregulation of inhibitory ECM molecules such as 
CSPGs.  
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1.6.5 Remodelling of the outer limiting membrane  
The OLM acts as a semipermeable diffusion barrier for extracellular components (Bunt-
Milam et al., 1985). This could be of particular importance in diseased conditions as 
loss of photoreceptors leads to extend remodelling of the retinal structure including the 
OLM (Chen and Ma, 2007; Daniele et al., 2007; Stuck et al., 2012; Hippert et al., 
2015). Hippert et al. reported that the OLM, which comprises of a number of adherens 
junctions, seems to be compromised in many models of retinal degenerations (Hippert 
et al., 2015). The Nrl-/- mouse mutant that shows an extensive disruptions to the OLM 
continuity, manifests aberrant photoreceptor packing, abnormal association between 
photoreceptors and RPE, retinal detachment, changed dendritic fields, vascular 
leakage, and ganglion cell death (Mears et al., 2001; DeAngelis et al., 2002). Loss of 
CRB1 protein was reported to lead to displaced photoreceptors and focal degeneration 
of all neural layers (Mehalow et al., 2003; van de Pavert et al., 2004). In humans, 
mutations in CRB1 gene have been associated with a variety of autosomal recessive 
retinal dystrophies, including LCA, RP type 12, RP with Coats-like exudative 
vasculopathy and other early-onset forms of RP (Bujakowska et al., 2011; Pellissier et 
al., 2014; Zhao et al., 2015). Recently, mutations in CRB1 were also linked to 
development of the vascular leakage similar to that observed in MacTel2 patients 
(Zhao et al., 2015).  
It is tempting to speculate that the disruption of the OLM could exacerbate the spread 
of retinal degeneration, as OLM integrity is critical for cell survival. The OLM has also 
been shown to act as a modulator of the size of the apical villi of Müller cells. lt is also 
possible that loss of the OLM proteins results in a decrease in the strength of the 
adherens junctions and subsequent susceptibility to retinal detachment. Although the 
retina makes some successful attempts to restore the lost connections by forming new 
junctions between the remaining cells (Hippert et al., 2015), these junctions may not 
have the same properties as the ones in a normal retina as there are differences in the 
expression of the junctional proteins between different cell types. Omri et al. reported 
that in a rat animal model of diabetic retinopathy in which the number of S-cone 
photoreceptors decreases, the expression of Occludin and aPKC was found to be 
downregulated (Omri et al., 2013). Recently, the importance of the OLM continuity has 
been implicated in the clinics. Mitamura et al. reported that patients with a continuous 
OLM have a better visual acuity than those in which OLM is disrupted making them 
more prone to increased vascular leakage upon mechanical stress (Mitamura et al., 
2013). Thus, the OLM appears to be an important element of retinal health and 
additional studies on OLM remodelling in degenerative disease could provide some 
invaluable insights on the pathological environment before therapeutic interventions.  
62"
1.6.6 Additional changes to the degenerative retina  
Due to their function, photoreceptors are constantly exposed to light photons and they 
are the primary consumers of oxygen in the CNS. These two factors put rod and cone 
cells at a high risk of the damage due to reactive oxygen species (ROS) (Stone et al., 
2008; Fernández-Sánchez et al., 2011). For example, the oxidative stress in the RPE 
leads to development of photoreceptor degeneration associated with AMD condition 
(Ardeljan and Chan, 2013). In the DR, high levels of glucose increase the metabolic 
rate of photoreceptors and as a consequence production of ROS (Du et al., 2003; 
Kowluru and Kanwar, 2007). El-Bab et al. demonstrated that the expression of several 
antioxidants in the DR retina is significantly reduced in comparison to healthy retina, 
resulting in even higher accumulation of ROS (El-Bab et al., 2013). As ganglion cells 
are highly susceptible to any changes in the concentration of ROS, this increase could 
induce ganglion cell apoptotic death in this pathological condition (Chrysostomou et al., 
2013; Himori et al., 2013).  
One of the hallmarks of retinal degeneration is the alteration in retinal protein 
expression. Studies on human post-mortem eyes, showed that AMD leads to region-
specific changes in retinal protein levels with the majority of observed changes being 
restricted to macula and the periphery (Ethen et al., 2006). Recent research findings 
showed that following the pathological insult several cell cycle components in 
photoreceptors become reactivated. For example, in a dog model of early retinal 
degeneration caused by a mutation in STK38L gene encoding the cell cycle regulator, 
Berta et al. reported photoreceptors starting to express markers of the cell cycle (Berta 
et al., 2011). Immunohistochemistry of the canine retina showed PCNA and phosphor-
PH-3 positive cells in the ONL, which was further confirmed by the RT-PCR analysis. 
Further studies of rodent models of RP, demonstrated that the levels of cyclin 
dependant kinases (CDK) are 4-5 times higher during neuronal apoptosis in 
comparison to healthy retina, indicating at Bmi1 as a key regulator of cell cycle proteins 
(Zencak et al., 2013).  
 
1.7 Current therapeutic strategies 
Advances in gene discovery and stem cell research have presented new opportunities 
for potential therapeutic interventions for many diseased conditions. The eye 
represents an ideal organ for testing the safety and efficiency of any of these novel 
treatments due to its accessibility, relative immune privilege, small size, 
compartmentalization, and the existence of a contralateral control (Figure 1.8). Here, a 
summary of some of the current therapeutic approaches to treat retinal degeneration 
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will be presented, with a particular focus on the treatments that are already in clinical 
trials or show the most promising potential for clinical application in the near future.  
1.7.1 Drug therapy  
Potential molecular targets for drug therapy are being identified for different retinal 
disorders. One of the main therapeutic strategies used to treat retinal degeneration 
associated with neovascularisation including DR and ‘wet’ form of AMD is anti-VEGF 
treatment. Vascular endothelial growth factor (VEGF) is a proangiogenic factor, which 
stimulates growth of (leaky) blood vessels in the eye leading to so-called vascular 
leakage (Adamis et al., 1995; Kvanta et al., 1996). Anti-VEGF drugs injected into the 
eye of a patient block VEGF protein, which in many cases leads to a very significant 
reduction in the formation of new blood vessels and can even reverse retinal damage 
such as edema, with many patients seeing an improvement in visual acuity (reviewed 
in (Ferrara and Adamis, 2016)). Unfortunately, despite its efficacy, targeting VEGF in 
the eye has presented several challenges, including the optimal route of administration, 
and the ocular and systemic safety of the anti-VEGF treatment, as patients require 
repeated intravitreal injections. VEGF mediates many signalling pathways and the 
retina needs it for normal functioning (Saint-Geniez et al., 2008; 2009); therefore 
blocking it completely may lead to secondary pathological events. Recent preclinical 
studies in mice have pointed towards a promising alternative to current anti-VEGF 
treatment. Westenskow et al. reported that inhibition of a specific signalling pathway, 
the Ras GTPase, which functions downstream of VEGF, by delivery of a chemically 
engineered oligonucleotide α-miR-132, can successfully prevent angiogenic sprouting 
(Westenskow et al., 2013). Importantly, however, approximately 40% of patients do not 
respond to VEGF treatment, suggesting that the pathological mechanisms responsible 
for neovascularisation may differ between different clinical presentations of AMD 
(Brown et al., 2006; Simó and Hernández, 2015; Usuelli and La Rocca, 2015; Holz et 
al., 2016). 
1.7.2 Gene therapy 
There are more than 250 gene mutations associated with retinal disorders and gene 
replacement represents an obvious therapeutic approach. The majority of inherited 
retinal diseases are caused by mutations in genes that affect photoreceptor function. 
Although there is currently no cure for RP, well-characterised animal models and a 
developed understanding of the genetic basis of the disease allow gene therapy to be 
a potentially viable therapeutic strategy. The first report of successful gene 
supplementation via the viral vectors was reported in 2000 by Ali et al., who 
demonstrated rescue of photoreceptor structure and function in the Prphrd2/rd2 mouse 
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(Ali et al., 2000). They showed that the injection of adeno-associated virus serotype 2 
(AAV2) vector carrying the Prph2 gene under the control of the Rho promoter targets 
rod cells, leading to expression of Prph2, increase in photoreceptor survival and rescue 
of function. However, greater improvements were seen when vector was delivered in 
early stages of retinal degeneration (Ali et al., 2000), than when injected in older mice 
(Sarra et al., 2001). These results illustrate a limitation of the gene supplementation 
approach, as it relies on sufficient numbers of endogenous cells being present at the 
time of treatment. This can be difficult since diagnosis is often not made until the 
patient has lost a significant proportion of their photoreceptors.   
Gene supplementation/augmentation therapy was also tested to treat murine and 
canine models of achromatopsia. Alexander et al. used an AAV5 vector to deliver a 
wild-type version of Gnat2 gene under the human M-opsin promoter into the retina of 
Gnat2cpfl3 mutant (Alexander et al., 2007). In 2010, a naturally occurring mutation in 
CNGA3 gene was discovered in improved Awassi sheep (Reicher et al., 2010), 
providing an excellent large animal model for studying the human phenotype. Later 
Banin et al. used this model to test the efficacy of AAV5 vector carrying either the 
mouse or the human wild-type version of CNGA3 gene under the control of the 
red/green opsin promoter (Banin et al., 2015). They reported a robust expression of 
CNGA3 gene and significant improvements in the visual function in the treated 
CNGA3-mutant sheep in comparison to untreated animals. 
The first gene to be targeted clinically was the RPE65 gene mutations, which are 
associated with LCA. As mentioned previously, the enzyme encoded by RPE65 is 
crucial for converting all-trans retinoid to 11-cis retinal during visual pigment 
regeneration (Moiseyev et al., 2005) and without a functioning enzyme, the 
photoreceptors gradually deteriorate. The researchers hoped to halt this process by 
using a virus to shuttle a functional RPE65 gene into the eye. First results published in 
2001 described a successful attempt to use a recombinant (r)AAV2 to treat naturally 
occurring Rpe65-/- mutant in Briard dogs (Acland et al., 2001). Acland et al. reported 
that treatment with AAV2 vector carrying a wild-type canine Rpe65 gene, under the 
control of the hybrid cytomegalovirus/chicken β-actin (CBA) promoter, led to substantial 
improvements in visual function. Further studies on a naturally occurring murine model 
of Rpe65 LCA, the rd12 mouse (Pang et al., 2005), confirmed the potential and 
efficiency of AAV use in treatment of LCA (Pang et al., 2006), which allowed for the 
first studies on human patients (Bainbridge et al., 2008; Maguire et al., 2008; Testa et 
al., 2013). Currently, there are a number of clinical trials, in different countries and at 
different phases, related to correcting the RPE65 mutation. These differ in surgical 
protocols, DNA promoter types, vector preparation and volumes or patient 
characteristics. A phase I safety profile trial of rAAV2 carrying human (h) RPE65 is 
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currently underway in the United States with five cohorts of LCA patients which aims to 
test the safety of uniocular subretinal administration of rAAV2-CBSB-hRPE65 vector 
(Clinicaltrials. gov Identifier NCT00481546). The most advanced clinical trial focused 
on the retinal diseases was recently completed in the United States. In October 2015, 
Spark Therapeutics published the phase III results of the SPK-RPE65 gene 
replacement therapy showing that patients who received a viral treatment navigated 
significantly better in different lighting conditions than individuals from the untreated 
group (http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2093863. 
Accessed February 20, 2016). This is the first to date gene therapy study conducted in 
humans that has reported a therapeutic benefit to patients.  
As previously mentioned, formation of new blood vessels is mainly controlled via 
angiogenic factor VEGF, which can be clinically treated with the anti-VEGF agents. 
Numerous reports showed that ocular neovascularization can be inhibited after 
subretinal injection of AAV2 vector carrying the sequence for the expression of a 
soluble portion of the R1 VEGF receptor, sFlt1 (Lai et al., 2005; 2011). SFlt1 normally 
binds extracellular VEGF protein, which prevents it from binding to its cell surface 
vascular endothelial receptors FLT-1 and FLK. These data indicate that subretinal 
injection of AAV2.sFlt-1 vector can be a promising therapeutic strategy for the long-
term treatment of neovascular diseases of the eye.  
There is no doubt that gene therapy offers an attractive approach for treatment of a 
number of inherited retinal diseases. The evolution of gene editing technologies, such 
as the CRISPR/Cas9 system, will certainly allow for targeting a wider spectrum of 
retinopathies. However, one of the main issues with the use of gene therapy is a lack 
of genetic diagnosis in patients suffering from inherited vision loss, which is crucial in 
designing treatments based on use of the viral vectors. 
1.7.3 Cell-based replacement therapy 
An important feature in both animal models of many retinal diseases is the death of rod 
and cone cells. Interestingly, despite this progressive photoreceptor degeneration 
much of the inner retinal neuronal architecture, including the visual pathways and GCL 
remain largely intact (Mazzoni et al., 2008; Damiani et al., 2012). As mentioned 
previously, gene therapy relies on there being sufficient numbers of endogenous 
photoreceptor cells present at the time of treatment; restoring vision in cases of severe 
and/or very rapid degeneration, therefore, may only be possible by either replacing the 
missing sensory cells, or by providing visual information to the remaining neurons of 
the retina. In recent years, considerable progress has been made concerning the 
prospects for cell transplantation as a potential treatment for retinal degenerations. 
Considerable effort has been made in order to find the best method to replace lost 
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photoreceptor and RPE cells, including transplantation of whole retinal sheets, 
microaggregates of foetal neural retina and suspensions of stem cells and progenitor 
cells (reviewed in (da Cruz et al., 2007; Pearson, 2014; Pearson et al., 2014)). While 
there have been some reports of success in preserving visual function using these 
strategies (Radtke et al., 1999; 2008), there is still only limited evidence to suggest that 
these transplants can both integrate within and make functional connections to the host 
tissue (Gouras et al., 1994; Gouras and Tanabe, 2003; Seiler and Aramant, 2012).  
In recent years, a number of different research groups have examined the 
transplantation potential of progenitor cells derived from immature retinae, which can 
differentiate into retinal neurons (Yang et al., 2002; Qiu et al., 2005; MacLaren et al., 
2006). Sakaguchi, Young et al. demonstrated that transplantation was more effective 
when transplanting cells into immature recipients. They showed that cultured murine 
neural progenitor cells transplanted into the eyes of neonatal Brazilian Opossums, 
successfully migrated into the recipient retina following cell transplant, but instead of 
integrating within the ONL, transplanted cells were only found within the inner retina 
(Sakaguchi et al., 2004; 2005). Later studies showed that rod cell transplants into the 
adult mouse retina are achievable, but they rely on donor cells being isolated from a 
particular stage in their development, when rod photoreceptors are immature (Kwan et 
al., 1999; MacLaren et al., 2006; Bartsch et al., 2008; Pearson et al., 2012). Kwan et al. 
reported that retinal progenitor cells isolated from postnatal day 7 - 9 animals and 
transplanted subretinally into adult rd1 mice were not only able to survive within the 
recipient retina but were also capable to extend their processes towards the outer 
nuclear layer (Kwan et al., 1999). In 2006, Ali and colleagues, used Nrl marked 
postmitotic rod cells (Akimoto et al., 2006; Eiraku et al., 2011) to transplant them into 
the adult retina (MacLaren et al., 2006). Their study showed that subretinal 
transplantation of post-mitotic receptor precursor cells led to the presence of reporter-
labelled cells within the host retina that bore all the hallmarks of mature 
photoreceptors. Further research with the use of photoreceptor precursor cells 
confirmed these results (Bartsch et al., 2008; Lakowski et al., 2010; Eberle et al., 2012; 
Barber et al., 2013) and even showed that these cells were capable of responding to 
light stimulus when transplanted into a mouse model of stationary night blindness 
(Pearson et al., 2012). Although these results provide a proof of concept for cell 
replacement, a better source of donor cells for human application is needed. Advances 
in recent years in the use of embryonic stem cells (ESCs) and induced pluripotential 
stem cells (iPSCs) provide a promising stem cell source for the use in human trials. 
The ground-breaking 3D culture systems developed by Sasai and colleagues enabled 
to generate from ES cells the isolated optic cups with a continuous epithelial structures 
showing clear laminar stratification similar to the early postnatal retina (Eiraku et al., 
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2011; Eiraku and Sasai, 2012). Further studies used this 3D system to develop rod 
precursor cells for cell transplantation that morphologically resembled normal 
photoreceptor cells of a mouse retina (Gonzalez-Cordero et al., 2013). With the 
development of methods to produce laminated retinal structures in vitro, an attempt to 
develop and transplant whole retinal sheets has been made by Takahashi’s group. 
Their study showed that transplanted retinal sheets into the subretinal space of 6-8-
week-old rd1 mice can integrate and differentiate into laminated, mature retinal 
structure (Assawachananont et al., 2014). A variety of retinal differentiation protocols 
for mouse and human iPSCs has also been described (reviewed in (Jayakody et al., 
2015)) and, after less than a decade from the first developed iPSCs protocol (Hirami et 
al., 2009) and further improvements of cell differentiation, the first transplants with 
human iPSCs are already on the way (Zhong et al., 2014). Moreover, patient-specific 
iPSCs are being developed for autologous cell transplantation and as a tool for 
modelling specific retinal diseases, testing gene therapies, and drug screening. 
Because normal RPE physiology needs a polarized monolayer of tight junctions, post-
cell suspension transplantation of the monolayer formation is the most important part 
for successful transplantation. Current research uses biodegradable substrates as 
retinal scaffolds to growth a polarized monolayered RPE (Lu et al., 2001; Kamao et al., 
2014; Yao et al., 2015). After the monolayer is formed, the scaffold can be dissolved 
and the whole sheets can be used in RPE cell transplants. The first trials of hES-
derived RPE cell transplants into patients with Stargardt disease are underway in the 
US and the UK (Schwartz et al., 2012). If shown to be safe, such studies set the stage 
for future clinical trials of ES-derived donor cells.  
Studies of developing and injured retinae have shown that there are cells within the 
adult retina that possess neurogenic potential; thus opening new avenues for 
regenerative medicine. The retinal stem cell niche in the peripheral region, the ciliary 
marginal zone (CMZ) (Perron and Harris, 2000), has been extensively studied 
regarding its proliferation properties and signalling pathways (Johns, 1977; Wehman et 
al., 2005; Agathocleous and Harris, 2009); however, it was not until 2011 when the 
evidence for genuine stem cells in the CMZ was reported (Centanin et al., 2011). By 
using a chimeric approach with Wimbledon, a permanent and ubiquitously EGFP-
expressing fish, Centanin et al. demonstrated that postembryonic cells in the CMZ are 
multipotent and can generate all cell types of the differentiated neural retina including 
neurons and glia. The other endogenous retinal cells with proliferating properties found 
in fish are the Müller glia, which are distributed all along the differentiated retina and 
were shown to be capable of generating different retinal cell types upon pathological 
insult (Johns and Fernald, 1981; Bernardos et al., 2007; Fimbel et al., 2007; 
Ramachandran et al., 2010). In the mammalian retina, the progenitor-like profile of 
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Müller glia was also described with Müller glia cells showing a significant transcriptome 
overlap with retinal progenitor cells (Blackshaw et al., 2004; Roesch et al., 2008; 2012). 
Since then, the identification of factors that could be used to recruit Müller cells and 
stimulate their regenerative potential is a subject of intense research. In 2004, Ooto et 
al. reported that in response to NMDA-induced excitotoxic retinal damage, Müller glia 
cells re-enter the cell cycle, de-differentiate and generate new bipolar and rod 
photoreceptor cells (Ooto et al., 2004). Further evidence coming from the in vitro 
studies revealed that rodent and human Müller cells are capable of producing both glial 
cells and neurons (Das et al., 2006; Lawrence et al., 2007; Zhao et al., 2014). In the 
study by Giannalli et al., human Müller glial cells were found to differentiate toward 
rods four to six times faster than normal stem cells in vitro (Giannelli et al., 2011). 
Interestingly, when transplanted into a rat retina that lacks photoreceptor or ganglion 
cells, these Müller cell-derived neurons are able to migrate and integrate into the 
appropriate retinal layer (Singhal et al., 2012; Jayaram et al., 2014). These studies 
provide evidence that Müller cells could be a source of retinal neuronal cells within the 
adult mammalian retina used for treatment of retinopathies.  
Until very recently, the primary method to treat cataract was an extraction of the 
damaged lens and replace it with an artificial intraocular lens 
(http://www.nhs.uk/Conditions/Cataract-surgery/Pages/Introduction.aspx). Two recent 
studies, published in 2016, demonstrated that there is an alternative to cataract surgery 
using the novel stem cells approach. Lin et al. study showed that in rabbits and 
macaques, as well as in human infants with cataracts, it is possible to remove the 
damaged parts of the lens without damaging the endogenous pool of lens epithelial 
stem cells, in order to promote lens regeneration (Lin et al., 2016). In the second study, 
Nishida’s lab developed a protocol for in vitro generation of a self-formed ectodermal 
autonomous multi-zone (SEAM) from human iPS cells (Hayashi et al., 2016). The 
generated SEAM included distinct cell lineages from the ocular surface ectoderm, lens, 
neuroretina, and RPE and were shown to form a functional corneal epithelium when 
transplanted to a rabbit model of blindness. These reports further underlie the 
enormous potential of the stem cells for tissue regeneration and treatment of many 
pathological eye conditions. 
1.7.4 Retinal prosthesis  
Advances in microelectromechanical systems and computer science have allowed 
researchers to explore new avenues for future treatment options for the patients with a 
severe vision loss. Retinal prostheses have been designed to restore rudimentary form 
vision to patients with RP by replacing the function of lost photoreceptor cells through 
the stimulation of a relatively preserved inner neurosensory retina. The pioneer in this 
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field was a German Neurosurgeon, Otfrid Foerster, who demonstrated that electrical 
stimulation of the visual cortex in humans could lead to the perception of light spot 
(phosphene). Years of research led to the development of so-called bionic eyes, a 
small retinal implant that can be implanted within the human eye with an external 
device attached to the human body (reviewed in (Iezzi, 2016)). This bionic eye mimics 
the original functioning of the human eye by receiving a radio signal, which is then 
transferred to the brain via the optic nerve. Findings from the first studies in patients 
showed that following the implantation of a bionic eye, some individuals regain their 
ability to decipher outlines of objects and people improving patient’s social interactions 
(Ho et al., 2015).  
As discussed in this chapter, any of the presented retinopathies leads to different 
remodelling events within the retina, which involve a variety of cellular and signalling 
cascades. Therapeutic approaches are available, but none of them is sufficient to stop 
and/or reverse the detrimental effects of the disease. Based on the recent findings it 
seems reasonable to suggest that at least in advance stages of retinal degeneration a 
combined treatment strategy, which first aims at stopping the disease progression and 
then repairs the damaged tissue will be able to help patients to regain their lost sense 
of vision. 
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Figure 1.8 Ocular therapies for retinal disease: From drug delivery to retinal implants. 
A) The accessibility of the eye and retina allows for delivery of appropriate drugs (e.g. neurotropic factors), 
gene therapy vectors (viral vectors used for specific gene replacement in recessive disease) and even 
cells using intravitreal or subretinal injections/ transplantation. B) In vivo images of the transplanted cells 
(green) in rd1 mouse eye. C) Delivery of gene therapy vectors into photoreceptors or RPE cells can lead 
to widespread viral expression in order to facilitate rescue of function and phenotype. D) Components of 
the bionic eye, as designed in the Argus II system.  
Copyright note: Figure A was taken from (Veleri et al., 2015). Image B was reprinted by permission from 
Nature Publishing Group: (Pearson et al., 2012), Nature. Image C was reprinted by permission from 
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Nature Publishing Group: (Nishiguchi et al., 2015), Nature Communications. Figure D was taken from 
http://www.secondsight.com/. Accessed online 20.05.2016.  
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1.8 Experimental aims 
As described above, different genetic defects can lead to profound structural and 
environmental remodelling, which can manifest as a unique degenerative phenotype. 
In turn, these changes may have positive or negative influences on the outcome of 
therapeutic strategies such as cell transplantation and implant devices. In 2013, Barber 
et al. performed rod - photoreceptor transplantation in different murine models of slow, 
moderate and fast photoreceptor degeneration (Barber et al., 2013). Their study 
showed that photoreceptor precursor transplantation is feasible in all examined 
animals; however, disease type has a significant impact on both the number of 
reporter-labelled cells and their morphology. Although gliosis is characteristic of many 
retinal disease models (Ekström et al., 1988; Sheedlo et al., 1995; Fan et al., 1996), no 
characterization and/or direct comparison between different RP models has been 
made. Given the apparent complexities of the gliotic process, more precise dissections 
of the links between glial reactivity and progressive neurodegeneration are needed. 
Moreover, understanding the processes behind glial scar formation and changes to 
retinal environment may help us to develop more effective strategies to treat a wide 
range of retinal dystrophies. This represents a major challenge to the advancement of 
the ocular therapies. This thesis addresses two main questions: 
1) Is the process of retinal remodelling and development of gliosis equivalent 
across different forms of retinal degeneration?  
Studying changes within the recipient microenvironment, especially how the gliotic 
process differs in different types of retinal degeneration, will help us to understand 
where, when and how much gliosis is present in a diseased retina at different times in 
the degenerative process and influence the timing of therapeutic intervention.  
- A comprehensive assessment of the expression of IFs and ECM molecules, 
particularly the CSPGs, was performed in different animal models at early, mid 
and late time points and the retinae were examined in different regions to 
account for any local changes within the recipient environment.  
- The examination of the OLM adherens junctions was performed in order to 
assess the extent of the retinal remodelling and any alterations to retinal 
integrity and permeability under pathological circumstances.  
 
2) How can the glial scar be manipulated using molecular tools in models of 
retinal degeneration to improve therapeutic outcomes?  
The second part of this thesis focused on developing molecular tools that aimed to 
manipulate or remove some of the potentially inhibitory aspects of retinal remodelling.  
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- The role of IF proteins in the development of glial scar was studied by suppressing 
GFAP and Vimentin expression in a model of chronic retinal degeneration. 
-  The CSPGs represent a large family of proteins and understanding the changes in 
their expression may be crucial in designing effective therapeutic strategies. In this 
study, for the first time, the spatio-temporal expression of the CSPG, Aggrecan, and 
the CSPG receptor LAR were assessed to determine their role in the diseased retina. 
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2.1 Animals 
Male and female C57BI/6J (Harlan, UK), Crb1rd8/rd8 (Mehalow et al., 2003), Prph2+/Δ307 
(McNally et al., 2002), PDEβ6rd1/rd1 (Danciger et al., 1995), Rho-/- (Humphries et al., 
1997), Rlbp.GFP+/+ (Vázquez-Chona et al., 2009), Prph2rd2/rd2 (Kedzierski et al., 1997), 
R91W;Nrl-/- (Samardzija et al., 2014), Nrl-/- (Mears et al., 2001) and Nrl.GFP+/+ mice 
(Akimoto et al., 2006) were used in this project. All mice were maintained in the animal 
facility at University College London (UCL). All animal procedures have been 
performed under the Policies on the Use of Animals and Humans in Neuroscience 
Research (UK Home Office regulations, Scientific Procedure, Act of 1986). Mice were 
maintained under standard 12/12 hour light-dark cycle. Eyes were collected for each 
animal model at different ages specified in each relevant section. C57BI/6J mice were 
used as wild-type controls.  
2.2 Cell dissociation, FAC sorting and cell cultures 
2.2.1 Müller glial cell cultures 
Primary Müller glial cell cultures were established using an adapted version of 
previously published protocols (Sarthy, 1985; Hicks and Courtois, 1990; Kljavin and 
Reh, 1991). Retinae from postnatal (P) day 7-8 mice Rlbp.GFP+/+ mice (GFP 
expressed in Müller cells under the control of the RLBP promoter) were dissected in 
Earle's Balanced Salt Solution (EBSS) (Sigma Aldrich, UK) + Antibiotic-Antimycotic 
(AA) (ThermoFisher Scientific, UK) and cells were dissociated using a papain-based 
dissociation kit (Worthington Biochemical, Lorne Laboratories, UK). All the reagents 
were made up according to manufacturer’s instructions. Papain with 0.005% DNase, 
ovomucoid inhibitor albumin (OMI), DNase and sterile EBSS were preincubated at 
37oC. Dissected retinae were added to papain solution (7-8 retinae per 0.5 mL of 
papain) and incubated for 30 min at 37oC in a humidified 5% CO2 incubator. After 
incubation, dissociated retinae were passed through a cell strainer mesh (70 µm) (BD 
Biosciences, UK), washed with 200 µL of EBSS and spun down for 5 min at 200g. The 
supernatant was removed and cells were resuspended in 200 µL of papain inhibitor 
solution (900 µL EBSS with 5% DNase and 10% OMI) and incubated for 10 min in the 
incubator. After 10 min, cells were layered on the top of 500 µL of OMI in clean 1.5 mL 
eppendorf tube and spun down for 5 min at 100 G. The supernatant was then removed 
and 200 µL of resuspension solution (900 µL EBSS with 5% DNase) was added to 
cells. Live cells were counted using a haemocytometer before the fluorescence-
activated cell sorting (FACS). For FACS procedure, cells were resuspended in 2 mL of 
EBSS medium with 1% Foetal Calf Serum (FCS), kept on ice and either taken to the 
Institute of Child Health or Institute of Ophthalmology (UCL) (see Section 2.2.2). 
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Following FACS, cells were resuspended in Dulbecco's Modified Eagle Medium 
(DMEM) containing 10% FCS and 1% AA and then seeded into eight-well imaging 
chamber plates (PAA, GE Healthcare, Austria) that were pre-coated with laminin (5 
µg/mL, Sigma Aldrich, UK) at a density of 35,000 cells per well and incubated at 37oC 
in a humidified 5% CO2 incubator for 2 weeks. Separate Rlbp.GFP+/+ cell preparations 
were used for each experimental repeat; therefore, n number indicates the number of 
independent cell preparations used per experiment.  
2.2.2 Fluorescence-activated cell sorting (FACS) 
FACS was carried out with either Cell Sorter MoFlo XDP (Beckman Coulter, UK) or BD 
InfluxTM (BD Biosciences, UK) fitted with a 200 mW 488 nm blue laser (adjusted to 150 
nW) to excite GFP. GFP was collected using the 530/40 nm channel. The sort used 
sterile PBS and a sample pressure of 60 psi and a sheath pressure of 60.8 psi using a 
70 or 100 nm nozzle. Viability of both the original and sorted sample was assessed 
using DRAQ7 (Biostatus, UK) to label dead and dying cells. GFP+ cells (Rlbp.GFP+/+ 
and Nrl.GFP+/+) were separated from the other retinal cells, and collected in 50% 
EBSS/50% FCS medium. The total number of collected and sorted cells and the 
efficiency of the sort were noted (Figure 2.1A). A normal non-GFP expressing retina 
was used as a negative control to set the GFP signal gate (Figure 2.1B). Following the 
sort, cells were spun down for 20 min at 200 G, the supernatant was removed and the 
cell pellet was resuspended in 200 µL of resuspension solution (EBSS with 5% 
DNase). GFP+ cells were counted and taken either for primary cell cultures (see 
Section 2.2.1) or cell transplantation experiments (see Section 2.3.5.2.3) 
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Figure 2.1 FACS analysis.  
Representative FACS plots showing A) Rlbp.GFP+/+ cells within the whole populations of retinal cells and 
B) the negative control taken from the retina which does not express GFP that was used to set the GFP+ve 
signal gate.  
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2.2.3 Growth of Müller glial cell cultures in presence of a purified CSPG 
mixture 
Two methods were chosen to assess effect of Chondroitin sulphate proteoglycans 
(CSPGs) on Müller glial cells. In the first experiment, the 8-well plates were coated with 
10-20 µg/mL solution of purified CSPGs, a commercially available mixture containing 
Aggrecan, Neurocan, Phosphacan, and Versican (CC-117, Millipore, UK) at 37oC in a 
humidified 5% CO2 incubator for 3 hrs, followed by a rinsing with D-10 medium (Siebert 
and Osterhout, 2011). The control wells were coated with 5 µg/mL laminin. After FACS, 
Rlbp.GFP+/+ cells were seeded at a density of 35,000 cells per well and incubated at 
37oC in a humidified 5% CO2 incubator for 2 weeks. In the second experiment, 
Rlbp.GFP+/+ cells were grown on 5 µg/mL laminin coated plates for 2 weeks at 37oC in 
a humidified 5% CO2 incubator and pre-assessed under a white-light microscope 
before the addition of CSPGs mix. Two concentrations were used of 50-100-µg/mL and 
added to cultures at intervals of 2 days for 1 week to account for any intrinsic 
degradation mechanisms. Cells were assessed for morphological changes 1 week 
post-treatment with immunocytochemistry (ICC) analysis. 
To assess the effect of CSPGs on Nrl.GFP+/+ cells neurite outgrowth, after first day of 
CSPGs treatment, FACS isolated Nrl.GFP+/+ cells were added to Rlbp.GFP+/+ cell 
cultures at a density of 10,000 cells per well and left in culture for 4 days. The cells 
were fixed with 4% paraformaldehyde (PFA) at 4!°C for 30!min before 
immunocytochemistry. The neurite number was counted per each cell and expressed 
as an average per experimental condition; therefore, n number indicates the number of 
independent cultures used. 
 
2.3 Molecular Biology 
2.3.1 Bacterial cloning and plasmid production 
2.3.1.1 General cloning strategy 
Cloning was achieved by excising the relevant insert fragment and opening the 
appropriate backbone vector with restriction enzymes that created mutually compatible 
‘sticky ends’ to facilitate DNA ligation in the correct location. All cloning products were 
validated by both diagnostic restriction enzyme digests and DNA sequencing 
(Genomics, UK). Concentration of all DNA products was measured by 
photospectroscopy at 260 nm using a NanoDrop® ND-1000 Spectrophotometer 
(LabTech Int., UK). 
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2.3.1.2 Restriction digests 
To characterize DNA plasmids or fragments, or to isolate fragments of interest, DNA 
was selectively cut using restriction enzymes (New England Biolabs, UK,).  
Digestions were performed as follows: 
(A) 0.5 – 1 µg of DNA 
(B) 0.5 µL of each restriction enzyme (10 U/µL) 
(C) 1.6 µL of appropriate 10x Buffer 
(D) 1.6 µL of 10x BSA 
(E) Sterile, deionized water added to a total volume of 16 µL 
The mix was incubated for 4 hrs at 37°C. 
2.3.1.3 DNA electrophoresis and gel extraction of DNA 
DNA fragments resulting from restriction enzyme digests were separated by size using 
electrophoresis (BioRad, UK). Each DNA sample had 4 µL of a loading dye 
(Blue/Orange Loading Dye, 6x: Promega, UK) added to it before being loaded on to a 
1% (w/v) agarose gel prepared in 1x TBE buffer containing SafeView Nucleic Acid 
Stain (NBS Biologicals Ltd., UK) 15 µL of 1 mL SaveView per 100 mL of gel).  
For a 100 - 150 mL gel volume, a voltage of 170 V was applied across the gel for 60 - 
120 min, according to the expected size of the DNA bands. Gels were photographed 
digitally on an ultraviolet transilluminator (BioRad, UK).  
For further cloning, DNA fragments were excised from the gel and extracted using a 
silica gel based purification kit (QIAquick Gel Extraction Kit, Qiagen, UK) according to 
the manufacturer’s instructions.  
2.3.1.4 DNA ligation  
Ligation of the gel purified DNA fragments into the appropriate vector backbone was 
performed using 1:5 molar ratio of backbone to insert. DNA was first heated to 45°C for 
5 min to melt any annealed cohesive ends, and then rapidly cooled on ice.  
Ligations were performed in a mix formulated as follows: 
(A) 4 µL of DNA (insert and backbone in 1:5 ratio respectively) 
(B) 5 µL of 2x Ligation Buffer (LigaFast: Promega, UK) 
(C) 1 µL of T4 DNA Ligase (3 U/mL, LigaFast: Promega, UK) 
Ligations were then incubated overnight (o/n) at 4°C after which the ligase was used to 
transform competent bacterial cells. 
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2.3.1.5 Transformation of bacteria and DNA amplification 
All plasmids used contained the ampicillin antibiotic resistance gene as a selection 
marker for successfully transformed bacteria. For transformation, chemically competent 
DH5α™ cells (α-Select, Bioline, UK) were thawed on ice from -80°C. Cells were 
incubated with construct containing DNA clone for 30 min on ice, before heat-shock for 
1 min at 42oC and then incubated back on ice for 5 min. 60 µL of super optimal 
catabolite (SOC) medium (Thermo Fisher Scientific, UK) was added to cell mix and 
incubated for 1 h at 37oC. After the incubation time, cells were spread on a lysogeny 
broth (LB) - agar plate containing 50 µg/mL ampicillin (Aldrich, UK). Plates were 
incubated at 37oC o/n to allow resistant bacteria to grow. The following day, bacterial 
colonies were picked using a sterile pipette tip and DNA was amplified. Briefly, 5 mL of 
LB medium containing 100 µg/mL ampicillin was inoculated with a single bacterial 
colony and incubated at 37oC o/n. For small scale preparations, plasmids were 
recovered using QIAGEN® Miniprep Kit (Qiagen, UK). The concentration of the eluted 
DNA was measured with a spectrophotometer. The isolated DNA was analysed by the 
appropriate restriction enzymes digests and subsequent gel electrophoresis. Plasmids 
were then sequence checked and clones containing the desired vector products were 
prepared as glycerol stocks for long term storage at -80°C. If needed, the correct 
clones were amplified using MEGA-prep kit (Thermo Fisher Scientific, UK) for further 
experimental use.  
2.3.2 Plasmid constructs 
2.3.2.1 pCMV.Crb1.GFP plasmid construct  
pCMV6.Crb1.GFP vector plasmid containing the human cytomegalovirus (CMV) 
promoter was designed using the PrecisionShuttle vector system and made 
commercially (OriGene Technologies Inc., USA; Figure 2.2). The GFP-tagged plasmid 
was amplified using DH5α™ competent cells and sequenced to check for any possible 
mutations, as described in Section 2.3.1.5.  
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Figure 2.2 Plasmid map of pCMV6.Crb1.GFP construct.  
The Crb1 expression sequence with the GFP reports was placed downstream of the 
human cytomegalovirus (CMV) promoter. The construct’s sequence was verified and 
tested in vitro for its efficiency. 
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2.3.2.2 pd10.MU6.RFP.shCrb1 and pd10.MU6.RFP.shControl vectors  
CRB1 targeting sequences were generated by subcloning the target hairpins (shCrb1) 
into the mU6 promoter plasmid. The target hairpins were placed downstream of the U6 
promoter to form an RNAi-expression cassette. The RNAi cassettes were excised and 
cloned into the AAV pD10.CBA/RFP backbone. The shCrb1 targets the Crb1 sequence 
5’-GGAAGTGGATGAATGTGTTTCTGAT-3’ (position nt 718. NM_133239). ShCrb1 
hairpin was designed using a standard shRNA motif of sense-loop-antisense in which 
the loop consisted of nine nucleotides. A non-targeting hairpin (sequence: 5’-
GATCGGACACTCCTCATAA-3’) was used as a control. The resulting constructs were 
named pD10.RFP.shCrb1 (Figure 2.3) and pD10.RFP.shControl respectively (Figure 
2.4). Both constructs were verified by sequencing (Beckman Coulter Genomics, UK) 
and tested in vitro for their efficiency.  
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Figure 2.3 Plasmid map of pd10.MU6.shCrb1.RFP vector.  
The target hairpin was placed downstream of the U6 promoter to form an RNAi-expression cassette. The 
RNAi cassettes were excised and cloned into the AAV pD10.CBA/RFP backbone. The shCrb1 targets the 
Crb1 sequence 5’-GGAAGTGGATGAATGTGTTTCTGAT-3’ (position nt 718. NM_133239). 
 
  
shRN
A 
pd10.MU6.shCrb1.RFP 
7039bp 
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 Figure 2.4 Plasmid map of pd10.MU6.shControl.RFP vector. 
The on-targeting hairpin (sequence: 5’-GATCGGACACTCCTCATAA-3’) was placed 
downstream of the U6 promoter to form an RNAi-expression cassette. The RNAi 
cassettes were excised and cloned into the AAV pD10.CBA/RFP backbone and was 
used as a control. 
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2.3.2.3 Targeting constructs for intermediate filament proteins  
Generation of shGfap and shVimentin vectors was performed by Dr Claire Hippert and 
is briefly described here. Targeting constructs for Gfap and Vimentin were generated 
by subcloning the target hairpins (shGfap or shVimentin) into the mU6pro plasmid. The 
target hairpins were placed downstream of a U6 promoter to form an RNAi-expression 
cassette. The RNAi cassettes were excised and cloned into the AAV pD10.CBA/RFP 
backbone. The shGfap targets the Gfap sequence 5′-GCACGAAGCTAACGACTAT-3′ 
(position nt 911. NM_010277) and the shVimentin targets the Vimentin sequence 5’-
GTGAGATGGAAGAGAATTT-3’ (position nt 1155. NM_011701). ShGfap and 
shVimentin hairpins were designed using a standard shRNA motif of sense-loop-
antisense in which the loop consisted of nine nucleotides. An additional long shRNA 
(lh) targeting both Gfap and Vimentin was designed using shGfap targeting sequence 
linked by 3 nucleotides (CAC) to the shVimentin and cloned into the mU6pro plasmid. 
As for the single RNAi constructs, the long RNAi cassette was excised and cloned into 
the AAV pD10.CBA /RFP backbone. A non-targeting hairpin was designed and used 
as a control and the sequence used for shControl was as follows: 5’-
GATCGGACACTCCTCATAA-3’. The resulting constructs were named 
pD10.RFP.shGfap (Figure 2.5), pD10.RFP.shVimentin (Figure 2.6), and pD10.RFP.lh 
(Figure 2.7). All constructs were sequence verified and tested in vitro for their 
efficiency. 
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Figure 2.5 Plasmid map of pd10.MU6.shGfap.RFP vector.  
The target hairpin was placed downstream of the U6 promoter to form an RNAi-
expression cassette. The RNAi cassettes were excised and cloned into the AAV 
pD10.CBA/RFP backbone. The shGfap targets the Gfap sequence sequence 5′-
GCACGAAGCTAACGACTAT-3′ (position nt 911. NM_010277).
shRN
A 
pd10.MU6.shGfap.RFP 
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Figure 2.6 Plasmid map of pd10.MU6.shVim.RFP vector.  
The target hairpin was placed downstream of the U6 promoter to form an RNAi-
expression cassette. The RNAi cassettes were excised and cloned into the AAV 
pD10.CBA/RFP backbone. The shVimentin targets the Vimentin sequence 5’-
GTGAGATGGAAGAGAATTT-3’ (position nt 1155. NM_011701). 
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Figure 2.7 Plasmid map of pd10.MU6.lh.RFP vector.  
The target hairpin was placed downstream of the U6 promoter to form an RNAi-expression cassette. The 
RNAi cassettes were excised and cloned into the AAV pD10.CBA/RFP backbone. The long shRNA (lh) 
targeting both Gfap and Vimentin was designed using shGfap targeting sequence linked by 3 nucleotides 
(CAC) to the shVimentin and cloned into the mU6pro plasmid. 
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2.3.3 Viral vector production 
2.3.3.1 HEK 293T cell cultures 
Human embryonic kidney cells, also known as HEK293T cells (American Type Culture 
Collection (ATCC)), were routinely grown in DMEM/GlutaMAX medium (Gibco, UK) 
with the addition of 10% (v/v) heat inactivated FCS (Gibco, UK) and 1% (v/v) AA 
(Thermo Fisher Scientific, UK) at 37oC in a humidified 5% CO2 incubator. Cells were 
grown on either 24-well plate or 15 cm2 and used at confluence between 85-90% (see 
relevant sections).  
2.3.3.2 Production of adeno-associated virus (AAV) 
AAV was produced through a tripartite transfection of 293T cells using a three plasmid 
system and then purified by Fast protein liquid chromatography (FPLC, as described 
by others (Gao et al., 2002). A typical AAV production batch consisted of 20 x 15 cm2 
plate. Plasmids used for viral production were as follows: 
(A) Viral Genomic plasmid based upon pd10.RFP backbone (see Section 2.3.2). 
This plasmid contains the viral genome to be packaged between AAV based 
inverted terminal repeat sequences. Providing this plasmid in trans to the 
replication and packaging genes minimises the risk of generating replication 
competent viral particles.  
(B) Packaging Plasmid. This plasmid contains the AAV.ShH10.Y445F gene and 
Viral Capsid gene. Different packaging plasmids are used to produce different 
AAV serotypes; here AAV.ShH10.Y445F serotype of AAV2 was used as it was 
reported to transduce mainly Müller glial cells in the retina when administered to 
the intravitreal space (Klimczak et al., 2009). 
(C) Helper Plasmid (pHGTI-Adeno1). This plasmid contains three large chunks of 
the Adenovirus four genome ligated together. This plasmid provides all the 
adenovirus genes that AAV requires to package and assemble. 
The above plasmids were used in 1:1:3 (Genomic plasmid: Packaging plasmid: Helper 
plasmid). A total of 50 µg of total plasmid was introduced into 293T cells using 
polyethylenimine (PEI, Polysciences, Germany) transfection reagent at 1:2.25 weight 
per weight (w/w) ratio respectively.  
All reagents were mixed in DMEM (without any supplements added) and incubated at 
room temperature (RT) for 15 min to allow DNA/PEI complex formation. After the 
incubation time, the mix was added to all prepared plates. Transfections were left o/n 
and replaced with fresh medium (with 10% FCS/1% AA) the following day. Three days 
post-transfection, cells were physically detached from the plates by scraping and 
collected together with a growth medium in the falcon tubes. Cells were pelleted at 
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2000 G for 10 min in a centrifuge. Supernatant medium was discarded and the cell 
pellet resuspended in 20 mL of 1X Tris density (TD) buffer.  
In order to release the AAV virons, cells underwent 4 ‘Freeze - Thaw - Vortex’ cycles 
comprising the following steps: 
(A) Freeze – 20 min at -80°C 
(B) Thaw – 20 min in at 37°C 
(C) Vortex – 10 min at RT 
After the 4th cycle, the resulting cell lysate was stored at -80°C until purification. On the 
day of viral purification, the cell lysate was defrosted at 37°C and treated with 
Benzonase (Sigma Aldrich, UK) at 37°C for 30 min at 50 U/mL concentration to destroy 
any non-packaged DNA remaining in the cell lysate. 
Before viral purification 1X TD buffer was added to cell lysate to make a total volume of 
40 mL which was then clarified by centrifugation and filtration as follows: 
(A) Spun at 18,000 G for 20 min, pellet discarded. 
(B) Syringe filter 5 µM dead-end. 
(C) Spun at 18,000 G for 20 min, pellet discarded. 
(D) Syringe filter 0.45 µM dead-end. 
(E) Spun at 18,000 G for 20 min, pellet discarded. 
(F) Syringe filter 0.22 µM dead-end. 
The resulting clarified lysate was then purified using a two-step protocol performed on 
an AKTA Pure column using AVB Sepharose high performance affinity medium (GE 
Healthcare, UK). After purification, the viral fractions were concentrated by 
centrifugation at 5000 G using a Vivaspin 4 concentrator (10 kDa, Sartorius Stedim 
Biotech, Viral Fisher Scientific, UK) to 200 µl. 2 mL of PBS-MK was then added (to 
dilute out high salt elution buffer) and the eluate was concentrated to a final volume of 
60 µl. Viral particle titres, in terms of viral genomes (vg)/mL, were determined by 
quantitative PCR relative to known reference standards. The resulting AAV 
preparations (AAV.ShH10.shControl.RFP, AAV.ShH10.shCrb1.RFP, 
AAV.ShH10.shGfap.RFP, AAV.ShH10.shVimentin.RFP and AAV.ShH10.lh.RFP) were 
titre matched before use.  
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2.3.4 siRNA intervention  
2.3.4.1 Design of RNAi molecules targeting CRB1 protein 
RNAi against Crb1 mRNA was designed using the BLOCK-IT™ RNAi software 
(Thermo Fisher Scientific, UK). Two sequences were generated:  
(A) 5′-ACTCCTGCTTCTGTGTGCCTGGATA-3′ (termed ‘672’) 
(B) 5′- GGAAGTGGATGAATGTGTTTCTGAT-3′ (termed ‘718’) 
and were obtained commercially (Thermo Fisher Scientific, UK). A proven non-
targeting siRNA with 654-Alexa-Fluor was used as a negative control (All-Stars, 
Qiagen, UK). This negative control matched the general chemistry of the RNAi against 
Crb1 mRNA molecule in length and modification and was used to determine any side 
effects of siRNA delivery and to provide a baseline to compare siRNA-treated samples.  
All siRNAs were diluted to the desired concentration in RNAse-free DEPC-treated 
water (Thermo Fisher Scientific, UK). 
2.3.4.2 RNAi transfection in vitro  
HEK293T cells (see Section 2.3.3.1) were split and seeded onto a 24 well plate at a 
density of between 50,000 to 125,000 cells per cm3 24 hrs before siRNA transfection. 
Müller glia cultures (see Section 2.2.2) were not split prior the RNAi experiment but 
they were used at 2 weeks in culture. Briefly, 20 µM siRNA was used as a standard 
stock solution. A co-transfection procedure (based on that available from www.Thermo 
Fisher Scientific.com) was used to simultaneously treat 293T cells with siRNA and a 
plasmid containing the murine Crb1 cDNA. For Müller glia cultures, no plasmid was 
used as the Müller glia cells express endogenous Crb1. Transfection was performed by 
conjugating the RNAi with a lipid based transfection reagent (TR). 160 ng (40 pmol) of 
siRNA and 200 ng of the Crb1 plasmid were added per well, along with 2 µl 
Lipofectamine 2000TM or Oligofectamine reagent (Thermo Fisher Scientific, UK), both 
diluted in OptiMEM reduced serum medium (Thermo Fisher Scientific, UK). Medium 
was changed after 6 hrs to DMEM/10% FCS/1% AA medium and cells were kept at 
37oC in a humidified 5% CO2 incubator for 48 hrs. After post-transfection period cells 
were either harvested for quantitative PCR or fixed for immunohistochemistry. The 
non-targeting siRNA Alexa Fluor 488 was used as a control for transfection efficiency. 
The wells with TR only were used as a negative control.  
2.4 In vivo work 
2.4.1 Anaesthesia 
Animals were anaesthetized using a mixture of ketamine (100 mg/mL), medetomidine 
hydrochloride (1 mg/mL, Dormitor, Pfizer Pharmaceuticals, UK) and sterile water in 
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ratio 3:5:42. Postnatal mice (P10-P16) weighed approximately 0.2 g and adult animals 
weighed approximately 20 g received an intraperitoneal injection of 20 and 200 µL 
respectively. After the surgical procedure, anaesthesia was reversed with equal volume 
of intraperitoneal atipamezole hydrochloride (0.1 mg/mL, Antisedan, Pfizer 
Pharmaceuticals, UK). Animals were kept warm throughout the period of anaesthesia 
and recovery. Recovering animals were monitored constantly until fully awake and 
provided with soft bedding and softened food ad lib.  
2.4.2 Eye injections 
2.4.2.1 AAV.SHh10 administration in vivo 
Intravitreal injections were performed under general anaesthesia using an operating 
microscope and were used for injections of the viral vectors. The eye was dilated using 
1% tropicamide (Chauvin Pharmaceuticals, UK). Corneal reflective power was 
neutralised by placing a 5 mm coverslip (VWR, Germany) on the cornea covered with a 
coupling medium solution, Viscotears (Novartis Pharmaceuticals, UK). The fundus was 
brought into focus as a reference point. The eye was secured in position by grasping 
the conjunctiva using corneal notched forceps (John Weiss & Sons Ltd, UK). Where 
stated, a scleral puncture wound was performed at the level of the anterior chamber 
using a sterile 8 mm 34-gauge hypodermic needle mounted on a 5 µL Hamilton syringe 
(Hamilton, Switzerland). The tip of the needle penetrated the eye tangentially through 
the sclera just below the limbus above the edge of peripheral retina. The needle was 
guided through the vitreous towards the back of the eye into a position close to the 
optic nerve and without touching the lens at any point. 1-2 µL of the vector (1013 
particles) was injected per eye. After injection, the needle was kept in place for 15 
seconds while the intraocular pressure reduced slightly, before being slowly retracted 
from the eye in order to reduce reflux of the injected material. After procedure, animals 
were injected intraperitoneally with a reversal and kept on a heat mat until fully 
recovered. 1% chloramphenicol (Martindale Pharmaceuticals, UK) ointment was 
applied topically on the cornea as post-operative care for the eye.  
2.4.2.2 RNAi transfection in vivo 
RNAi sequences (see Section 2.3.4.1) were introduced subretinally at concentrations 
of 15 µM per eye. siRNA was mixed with Oligofectamine TR in OptiMEM and incubated 
at RT for 15 min to allow siRNA/TR complex formation. Formed complexes were 
administrated subretinally in a manner similar to intravitreal injections. Briefly, a 
Hamilton needle with bevel uppermost was inserted tangentially into the eye though 
the sclera below the equator of the globe into the subretinal space. The material was 
slowly injected into the space after which a retinal detachment could be observed. The 
needle was carefully withdrawn and any reflux of the material or change in the size of 
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the retinal detachment was noted, as described above. After surgery, mice were 
recovered as described above. Eyes were harvested after 48 or 72 hrs post-injections 
to assess effectiveness of RNAi, as reported previoulsy (Pearson et al., 2010; Yu et al., 
2016). 
2.4.2.3 Nrl.GFP+/+ cell transplantation 
The transplant procedure is illustrated in the methods schematic presented in Figure 
2.3.  
The use of the Nrl.GFP+/+mouse as a source of donor cells provided a genetic marker 
for the identification of rod photoreceptors (Akimoto et al., 2006). NRL is a rod specific, 
basic motif-leucine zipper transcription factor (Landschulz et al., 1988; Swaroop et al., 
1992; Rehemtulla et al., 1996) whose expression is switched on during terminal mitosis 
(Akimoto et al., 2006). In the Nrl.GFP+/+ mouse, GFP is expressed under the Nrl 
promoter; hence GFP expression is restricted to post-mitotic rod photoreceptor cells 
(Akimoto et al., 2006). Cells for cell transplantations were prepared as described 
previously (Pearson et al., 2012). Cells were dissociated and prepared for FACS in the 
same manner as Rlbp.GFP+/+ cells using papain-based kit (Section 2.2.1).  After the 
sort, cell viability count was performed using trypan blue (Sigma Aldrich, UK) and a 
haemocytometer counting chamber. Dead or dying cells were identified by trypan blue 
labelling and excluded from live cell counts. Nrl.GFP+/+ cells were made up to a final 
concentration of 200,000 live cells/µl in a solution containing DNase (100 U/ml) in 
EBSS and kept on ice until used for transplants unless otherwise stated. A total of 
200,000 cells was injected into the superior subretinal space per eye in a single 
injection (Figure 2.8). Eyes were harvested and analysed three weeks post-injections. 
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Figure 2.8 A schematic image of photoreceptor cell transplantation.  
A schematic image of a dissection of the Nrl.GFP+/+ donor cells which is followed by a subretinal injection 
within the recipient retina. 
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2.4.2.4 Enzymatic treatment for CSPGs degradation 
Bacterial Chondrotinase (Sigma Aldrich, UK) was prepared according to 
manufacturer’s instructions and was reconstituted in 0.01% bovine serum albumin 
(BSA) aqueous solution. Immediately prior to use, subsequent dilutions were made 
with buffer (50nM Tris, 0.02% BSA), containing 60 mM sodium acetate to activate the 
ChABC. The buffer solution was adjusted to the optimal pH (8.0) for ChABC activity 
and was used at a final concentration of 0.025U/µL, containing 0.005% DNAse (Suzuki 
et al., 2007; Singhal et al., 2008).  
Recombinant Human ADAMTS-4 enzyme (Millipore, UK) was prepared and used 
according to manufacturer’s instructions. Enzyme was kept at -80oC until the day of 
experiment and used at a final concentration of 100 ng/µL per eye. 
Prior the subretinal injections, enzymes were incubated in water bath at 37o C to allow 
their activation. Eyes were harvested for immunohistochemistry and Western Blot 
analysis after 24 - 48 hrs to assess the effectiveness of the enzymes in digesting CS 
sugar chains. EBSS was used as a control solution that followed the same preparation 
protocol as the enzymes.  
 
2.5 RNA extraction, reverse transcription and quantitative 
polymerase chain reaction 
2.5.1 Laser extraction of retinal tissue  
To determine levels of CRB1 in a wild-type retina, the tissue was extracted from the 
superior and inferior regions using the laser capture technique. Frozen unfixed eyes 
were sectioned at 10 µm and 5-6 cryosections were collected on PEN polymer coated 
slides (Zeiss, Germany). Slides were fixed for 1 min with 70% ethanol, washed with 
distilled water and dipped in 100% ethanol to remove any excess of water. Slides were 
viewed on a Palm Zeiss laser microscope (Axiovert 200M, Zeiss, Germany) with 
20X/0.4 objective using Palm Robo 3.1 computer software (Palm® Robo Software, 
MicroLaser Systems, Germany). Regions of the superior and inferior retina adjacent to 
optic nerve were cut with a laser (P.A.L.M MicroLaser Technologies AG, Germany) and 
collected in silicone-coated eppendorfs (Adhesive Cap 500, Zeiss, Germany). 
Captured tissue (5-6 sections) was homogenized with 300 µL of RLT buffer before 
being processed with RNeasy Micro Kit (Qiagen, UK) to extract RNA. 
2.5.2 RNA extraction and quantitative polymerase chain reaction 
Real-time quantitative polymerase chain reaction (qRT-PCR) was used to determine 
the relative gene expression levels. RNeasy Mini or Micro Kit (Qiagen, UK) was used 
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for RNA extraction of cultured cells, FACS sorted cells, laser-captured cells or whole 
retinae according to the manufacturer’s instructions. RNA concentration and purity 
were measured with a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher 
Scientific, USA). RNA was stored at -80°C.  
For cDNA generation, the QuantiTect® Reverse or Whole Transcription kit (Qiagen, 
UK) was used according to the manufacturer’s instructions.  Standard qPCR reaction 
consisted of cDNA (50 ng/µL) diluted 1:16, TaqMan® Universal PCR Master Mix 
(Roche, UK), 2 µM forward primer, 2 µM reverse primer and 0.2 µM probe (Universal 
Probe Library; Roche, Germany). Primers for the target markers as well as 
endogenous reference control (β-actin) were designed and appropriate hydrolysis 
probes were chosen via the Universal Probe Library Design Centre (Roche, UK) (Table 
2.2). QRT-PCR was run on an ABI Prism 7900HT Fast Real-time Sequence Detection 
System (Applied Bioscience, USA). All samples were run in triplicates. The general 
conditions used had an initial denaturation at 94°C of 2 min. Reactions followed by 40 
cycles of:  
(A) Denaturing step at 95°C for 30 sec. 
(B) Annealing step at 42°C for 30 sec. 
(C) Extension step at 72°C for 1 min. 
(D) A final extension of 5 min at 72°C was performed to finish the reaction.  
The relative expression between comparable samples in relation to the expression of 
the genes was normalised using the following methodology: signal thresholds were first 
manually determined and maintained for each individual experimental run on 
Sequence Detection Systems software 2.2.2 (Applied Biosystems, USA). They were 
chosen such that they laid in the middle of the linear part of log-based fluorescence 
amplification curves on fluorescence intensity vs. cycle number plots. To normalise 
target against β-actin control expression levels, cycle numbers at threshold (Ct) were 
used to calculate ΔCt.  
(A) ΔCt = Ct (target) - Ct (β-actin)  
To normalise sample (e.g. treated) against control levels of target expression (e.g. non-
treated), ΔΔCt was calculated: 
(B) ΔΔCt = ΔCt (sample) - ΔCt (control)  
Finally, to obtain normalised relative target expression levels in ‘% of control levels’, the 
following formula was applied: 
(C) Normalised expression levels (%) = (2-ΔΔCt) x 100 
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Gene Name 
Forward primer 
sequence (5’- 
3’) 
Reverse primer 
sequence    (5’- 
3’) 
Probe 
(Universal 
Probe Library) 
Mouse β-actin AAGGCCAACCGT
GAAAAGAT 
GTGGTACGACC
AGAGGCATAC 
56 
Human β-actin CCAACCGCGAGA
AGATGA 
CCAGAGGCGTA
CAGGGATAG 
64 
Crb1 
CAACTCAGCCC
ATGTCCTC 
AAAACAGCCTT
TGCGATACA 
32 
Crb2 
CAGGATTCTCT
GGCCAGTTC 
CAGGCACTGCT
ACCTCCAG 
34 
Gfap GACAACTTTGCA
CAG GACCTC 
ATACGCAGCCAG
GTT GTTCT 
19 
Gs CATCGTGCAGGC
TCACTACC 
CCCTCACAGGGT
CCTATCTG 
67 
Rlbp CCCCTCGGATCT
CAAGAAG 
TTTGAACCTGGCT
GGGAAT 
1 
Sox9 GTACCCGCATCT
GCACAAC 
CTCCTCCACGAA
GGGTCTCT 
66 
S-100 
ACAACTGGGCC
AGGATCTTC 
CCACCAGGACA
ACAACTGC 
17 
Vimentin TGCGCCAGCAGT
ATGAAA 
GCCTCAGAGAGG
TCAGCAA 
50 
 
Table 2.1 Primer sequences.  
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2.6 Histology and immunochemistry 
2.6.1 Immunochemistry 
Immunochemistry was performed on both cryosections and cell cultures. For 
immunohistochemistry, mice were killed at various time points and their eyes were 
dissected out. A small corneal burn was used to provide a landmark for the superior 
retina. Eyes were embedded in optimal cutting temperature (OCT) embedding medium 
(TissueTek, Thermo Fisher Scientific, UK) using isopentane and liquid nitrogen. Tissue 
was left o/n at -20oC. Serial transverse sections were cut at 18 µm on a Reichert-Jung 
2050 microtome and collected onto Superfrost Plus slides (VWR International, UK) and 
air-dried for 30 min prior to staining. For immunocytochemistry on 293T and Müller glial 
cell cultures, the medium was aspirated out of the wells and cells were washed with 
phosphate buffer saline (PBS). Sections or cells were post-fixed in 1% (w/v) 
paraformaldehyde (PFA) for 5 or 30 min, respectively, and washed with phosphate 
buffer saline (PBS).  Both slides and cells were blocked for 2 hrs at RT and then 
incubated with appropriate primary antibody o/n at 4oC (see Table 2.3 for antibodies 
and staining protocols). The following day, retinal sections were washed with PBS (3 x 
5 min) and incubated with secondary antibody (mouse or rabbit, 1:500 dilution in 
working solution) for 2 hrs at RT. After rinsing with PBS (3 x 5 min), slides were 
counterstained with Hoechst 33342 (stock solution 5 mg/mL diluted in 1:1000 with PBS 
for working solution) and cover-slipped with mounting medium. Negative controls were 
processed as above and in parallel, except that the primary antibody was omitted. 
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Primary 
antibody Fixation 
Blocking 
solution 
Primary 
antibody 
dilution 
Secondary 
antibody 
Polyclonal rabbit 
anti-Aggrecan 
(Millipore, 
#AB1031) 
1% PFA for 
30 min at RT 
Pre-treated 
for 3 hrs with 
ChABC at 
37oC 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.1% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
rabbit Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Monoclonal 
mouse anti-
CRALBP (Abcam, 
#ab15051) 
1% PFA post-
fix for 30 min 
at RT 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Polyclonal rabbit 
anti-CRB1 (gift 
from J. Wijnholds) 
no fixation or 
1% PFA post-
fix for 5 min 
(or 30 min for 
cell cultures) 
at RT 
5% (w/v) 
NGS, 3% 
(w/v) BSA, 
0.05% (w/v) 
Triton-X in 
PBS 
1:300 in 
BS 
Goat- anti-
rabbit Alexa 
546 (Thermo 
Fisher 
Scientific, #A-
21085) 
1:500 in BS 
Monoclonal 
mouse anti-CS56 
(Sigma Aldrich 
#C8035) 
No fixation 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
546 (Thermo 
Fisher Scientific 
1:500 in BS 
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Primary 
antibody Fixation 
Blocking 
solution 
Primary 
antibody 
dilution 
Secondary 
antibody 
Purified mouse 
anti-Glutamine 
Synthetase (BD 
Transduction 
Laboratories, 
#610517) 
1% PFA post-
fix for 30 min 
at RT 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Polyclonal rabbit 
anti-GFAP (Dako, 
#Z0334) 
No fixation 
(1% PFA for 
30 min at RT 
only for cell 
cultures) 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.05% (w/v) 
Triton-X in 
PBS 
1:500 in 
BS 
Goat- anti-
rabbit Alexa 
488 (Thermo 
Fisher 
Scientific, 
#R37116) 
1:500 in BS 
Monoclonal 
mouse anti-GFAP 
(Sigma Aldrich, 
#G3893) 
4% PFA for 
1h 
Post-
treatment in 
30% sucrose 
3% (w/v) 
NGS, 0.3% 
(w/v) Triton-X 
in PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Monoclonal 
mouse anti-
Laminin 1 A&B 
chains (Millipore, 
#MAB1904) 
No fix 
5% (w/v) 
NGS, 3% 
(w/v) BSA, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
546 
(Thermo Fisher 
Scientific 
1:500 in BS 
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Primary 
antibody Fixation 
Blocking 
solution 
Primary 
antibody 
dilution 
Secondary 
antibody 
Polyclonal rabbit 
anti-LAR (Santa 
Cruz, #sc25434) 
No fix 
5% (w/v) 
NGS, 3% 
(w/v) BSA, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
633 
(Thermo Fisher 
Scientific 
1:500 in BS 
Monoclonal 
mouse anti-S-100 
(Abcam, 
#ab7852-500) 
1% PFA post-
fix for 30 min 
at RT 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Polyclonal rabbit 
anti-SOX9 
(Millipore, 
#AB5535) 
1% PFA post-
fix for 30 min 
at RT 
1% (w/v) 
NGS, 5% 
(w/v) milk, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
rabbit Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Monoclonal 
mouse anti-
Vimentin (Sigma 
Aldrich 
#099K4753) 
no fixation or 
1% PFA post-
fix for 5 min 
at RT 
5% (w/v) 
NGS, 3% 
(w/v) BSA, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
mouse Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
Monoclonal 
chicken anti-
Vimentin 
(Millipore, 
#AB5733) 
1% PFA for 
30 min at RT 
for cell 
cultures 
5% (w/v) 
NGS, 3% 
(w/v) BSA, 
0.05% (w/v) 
Triton-X in 
PBS 
1:200 in 
BS 
Goat- anti-
chicken Alexa 
488 (Thermo 
Fisher Scientific 
1:500 in BS 
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Primary 
antibody Fixation 
Blocking 
solution 
Primary 
antibody 
dilution 
Secondary 
antibody 
Polyclonal rabbit 
anti-ZO-1 
(Thermo Fisher 
Scientific, #40-
2300) 
no fixation or 
1% PFA post-
fix for 5 min 
at RT 
5% (w/v) 
NGS, 3% 
(w/v) BSA, 
0.05% (w/v) 
Triton-X in 
PBS 
1:250 in 
BSA 
Goat- anti-
rabbit Alexa 
546 (Thermo 
Fisher 
Scientific, #A-
21085) 
1:500 in BS 
 
Table 2.2 Immunochemistry staining protocol.  
(ChABC, chondrotinase ABC (Sigma Aldrich, UK); NGS, Normal Goat Serum (Abd serotec, UK); BSA, 
Bovine Serum Albumin (Sigma Aldrich, UK); PBS - 1X Phosphate Buffer Saline)).  
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Figure 2.9 Immunohistochemistry controls.  
A) Negative  (no primary antibody) and positive controls for each of the antibodies used in this study. 
Scale bar, 25 µm. 
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2.6.2 Preparation of retinal flatmounts 
Mice were killed using an approved Schedule 1 method and the eyes enucleated. The 
globe of the eye was punctured at the posterior pole using a 25-gauge needle and the 
eye was placed in a petri dish containing 4% PFA. The retina was dissected away from 
the rest of the globe with an orbital cut just posterior to the limbus. Any non-retinal 
tissue that came away attached to the retina was carefully removed. Once dissection 
was complete, four radial cuts were made in the 3, 6, 9 and 12 o’clock positions using 
a scalpel (No.15 Swann-Morton) to allow the retina to be flattened.  Individual retinas 
were then fixed for a further 30 min. After fixation, the retina was placed on a 
microscope slide to allow its positioning for imaging with the layer of interest positioned 
upper most. The retina was then flattened on the slide using a pair of forceps before a 
20-50 µL drop of fluorescent mounting medium (DAKO Ltd., Denmark) was placed 
upon the sample. A coverslip was then carefully placed upon the tissue and flattened 
on to the retina by a combination of capillary action and gentle pressure. The slide was 
then incubated left at RT for 30 min to allow the mounting medium to harden. All the 
flatmounts were imaged on the day of an experiment (Figure 2.10).  
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 Figure 2.10 Retinal flatmount.  
A) Schematic of the retina that was injected with AAV.shH10.RFP vector processed for a flatmount. B) 
Examples of the orthogonal confocal projections that were used for image analysis and 3D reconstruction 
of the Müller glial cells. 
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2.7 Microscopy 
2.7.1 Confocal Microscopy 
Leica TCS confocal microscope with 10x/0.30 and 40x/1.15 oil immersion objectives 
was used to capture fluorescence images of the retinal sections. (Leica TCS SPE, 
Leica Microsystems, UK). Images of the retinae were captured with Leica DFC360FX 
microscope camera and saved on the computer by using LAS AF software (Leica 
Microsystems, UK). Single confocal sections or merged projection images of a x-y-z 
stack are presented. Confocal stacks were approximately 15 µm thick with a step size 
of approximately 1 µm. Hoechst 33342 was excited by the 405 nm laser, Alexa-488 
fluorophore using the 488 nm laser and the Alexa-546 fluorophore using the 543 nm. 
Images were taken at a resolution of 1024x1024. The images were taken using the 
same laser intensity, gain and offset settings wherever possible. For figures, digital 
images were adjusted for contrast using Adobe Photoshop CS4. All qualitative 
comparisons between conditions/models were made on the raw image files. 
2.7.2 Electron Microscopy  
Mice were sacrificed and the eyes were fixed in 3% glutaraldehyde/ 1% PFA (w/v) 
buffered to pH 7.4 with 0.08 sodium cacodylate HCl and left for one week at 4oC. The 
cornea and lens were removed and a nasal stitch was made to orientate the eyecups, 
as previously described (West et al., 2008). Following a washing step (2.5% 
glutaraldehyde and 0.1M cacodylate buffered to pH 7.4 for 15 min), the eyes were 
osmicated for 2.5 hrs in a 1% aqueous solution of osmium tetroxide in the dark, 
followed by dehydration steps though ascending ethanol series (50-100%, 10 min per 
step with rotation). After three submersions in 1,2-epoxypropane (10 min each), the 
samples were left in a 50:50 mixture of 1,2-epoxypropane and araldite resin for a 
minimum of 3 hrs at RT with rotation. The submersion solution was changed to fresh 
araldite resin and specimens were left o/n with rotation at RT. The following day, the 
eyecups were embedded in fresh araldite resin and cured for 48 hrs at 60oC. Semithin 
(0.7 µm) and ultrathin (0.07 µm) sections were taken using Leica ultracut S microtome 
(Diatome histoknife Jumbo or Diatome Ultrathin, respectively). Semithin sections were 
collected on Super Frost slides and stained with 1% toluidine blue and analysed using 
a Leitz Diaplan microscope with 100x/1.32 oil objective fitted with a Leica digital 
camera DC500 (Leica Microsystems, UK). Images were captured using Q-Capture Pro 
5.1 software (QImaging Ltd., Canada). Ultrathin sections were collected on the copper 
grids and contrast-stained with lead citrate and evaluated using a JEOL1010 
Transmission Electron Microscopy (80 kV). Images were taken using a digital camera 
and DigitView 1.82.366 software (Gatan Inc., USA).  
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2.8 Histology assessment 
2.8.1 Degeneration assessments 
The outer nuclear layer (ONL) thickness (from outer to inner edge of the ONL) and 
ONL density were measured using single section confocal images (Leica TCS SPE, 
Leica Microsystems, UK) taken at x80 magnification. Images were acquired from three 
standardised regions of the superior retina immediately adjacent to the optic nerve 
(here in termed superior-posterior) from at least three independent animals, for each 
model per time point. The rate of degeneration was calculated using the ONL thickness 
measurements: the total loss of ONL thickness between early and late stage 
degeneration was divided by the number of days over which the degeneration had 
taken place. In parallel, the number of photoreceptor rows was counted at each 
examined stage of disease. ONL density was calculated by counting the number of cell 
nuclei and normalised to the area of the ONL, and expressed as the number of nuclei 
per 100 µm2. Measurements were taken using ImageJ software and analysed in a fully 
blinded manner.  
2.8.2 Assessment of photoreceptor transplantation 
Recent findings showed that transplantation of door labelled Nrl.GFP+/+ cells leads to 
both ‘true integration’ and so-called material transfer/cytoplasmic fusion (Pearson et al., 
2016; Santos-Ferreira et al., 2016; Singh et al., 2016). At the time when this study was 
designed and implemented, cell integration was genuinely thought to be the only 
biological mechanism that led to detection of GFP+/+ cells within the host ONL. Due to 
the length of each experiment with the viral vectors, it was not possible to repeat the 
cell tranplantation experiments. Although, the presented findings do not enable to 
distinguish between true integration and material transfer/cytoplasmic fusion, they can 
indicate whether knockdown of IF proteins has any impact on the cell transplantation 
outcome.  
Counts of GFP+ cells were taken using a fluorescence microscope (Axio Observer Z.1, 
Zeiss, UK) and were performed by Prof. Rachael Pearson according to previously 
established protocol (MacLaren et al., 2006; Pearson et al., 2012). The donor labelled 
cells were only counted if the whole cell body was correctly located within the recipient 
outer ONL, above the outer limiting membrane (OLM). Eyes were fixed in 4% PFA, 
cryopreserved and serially sectioned across three slides. The Nrl.GFP+/+ cells were 
counted in every third section throughout the whole eye and multiplied by three to give 
a total number per retina. Eyes were omitted from analysis if there was a clear 
evidence of an injection having been inadvertently administrated into the vitreal cavity, 
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instead of subretinally, or if there was an absence of the cell mass in the subretinal 
space (defined as less than 200 cells in the SRS), which is an indication either of the 
reflux at the time of a cell transplant, or of acute inflammatory response (this occurs in 
approximately 20% of injections; (see (West et al., 2010)). For the experiments with the 
viral vectors additional condition, the transduction efficiency was also taken into 
account where eyes with poor transduction were omitted from the study. All counts 
were done in a fully blinded manner.  
2.9 Western Blot Assessment 
Neuronal retinae were dissected from 3-5 mice per time point, snap frozen in liquid 
nitrogen and stored in -80oC. Retinal tissue was then lysed in 100 µl of RIPA buffer 
(Sigma Aldrich, UK) with 1 µl protease inhibitor (Sigma Aldrich, UK). Cell membranes 
were disrupted using a sonicator (Soniprep 150, MSE London, UK). Protein 
concentrations were determined with a BCA assay (Bio-Rad, UK). Equal amounts of 
protein (20 µg) were resuspended in Laemmli’s loading buffer or non-reducing loading 
buffer (see Table 2.2 and 2.3). The samples were then run on a sodium 
dodecylsulphate-polyacrymalide gel for 90 min 120 mV. The separated proteins were 
electrotransfered to PVDF membranes (Millipore, UK) for 30 min 25 mV using Transfer 
System machine (Bio-Rad, UK) and then separated into two blots at 25 kDa. 
Membranes were incubated in an appropriate blocking solution for 1 hr at RT and 
incubated with primary antibody o/n at 4oC (Table 2.3). The following day the 
membranes were washed with PBST (0.05% Tween in PBS) and incubated for 2 hrs 
with secondary antibody. Chemiluminescence detection was performed using a Fujifilm 
LAS-1000 Luminescence Image Analyser (Fujifilm Corp., Japan) after incubation with 
enhanced luminescence reagent (ECL Plus, GE Healthcare, UK). Band intensities 
were quantified using Image J software and normalized to Histone 2B (H2B) levels. 
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Antibody 
Laemmli’s 
Buffer 
Blocking 
solution 
Primary 
antibody 
Secondary 
antibody 
Monoclonal mouse 
anti-Histone-2B 
(Cell Signalling, 
#2934) 
Reducing 
5% BSA 
0.05% PBST 
1:10000 in 
5% Non-fat milk 
1% BSA 
0.05% PBST 
Goat-anti-mouse 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #31430) 
1:10000 in BS 
Polyclonal rabbit 
anti-Neurofilament 
L (Cell Signalling, 
#2837) 
Reducing 
5% BSA 
0.05% PBST 
5% BSA 
0.05% PBST 
Goat anti-rabbit 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #G-
21234) 
1:5000 in BS 
Polyclonal rabbit 
anti-Brain 3B (Brn-
3, Santa-Cruz, #sc-
6026) 
Reducing 
5% BSA 
0.05% PBST 
1:2500 in BS 
Goat anti-rabbit 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #G-
21234) 
1:5000 in BS 
Polyclonal rabbit 
anti-GFAP (DAKO, 
#Z0334) 
Reducing 
5% Non-fat milk 
1% BSA 
0.05% PBST 
1:2500 in BS 
Goat anti-rabbit 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #G-
21234) 
1:5000 in BS 
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Antibody 
Laemmli’s 
Buffer 
Blocking 
solution 
Primary 
antibody 
Secondary 
antibody 
Monoclonal mouse 
anti- Vimentin 
(Sigma Aldrich, 
#V5255) 
Reducing 
5% Non-fat milk 
1% BSA 
0.05% PBST 
1:3000 in BS 
Goat-anti-mouse 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #31430) 
1:10000 in BS 
Monoclonal mouse 
anti-CS56 (Sigma 
Aldrich, #C8035) 
Non-reducing 
10% Non-fat milk 
0.05% PBST 
1:1500 in 
5% Non-fat milk 
0.05% PBST 
Goat-anti-mouse 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #31430) 
1:10000 in BS 
Polyclonal anti-
Aggrecan produced 
in rabbit (Millipore, 
#AB1031) 
Non-reducing 
(pre-treatment 
with ChABC 
for 3 hrs at 37 
oC) 
5% Non-fat milk 
1% BSA 
0.05% PBST 
1:3000 in BS 
Goat anti-rabbit 
conjugated to 
HRP, 
(ThermoFisher 
Scientific, #G-
21234) 
1:5000 in BS 
 
Table 2.3 Antibodies and protocols used for Western Blot analysis. 
PBST, PBS-Tween-20; HRP, Horseradish peroxide; BS, blocking solution; BSA, Bovine Serum Albumin; 
ChABC, Chondroitinase ABC. 
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2.10 Image analysis and 3D reconstruction 
2.10.1 Assessment and quantification of the adherens junctions  
Nature and number of adherens junctions across different degenerative models at 
early and late ages were assessed using electronmicrograph images taken at x1000 
using ImageJ software. Two grids with two independent regions taken at the optic 
nerve area from both middle inferior and superior retina were assessed. All the 
measurements were averaged and expressed as a total number of junctions counted 
over a distance of 100 µm.  
2.10.2 Quantification of the Müller glia end-feet 
Müller glia end feet were measured using a sub-stack projection that was created in 
Image J (from the confocal z-stack of a flatmount; (imagej.nih.gov/ij/), see Figure 2.6 
B). The created image was then converted to RGB image and opened in GNU Image 
Manipulation Program (GIMP; Open Source; https://www.gimp.org/). Orthogonal views 
of the individual sub-stacks were used to track individual cells to their end-foot 
processes. Only those endfeet that could be clearly traced down to cell bodies that 
occupied an appropriate position in the inner nuclear layer were used for assessment. 
Sub-stack xy projections encompassing the first 15-20 µm at the apical margin of the 
retina were generated from the flatmount confocal xyz stacks described above. The 
resulting image was then opened using GIMP software and converted to grayscale. 
Threshold Alpha tool was used to separate signal from background and the same 
threshold was applied to all analysed images. Regions of interest (ROI) were selected 
using the free selection tool. The perimeter of each individual end-foot process was 
manually delineated and the histogram dialogue was used to quantify the total number 
of pixels within the selected area. The measured values for the total area were then 
converted to µm2. All quantifications were performed in a fully blinded manner by an 
independent assessor. 
2.10.2 3D reconstruction of Müller glial cells 
Leica confocal xyz images (in tif format) were directly opened in Amira 5.5.0 (FEI.com). 
Data series were filtered using a noise reduction median filter and then individual cells 
were semi-automatically segmented using a Wacom drawing tablet. The segmentation 
data was smoothed with voxels smaller than or equal to the size value specified being 
removed. 3D surfaces were generated and shown using vertex normals. Three to five 
cells were reconstructed per file. All data were treated in the same way. An 
independent assessor performed all reconstructions in a blinded manner. 
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2.11 Statistics 
All means are ± standard deviation, unless otherwise stated. N corresponds to a 
number of eyes examined where appropriate (one eye per animal was used for any 
given method of assessment) or independent cell cultures used per study. All 
experiments concerning RNAi/viral injections were conducted as paired experiments, 
whereby the contralateral eye served as a within- animal control. Pearson’s test was 
used to determine normal distribution of data sets. Where appropriate, statistical 
significance was assessed using a Student’s t-test with Holm-Sidak corrections or 
ANOVA test with Tukey’s correction applied for multiple comparisons, using Graphpad 
Prism 5.0 software (Graphpad Inc., USA). P values are presented as *P < 0.05, **P < 
0.01, ***P < 0.001 and ****P < 0.0001. 
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CHAPTER 3
Characterisation of the retinal 
environment in different murine 
models of retinopathy 
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3.1 Overview 
The vast majority of degenerative retinal diseases lead either directly or indirectly to 
dysfunction and/or loss of photoreceptor cells. As degeneration progresses the 
microenvironment of the retina undergoes a number of significant changes. The loss of 
photoreceptors causes the cytoarchitecture of the nuclear layers together with the 
outer limiting membrane (OLM), a network of adherens junctions (AJs) formed between 
photoreceptors and Müller glia, to remodel. In addition, Müller glial cells undergo 
reactive gliosis, leading to the formation of a glial scar that can envelope the entire 
retina at later stages of degeneration (Jones et al., 2003a). This scar can act as a 
reservoir for the accumulation of extracellular matrix (ECM) molecules including 
chondroitin sulphate proteoglycans (CSPGs), which are known to be inhibitory to 
axonal growth and regeneration (Inatani et al., 2001; Jones et al., 2003b; Escher et al., 
2008). Each of these processes is likely to have a significant impact upon the retina, its 
health and physiology. Previously, retinal gliosis has been shown to negatively impact 
on the efficiency of viral transduction in gene therapy (Grüter et al., 2005), 
photoreceptor transplantation outcome (reviewed in (Pearson et al., 2014; Hippert et 
al., 2016) and the ability of retinal grafts (reviewed in (Zhang et al., 2004)) and 
electronic implants (Pardue et al., 2001) to contact the underlying retina. Elsewhere in 
the CNS, reactive gliosis has long been considered as the major impediment to axonal 
regrowth after an injury (Fawcett and Asher, 1999; Busch and Silver, 2007). 
Nonetheless, the formation of a glial barrier around a lesion site is also an advantage, 
because it isolates the still intact CNS tissue from secondary lesions. In addition, there 
are reports to suggest that in certain conditions reactive astrocytes could even provide 
a permissive substrate for neurite extension (reviewed in (Ridet et al., 1997)). For 
these reasons, understanding the process of glial scar formation, how this process 
differs in different models of degeneration, and finding strategies to circumvent these 
barriers, represent major challenges to the advancement of many ocular therapies.  
Typically, gliosis in the eye is characterized by a dramatic increase in intermediate 
filament (IF) expression and a pronounced activation of Müller cells (Fisher and Lewis, 
2003). In addition to the upregulation of the IF proteins, Glial Fibrillary Acidic Protein 
(GFAP) and Vimentin, reactive Müller cells may undergo hypertrophy, presenting a 
proliferation of fibrous processes and deposition of proteoglycans, particularly CSPGs, 
at the outer edge of the retina (Lewis and Fisher, 2003; Jones et al., 2003b; Fisher et 
al., 2005; Jones and Marc, 2005; Inman and Horner, 2007). This process of gliosis is 
characteristic of many retinal disease models (Ekström et al., 1988; Sheedlo et al., 
1995; Fan et al., 1996; Inatani et al., 2001; Escher et al., 2008), although the temporal 
relationship between the onset of gliosis and degeneration may vary between disease 
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models. Given the apparent complexities of the gliotic process, more precise 
dissections of the links between the onset of glial reactivity and progressive 
neurodegeneration are needed.  
Over the past decade, progress in creating genetically engineered animal models that 
more accurately model human retinopathies has allowed scientists to advance our 
understanding of the mechanisms underlying disease pathology. As different biological 
causes may lead to changes in different physiological pathways, the assessment of the 
retinal microenvironment across a number of different murine models of retinal 
degeneration is needed. In this chapter, seven clinically relevant mouse models (three 
carrying a spontaneous gene mutation and four having been genetically modified) have 
been compared against wild-type controls across different time points in a course of 
disease progression. 
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3.2 Results 
3.2.1 Assessment of retinal cytoarchitecture 
Each of the studied murine models undergoes a progressive loss of photoreceptors 
over time ranging from a normal cell loss due to ageing to near complete reduction of 
all the cells in ONL. For the purpose of this thesis, the examined mouse models were 
divided into naturally occurring (spontaneous mutations) or genetically modified 
mutants (targeted genetic mutations) of inherited retinal degeneration (Table 3.1). The 
time points examined were chosen to encompass a range of degeneration stages 
within each model. These can be described broadly as early, mid, and late 
degeneration. These were further characterised in terms of ONL cell nuclei density, 
thickness and number of photoreceptor cell rows. 
  
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Model 
Phenotype 
Early time 
point 
Mid time 
point 
Late time 
point 
Spontaneous genetic mutations 
Crb1rd8/rd8 
Focal retinal degeneration; 
‘rosette’ formation; cones 
and rods present 
3 weeks 6 weeks 12 weeks 
Prph2rd2/rd2 
Mild retinal degeneration; 
rods die first 
4 weeks 8 weeks 12 weeks 
Pde6brd1/rd1 
Early onset; severe retinal 
degeneration; rods die first 
10 days 3 weeks 6-8 weeks 
Targeted genetic mutations 
Rho-/- 
Moderate retinal 
degeneration; rods die 
first; lack of OS 
4 weeks 6 weeks 10 weeks 
Prph2+/Δ307 
Very slow progressive 
retinal degeneration 
2 months 4 months 6 months 
Nrl-/- 
Cone-like retina; ‘rosette’ 
formation 
3 weeks 6 weeks 12 weeks 
 
R9191; Nrl-/- 
Cone-like retina 3 weeks 6 weeks 12 weeks 
 
 
Table 3.1 Summary of the different murine models with retinal phenotype and the stages of 
retinal degeneration studied.  
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3.2.1.1 Rate of photoreceptor degeneration 
 
An indication of the rate of degeneration can be obtained by dividing the overall loss of 
ONL thickness by the number of days between early and late stage. In wild-type mice, 
ONL thickness is approximately 58 µm (± 7.8) at the early stage examined and stays 
stable over time (Table 3.2). Of the seven examined retinal phenotypes, the Pde6brd1/rd1 
mouse demonstrates the most dramatic phenotype with photoreceptor degeneration 
starting as early as postnatal day (P) 10 (Carter-Dawson et al., 1978). Even though 
neurogenesis is not fully completed by this time, the number of cells is already reduced 
by ~20% in comparison to wild-type (Figure 3.1). By 3 weeks, the thickness of the ONL 
is lessened to only 15% of wild-type. At the latest examined stage, only sporadic cone 
nuclei are observed indicating that this model experiences an average loss of 3.4 µm 
per day from the ONL thickness (Table 3.2). In the Rho-/- mouse, by 6 weeks of age, 
the retina is already reduced to 50% of a wild-type and decreases to 20% by the age of 
10 weeks (Figure 3.1) meaning that on average 0.5 µm of the ONL is lost per day 
(Table 3.2). The Prph2rd2/rd2 model manifests a mild retinal phenotype of retinitis 
pigmentosa (RP), with the initial 36% loss in the ONL thickness to ~53% later on 
(Figure 3.1) which corresponds to an average loss of 0.44 µm per day (Table 3.2). 
Interestingly, two models that exhibit undulations of the ONL, commonly known as 
rosettes, the Crb1rd8/rd8 and the Nrl-/- mouse, undergo a relatively small decrease in the 
ONL thickness of about 20% and 10% respectively (Figure 3.1) with an average loss 
between 0.016 and 0.12 µm per day respectively (Table 3.2). The cone-like retina of 
the R91W; Nrl-/- mutant shows little sign of photoreceptor degeneration with no major 
changes in the ONL thickness over time (Figure 3.1). Prph2+/Δ307 mouse manifests a 
slow rate of degeneration with an initial reduction in the ONL thickness of ~20-25%, 
followed by almost 80% loss at 6 month of age (Figure 3.1).  
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Model 
Early time 
point 
Mid time point Late time point 
Wild-type 58.1±7.8 59.6±2.5 58.2±5.0 
Crb1rd8/rd8 48.1±14.2 46.9±3.0 47.9±6.5 
Prph2rd2/rd2 52.4±3.5 38.0±4.5 27.6±1.1 
Pde6brd1/rd1 43.5±2.7 12.3±3.5 4.9±1.2 
Rho-/- 44.5±5.1 30.1±7.4 11.6±3.5 
Prph2+/Δ307 46.2±5.0 32.3±1.6 12.5±1.9 
Nrl-/- 54.2±5.8 ±47.8±8.4 53.3±8.2 
R9191; Nrl-/- 64.5±6.9± 56.2±2.5 56.7±2.4 
 
Table 3.2 The ONL thickness for each of the examined murine model at early, middle and 
late stage of retinal degeneration.  
All the measurements are expressed in µm (±SD); n=3 animals examined per time 
point. 
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Figure 3.1 Rate of photoreceptor degeneration for each of the examined murine model 
expressed as a percentage of the wild-type ONL thickness.  
Error bars, SD; n=3 animals examined per time point. 
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3.2.1.2 Impact of retinal degeneration on ONL cell density  
Next, we sought to determine the impact of photoreceptor cell loss on cell density 
within the ONL. The comparison of the average cell density within the ONL showed 
that each of the examined models, including wild-type, undergoes some nuclei loss 
over time (Figure 3.2A). In Prph2rd2/rd2 animals, changes in cell density were small and 
resembled that observed in the control mice. A marked reduction in nuclei density was 
observed in several mutants, including Pde6brd1/rd1 and Prph2+/Δ307 animals. This was 
particularly evident at the latest examined stage. Nrl-/- and R91W;Nrl-/- models, which 
are notable for their cone-like retinae, exhibited a very similar and statistically 
significant reduction in ONL cell density over time for both mid and late stages. 
Interestingly, a small initial increase in cell density with degeneration was observed in 
Crb1rd8/rd8 and Rho-/- mutants, which then followed a predicted decrease. These 
differences seen in the cell density may reflect the alterations in cell morphology and 
size of the photoreceptor nuclei as the course of a disease progresses. As the 
photoreceptors fail to function normally and start to die, their nuclei undergo significant 
changes that may lead to their shrinkage or bulging.  
In the next instance, changes to the number of photoreceptor rows were assessed. In 
the adult wild-type retina there are on average 12.9 (±0.9) cell rows in the ONL, which 
then decreases to 11.6 (±0.5) with time (Figure 3.2B). This loss is associated with a 
normal ageing process as the oldest animals that we examined were 1 year of age. A 
similar decrease was observed in Crb1rd8/rd8 mutants, where the number of 
photoreceptor rows dropped from 13 (±0.9) at the early stage to 11.4 (±0.5) at the late 
stage. In the Nrl-/- and R91W;Nrl-/- mice there were, on average, 9.4 (±2.1) and 10.8 
(±0.7) cell rows, respectively; each was further reduced by approximately two rows 
over the time frame examined. The animal models that displayed mild and moderate 
rate of degeneration, including the Rho-/-,  Prph2rd2/rd2 and Prph2+/Δ307 have a decreased 
number of cell rows, about 10, compared to wild-type, even at the earliest stages 
examined here, which then decrease markedly as photoreceptors die leaving between 
2-5 rows by the latest stage examined. The Pde6brd1/rd1 mutant, which undergoes a 
very rapid cell loss, already shows a noticeable reduction in row numbers (8.6 (±0.7) 
cell rows) even at P10. These reduced rapidly, to about 1.6 (±0.5) at 3 weeks of age 
and 0.8 (±0.4) at the latest examined age. 
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Figure 3.2 Changes in ONL cell density and photoreceptor row numbers at the early (dark 
purple), mid (purple) and late (pink) stages of a disease for all examined models. 
A) ONL nuclear cell density expressed as a number of nuclei per 100 µm, and B) number of 
photoreceptor rows counted per each of the examined model per every time point. Statistical significance 
was assessed using one-way ANOVA with Tukey’s corrections for multiple comparisons; *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. Error bars: SEM; n=3 animals examined per time point. 
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3.2.2 Development of a glial scar in different models over disease 
progression  
3.2.2.1 Alterations in IF protein levels !
As mentioned before, progressive retinal degeneration is frequently associated with 
development of gliosis. Here, immunohistochemistry (IHC) and Western Blot (WB) 
analysis were used to perform qualitative and semi-quantitative assessments of 
regional changes in the levels of IF proteins GFAP and Vimentin. There are reports 
showing that a given disease type may lead to some geographical differences; for 
example, the inferior region may manifest a faster rate of photoreceptor degeneration 
(LaVail and Battelle, 1975; LaVail et al., 1992; García-Fernández et al., 1995; LaVail et 
al., 1997; Lin et al., 2009). Therefore, in each model, both the superior and inferior 
retina were examined at the anterior margin, equatorial region and the posterior retina 
immediately adjacent to the optic nerve (positions indicated in schematics on each 
figure). Main figures show representative examples of staining at the equatorial region 
for each model at early, mid and late-stage degeneration. Full representation of all 
regions examined in each of the models is shown in Appendix A-Y. Changes in global 
protein levels were assessed with WB of whole neural retina.  
A primary objective of studying protein expression is to define the patterns that could 
allow the distinction between normal and pathological conditions. In many studies, 
especially those involving WB analysis, the protein of interest is usually compared 
against the levels of ‘housekeeping’ proteins. However, there is a growing body of 
evidence to illustrate the variability in the expression of commonly used internal 
standards between different tissues and diseased states (Blanquicett et al., 2002; 
Ferguson et al., 2005). For example, in models such as Pde6brd1/rd1 the death of 
photoreceptors occurs very rapidly, which may lead to significant changes in gene 
expression, including housekeeping genes; therefore, an appropriate control marker for 
WB analysis is needed. To address this issue, three independent markers were 
examined to determine which is least affected by retinal degeneration. They were 
Histone2-B (H2B) and two markers of the (largely unaffected) ganglion cells, 
Neurofilament 68 (NF-68) and Brain-3b (Brn3b). These markers were tested in the 
Pde6brd1/rd1 model at different disease stages, as well as in age-matched wild-type 
controls. Previous reports showed that despite the axonal arborisation during the 
period of rod and cone death, cells within the inner nuclear layer (INL) and ganglion 
cell layer (GCL) survive in significant numbers (Grüter et al., 2005; Punzo and Cepko, 
2007; Mazzoni et al., 2008). Although, no major changes to these cell types were 
observed, the levels of Brn3b and NL-68 proteins did vary between different ages even 
in wild-type (Figure 3.3). These inconsistencies in the protein expression could be 
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explained by the fact that both Brn3b and NL-68 are markedly up-regulated during 
axonal growth and stabilisation of the neuronal connections respectively. Moreover, 
photoreceptor death causes alterations in the dendritic arbors of the neuronal cells. A 
study by Punzo and Cepko (2007) argued that retinal remodelling, especially in the 
Pde6brd1/rd1 mutant, may lead to changes in gene expression in all retinal cell types as 
the retina tries to adapt to the new environment (Punzo and Cepko, 2007). These 
findings could explain the significant variations in Brn3b and NF-68 levels between 
different disease stages in the Pde6brd1/rd1 samples (Figure 3.3B). Interestingly, H2B 
levels remained broadly constant across all examined time points in both animal 
models in comparison to NF-68 and Brn3b (Figure 3.3).  
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Figure 3.3 Comparisons of the three protein markers for semi-quantitative WB analysis in 
a wild-type and Pde6brd1/rd1 mutant across four different time points.  
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Ai-iii) Protein levels in a wild-type (Ai NL-68, Aii Brn3b and Aiii H2B). Bi-iii) Protein levels in Pde6brd1/rd1 
retinae (Bi NL-68, Bii Brn3b and Biii H2B). All the samples were normalised to H2B levels at 3 weeks as a 
reference point for protein expression. Statistical significance was assessed using one-way ANOVA with 
Tukey’s corrections for multiple comparisons. No statistical differences were assessed. Error bars, SEM; 
n=3 animals examined per time point. 
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C57Bl/6J wild-type mice were used as background-matched (either wholly or partially) 
non-degenerating controls. As expected, there was little evidence of GFAP expression 
in either the inferior or superior wild-type retina at 6 weeks of age and this did not 
change significantly with time (Figure 3.4A i-vi; Appendix A). GFAP+ve processes within 
the retina were largely restricted to astrocytes at the inner retinal margin, adjacent to 
the ganglion cell layer (GCL). Some GFAP+ve basal processes of Müller glia were also 
observed; these were mostly restricted within the anterior margin of the retina and 
there were no appreciable differences between the inferior and superior retina. WB 
analysis revealed no significant change in global GFAP across the three ages 
examined (Figure 3.4A vii). In contrast, robust levels of Vimentin were observed in both 
the superior and inferior retina (Figure 3.6A i-vi; Appendix B). Vimentin+ve Müller glial 
fibres could be seen extending up into the inner nuclear layer (INL) as far as the outer 
plexiform layer (OPL) at all ages examined. Interestingly, this appeared to increase 
with age. Similarly, WB analysis also indicated a trend of increasing global levels of 
Vimentin over time, although this was not statistically significant (Figure 3.6A vii).  
Degeneration occurs in a focal manner in the Crb1rd8/rd8 mouse (Mehalow et al., 2003; 
van de Pavert et al., 2004; Barber et al., 2013). Interestingly, the undulations of the 
ONL that have been previously reported in the inferior nasal quadrant of the fundus in 
these mice were also seen in the superior posterior part of the retina (Appendix D). 
Similar to the wild-type mouse, only very few GFAP+ve processes were observed in the 
retina at early and mid-stage disease with the majority restricted to the anterior margins 
of the retina (Figure 3.4B i, ii, iv, v). However, at the latest stage examined, many more 
Müller glial fibres contained GFAP and GFAP+ve filaments extended into the apical 
processes within the ONL (Figure 3.4B iii, vi). Such patterns of GFAP localisation were 
typical around sites of rosette formation, which were most numerous in the posterior 
retina (Appendix D; arrows). These changes were mirrored by a statistically significant 
increase in global GFAP (Figure 3.4B vii). In contrast, significant levels of Vimentin 
were observed throughout the retina at the earliest stages examined and this was 
maintained as degeneration progressed (Figure 3.6B i-vi; Appendix E). A qualitative 
assessment of Vimentin staining indicates that the level was higher in Crb1rd8/rd8 retinae 
than in wild-type retinae at all stages examined. Analysis of global Vimentin by WB 
also indicated a small increase in protein levels at the latest time point examined, 
although this was not statistically significant (Figure 3.6B vii). 
When assessing the microenvironment of Prph2rd2/rd2 mice using IHC, we observed 
markedly higher levels of GFAP at all-time points examined, compared to wild-type 
(Figure 3.4C i-vi; Appendix G). Even at the earliest stage examined (4 weeks), when 
the ONL is of similar thickness to wild-type, GFAP+ve processes were observed 
extending throughout the retina towards the OPL. By 12 weeks, glial GFAP+ve 
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processes expanded throughout the ONL, with many extending beyond the limits of the 
ONL and intertwining along the outer edge of the neuroretina. These changes were 
confirmed using WB as a significant upregulation of GFAP over time was noted (Figure 
3.4C vii). IHC analysis of Vimentin also showed an increase with time (Figure 3.6C i-vi; 
Appendix H). A global increase in Vimentin levels was also observed at the later stages 
of degeneration, in comparison to levels at the first assessed time point (Figure 3.6C 
vii).  
In the Pde6brd1/rd1 mouse, IHC indicated a bimodal pattern for GFAP, with levels being 
particularly strong at the middle stage, but decreasing thereafter. At the earliest time 
point examined, P10, the retina is still undergoing neurogenesis. GFAP staining was 
similar to that seen in adult wild-type retinae and was restricted to a few basal 
processes only (Figure 3.4D i, iv; Appendix J). However, from as early as P15 
(Appendix L) onwards the vast majority of Müller cells contained GFAP and protein 
expression extended throughout the thickness of the retina into the apical processes 
(Figure 3.4D ii, v). Notably, by very late stage degeneration, when the ONL is reduced 
to a single layer of cone photoreceptors (6 weeks), GFAP was much reduced, 
particularly around the remaining ONL (Figure 3.4D iii, vi; Appendix J). WB analysis 
also revealed a statistically significant upregulation of global GFAP levels between 
early and mid-degeneration although the decrease seen by IHC in very late 
degeneration was not reflected at the global level (Figure 3.4D vii). Surprisingly, and in 
contrast to the other models of degeneration, Vimentin levels appeared to remain fairly 
low in the Pde6brd1/rd1 mouse throughout degeneration with Vimentin+ve processes 
largely being restricted to the inner retina. As degeneration Vimentin+ve processes 
started to project into the remaining ONL (Figure 3.6D i-vi; Appendix K). A statistically 
significant increase in global Vimentin levels was observed between the early and 
latest time points examined.  
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Figure 3.4 GFAP expression in the animal models carrying a spontaneous mutation.  
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Ai-vii) C57Bl/6J wild-type; Bi-vii) Crb1rd8/rd8; Ci-vii) Prph2rd2/rd2; Di-vii) Pde6brd1/rd1. Cryosections were 
immunostained for GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Semi-
quantitative assessments of GFAP levels in whole neural retina were determined by Western blot. GFAP 
was normalized against H2B. Statistical significance was assessed with a one-way ANOVA test with 
Tukey’s correction for multiple comparisons; *P < 0.05, **P < 0.01, and ***P < 0.001. Error bars, SEM; n=3 
animals examined per time point. 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm.  
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 Figure 3.5 GFAP expression in animals carrying a targeted genetic mutation.  
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Ai-vii) Rho-/-; Bi-vii) Prph2+/Δ307; Ci-vii) Nrl-/- Di-vii) R91W;Nrl-/-. Cryosections were immunostained for 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Semi-quantitative 
assessments of GFAP levels in whole neural retina were determined by Western blot. GFAP was 
normalized against H2B. Statistical significance was assessed with a one-way ANOVA test with Tukey’s 
correction for multiple comparisons; **P < 0.01, and ***P < 0.001. Error bars, SEM; n= animals examined 
per time point.  
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm.  
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Figure. 3.6 Vimentin expression in the animal models carrying a spontaneous mutation.  
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Ai-vii) C57Bl/6J wild-type; Bi-vii) Crb1rd8/rd8; Ci-vii) Prph2rd2/rd2; Di-vii) Pde6brd1/rd1. Cryosections were 
immunostained for Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Semi-
quantitative assessments of Vimentin levels in whole neural retina were determined by Western blot. 
Vimentin was normalized against H2B. Statistical significance was assessed with a one-way ANOVA test 
with Tukey’s correction for multiple comparisons; *P < 0.05. Error bars, SEM; n= animals examined per 
time point. 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm.  
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Figure 3.7 Vimentin expression in animals carrying a targeted genetic mutation. 
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Ai-vii) Rho-/-; Bi-vii) Prph2+/Δ307; Ci-vii) Nrl-/- Di-vii) R91W;Nrl-/-. Cryosections were immunostained for 
Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Semi-quantitative 
assessments of Vimentin levels in whole neural retina were determined by Western blot. Vimentin was 
normalized against H2B. Statistical significance was assessed with a one-way ANOVA test with Tukey’s 
correction for multiple comparisons. Error bars, SEM; n=3 animals examined per time point. 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm.  
  
137"
Of all the models examined, the Rho-/- mouse presented the most marked upregulation 
of expression of IFs. IHC for GFAP showed a significant increase in protein levels as 
degeneration progressed. Even at the earliest stage examined, the vast majority of 
Müller glia contained GFAP throughout both basal and apical processes. Moreover, 
GFAP+ve apical processes were observed extending to the outer edges of the retina 
and there was evidence of hypertrophy, with processes extending along the outer edge 
of the retina (Figure 3.5A i). This pattern of GFAP localisation was seen at all stages 
examined (Figure 3.5A ii, iii, v, vi; Appendix N). Interestingly, both basal and apical 
Müller glial processes appeared thicker compared to other models, although further 
histological analysis would be required to confirm whether this reflects a true 
morphological change or simply reflects the high levels of GFAP within any given 
process. WB revealed a statistically significant increase in global GFAP levels between 
early and late stage disease (Figure 3.5A vii). Vimentin levels also increased with age 
and degeneration, although staining of the apical processes was not as strong as that 
of GFAP, at least at the earlier time points. As for GFAP, Vimentin+ve processes 
appeared thicker compared to wild-type (Figure 3.7A i-vi; Appendix O). A trend of 
global Vimentin levels increasing with disease progression was noted, although this 
was not statistically significant (Figure 3.7A vii).  
When assessing the microenvironment of Prph2+/Δ307 mice using IHC, markedly higher 
levels of GFAP were noticed at all time points examined, compared to wild-type (Figure 
3.5B i-vi). Even at the earliest stage examined (2 months), when the ONL is of similar 
thickness to wild-type, GFAP+ve processes were observed extending throughout the 
retina to the outer edges of the ONL. Strikingly, however, although there was no 
significant decrease in global GFAP levels with degeneration as assessed by WB 
(Figure 3.5B vii), IHC revealed that while the basal processes of the Müller glia 
continue to stain for GFAP, there was a consistent and marked reduction of GFAP in 
the apical processes over time (Figure 3.5B i-vi; Appendix Q). IHC analysis of Vimentin 
showed a pattern similar to wild-type with time, although overall levels were 
qualitatively higher at all stages examined, particularly in the basal processes (Figure 
3.7B i-vi; Appendix R). WB revealed a slight increase in global Vimentin levels at the 
latest stages examined compared to early stage of degeneration (Figure 3.5B vii).  
The Nrl-/- mutant presented a marked upregulation in IFs from the earliest examined 
time-point with a gradual progression in a thickening of GFAP+ve processes over time 
(Figure 3.5C i-vi). Even at the earliest stage examined, the vast majority of Müller glia 
stained for GFAP with many of them extending throughout the apical surface. 
Surprisingly, the GFAP+ve glial processes were absent around sites of rosette 
formation, which were present in both superior and inferior regions of a retina 
(Appendix T; arrows). Upregulation in GFAP was also evident, as assessed by WB 
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analysis, with much higher protein levels in comparison to wild-type (Figure 3.5C vii). 
No striking differences in Vimentin staining were observed between the examined ages 
(Figure 3.7C i-vi); however a noticeable band of Vimentin+ve processes was noticed at 
the outer edge of the photoreceptor layer especially at the the latest examined time 
point compared to wild-type or any other examined phenotype (Figure 3.7C v-vi; 
Appendix U). A small trend of global Vimentin levels increasing with disease 
progression was noted, although this was not statistically significant (Figure 3.7C vii).  
The R91W;Nrl-/- mouse is a relatively new genetically engineered murine model 
designed for the study of the mechanisms of cone specific degenerations (Samardzija 
et al., 2014). As there is only one study that used this mutant, a comprehensive 
assessment of these animals was carried out as part of this project. The R91W;Nrl-/- 
phenotype has a functioning all-cone retina, which manifests with a very slow rate of 
degeneration. In comparison to the Nrl-/- model, it expresses a hypomorphic Rpe65 
allele (R91W), which appears to prevent the development of rosettes (Samardzija et 
al., 2014). Although the maximum retinal thickness is similar to the wild-type and the 
rate of photoreceptor loss is minimal, this model presents with a significant Müller glia 
cell reactivity, as shown with GFAP staining (Figure 3.5D; Appendix W). IHC indicated 
that GFAP+ve processes were seen as early as 3 weeks of age, with a gradual increase 
in their number over time. Interestingly, with time more GFAP+ve processes extended 
towards the ONL (Figure 3.5D iii-vi). Global levels of GFAP also increased over time, 
as assessed by WB, although these changes were not statistically significant (Figure 
3.6D vii). This is in contrast to previously reported findings, which showed no GFAP+ve 
glial processes other than those observed in astrocytes at the GCL level (Samardzija et 
al., 2014). To examine these apparently contradictory results, a further analysis was 
performed using the same IHC protocol, including GFAP antibody, as that reported in 
the Samardzija et al. study. In parallel, the antibody was tested with antigen retrieval 
pre-treatment, as suggested by the manufacturer (Sigma Aldrich, UK). Using the same 
IHC protocol, no GFAP staining was observed at 6 weeks of age in R91W;Nrl-/- apart 
from a thin layer at the GCL (Figure 3.8A). In comparison, a section from the same 
eye, but pre-treated with antigen retrieval, revealed a positive GFAP staining of the 
Müller glia processes (Figure 3.8B) similar to those presented in Figure 3.5D. Although 
Grimm’s group did report an upregulation in Gfap mRNA levels with progressive 
degeneration, which corresponds with our WB analysis, they did not show this data in 
the paper (Samardzija et al., 2014). As for Vimentin, a qualitative assessment using 
IHC showed no major differences between the R91W;Nrl-/- mutant and wild-type 
controls (Figure 3.7D i-vi; Appendix X). Although, a gradual upregulation in global 
protein levels was noticed, no significant differences between the examined ages were 
observed (Figure 3.7D vii).  
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Figure 3.8 Differences in the GFAP staining in R91W;Nrl-/- mutant.  
Images of the R91W;Nrl-/- retina (6 week old) stained with GFAP antibody (Sigma Aldrich, UK) A) without 
and B) with antigen retrieval treatment. Cryosections were immunostained for GFAP (green) and 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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3.2.2.2 Changes in CSPG levels with degeneration 
In the CNS, glial cell reactivity is accompanied by changes in the deposition of CSPGs 
(reviewed in (Sharma et al., 2012a)). In this study, the CS-56 antibody was used for 
both IHC and WB to assess whether there were any global alterations in these proteins 
with degeneration. This is a well-characterised antibody, which targets a large panel of 
CSPGs (Inatani and Tanihara, 2002; Escher et al., 2008; Bringmann et al., 2009a), 
providing an overview of CSPG deposition. In wild-type retinae, CSPGs were sparsely 
distributed throughout the photoreceptor inner/outer segment (IS/OS) region and inner 
plexiform layer (IPL), with much higher levels, exhibited as dense staining, in the OPL 
and in the GCL at all-time points examined (Figure 3.9A i-vi; Appendix C). No 
consistent differences were observed in the pattern of CSPG level between the 
superior and inferior retina. A gradual increase in CS-56 staining was observed with 
age and was particularly noticeable within the IS/OS region. This was mirrored by a 
statistically significant increase in global CSPG levels with age, as assessed by WB 
(Figure 3.9A vii). 
A qualitative assessment of IHC in the Crb1rd8/rd8 mouse indicated that CSPG 
deposition, as assessed by CS-56 staining, appeared to be reduced compared to that 
seen in the wild-type retina. Protein was most noticeable at the outer edge of the ONL 
in the IS/OS region (Figure 3.9B i-vi), and around sites of presumptive rosette 
formation (see posterior retina in Appendix F; arrows). Notably, and in contrast to the 
wild-type retina, staining for CSPG in the GCL was largely restricted to the posterior 
retina with very little labelling in equatorial and anterior regions of the retina (Appendix 
F). There were no noticeable differences in the CSPG levels between superior and 
inferior regions of the retina. WB analysis revealed a trend for increasing global CSPG 
with age, which correlates with the increase in GFAP and Vimentin (Figure 3.4B and 
Figure 3.6B), although this was not statistically significant.  
In Prph2rd2/rd2 mutants, CS-56 staining was evident in the IS/OS region and the GCL 
(Figure 3.9C i-vi, Appendix I), although appeared more intense in the IS/OS region. 
Staining presented as a thin band abutting the ONL indicating a more dense deposition 
of CSPGs, compared to wild-type, at 3 weeks, the earliest examined time point (Figure 
3.9C i-ii). As degeneration progressed, the intensity and size of the CS-56 band at the 
IS/OS region gradually decreased. These reductions were also reflected in the global 
levels of CSPGs, as examined by WB, with a marked reduction by 12 weeks (Figure 
3.9C vii).  
In the Pde6brd1/rd1 mice at P10, a thin band of CSPGs was observed at the outer margin 
of the ONL with some sating at the GCL level (Figure 3.9D i, iv; Appendix M). By mid-
stage degeneration, CSPGs were seen throughout the remaining ONL, extending into 
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the OPL and IPL, before decreasing at very late stages of degeneration (Figure 3.9D ii, 
iii, v, vi; Appendix M). Notably, CSPG deposition was also significantly reduced in the 
inner retina, with little CS-56 staining in the astrocyte layer. These changes were 
mirrored by a significant reduction in global CSPG levels over time (Figure 3.9D vii).  
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 Figure 3.9 CSPG deposition in the naturally occurring mutants.  
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Ai-vii) C57Bl/6J wild-type; Bi-vii) Crb1rd8/rd8; Ci-vii) Prph2rd2/rd2; Di-vii) Pde6brd1/rd1. Cryosections were 
immunostained for CS-56 (red) and counterstained with nuclei marker Hoechst 33342 (blue). Semi-
quantitative assessments of CSPGs levels in whole neural retina were determined by Western blot. 
CSPGs were normalized against H2B. Statistical significance was assessed with a one-way ANOVA test 
with Tukey’s correction for multiple comparisons; *P < 0.05. Error bars, SEM; n=3 animals examined per 
time point. 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm.  
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When assessing the microenvironment of Rho-/- mice by IHC, we found that the 
distribution of CSPGs was largely restricted to the IS/OS, IPL, OPL and GCL at all-time 
points examined (Figure 3.10A i-vi). However, staining was particularly noticeable in 
the IS/OS region and even extended into the ONL in the later time points (Figure 3.10A 
v-vi; Appendix P). Surprisingly, and in contrast to the other models examined, CSPG 
levels appeared to be reduced in the inferior part of the retina in the late time point, 
particularly around the equatorial region (Figure 3.10A vi; Appendix P), which could 
suggest that the inferior retina degenerates faster than the superior. Interestingly, for 
each stage studied, CSPG staining seemed stronger in the GCL, compared to the 
same region in the wild-type. WB analysis revealed a significant increase in global 
CSPG levels between early and mid/late degeneration (Figure 3.10A vii).  
In Prph2+/Δ307 mice, the overall distribution of CSPGs was broadly similar to that seen 
for wild-type mice and this did not change significantly with degeneration. CS-56 
staining was evident in the IS/OS region, the OPL, the IPL and the GCL (Figure 3.10B 
i-vi) although appeared to be more intense in the IS/OS region, compared to wild-type, 
and formed a thin band abutting the ONL, indicating a denser deposition of CSPGs. 
Interestingly, qualitative assessments of IHC indicated some regional differences 
between the superior and the inferior retina (Appendix S); CSPG levels appeared to be 
higher within the inferior, compared to the superior retina. When examining global 
amounts of CSPGs by WB, the Prph2+/Δ307 animals showed a significant increase in 
CSPG levels with disease progression between early and late time-points (Figure 
3.10B vii).  
Although Nrl-/- mutant retinae showed high levels of glial reactivity, as indicated by a 
significant upregulation in GFAP, the levels of CSPGs stayed relatively low at all 
examined time points (Figure 3.10C i-vi; Appendix V). CS-56 staining was only 
observed within the IS/OS region and within presumptive rosettes, as also seen in the 
Crb1rd8/rd8 animals. No noticeable differences between any of the analysed retinal 
regions were observed. Further, WB analysis showed no changes in global levels of 
CSPGs over time (Figure 3.10C vii).  
As shown in Figure 3.5D, Müller glia become reactive in the R91W;Nrl-/- model as early 
as 3 weeks of age, which might suggest that the levels of CSPGs may be also altered. 
IHC analysis with CS-56 antibody showed that these proteins were restricted to the 
IS/OS region (Figure 3.10D i-vi; Appendix Y). Further WB assessment revealed no 
significant changes at the global protein levels with disease progression (Figure 3.10C 
vii) indicating that levels of CSPGs do not change over a course of retinal degeneration 
in this model.  
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Figure 3.10 CSPG deposition in the genetically engineered mutant mice.  
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Ai-vii) Rho-/-; Bi-vii) Prph2+/Δ307; Ci-vii) Nrl-/- Di-vii) R91W;Nrl-/-. Cryosections were immunostained for CS-
56 (red) and counterstained with nuclei marker Hoechst 33342 (blue). Semi-quantitative assessments of 
CSPGs levels in whole neural retina were determined by Western blot. CSPGs were normalised against 
H2B. Statistical significance was assessed with a one-way ANOVA test with Tukey’s correction for multiple 
comparisons; *P < 0.05. Error bars, SEM; n=3 independent eyes examined. 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm.  
  
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3.3 Discussion 
The degenerating retina represents a complex environment, which undergoes constant 
changes over the course of disease. While variations in the timing and magnitude of 
response have been reported by various studies looking at different initiating insults, 
there have been no within-study comparative assessments of gliosis across time in 
multiple models of retinal degeneration. The results presented in this chapter show that 
each of the seven examined mouse models of inherited retinal degeneration manifests 
a unique pattern of alteration to the retinal microenvironment. Moreover, they show that 
the nature of the Müller glial response and its magnitude are not correlated with 
disease severity. These observations emphasise that the aetiology of a given retinal 
degenerative disease, including age, retinal cytoarchitecture and disease stage, is 
likely to represent an important factor that must be considered when developing any 
clinical intervention.  
Gliosis in the retina can be induced by retinal degeneration (Kinouchi et al., 2003; 
Zhang et al., 2003b), mechanical insult (Lewis et al., 2010), inflammation (Dinet et al., 
2012) and/or ageing (Kim et al., 2004). Reactive gliosis encompasses a wide range of 
molecular, biochemical, and morphologic events and is easily demonstrated by IHC 
due to the overproduction of the IF proteins, GFAP and Vimentin, and hypertrophy of 
the terminal processes of Müller glial cells. Despite numerous studies, to date there is 
no clear answer for the function and purpose of the glial scarring. Previous reports 
have shown that gliosis has both protective and detrimental effects, potentially 
determined by whether it is initiated by an acute insult or by a prolonged chronic 
condition ((Sofroniew, 2005), reviewed in (Ridet et al., 1997)).  
Initially, upregulation of IFs is thought to stabilise the processes of Müller glia, which 
attempt to undergo hypertrophy in order to limit the extent of a lesion (Lundkvist et al., 
2004). As the retina starts to remodel, these glial cells help to maintain the integrity of 
the tissue and provide a protection from a further mechanical damage (Verardo et al., 
2008). On the other hand, chronic reactivity of the glial cells may interfere with 
neuronal survival and regeneration. Following extensive loss of the photoreceptors 
within the ONL, the hypertrophied side branches of Müller cells may grow into the OPL 
in an attempt to protect the inner retina from further degeneration. However, this action 
may also limit synaptic remodelling by the remaining neurons (Coulombe and Wong, 
2004; Vázquez-Chona et al., 2011). On the other hand, glial scarring has been linked 
to severity of the retinal detachment and the loss of photoreceptor OS (Linberg et al., 
2002). 
As anticipated, in this study we found that the levels of GFAP and Vimentin typically 
increased with disease progression (and age) in the majority of examined models, 
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including wild-type animals. This upregulation was particularly striking in the Rho-/- and 
Prph2rd2/rd2 models of RP, where GFAP+ve Müller glial fibres extended beyond the ONL 
and along the outer margins of the retina, similar to the glial scars formed in the brain 
(Myer et al., 2006). The two mutants, Nrl-/- and Crb1rd8/rd8, which suffer from rosette 
formation in the ONL, exhibited high levels of IFs around these presumptive rosettes, 
which could be linked to the changes associated with retinal structural remodelling. 
Interestingly, in the cone-only retina of R91W;Nrl-/- mice, a marked upregulation of 
GFAP and Vimentin was also observed despite the fact that this model is 
comparatively normal, lacks rosette formation and does not undergo significant 
photoreceptor degeneration over time (Samardzija et al., 2014). More surprising, 
however, was the observation that the levels of both GFAP and Vimentin, although 
increasing initially, undergo a regional decrease in the outer retina in both Prph2+/Δ307 
and Pde6brd1/rd1 animals at the later stages of degeneration. This is striking, when one 
considers that these models represent very different rates of degeneration (slow and 
fast, respectively). Conversely, the same phenomenon was not seen in the Rho-/- or 
Prph2rd2/rd2, models that fall in between these two in terms of degeneration rate.  
Cepko and colleagues performed a microarray data analysis on single Müller cells 
isolated from Rho-/- and Pde6brd1/rd1 neural retinae where they examined expression of 
Gfap (Roesch et al., 2012). In the Rho-/- mutant, at 8 weeks of age, which corresponds 
with a peak of rod degeneration, four out of five examined Müller cells were positive for 
GFAP expression. However, at the peak of cone death at 22 weeks, only one cell 
showed significant levels of GFAP. In contrast, our study reported that in 22 weeks old 
mice, immunostaining for GFAP was still robust, with no evidence of a decrease 
(Hippert et al., 2015). Similarly, when Roesch et al. looked at the Pde6brd1/rd1 model, 
they found a robust expression of Gfap in four of five of the Pde6brd1/rd1 Müller cells at 
early postnatal age (P12). In this study, little GFAP at the slightly earlier time point of 
P10 was found, but robust levels by P15 were observed (Appendix L). However, at 5 
weeks, Cepko and colleagues reported a significant expression of Gfap in five out of 
five cells (Roesch et al., 2008). This is in contrast to the findings here and those of 
Strettoi et al. where a reduction in GFAP protein was reported (Strettoi et al., 2002). 
The apparent discrepancies almost certainly lie in the different techniques used. In the 
Roesch et al. study, they used a powerful, single cell profiling approach, which reflects 
RNA levels at a given point in time while most studies, including this one, examined 
GFAP protein, which may undergo changes on a different timescale. In addition, there 
are many studies, which report a significant heterogeneity among Müller cells in levels 
of different proteins that could provide a valid explanation for the discrepancies found 
between this, and Roesch et al. study. Since cell death in the RP retina typically 
spreads from the centre to the periphery of the mouse retina, cells originating from the 
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centre can differ significantly from those at the periphery. The data in the study by 
Cepko and colleagues come from only a very small number of cells (5 in each 
condition) and thus may not reflect the overall changes occurring in the diseased retina 
as a tissue.  
Another reported feature of reactive gliosis associated with disease and injury is an 
increase in a deposition of CSPGs. CSPGs belong to a large family of glycoproteins 
that are found both on the cell surface and in the extracellular space and are the major 
proteoglycans found in the retina. They consist of a core protein covalently attached to 
long carbohydrate chains known as glycosaminoglycans (GAGs). These GAG chains 
can vary markedly in length, number and sulphation pattern, which in turn influences 
the unique functions of different proteoglycans within and between classes (Properzi et 
al., 2003; Wang et al., 2008). By interacting with other components of the ECM, 
proteoglycans play an important role in many biological processes, including cell 
development, migration and regulation of synaptic plasticity (Fawcett and Asher, 1999). 
In the spinal cord and brain, CSPGs are upregulated by reactive astrocytes in 
response to injury and disease and participate in the inhibition of axon regeneration, 
mainly through their GAG side chains ((McKeon et al., 1991; Crespo et al., 2007), 
reviewed in (Busch and Silver, 2007)). However, our understanding of CSPG 
biosynthesis and the role of these molecules in retinal degeneration is very limited. 
Here, CSPGs were found in several regions of the healthy neural retina including the 
GCL, IPL, OPL, and the IS/OS region. Taylor et al. reported alterations in the 
biosynthesis and turnover of proteoglycans with age (Taylor, 2006), which is supported 
by the observations from this study of an increase in CS-56 staining in aged (1 year), 
compared to young (6 weeks), wild-type mice. Importantly, others have linked age-
related changes in the glycomatrix to the development of AMD pathogenesis (Clark, 
2006; Day et al., 2011). Here, we report that in the degenerating retina CSPG levels 
usually, but not always, followed the trends in IF expression, becoming highly 
expressed in the Rho-/- model, but decreasing in the Prphr2rd2/rd2 and Pde6brd1/rd1 
mutants. Interestingly, in models such as Nrl-/-, the expression of CSPGs was relatively 
low despite major alterations to retinal architecture and high levels of GFAP and 
Vimentin.  
Having identified marked, but contrasting, changes in the expression of CSPGs as 
assessed with the broad-spectrum CSPG marker, CS-56, further work is required to 
examine changes in specific CSPGs within the diseased retina. While a number of 
different proteoglycans have been identified, only a few have been studied in any detail 
in the eye. One that has received attention is Neurocan (Ncan). Ncan gene expression 
is increased in retinae injured by transient ischemia, Rho-/- and Pde6brd1/rd1 mutants, and 
the Royal College of Surgeons (RCS) rat model of inherited retinal degeneration 
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(Inatani et al., 2001; Zhang et al., 2003b; Singhal et al., 2008). Interestingly, it has also 
been shown that Neurocan inhibits the outgrowth of RGCs in vitro (Inatani et al., 2001). 
This inhibition persists even after removal of chondroitin sulphate sugar chains from 
the core protein, suggesting that the Neurocan core protein itself is inhibitory. Similarly, 
Acan, one of the major CSPGs expressed in nervous tissue (Oakley and Tosney, 
1991; Schwartz et al., 1996), is expressed in the optic nerve and the inner retinal layers 
from embryonic day 16 (rat) and 18 (mouse) (Popp et al., 2004; Ali et al., 2011). In 
development, Aggrecan is produced by glial precursor cells and plays a significant role 
in neurite outgrowth (Domowicz et al., 2008; Afshari et al., 2010a) and astrocyte 
differentiation (Smith and Strunz, 2005), amongst other roles. IHC analysis of the adult 
wild-type retina showed Aggrecan in the GCL, INL, ONL and weak staining in the 
plexiform layers, which is similar to what has been shown in human retina (Keenan et 
al., 2012). Several groups have also identified glial scarring, and, more specifically the 
accumulation of CSPGs, as a potential factor involved in transplantation success both 
in the retina and the CNS (Moon et al., 2001; Bradbury et al., 2002; Kim et al., 2006; 
Suzuki et al., 2007; Bull et al., 2008; Bradbury and Carter, 2011). Findings from many 
studies corroborate the findings presented by other groups where the number of 
GFPve+ cells was increased following enzymatic degradation of subretinal CSPGs using 
chondrotinase ABC (ChABC) (Suzuki et al., 2007; Bull et al., 2008; Singhal et al., 
2008). The role of CSPGs in axon regeneration inhibition is well documented (Dou and 
Levine, 1994; Friedlander et al., 1994; Emerling and Lander, 1996; Mitashov, 2001; 
Bradbury et al., 2002; Jones et al., 2002; Kim et al., 2006; Bradbury and Carter, 2011), 
however, there are several subtypes of CSPG, including Neurocan and Versican, and 
ChABC has a different enzymatic affinity for each subtype. The exact expression 
profile in each model maybe different and further profiling may facilitate a more 
targeted enzymatic approach to degrade these specific subtypes and produce a 
greater improvement in transplanted cell integration. Indeed, a variety of different 
CSPGs, including Neurocan, Versican, Aggrecan, Phosphacan and NG2, are 
upregulated in the brain at varying rate after injury (Dou and Levine, 1994; Lemons et 
al., 1999; Asher et al., 2000) and this is likely to be the case in the retina. Furthermore, 
degradation of extracellular matrix proteins via induction of matrix metalloproteinase-2 
(MMP-2) has been shown to increase neurite outgrowth in retinal explants (Suzuki et 
al., 2006) and in vivo in the PDE6brd1/rd1 mouse (Zhang et al., 2007). Further, when co-
injected with RPCs, polymer scaffolds that deliver MMP2 were shown to degrade the 
ECM proteins, CD44 and Neurocan, in the degenerating retina and enhance donor cell 
integration (Tucker et al., 2008).  
Gliosis has also been reported to have a detrimental effect on the application of viral 
vectors. Lentiviral vector is known to have better transduction efficiency in newborn 
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photoreceptors and immature retinae than in adult mice after either intravitreal or 
subretinal injection (Miyoshi et al., 1997; Takahashi et al., 1999; Kostic et al., 2003). 
Arsenijevic and colleagues hypothesised that this might be because in adult mice the 
CSPG-rich interphotoreceptor matrix acts as a physical barrier (Grüter et al., 2005). By 
applying CSPG-digesting enzymes to the subretinal space in conjunction with lentiviral 
vector delivery, they obtained an improvement of viral diffusion and transduction of 
photoreceptors. It is interesting to note, however, that the transduction efficiency of 
lentivirus is still markedly lower than that achieved by adeno-associated virus (AAV) 
vectors without any treatment. One of the major differences between these two vectors 
is their viral particle size, ~20 nm for AAV vectors compare to ~80-100 nm for the 
lentiviral vector. The smaller particle size may facilitate the diffusion of the AAV vector 
through barriers, such as the OLM, and so enhance its access to the photoreceptor 
layer.  
This study shows that gliosis, as assessed by IF expression, and the associated 
changes in CSPG deposition do not change in an equivalent manner between different 
degenerations and, importantly, are unrelated to disease severity. Here we examine 
only inherited causes of retinal degeneration and further studies are required to directly 
compare these with age-related pathology and injury-induced changes. It is also 
important to remember that the changes in GFAP, Vimentin and CSPGs deposition 
represent just a few changes in what is an incredibly complex event. Nonetheless, the 
presented findings underlie the need to study these processes and how they differ in 
various disease models. Such knowledge will be crucial to designing therapeutic 
strategies that will be required to circumvent these obstacles in the diseased retina by 
either preventing the formation of the glial scar or breaking aspects of the scar down.  
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Chapter 4 
Modulation of intermediate filament 
proteins in a murine model of 
retinitis pigmentosa 
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4.1 Overview 
Müller glia are very sensitive to any type of environmental change and can therefore 
serve as an early indicator of the retinal stress. In response to virtually any pathological 
condition, these cells undergo gliosis, a cellular hypertrophy that includes (but is not 
limited to) an elevation in expression of the intermediate filament (IF) proteins glial 
fibrillary acidic protein (GFAP) and Vimentin. Following their activation, reactive Müller 
glia undergo changes in their biomechanical properties, enlarging their cell bodies and 
becoming stiffer, especially in the inner stem processes and the apical terminal region, 
due to an increase in the density of IFs (Lu et al., 2011). The upregulation of IFs in 
Müller glia is also associated with hypertrophy of the glial processes, which contributes 
to the formation of a glial scar at the outer edge of the neuroretina (Fisher and Lewis, 
2003), similar to that observed elsewhere in the CNS (Eng and Ghirnikar, 1994). This 
subretinal scar formed at the outer surface of the photoreceptors may impede tissue 
regeneration, including the outgrowth of photoreceptor outer segments (OS) following 
retinal detachment (Fisher and Lewis, 2003), or interactions between grafted tissues or 
cells and the underlying recipient retina (Zhang et al., 2003a). Modulating these 
changes in reactive Müller glia may therefore be important for the development of new 
therapeutical strategies.  
Despite numerous studies, to date the purpose of IF upregulation in the process of 
gliosis remains a matter of considerable debate. Researchers propose that it can have 
both protective and detrimental effects, depending upon whether there is an acute 
insult or prolonged chronic condition (reviewed in (Ridet et al., 1997; Sofroniew, 2005)). 
In particular, the role of GFAP in the retina has been the subject of many apparently 
contradictory findings. In the degenerative retina, it has been suggested that the 
increased production of GFAP and Vimentin helps Müller glia stabilise the retinal 
architecture, which necessarily undergoes cellular remodelling after pathological insult 
(Fisher and Lewis, 2003). Moreover, it has been proposed that the hypertrophied apical 
terminals help to seal the neuroretina, by building a glial barrier at the outer edge of the 
ONL, to prevent neurovascularisation and any potential increase in monocyte 
infiltration (Nakazawa et al., 2007).  
Alterations in glial reactivity have been suggested to present challenges for therapeutic 
interventions, such as gene therapy (Calame et al., 2011) or cell transplantation 
(Barber et al., 2013). One prominent study used the Gfap-/-/Vim-/- double knockout 
mouse and reported significantly improved integration of early postnatal retinal cells 
compared to wild-type control recipients (Kinouchi et al., 2003). However, the Gfap-/-
/Vim-/- model does not degenerate and it may not, therefore, accurately reflect the role 
of these two IF proteins in the diseased environment. Indeed, GFAP positive glial cells 
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have been proposed to provide a permissive substrate for retinal axonal regrowth and 
neural stem cells transplanted into the mechanically injured retina preferentially 
integrated in regions that coincided with increased Gfap expression (Nishida et al., 
2000). Here, we sought to examine the role of IF proteins in a model of chronic retinal 
degeneration and the effect of suppressing their expression on photoreceptor cell 
transplantation outcome. 
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4.2 Results 
In this study shRNA-containing AAVShH10-Y445F viral vectors (Klimczak et al., 2009) 
were developed to selectively knockdown the expression of Gfap and Vimentin and 
applied to the degenerating murine retina. The initial design and characterisation of the 
vectors to knockdown GFAP and Vimentin proteins was performed by Dr Claire Hippert 
(Hippert, Graca et al., in review) and only the most pertinent data is presented here. 
The three most effective plasmids (pshGfap2, pshVim4 and plh) of those designed 
were used to generate AAVShH10-Y445F viral particles that were titre matched before 
use. Each shRNA plasmid construct also contained an RFP reporter gene under the 
control of a CMV promoter. This reporter allowed viral transduction efficiency to be 
quickly and easily assessed. Herein, these will be referred to as AAV.shGfap, 
AAV.shVim and AAV.Lh, respectively. AAV.shCon vector was used as a control for 
transduction efficiency.  
4.2.1 Müller glia primary culture to study the RNAi vectors 
To assess whether knockdown of GFAP or Vimentin has any effect upon the 
development of gliosis, the effectiveness of the designed vectors was first tested in 
vitro by transducing primary Müller glia cultures. A full description of the methods 
employed to establish purified Müller glial cultures is provided in Chapter 2, Section 
2.2. Briefly, retinae of Rlbp1.GFP+/+ mice, in which GFP expression is restricted to 
Müller glia by the Rlbp1 promoter (Vázquez-Chona et al., 2009), were dissociated 
enzymatically using a papain-based kit, then FACS sorted and left in culture for 2 
weeks before being used in the study. As this cell system was a relatively new method 
within our lab, a full characterisation of the cultured Müller glia using 
immunocytochemistry (ICC) and quantitative RT-PCR analysis was performed to 
confirm their glial identity (Figure 4.1). Five glial markers were chosen including 
CRALBP (RLBP1), Vimentin, GFAP, SOX9 and Glutamine Synthetase (GS).  
ICC analysis confirmed that all the markers detailed above were expressed in the 
cultured cells (Figure 4.1A), and this was confirmed with QRT-PCR (Figure 4.1 B). 
Surprisingly, the GFP fluorescence that was used for FACS purification (Figure 4.2B ii) 
was not retained by these cells in vitro (Figure 4.2B iii-vii), despite CRALBP being 
detectable both by ICC (Figure 4.1A i) and QRT-PCR (Figure 4.1B).  
In this study, GFAP staining of the glial cells was found to be quite variable between 
individual cells, even within the same well (Figure 4.1A v and Figure 4.3B i) similar to 
that reported by Abrahan et al. (Abrahan et al., 2009). In contrast, Vimentin was highly, 
and quite uniformly, expressed by cells in the same culture, as confirmed by ICC 
(Figure 4.1A iv).  QRT-PCR confirmed a robust expression in all wells examined 
156"
(Figure 4.1B). Having shown the expression of Gfap and Vimentin mRNA in cultured 
Müller glia, we then used this system to examine the effectiveness of the designed 
vectors in reducing the levels of both IFs within this cell type.   
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Figure 4.1 Typical glial markers are expressed by primary Müller glial cells in culture.  
Ai-v) Mu ̈ller glia showed a positive staining for Ai) CRALBP; Aii) GS; Aiii) SOX9; Aiv) Vimentin and Av) 
GFAP (white). Images of the negative controls with no primary antibodies added (I’’’’-v’’’’). Cells were 
counter-stained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. B) QRT-PCR analysis 
confirmed the RNA expression of all the examined glial markers. Error bars: SD, n=3 independent cultures 
examined. 
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4.2.2 Endogenous Gfap and Vimentin are effectively knockdown with 
AAV.shGfap and AAV.shVim vectors in Müller glia cells in vitro 
As shown in Section 4.2.1, Müller glia express Vimentin and Gfap, among other glial 
markers, in vitro. Having established that AAV.shGfap, AAV.shVim and AAV.lh are 
able to silence exogenous expression of Gfap and Vimentin in HEK-273T cells in vitro 
(see Appendix Z; Hippert, Graca et al., in review), in the next instance the efficiency of 
the designed plasmids was tested in cultured Müller glia. After 2 weeks in culture, 
Müller glial cells were transduced with each of the four vectors (AAV.shGfap, 
AAV.shVim, AAV.lh and AAV.shCon) and assessed against non-transduced control 
cultures (Figure 4.2B ii) after 1 week post-transduction. RFP expression was used as a 
read-out for viral transduction efficiency and assessed by fluorescence microscopy 
(Figure 4.2A i-v) and FACS analysis (Figure 4.2B i-vii). Each of the four used vectors 
robustly transduced Müller glia in vitro and the RFP signal was detectable as early as 2 
days after infection with the virus (Figure 4.2A i). FACS analysis showed that after 1 
week post-transduction more than 95% of cells subject to AAV.shCon (Figure 4.2A ii, B 
iv), AAV.shGfap (Figure 4.2A iv, B v) and AAV.shVim (Figure 4.2A iii, B vi), treatment, 
and 75% of cells transduced with AAV.lh (Figure 4.2A v, B vii) expressed RFP in vitro. 
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 Figure 4.2 AAVShH10-Y445F vectors successfully transduce Müller cells in vitro. 
Ai-v) After 2 weeks in culture, Müller cells were treated with AAV.SHh10 RNAi vectors. Ai) Robust 
expression of RFP (red) was seen within 2 days after treatment with AAV.shCon and Aii) almost all cells 
expressed RFP by 1 week post-transduction. Cells transduced with Aiii) AAV.shVim; Aiv) AAV.shGfap or 
Av) AAV.lh. Cells were counterstained with nuclei marker Hoechst 33342 (blue). Scale bar: 25 µm. Bi-vii) 
AAV-RNAi vectors rapidly and robustly transduced Müller glial cells in vitro. Representative FACs plots 
taken at 1 week post-transduction of Müller glial primary cultures showing Bi) viable cells only; Bii) the 
GFP (y axis) and RFP (x axis) expression in non-transduced cells; the GFP (y axis) and RFP (x axis) 
expression in Müller cells transduced with Biii) AAV.CBA.RFP; Biv) AAV.shCon; Bv) AAV.shGfap; Bvi) 
AAV.shVim or Bvii) AAV.lh. More than 97% of Müller glial cells expressed the RFP reporter following 
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transduction with AAV.shCon, AAV.shGfap, or AAV.shVim and more than 78% did so following 
transduction with AAV.CBA.RFP or AAV.lh.  
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Next, ICC and QRT-PCR were used to assess the efficiency with which these vectors 
knockdown endogenous GFAP and Vimentin in cultured Müller glia. As mentioned 
previously (Section 5.2.1), the endogenous levels of GFAP protein are not uniform 
between Müller glia as observed in non-transduced Müller glia cultures (Figure 4.3A i). 
A similar pattern was observed in the wells transduced with AAV.shCon, where GFAP 
was expressed to varying extents, both in transduced (RFP+ve) cells and non-
transduced (RFP-ve) cells in the same well (Figure 4.3A ii). In contrast, GFAP 
expression was much lower in wells subject to AAV.shGfap treatment and was 
restricted to non-transduced, RFP-ve cells (Figure 4.3A iii). GFAP staining was also 
much lower in the RFP+ve cells in cultures transduced with AAV.lh (Figure 4.3A iv). 
Further, QRT-PCR analysis showed that Gfap RNA levels were significantly reduced, 
both by AAV.shGfap and by AAV.lh, to 2.4% ±1.9 and 13.6% ±5.4 of the AAV.shCon 
levels, respectively (Figure 4.3B).  
In Section 4.2.1, it was shown that Vimentin is highly expressed in the vast majority of 
Müller glia in vitro. This expression was visibly reduced in the RFP+ve cells transduced 
with AAV.shVim (Figure 4.3C iii), in comparison to RFP+ve cells treated with the control 
vector (Figure 4.3C ii) and non-transduced controls (Figure 4.3C i). Reduction in 
Vimentin staining was also noted in AAV.lh transduced cells, although some of the 
RFP+ve cells retained a degree of Vimentin expression (Figure 4.3C iv). QRT-PCR 
results revealed a significant knockdown of endogenous Vimentin RNA levels after 
AAV.shVim treatment, to 1.4 % ±0.4 of the AAV.shCon (Figure 4.3D; n = 3 
independent culture plates for each experimental condition). Application of AAV.lh also 
led to a statistically significant, but much smaller, decrease in Vimentin mRNA (to 
57.1% ±6.8 of the control vector levels).  
Interestingly, a closer examination of the morphology of the transduced cells revealed 
changes associated with a treatment with different viral vectors. Those transduced with 
AAV.shVim (Figure 4.3C iii) showed an enlarged, flattened morphology, compared to 
cells transduced with AAV.shCon (Figure 4.3A ii or 5.3C ii), while those transduced 
with AAV.shGfap (Figure 4.3A iii) or AAV.lh (Figure 4.3A iv or 5.3C iv) became thinner 
and with a more elongated profile. No obvious differences in cell number were 
apparent, although this was not quantified. 
Having confirmed the efficacy of AAV.shGfap and AAV.shVim to silence Gfap and 
Vimentin expression in vitro, in the next instance, the effectiveness of these vectors 
was tested in the mouse retina. 
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Figure 4.3 RNAi targeting vectors mediate robust knockdown of GFAP and Vimentin in 
cultured Müller glia in vitro.  
Ai-iv) Immunocytochemistry shows that GFAP expression (green) is highly variable between cells both in 
Ai untreated and Aii AAV.shCon treated (red) cultures. However, GFAP was significantly reduced in cells 
transduced with Aiii AAV.shGfap (red) or Aiv AAV.lh (red), compared to controls. (Ai’-iv’ show ROIs 
outlined in Ai-iv). B) Histogram shows RNA levels, assessed by QRT-PCR one week post-transduction, 
for Gfap following transduction of Müller glial cultures with AAV.shGfap or AAV.lh. Both vectors mediated 
a significant reduction in Gfap mRNA, compared to AAV.shCon. Ci-iv) Immunocytochemistry shows 
robust expression of Vimentin (green) in the majority of Ci untreated and Cii AAV.shCon treated (red) 
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cells. Expression was markedly reduced in cells transduced with Ciii AAV.shVim (red) or Civ AAV.lh (red), 
compared to controls. D) Histogram shows RNA levels, assessed by QRT-PCR one week post-
transduction, for Vimentin following transduction of Müller glial cultures with AAV.shVim or AAV.lh. Both 
vectors mediated a significant reduction in Vimentin mRNA, compared to AAV.shCon, albeit that AAV.lh 
mediated a smaller reduction here than seen in 293T cells (Hippert, Graca et al., MS in prep). Cells were 
counterstained with nuclei marker Hoechst 33342 (blue). *P < 0.05, **P < 0.01 and ***P < 0.001 with a 
one-way ANOVA. Error bars: SEM; n=3 independent cultures examined. Scale bar: 25 µm. 
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4.2.3 AAV.shGfap and AAV.shVim mediate effective knockdown of 
endogenous GFAP and Vimentin in Rho-/- mice 
An increase in IF protein levels is considered the hallmark of reactive gliosis and 
occurs in response to various pathologies, including retinal degeneration (Okada et al., 
1990a; Hippert et al., 2015), but the functional changes associated with this increase 
are not fully understood. The Rho-/- mouse model was chosen as it manifests a marked 
upregulation of both GFAP and Vimentin and a moderate rate of degeneration of 
photoreceptors (see Chapter 3, Section 3.2). Since majority of the retinogenesis is 
complete by P10 (Young, 1985; Close et al., 2005) and Müller cells become reactive by 
three weeks of age in the Rho-/- mouse (Humphries et al., 1997), P10 was picked as an 
appropriate time to administer the vectors. First, to confirm reports that AAV.ShH10-
Y445F preferentially transduces Müller glia following intravitreal injection (Klimczak et 
al., 2009), recipient wild-type mice received AAV.shCon at P10 and were assessed 3 
weeks later by IHC. A widespread transduction of about 70% of Müller glial cells was 
observed (Figure 4.4). Next, recipient P10 Rho-/- mice received intravitreal 
administration of either AAV.shCon, AAV.shGfap, AAV.shVim and were initially 
assessed 3 weeks later by QRT-PCR and IHC.   
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 Figure 4.4 Robust transduction of Müller glia in vivo by AAV.SHh10 vector.   
Representative confocal projection image of a mouse wild-type retina injected with AAV.shCon postnatal 
day 10. A) At 3 weeks post-transduction, widespread expression of RFP (red) was observed and B) this 
was predominantly restricted to Müller glial cells, as assessed by morphology. Scale bars: A, main panel = 
100 µm; B, insert = 20 µm.  
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In the first instance, the generated vectors were tested for their ability to prevent Gfap 
upregulation during chronic degeneration. In the untreated P10 Rho-/- mouse, GFAP 
expression is very low (Figure 4.5A i and 5.5B i), but is markedly upregulated during 
the course of degeneration (Figure 4.5A i and 5.5B ii; (Hippert et al., 2015)). As 
assessed with IHC, at P10 GFAP staining is largely restricted to astrocytes that reside 
at the vitreal side of the inner retina, with some additional labelling around the OPL 
(Figure 4.5B i). Three weeks later, GFAP expression is widespread and demarcates 
the full extent of both apical and basal Müller glial processes, which also appeared 
thickened and with increased branching from the central process (Figure 4.5B ii). Close 
inspection of the apical margin of the neural retina revealed the lateral extension of 
GFAP+ve terminal processes along the outer edge of the ONL (Figure 4.5B iii).   
QRT-PCR analysis showed that administration of AAV.shCon alone led to a small 
decrease in Gfap mRNA when compared to untreated controls (Figure 4.5A i). 
Although statistically significant, this did not translate to a visible reduction in GFAP 
staining, as assessed by IHC (Figure 4.5C i-ii). Nonetheless, given this small effect of 
viral administration, the effects of AAV.shGfap, AAV.shVim and AAV.lh were compared 
against the control vector rather than untreated controls.  
Levels of Gfap RNA were significantly decreased by both AAV.shGfap and AAV.lh, to 
31.5% ±23.2 and 44.9% ±13.8 of AAV.shCon, respectively (Figure 4.5A ii). Further 
analysis with IHC showed that GFAP staining was absent in those Müller glia 
transduced with AAV.shGfap (Figure 4.5C iii-iv). Similarly, a noticeable reduction in 
GFAP protein levels was also observable in the retinae transduced with AAV.lh (Figure 
4.5C v-vi) compared to those transduced with AAV.shCon (Figure 4.5Ci-ii).  
As it was reported that Vimentin indirectly affects GFAP expression (Galou, 1996), we 
also assessed whether AAV.shVim had any indirect effects on the expression of 
endogenous Gfap, but no significant changes in Gfap mRNA levels were observed 
(Figure 4.5A ii). 
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Figure 4.5 RNAi targeting vectors mediate knockdown of GFAP in Müller glia in vivo in the 
degenerating Rho-/- retina.  
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Ai) Histograms show that Gfap mRNA levels, as assessed by QRT-PCR, are low at the time of 
administration (P10), but increase significantly during the course of degeneration. Administration of 
AAV.shCon vector led to a small but significant reduction in Gfap mRNA. Aii) Transduction with both 
AAV.shGfap or AAV.lh mediated significant reductions in Gfap mRNA, compared to AAV.shCon, while 
AAV.shVim had no significant effect. *P < 0.05, **P < 0.01 and ***P < 0.001 with a one-way ANOVA. Error 
bars: SEM; n=3 animals examined per time point. Bi) Immunohistochemistry shows that in the P10 Rho-/- 
retina, GFAP expression (green) appears largely restricted to astrocytes that reside at the vitreal surface of 
the ganglion cell layer (GCL), with some additional expression around the outer plexiform layer (OPL). Bii) 
By 4.5 weeks of age, in Rho-/- retina, GFAP is expressed by the majority of Müller glia cells and throughout 
the entire length of their processes. Biii) Close inspection of the outer retina reveals the extension of 
apical Müller glia GFAP+ve processes along the outer edge of the outer nuclear layer (ONL), which led to 
development of a ‘glial scar’. Ci-ii) GFAP expression was unchanged in the eyes injected with AAV.shCon 
vector at 3 weeks post-transduction (4.5 weeks of age). Ciii-iv In those eyes receiving AAV.shGfap, GFAP 
expression was largely absent in transduced cells (red) and only seen in non-transduced cells. Dv-vi) 
GFAP expression was also reduced in cells transduced with AAV.lh, albeit to a lesser extent. Retinal 
cryosections were counterstained with nuclei marker Hoechst 33342 (blue). GCL, ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer. Scale bar: 25 µm.  
 
  
169"
It is worth noting that both AAV.shGfap and AAV.lh failed to transduce the astrocytes 
located at the inner edge of the retina, as GFAP labelling remained in this region 
unchanged (Figure 4.5C iii-vi). This is surprising, as a previous study reported a robust 
transduction of brain astrocytes in vitro with an AAV.ShH10-Y445F vector (Klimczak et 
al., 2009). To test this, mouse astrocyte primary glial cultures derived from P7-8 brains 
were established and were subject to AAV.shCon vector treatment. In parallel, P10 
wild-type animals were injected with the same vector, as GFAP expression in the 
uninjured wild-type is largely restricted to astrocytes. After 1 week, cultured astrocytes 
stained for GFAP, but as with Müller glial cells GFAP expression varied between the 
individual cells (Figure 4.6A i). When transduced with AAV.shCon, cultured astrocytes 
showed robust RFP expression (Figure 4.6A ii) similar to that observed in cultured 
Müller glial cells (Figure 4.2A ii). In contrast, the transduction efficiency of retinal 
astrocytes in vivo was extremely low and GFAP protein levels in these cells remained 
unchanged (Figure 4.6B). Based on our findings, it appears that AAV.ShH10-Y445F 
does not effectively transduce retinal astrocytes in vivo. 
This result likely explains the smaller magnitude of the Gfap mRNA reduction following 
the AAV.shGfap transduction in vivo, which encompasses the whole neural retina, as 
compared to the in vitro examination of the pure population of Müller glial cells. No 
gross morphological changes in retinal architecture were observed following the 
reduction in GFAP levels following AAV.shGfap or AAV.lh administration. Together, 
these data show that injection of AAV.shGfap and AAV.lh prevent effectively the 
upregulation of GFAP protein in Rho-/- mouse Müller glial cells that normally occurs with 
retinal degeneration.   
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 Figure 4.6 AAV.SHh10 vector can transduce astrocytes in vitro but not in vivo.  
Ai-ii) Transduction of astrocytes with AAV.shCon resulted in these cells expressing RFP (red) as early as 
2 days post-administration. As with Müller glia, the expression of GFAP (green) is not homogeneous in the 
astrocyte cultures. Bi-ii) Using the same vector in vivo, RFP was robustly expressed by inner retinal 
neurons, but not by GFAP+ve astrocytes, when examined in retinal flat-mounts. Cultured cells and retinal 
flat-mounts were immunostained with GFAP (green) and counterstained with nuclei marker Hoechst 
33342 (blue). Scale bars: 25 µm. 
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Next, the effects of administration of AAV.shVim on Vimentin levels were assessed in 
vivo. In the untreated P10 Rho-/- mouse, Vimentin is expressed throughout the retina 
and its levels increase over the course of degeneration (Figure 4.7A i and 5.7B ii-iv; 
(Hippert et al., 2015)). Administration of AAV.shCon did not lead to any indirect effect 
on Vimentin mRNA levels (Figure 4.7A i) or Vimentin protein levels (Figure 4.7C i-ii), 
compared to untreated eyes at 3 weeks post-transduction (Figure 4.7B iii). Although no 
significant differences were found between AAV.shCon transduced and untreated 
controls, all presented data is normalised against the control vector for consistency 
with the analysis for AAV.shGFAP. As expected based on the in vitro results, 
AAV.shVim significantly reduced Vimentin RNA levels, to 57.5 ±14.5% of AAV.shCon 
levels (Figure 4.7A ii). Surprisingly, this knockdown was not reflected in a decrease in 
Vimentin staining (Figure 4.7C ii-iv) at this age. However, Vimentin expression is 
widespread, even in the normal wild-type P10 retina (Figure 4.7B i). Moreover, Privat 
and colleagues reported a significant delay in the time between RNAi-mediated knock 
down of the Vimentin mRNA and reduction in Vimentin protein in the injured spinal cord 
(Desclaux et al., 2015). Based on this report, it was reasoned that it might take longer 
for the knockdown in retinal Vimentin RNA to be reflected in a change at the levels of 
Vimentin protein. To test this hypothesis, Rho-/- eyes were transduced with AAV.shCon 
or AAV.shVim and compared against untreated controls at 6 weeks post-transduction 
(7.5 weeks of age). IHC analysis showed that there were no major differences in 
Vimentin protein levels between the untreated controls (Figure 4.7B iv) and AAV.shCon 
transduced retinae (Figure 4.7D i-ii). In contrast, Vimentin expression, while not 
completely abolished, was markedly reduced in transduced Müller glial cells following 
AAV.shVim administration (Figure 4.7D iii-iv). No gross changes in retinal architecture 
were observed following the knockdown of Vimentin. AAV.shGfap had no indirect 
effects on Vimentin mRNA expression (Figure 4.7A ii).  
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Figure 4.7 RNAi targeting vectors mediate knockdown of Vimentin in Müller glia in vivo in 
the degenerating Rho-/- retina.  
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Ai) Histograms show that Vimentin mRNA levels, as assessed by QRT-PCR, are already abundant at the 
time of injection (P10) and increase significantly during the course of degeneration. Administration of 
AAV.shCon vector had no effect on this increase. Aii) Administration of AAV.shVim led to a significant 
decrease in Vimentin mRNA at 3 weeks post-transduction (4.5 weeks of age), compared to AAV.shCon 
while AAV.shGfap had no effect. In contrast to the results in vitro, AAV.lh did not significantly reduce 
Vimentin mRNA in vivo. *P < 0.05, **P < 0.01 and ***P < 0.001 with a one-way ANOVA. Error bars: SEM; 
n=3 animals examined per time point. Bi-iv) Immunohistochemistry shows that Vimentin (green) 
expression is widespread in Müller glia in both P10 Bi wild-type and Bii Rho-/- animals, and Biii-iv 
increases throughout the course of degeneration. Ci-iv) Examination of the retinae transduced with RNAi 
targeting vectors (red) showed that at 3 weeks post-transduction there were no notable changes in 
Vimentin expression in any of the four conditions, compared to untreated age-matched eyes. Di-iv) 
Examination at a later time point (6 weeks post-transduction) showed that Vimentin expression remained 
robust in Di-ii AAV.shControl treated eyes. However, in those eyes that received Diii-iv AAV.shVim, 
Vimentin expression was reduced in transduced cells (red). Dv-vi No marked differences in Vimentin 
expression were observed in eyes receiving AAV.lh. Retinal cryosections were counterstained with nuclei 
marker Hoechst 33342 (blue). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. 
Scale bar: 25 µm. 
 
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Disappointingly, despite introducing a moderately robust knockdown of Vimentin in 
vitro, AAV.lh failed to reduce either Vimentin mRNA (Figure 4.7A ii) or protein in vivo to 
any significant degree at either time point examined (Figure 4.7C v-vi and 5.7D v-vi). 
The reasons for this are not fully understood, but we hypothesise that this may relate to 
in vivo differences in the processing of the lh RNA sequences. As an alternative, we 
combined AAV.shGfap and AAV.shVim together in a 1:1 ratio and injected the mix into 
the same eye. This application of AAV.shGfap/AAV.shVim together led to a notable 
reduction in GFAP protein levels at 3 and 6 weeks post-transduction (Figure 4.8A i-ii 
and 5.8B i-ii) and in Vimentin levels at 6 but not 3 weeks post-transduction, as 
assessed by IHC (Figure 4.8B iii-iv). However, this was also often (6/9 eyes) 
associated with exacerbated retinal degeneration including the ONL thinning and 
retinal detachment as well as other ocular complications. Conversely, retinae receiving 
titre-matched AAV.shCon showed no such changes, suggesting that the absence of 
two principal IF proteins may have a detrimental effect on a degenerating retina. In 
summary, these data show that administration of AAV.shGfap is effective in preventing 
the upregulation of GFAP, while transduction with AAV.shVim may reverse the 
upregulation of Vimentin; however targeting both IFs simultaneously may be 
associated with ocular pathologies in the Rho-/- mouse.  
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 Figure 4.8 Co-transduction with AAV.shGfap and AAV.shVim resulted in marked changes 
to retinal architecture in the Rho-/- mouse. 
Confocal projection images of GFAP and Vimentin expression following co-transduction with AAV.shGfap 
and AAV.shVim (1:1 ratio) into the same eye. At both Ai-ii) 3 (4.5 weeks of age) and Bi-ii) 6 weeks post-
transduction (7.5 weeks of age), a mark decrease in GFAP levels (green) was observed in transduced 
Müller glia cells (red). Aiii-iv) As before, there was little change in Vimentin expression (grey) at 3 weeks 
post-transduction. Biii-iv) At 7.5 weeks of age, Vimentin expression was reduced in transduced Müller 
glia. Retinal cryosections were counterstained with nuclei marker Hoechst 33342 (blue). GCL, ganglion 
cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar: 25 µm.  
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4.2.4 Photoreceptor number is not affected by a knockdown of IF proteins  
Previous studies indicated that absence of the IF proteins, GFAP and Vimentin, may 
attenuate photoreceptor apoptosis due to increase in monocyte infiltration (Nakazawa 
et al., 2007). In order to test whether the absence of GFAP or Vimentin has any effect 
on photoreceptor survival, we examined ONL thickness and the number of 
photoreceptor rows across all experimental conditions and compared the results 
against the uninjected eyes. 
Following the administration of AAV.shCon, the ONL was slightly thicker in comparison 
to untreated controls (60.4 (±7.5) µm vs 51.0 (±4.0) µm), AAV.shGFAP and the animals 
that received AAV.shGfap/AAV.shVim combined injection (50.6 (±6.1) µm at 3 weeks 
post-transduction (Figure 4.9A i). This difference between AAV.shCon and untreated 
eyes had resolved by 6 weeks (AAV.shCon treated, 36.0 (±8.6) µm; uninjected 
controls, 29.1 (±7.1) µm) (Figure 4.9A ii). Conversely, the ONL of 
AAV.shGfap/AAV.shVim co-transduced mutants appeared thinner than in any other 
condition, although this was not statistically significant (27.4 (±5.8) µm; Figure 4.9A ii). 
The assessment of the eyes transduced with AAV.shGFAP at 3 (55.9 (±4.2) µm) and 6 
(33.4 (±4.2) µm) weeks post-transduction or AAV.shVim at 3 (58.6 (±4.6) µm) and 6 
(42.1 (±8.8) µm) weeks post-transduction showed no major differences in the ONL 
thickness at any of the examined ages and was similar to that of the uninjected 
mutants (Figure 4.9A i-ii). When assessing the number of photoreceptor rows no 
significant changes between the untreated controls and the eyes transduced with 
different AAV vectors were observed apart from the ones that were co-transduced with 
AAV.shGfap and AAV.shVim (Figure 4.9B i-ii). This suggests that only the 
simultaneous downregulation of GFAP and Vimentin exacerbates the rate of 
photoreceptor degeneration.  
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 Figure 4.9 Knockdown of GFAP and Vimentin does affect photoreceptor cell number in 
degeneration.  
Ai) Administration of AAV RNAi vectors by intravitreal injection results in some subtle changes to ONL 
thickness, compared to untreated age-matched controls. At 3 weeks post-transduction, AAV.shCon 
resulted in a small but statistically significant increase to ONL thickness. Aii) No significant differences 
were observed at 6 weeks post-transduction in any of the cohorts examined. Bi-ii) No significant 
differences were observed when examining the number of photoreceptor rows at either 3 or 6 weeks post-
transduction, with the exception of a small, but significant, decrease in those eyes co-transduced with 
AAV.shGfap and AAV.shVim, compared to AAV.shCon transduced eyes. Bii) This decrease was 
maintained at 6 weeks post-transduction, although no longer statistically significant. *P < 0.05 and ***P < 
0.001, with a one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars: SD; n≥5 
independent eyes examined.  
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4.2.5 Hypertrophy of the Müller cells apical terminals is reduced in 
mutants treated with AAV.shVim 
One of the hallmarks of reactive gliosis in the retina is hypertrophy of the Müller glia 
apical processes (reviewed in (Bringmann et al., 2006)). Having shown that the 
generated AAV.shVim and AAV.shGFAP vectors can successfully reduce Vimentin 
levels and prevent the upregulation of GFAP in Müller glia cells, respectively, we next 
sought to determine their impact on hypertrophy at the outer margin of the retina. By 
using serial reconstructions of individual RFP+ve Müller glial cells, the morphology of 
these cells and the extent of lateral spread of their terminal processes at the apical 
margin of the retina was exmained (Figure 4.10). As previously shown, intravitreal 
injection of AAV.shCon vector at P10 results in widespread transduction of the whole 
Müller glia cell, which allows for identification of individual cells throughout the depth of 
the retina (see Figure 4.4). Following the injection of AAV, Rho-/- retinae were fixed and 
flat-mounted at 3 (AAV.shGfap) or 6 (AAV.shVim) weeks post-transduction, 
respectively, and high-resolution xyz confocal stacks were taken throughout the 
thickness of the retina and individual Müller glial cells were 3D reconstructed using 
Amira software. All assessments were compared to the appropriate age-matched 
AAV.shCon injected controls. As the size of the Müller glia apical terminals has not 
been assessed before, we also injected wild-type mice with AAV.shCon in parallel to 
Rho-/- animals to determine the normal size of the glial processes at the ONL margin.  
In the wild-type retina, the average lateral spread achieved by Müller glial apical 
terminal processes was 73.4 (±19.7) µm2 in AAV.shCon treated animals at 3 weeks of 
age and did not significantly change over time; the lateral spread achieved at 6 weeks 
was 85.8 (±22.6) µm2 (Figure 4.10A i). In Rho-/- retinae receiving the same control 
vector, we noticed a marked enlargement of the apical terminal region at 3 weeks post-
transduction, compared to age-matched wild-type controls (Figure 4.10A i). The 
average lateral spread of the glial terminals at 3 weeks of age was 93.4 (±25.8) µm2 
and this increased significantly, to 135.4 (±42.6) µm2, by 6 weeks post-transduction 
(Figure 4.10A i-ii). Further analysis of the overall morphology of 3-D reconstructed glia 
cells showed that wild-type Müller glia possess a single thin, apically-directed central 
process, which projects from the cell body and branches out into a number of fine 
processes at the level of the apical margin (Figure 4.10B i-ii). In contrast, in the Rho-/- 
mutant, the central process was much thicker and often bore many smaller lateral 
processes (Figure 4.10 i-ii). These results demonstrate that marked changes occur in 
Müller glial cell hypertrophy at the apical margin of the retina during chronic retinal 
degeneration.  
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We next examined the impact of GFAP or Vimentin removal on Müller glial 
hypertrophy. Gfap mRNA was robustly suppressed and GFAP protein was largely 
absent in transduced Müller glial cells at 3 weeks post-transduction with AAV.shGfap 
(see Figure 4.5). However, this had little or no effect on the lateral spread achieved by 
Müller glial apical terminal processes in AAV.shGfap injected eyes (88.5 (±23.3) µm2), 
compared to age-matched AAV.shCon injected Rho-/- mutants (Figure 4.10A ii). In 
contrast, when compared against AAV.shCon transduced wild-type eyes, the lateral 
spread of the Müller glial apical terminal processes transduced with AAV.shGfap vector 
was significantly higher. There were no major differences in the morphology of 
reconstructed glial cells transduced with AAV.shGfap (Figure 4.10C v), compared to 
AAV.shCon ones.  
As noted above, AAV.shVim vector successfully reduced Vimentin mRNA in vivo at 3 
weeks post-transduction, although this did not translate into a robust reduction at the 
protein level until 6 weeks post-transduction (see Figure 4.7). In keeping with the 
delayed timecourse of Vimentin knockdown, AAV.shVim treated glial cells presented a 
gross morphology (Figure 4.10C iii) and lateral spread of the apical terminal processes 
(92.4 (±20.9) µm2; Figure 4.10A ii) very similar to that of Müller glia transduced with 
AAV.shCon in the Rho-/- mutants. As noted above, by 6 weeks post-transduction, 
Müller glia transduced with AAV.shCon showed marked changes in morphology and 
increased lateral spread of the apical terminal region. In contrast, we did not observe 
any increase in the lateral spread of the apical terminals of Müller glia transduced with 
AAV.shVim (62.1 (±16.3) µm2; Figure 4.10A ii). In addition, 3D reconstructions revealed 
that at 6 weeks post-transduction Müller glia transduced with AAV.shVim more closely 
resembled those seen at 3 weeks post-injection (both AAV.shCon and AAV.shVim) 
(Figure 4.10C iv). These findings indicate that Vimentin is required for the development 
of degeneration-associated Müller glia hypertrophy at the outer edge of the 
neuroretina.  
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 Figure 4.10 Vimentin plays a role in hypertrophy of Müller glial apical processes.  
Ai) Scatter plots show the area occupied by the apical terminal processes of Müller glia in Rho-/- and wild-
type animals transduced with AAV.shCon. At 3 weeks post-transduction (4.5 weeks of age) there were no 
significant differences between the two strains, but at 6 weeks post-transduction (7.5 weeks of age) Rho-/- 
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Müller glial apical terminal processes were hypertrophic and occupied a significantly larger area, 
compared to Müller glia in both 4.5 week old Rho-/- and 7.5 week old wild-type controls. Aii) Comparison of 
the four RNAi vectors across two examined time points showed that AAV.shVim, but not AAV.shGfap, 
prevents the increase in area occupied by Müller glial apical terminal processes. *P < 0.05 with a one-way 
ANOVA with Dunett’s post-test for multiple comparisons. Error bars: SEM; n≥3 i animals examined per 
time point. Bi-ii) Representative confocal images of analysed apical surface areas and Bi’,ii’) typical 
examples of 3D reconstructed wild-type Müller glia at 3 and 6 weeks post-transduction with AAV.shCon. 
Ci-v) Representative confocal images of analysed apical surface areas and Ci’-v’) typical examples of 3D 
reconstructed Rho-/- Müller glia at 3 and 6 weeks post-transduction with Ci-ii) AAV.shCon; Ciii-iv); 
AAV.shVim and Cv) AAV.shGfap. At 3 weeks post-transduction (4.5 weeks of age), Rho-/- Müller glia 
apical processes already contain many more branching points than wild-type, a feature that increased with 
degeneration, and (inserts) the area occupied by the terminal processes at the apical surface expanded. 
In contrast, in eyes transduced with AAV.shVim, Müller glia retained a more normal morphology 
throughout the time period examined. Scale bar: 20 µm. 
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4.2.6 CSPG deposition is not affected by reduction in IF protein levels 
Upregulation of GFAP during gliosis in the CNS is typically associated with an increase 
in the expression of CSPGs and other related ECM molecules (reviewed in (Busch and 
Silver, 2007)). As described in Chapter 3, Rho-/- animals manifest high levels of 
CSPGs, therefore, we assessed whether reducing GFAP and Vimentin levels had any 
effect on CSPG deposition (Figure 4.11). In the untreated Rho-/- controls, staining for 
CS-56, a broad-spectrum marker of CSPGs, showed a modest increase in expression 
between 4.5 (Figure 4.11A i) and 7.5 weeks of age (Figure 4.11A ii), similar to previous 
observation for this model (Chapter 3, Section 3.2.2.2). Injecting AAV.shCon (Figure 
4.11B/C i-ii), AAV.shGFAP (Figure 4.11B/C iii-iv) or AAV.shVim (Figure 4.11B/C v-vi) at 
P10 had no effect on thie increase of CSPGs deposition at either 3 weeks post-
transduction (4.5 weeks of age) (Figure 4.11B) or 6 weeks post-transduction (7.5 
weeks of age) (Figure 4.11C), compared to the relevant controls. This suggests that 
downregulation of GFAP or Vimentin, alone, has no indirect effect on CSPG production 
by Müller glial cells. 
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Figure 4.11 Knockdown of the IF proteins GFAP and Vimentin has no discernible effect on 
CSPG deposition in the degenerating Rho-/- retina.  
Reactive gliosis is typically associated with upregulation of CSPG molecules within the extracellular 
environment. Ai-ii) Staining for CS-56 (grey), a broad-spectrum marker of CSPGs, showed that CSPGs 
are robustly expressed within the photoreceptor segment region of Rho-/- retinae at both Ai 4.5 and Aii 7.5 
weeks of age in untreated mutants, increasing moderately with age. Administration of RNAi targeting 
vectors (red) had no effect on CSPGs deposition within the photoreceptor segment region and no visible 
differences between any of the four examined vectors were observed at either Bi-vi) 3 (4.5 weeks of age) 
Ci-vi) 6 weeks post-transduction (7.5 weeks of age). Retinal cryosections were counterstained with nuclei 
marker Hoechst 33342 (blue). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; 
IS/OS – inner/outer segment region. Scale bars: 20 µm. 
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4.2.7 Downregulation of IF protein levels has no effect on the number of 
integrating cells following photoreceptor transplantation 
Previous studies have indicated that reactive gliosis and increased levels of IFs are 
associated with a poor photoreceptor transplantation outcome (Barber et al., 2013), 
and the impaired ability of retinal grafts (Zhang et al., 2004) and electronic implants 
(Pardue et al., 2001) to contact the host retina. However, it is not clear if these are 
causative, or simply correlative. Having shown that Gfap and Vimentin can be 
effectively suppressed in the degenerating retina, we next sought to assess whether or 
not these changes influence photoreceptor transplantation outcome.  First, P10 Rho-/- 
recipient mice received AAV.shCon in one eye and either AAV.shGfap or AAV.shVim 
in the contralateral one. After 3 (for AAV.shGfap) or 6 (for AAV.shVim) weeks, both 
eyes received a single injection of P8 donor Nrl.GFP+/+ cells into the subretinal space, 
between the host neural retina and the RPE, as previously described (Pearson et al., 
2012). The number of GFP+ve labelled cells within the host ONL was assessed 3 weeks 
post-cell transplantation. 
All recipient retinae, receiving AAV.shCon, AAV.shGfap or AAV.shVim followed by cell 
transplantation, tolerated the double surgery well and presented normal retinal 
structure with little or no signs of inflammation. Since transduction efficiency could only 
be determined post-hoc, only those retinae presenting robust expression of RFP in the 
same region as the donor cell mass were included in the assessments of 
transplantation outcome; in this instance, RFP expression serves as an indirect 
indicator of GFAP/Vimentin knockdown, as shown earlier. Each of the cohorts 
receiving the control vector presented low numbers of GFP+ve cells within the host 
ONL, similar to those seen in untreated 4 week old Rho-/- recipients (Barber et al., 
2013). Despite widespread viral transduction, we observed no significant differences in 
the number of GFP+ve cells within the host ONL in the eyes transduced with either 
AAV.shGfap (Figure 4.11A) or AAV.shVim (Figure 4.11B), compared to the 
contralateral ones treated with AAV.shCon (Figure 4.11). Others have reported 
significantly increased numbers of reporter labelled donor cells in the host retina 
following transplantation into retinae where both GFAP and Vimentin proteins are 
abolished (Kinouchi et al., 2003). To test this hypothesis, donor cells were transplanted 
into eyes injected with a combination of AAV.shGfap and AAV.shVim at 6 weeks post-
viral transduction and assessed transplantation outcome 3 weeks after that. As 
mentioned in Section 4.2.4, combining the two vectors is associated with a high 
incidence of ocular abnormalities; however, in the three eyes that retained reasonable 
retinal architecture, we observed numbers of GFP+ve cells similar to that seen in 
AAV.shCon treated retinae (Figure 4.11C). Taken together, these results indicate that 
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manipulating GFAP and Vimentin and the subsequent prevention of Müller glial 
hypertrophy at the apical margin of the degenerating retina does not affect 
photoreceptor transplantation outcome. The observed discrepancy between this and 
other studies could be explained by the fact that the majority of previous findings come 
from studies of the Gfap or Vimentin knowckout animals or where animal model 
suffered from an acute injury, rather than a chronically diseased state. Howver, findings 
presented int this chatpter are in line with previous reports where reporter labelled cells 
were observed in the retinae of other degenerative mutants including rds that showed 
elevated levels of IFs (Barber et al., 2013; Santos-Ferreira et al., 2014). In light of 
recent publications on cell transplantation (Pearson et al., 2016; Santos-Ferreira et al., 
2016; Singh et al., 2016), it is not possible to give any indication on whether the 
reporter labelled cells observed in the recipient retina were the truly integrated cells or 
whether they were a result of a material transfer/cytoplasmic fusion. Future studies 
should investigate this issue further as it would be interesting to see whether the 
removal of IFs and/or decreased glial hypertrophy have any direct impact on cell 
integration or material transfer/cytoplasmic fusion.   
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Figure 4.12 Knockdown of Gfap or Vimentin and inhibition of Müller Glial hypertrophy 
does not affect photoreceptor transplantation outcome in the degenerating retina. 
 Ai) Scatter plots show number of GFP+ve photoreceptors in the host ONL following transplantation into 4.5 
week old Rho-/- at 3 weeks post-transduction with AAV.shCon or AAV.shGfap. No difference between 
these two groups was observed. Aii-iii) Representative confocal projection images of GFP+ve cells (green) 
in Aii) AAV.shCon- and Aiii) AAV.shGfap-transduced (red) retinae. Bi) Scatter plots show number of 
GFP+ve photoreceptors in the host ONL following transplantation into 7.5 week old Rho-/- mice, at 6 weeks 
post-transduction with AAV.shCon or AAV.shVim. No difference between either two groups was observed. 
Representative confocal projection images of transplanted Nrl.GFP+/+ cells (green) in Bii) AAV.shCon- and 
Biii) AAV.shVim-transduced (red) retinae. Ci) A higher-than-average failure rate was observed in 
AAV.shGfap/shVim co-transduced eyes (5) eyes injected showed number of surviving donor cells (12 
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eyes in total received the combined injection). In those eyes treated with AAV.shGfap/shVim that retained 
donor cell masses (n = 3/8), the number of GFP+ve cells in the host ONL was unchanged, compared to 
eyes treated with AAV.shCon. Representative images of GFP+ve cells in Cii) AAV.shCon and Ciii) 
AAV.shGfap/shVim dual-treated retinae. Unpaired Student’s t - test. Error bars: SEM; n3 independent 
eyes examined. Retinal cryosections were counterstained with nuclei marker Hoechst 33342 (blue). INL, 
inner nuclear layer; ONL, outer nuclear layer. Scale bars: 20 µm. 
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4.3 Discussion 
Reactive gliosis is a complex process that is considered to represent a cellular 
response to protect the retina from further damage and to promote its repair following 
pathological insult. It includes morphological, biochemical, and physiological changes, 
which may vary depending on a type and degree of the initial injury. Given the 
contradicting evidence on the role of IF proteins in this process, we sought to assess 
GFAP and Vimentin in a mouse model of chronic retinopathy. This study showed that 
levels of GFAP and Vimentin in the Rho-/- mutant could be effectively reduced using 
AAV vectors. Interestingly, reducing levels of Vimentin prevented Müller glial cells from 
undergoing degeneration-associated hypertrophy at their apical terminal processes. 
With regard to therapeutic application, neither AAV.shGfap nor AAV.shVim had any 
significant effect on photoreceptor transplantation outcome. 
In the vertebrate retina, Müller cells account for approximately 90% of the glial 
population and exhibit a complex structural architecture spanning its entire thickness. 
Together, with astrocytes, these cells perform a variety of physiological roles, including 
supplying metabolic support by means of glutamine and taurine in the normal retina, 
maintaining K+, H+, and water balance, protecting against oxidative stress, recycling 
cone photopigments, releasing neuro- and vasoactive substances, and serving as 
scaffolds for neurovascular guidance (reviewed in (Bringmann et al., 2006)). Under 
normal conditions, retinal Müller cells are quite flexible and they predominately express 
Vimentin. After injury, however, they undergo a rapid change in the composition of their 
cytoskeleton, including the increase in the density of the IFs (Lu et al., 2011) and 
sprouting of their processes that grow widely throughout the retina (Lewis et al., 1989; 
Lewis and Fisher, 2003). Over the years, researchers have tried to identify the role that 
IF proteins may have in the development of gliosis, but there remains significant 
debate and little consensus, especially with reference to GFAP.  
In contrast to actin filaments, IF proteins are cell-specific, meaning they are found in a 
limited number of cell types and their expression may differ between developmental 
stages and adulthood as well as different pathological conditions. Interestingly, the 
filaments themselves may be composed of different IF proteins that co-depend on each 
other to assemble into a typical 10-nm IF bundle (Lewis and Fisher, 2003). Most cells 
retain relatively small amounts of soluble tetrameric oligomers of Vimentin and GFAP 
compared with their polymerized filamentous forms. Under normal conditions, Müller 
glial cells maintain high levels of filamentous Vimentin but GFAP is expressed only 
minimally. GFAP is, however, abundantly expressed in the retinal ganglion layer (GCL) 
astrocytes (Fernández-Sánchez et al., 2015). Although, Vimentin is the main IF protein 
expressed by both immature retinal progenitors and adult Müller glial cells, it is GFAP 
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that has received the most attention for study as it has been perceived as an indicator 
of retinal ‘stress’.  
In the uninjured retina, GFAP is normally found in astrocytes and inner half of the 
retinal Müller cells and their end feet terminals; however basal levels of GFAP in Müller 
glia may vary between different species, as well as between individual cells within the 
same retina (Dreher et al., 1992; Sarthy and Ripps, 2001; Lewis and Fisher, 2003). 
This likely explains why we found the levels of GFAP in cultured Müller glia fluctuating 
between individual cells even within the same well (Figure 4.3). In contrast, GFAP was 
reported to be uniformly distributed within the cytoplasm of astrocytes. Following 
trauma to the retina, such as retinal detachment, GFAP undergoes rapid upregulation 
in the Müller glia (Guérin et al., 1990; Fisher and Lewis, 2003). Elevated levels of 
GFAP have also been found after the introduction of retinal ischemia (Kim et al., 1998) 
or hypoxia (Kaur et al., 2007). In studies on experimental glaucoma, increases in the 
expression of Gfap and another IF, Nestin were reported as early as 2h after induction 
of elevated intraocular pressure (Xue et al., 2006). Although, the Gfap mRNA levels 
rapidly increase in Müller cells following the initial retinal insult, they do revert to normal 
levels a few days later (Sarthy and Egal, 1995); however, the newly formed filaments 
may remain in the glial cells for many months after injury (Seoane et al., 1999). Cao et 
al. reported that the magnitude of the GFAP response to mechanical insult is age-
dependent, meaning that the older the retina, the more marked the response (Cao et 
al., 2001). In contrast, in the models of inherited retinopathies, the increase in GFAP 
levels is a gradual process and it may take weeks or months depending on the type of 
retinal condition (Ekström et al., 1988; Hippert et al., 2015). In this study, AAV.shGfap 
successfully prevented upregulation of GFAP in the transduced Müller glia of the Rho-/- 
mutant (Figure 4.5); however, it did not lower the levels of GFAP in astrocytes (Figure 
4.5). One possible explanation for this discrepancy is the inability of the designed 
vector to transduce astrocytes in vivo (Figure 4.6). Another possibility is that although 
the vector may have been able to lower Gfap mRNA levels, but no observable effects 
at the protein level were observed in astrocytes as it takes time to remove the formed 
IF bundles (Lewis et al., 1989; Humphrey et al., 1997; Seoane et al., 1999). Future 
experiments to look at a later time point should be able to rule out this possibility. 
Another explanation is the difference in the GFAP response that could be cell specific. 
It is well known that in Müller glia, Gfap transcription is triggered by a variety of 
regulatory elements that differ from those that control Gfap expression in astrocytes 
(Brenner, 1994; Brenner et al., 1994; Verderber et al., 1995).  
Vimentin is present during development and its expression is maintained throughout 
adulthood (Cochard and Paulin, 1984). As one of the major IFs in the glial cells, 
Vimentin has multiple functions, including the regulation of cell cytoskeleton via its 
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intimate relationship with microtubules (Goldman et al., 1996). Ivaska et al. reported 
that Vimentin takes part in the regulation of proteins that are associated with cell 
migration, cell adhesion and signalling (Ivaska et al., 2007). They suggested that in the 
absence of Vimentin, or its malfunction, some processes become compromised, which 
could lead to abnormal protein expression or perturbations in normal signalling 
pathways. For example, it was reported that wounded mice that lack the Vimentin gene 
heal slower than their wild-type counterparts (Eckes et al., 2000).  
Although the precise role of GFAP and Vimentin is yet to be determined, studies with 
the use of transgenic animals helped to shed some light on the topic. Under normal 
conditions, Müller glia are much softer than neurons, which helps them to maintain 
structural integrity within the retina and protect neuronal cells in case of a mechanical 
insult. Following retinal damage and development of reactive gliosis, Müller glia lose 
this flexibility and become more rigid (Lundkvist et al., 2004), most likely due to an 
increase in the density of IFs (Lui et al., 2011; Lu et al., 2013). This increase in 
stiffness is a major factor that contributes to viscoelastic properties of the glial cells and 
is coupled with a remodelling of the glial network and is associated with changes in the 
retinal architecture, such as folding and shrinkage (Lu et al., 2011). Interestingly, in 
mutant mice lacking both GFAP and Vimentin, Müller glia show similar biomechanical 
properties as Müller glia in the uninjured wild-type retina, even when exposed to 
mechanical damage (Lu et al., 2011). Although, the exact purpose of this increased 
stiffness is not known, it has been suggested that it may serve as a regulatory 
mechanism that helps to stabilise the delicate neuronal network and compensate for 
any loss of mechanical tension caused by the loss of photoreceptors (or other retinal 
cells). This stiffness could also have a negative impact on regeneration and therapeutic 
interventions, as rigid scars may impair neurite outgrowth and may contribute to poorer 
regenerative abilities of the mammalian retina. Therefore, inhibition of the upregulation 
of IF proteins in Müller glia may ease neuronal plasticity and axonal sprouting after the 
retinal injury (Cho et al., 2005).  
In pathological conditions associated with photoreceptor degeneration, the 
upregulation of IFs in Müller glia is associated with their hypertrophy, which contributes 
to the formation of a glial scar at the outer edge of the neuroretina (Fan et al., 1996; 
Lewis and Fisher, 2000). For example, any trauma to a retina result in dramatic 
changes in Müller glia morphology which are mirrored by the alterations in IFs levels in 
the majority of the vertebrates. There are striking exceptions, however; Müller glial cells 
in the ground squirrel retina do not become activated and do not show any 
upregulation of IF proteins in response to retinal injury (Linberg et al., 2002). Studies 
on Gfap-/-/Vim-/- knockout mice have reported that, following retinal detachment, the 
absence of IFs results in fewer morphological alterations in the glial cells and a marked 
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reduction in reactive gliosis (Kinouchi et al., 2003; Lundkvist et al., 2004). On the other 
hand, in single Gfap-/- mutant mice, Tatzelt et al. reported that following scrape-induced 
neurodegeneration, the glial response was similar to that of wild-type animals (Tatzelt 
et al., 1996). This could be explained by the fact that formation of the ‘functional’ IFs 
depends on copolymerisation of different IF proteins and that in the absence of GFAP, 
IF can still be formed due to the presence of other IFs proteins, such as Vimentin. In a 
study by Pekny et al., the authors reported that in the ‘uninjured’ brain of the Gfap-/- 
mutant, Vimentin is enable to self-polymerise in the absence of GFAP to form IFs in 
astrocytes (Pekny et al., 1995). In contrast, following the mechanical insult and 
activation of astrocytes, IFs were formed due to an increase in Nestin expression and 
its copolymerisation with Vimentin, which also led to development of the glial scar. In 
the current study of a model of RP, despite successful prevention of GFAP 
upregulation, Müller glial cells still underwent morphological changes associated with 
glial hypertrophy (Figure 4.5 and Figure 4.10). In line with these findings, Cuenca et al. 
also demonstrated that knockdown of Gfap gene in Xenopus does not prevent Müller 
glia from a formation of a glial scar (Martinez-De Luna et al., 2016). Interestingly, our 
study indicates that Vimentin may play a previously underappreciated role in 
establishing Müller glial cell hypertrophy; reducing Vimentin in a model of chronic 
retinal degeneration results in changes in glial hypertrophy and a reduction in the 
extent of the glial scar, compared to (degenerating) control retinae (Figure 4.10). This 
finding is in accordance with Lewis and Fisher study in the feline retina, where only the 
Vimentin+ve Müller glial processes grew into the subretinal space and formed the glial 
scar following the retinal detachment (Fisher and Lewis, 2003; Lewis and Fisher, 
2003). Further evidence for the role of Vimentin in the extension of Müller glia 
processes may come from the studies on the retina of ground squirrels. As mentioned 
previously, following retinal detachment Müller glia do not become reactive, proliferate 
or migrate in this species and show no upregulation of GFAP protein (Linberg et al., 
2002; Merriman et al., 2016). Interestingly, Linberg et al. reported an increase in 
Vimentin levels in the Müller glia end feet and around surviving photoreceptors 
(Linberg et al., 2002). They also reported that despite the lack of Müller glia reactivity, 
the glial processes were still able to fill the empty spaces left by dead photoreceptors, 
preserving the general retinal structure. Moreover, it has been found that in Vimentin 
knockout mice, reactive brain astrocytes are able to form some IF that consist mainly of 
GFAP, but the filaments instead of assembling into loose bundles, form abnormal 
packed ones (Eliasson et al., 1999). This is perhaps not surprising as Vimentin has an 
intimate relationship with microtubules and it has been suggested that it serves as a 
facilitator in the assembly of other IF proteins, including GFAP (Galou, 1996). In this 
study following downregulation of Vimentin with AAV.shVim we did not observe any 
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major structural abnormalities. Müller glia apical terminals did not increase over time as 
in the AAV.shCon transduced eyes, but the knockdown effect was only visible at the 
later time point (Figure 4.7 and Figure 4.10). Moreover, studies of Vimentin knockout 
mice showed that in the injured brain, astrocytes may be able to form some GFAP-only 
IFs, as alterations of Vimentin significantly decrease Nestin and Synemin protein 
expression (Eliasson et al., 1999). Of the latter, Jing et al. reported that accumulation 
of Synemin at the protein level requires functional Vimentin (Jing et al., 2007). Further 
support for the intimate relationship between IF proteins comes from our study, as 
targeting both GFAP and Vimentin resulted in more prominent structural abnormalities 
in chronic retinal degeneration (Figure 4.8). These findings could indicate that the 
formation of IFs in Müller glia requires at least one of the two IFs studied, but when 
both of them are removed, functional IFs may not be able to form efficiently, if at all. 
Although, the lateral spread of Müller glia processes was not inhibited in the 
AAV.shGfap injected eyes at 3 weeks post-transduction, future experiments should 
look into the 6 weeks time-point to confirm this result. It would also be interesting to 
examine the impact of Vimentin removal from Müller glia in the non-degenerating 
retina, as in the non-activated state, Vimentin is the primary IF protein expressed in this 
cell type. Further experiments should also look into the expression of different IF 
proteins, such as Nestin and Synemin, in those retinae treated with AAV.shGfap and 
AAV.shVim, as well as examining the assembly of IFs following the removal of the 
Vimentin using electron microscopy.  
Retinal glial cells are responsible for the maintenance of the inner and outer blood-
retinal barrier integrity, which consists of densely-packed tight junctions between 
endothelial cells (Kaur et al., 2007). Disruptions to it and abnormal migration of 
microglial and vascular cells into the vitreous are common to a variety of retinal 
pathologies, including diabetic retinopathy and retinal detachment (reviewed in 
(Bringmann et al., 2009a)). These migrated cells exert traction on the retina, which can 
lead to retinal detachment. The formation of the glial scar has been proposed to protect 
the neuroretina from further damage, especially pathogenic factors present in the 
vitreous and/or injured RPE. In order to increase the neuronal cell survival, activated 
Müller glia start to produce a number of neurotrophic, and other, growth factors 
including FGF, as well as several antioxidants, molecules that are not normally 
secreted in the healthy retina (reviewed in (Bringmann and Wiedemann, 2012)). 
Studies with Gfap-/-/Vim-/- animals showed that genetic removal of GFAP and Vimentin 
leads to accelerated monocyte infiltration and faster degeneration of photoreceptors 
following retinal trauma (Nakazawa et al., 2007). In the genetic absence of both GFAP 
and Vimentin together, the end terminals of Müller glia become thinner, which leads to 
abnormal morphology of the glial cells and shearing of the glial end feet. As a result, 
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the glial terminals may separate from the rest of the cell body and eventually detach 
from the neuroretina (Lundkvist et al., 2004; Verardo et al., 2008). Moreover, it was 
reported that mortality rate is much higher in Gfap-/-/Vim-/- animals following a brain 
trauma, in comparison to controls (Lundkvist et al., 2004). In this study, the combined 
injection of AAV.shGfap and AAV.shVim resulted in major structural defects including 
collapse of the neuroretina, retinal detachment or the failure of the eye to develop in 
the majority of injected eyes, which further supports the importance of IFs in 
maintaining the retinal architecture under degenerative conditions. However, others 
have reported that neural regeneration increased and CNS functions improved 
following pathological insult to Gfap-/-/Vim-/- retina (Kinouchi et al., 2003; Verardo et al., 
2008) or spinal cord (Menet et al., 2011). Moreover, it has been illustrated that in the 
injured spinal cord, silencing of GFAP and Vimentin mediated by RNAi-containing 
lentiviral vectors (under the PGK promoter and pseudotyped with the Mokola envelope 
for glial specificity) leads to a significant reduction in the extent of astrogliosis, increase 
in axonal sprouting and improvement in functional motor recovery (Desclaux et al., 
2015). However, the majority of these reports come from studies using an acute injury 
or induced pathological condition, rather than a chronically diseased state. In this 
study, we assessed the impact of GFAP and Vimentin removal paired with 
photoreceptor cell transplant in a mouse model of degenerative retinopathy, which is 
caused by a knockout of Rhodopsin gene that leads to photoreceptor loss. We found 
that reduction of GFAP and/or Vimentin had no effect on the outcome of the cell 
transplantation, which is in line with previous findings where donor cells successfully 
integrated in the retinae of other degenerative mutants that showed elevated levels of 
IFs (Barber et al., 2013; Santos-Ferreira et al., 2014).  
Taking into account contradicting reports from numerous studies, it is reasonable to 
conclude that the absence or malfunction of IF proteins has different effects on 
vulnerability of the retina based on both the type of the pathological insult and the 
species. This is supported by findings from a variety of studies examining signalling 
pathways that are proposed to inhibit the up-regulation of IFs. For example, 
upregulation of GFAP and glial scarring following retinal detachment were reduced by 
introducing exogenous brain derived neuronal factor (BDNF) (Lewis et al., 1999). The 
same approach, however, did not affect the GFAP up-regulation induced by optic nerve 
crush (Chen and Weber, 2002), which further supports the complexity of the IF 
responses.  
The complexity of retinal glial reactivity to pathological insult is further complicated by 
the heterogeneity of Müller cells, which may lead to different responses among 
individual cells and between Müller cells in different species. As mentioned before, 
there are species-specific differences in the distribution of IF proteins even in non-
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reactive Müller glial cells. For example, in mouse, squirrel and rabbit Vimentin is found 
in high levels across the entire Müller cell, whereas in feline and human cells Vimentin 
is only expressed in their outer glial terminals (Okada et al., 1990b). In most 
mammalian species, retinal detachment results in Müller cell proliferation, hypertrophy, 
and an increase in the expression of GFAP. However, these alterations were not 
observed after detachment of the cone-dominant ground squirrel retina (Linberg et al., 
2002; Merriman et al., 2016). In the chick retina, NMDA-induced retinal damage 
caused heterogeneity of glial response even within the same region of the retina (Lewis 
and Fisher, 2003). In the injured regions, around 65% of the Müller cells re-entered the 
cell cycle, while the remaining 35% did not. Luna et al. showed that following retinal 
injury Müller cells started to upregulate GFAP, Vimentin and Nestin on individual basis 
rather than across all the cells in a uniform manner (Luna et al., 2010). Moreover, it 
was suggested that GFAP plays a role in regulating glial proliferation as only cells that 
failed to increase GFAP expression re-entered cell cycle (Fisher and Lewis, 2003). 
This heterogeneity of glial responses has also been reported following spinal cord 
injury. In recent study by Wanner et al. reactive astrogliosis was noted to be very 
heterogeneous and it can be graded with respect to distance from the injury and the 
type of activated astrocytes found around the lesion site (Wanner et al., 2013). 
Additionally, as in the retina, neighbouring astroglial cells have also been reported to 
present a unique pattern of molecular expression that further contributes to complexity 
of glial responses. Such observations raise some fundamental questions about the 
heterogeneity of signalling pathways that activate the glia cells, a diversity of glia 
participating in the cellular response, and the signalling mechanisms that are activated 
in response to different types of injury. The above examples only highlight the 
complexity of gliosis, indicating that it is not a simple all or nothing response, but rather 
a variable process with respect to alterations in cell morphology, proliferation and 
molecular expression, all of which are tuned in a situation-specific manner to different 
pathological stimuli. 
In the retina of warm-blooded vertebrates, development of the glial scar within and at 
the margin of the injured tissue is one reason for the failure of the system to 
regenerate. In contrast, cold-blooded vertebrates such as fish and amphibians retain 
the capability of full retinal regeneration into adulthood. It is tempting to ask what the 
relationship between the development of gliosis and regeneration is, and whether 
gliosis is just a failed regenerative programme in the mammalian retina. Numerous 
studies showed that activation of Müller cells causes upregulation of Vimentin and 
Nestin, which are the markers of progenitor cells. The re-expression of Nestin by 
reactive glia in the injured mature retina may reflect the differentiation of the cells 
toward becoming neurogenic progenitors (Goel and Dhingra, 2012). It was reported 
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that after retinal detachment, Nestin is localised to the foremost processes of the glial 
cells that grew into the subretinal space, as well as in proliferating Müller glia (Luna et 
al., 2010). Lewis et al. demonstrated that following the detachment the nuclei of Müller 
cells migrate towards the outer retina using Vimentin filaments, where they proliferate 
and re-enter the cell cycle (Lewis et al., 2010). Future studies should look into this idea 
to see how GFAP and Vimentin knockdown affects other IFs and whether this may 
have any impact on cell proliferation. 
To conclude, in this study we showed that two IFs, Vimentin and GFAP, could 
successfully be decreased in a mouse model of chronic retinal degeneration using AAV 
vectors. We showed that, in this context, knockdown of Vimentin alone is sufficient to 
largely prevent Müller cell hypertrophy indicating that the role of Vimentin in glial 
scarring may have been largely overlooked. Although we did not see any significant 
impact on the outcome of cell transplantation, decreasing levels of IF proteins may be 
still of therapeutical interest. For example, reactive Müller cells contribute to two 
causes of blindness: subretinal fibrosis and proliferative vitreoretinopathy. In this study, 
the hypertrophy of the Müller processes was shown to be minimised following RNAi. 
This strategy may help to regenerate the photoreceptor OS following retinal 
reattachment. Moreover, the designed vectors may be of potential use when 
considering the implantation of retinal prosthetics or retinal sheets as glial remodelling 
may be a major limiting factor with these therapeutic approaches. It has been 
suggested that development of the glial scar impedes the contact between the 
implants/grafts and the host neuroretina by creating a physical barrier between the two. 
For example, transplantation of the whole retinal sheets was proved to be feasible with 
the establishment of proper neuronal connections between the graft and host retina; 
however in many cases the transplanted retina and the host were not well integrated 
(Radtke et al., 1999; Peng et al., 2008; Seiler et al., 2009). The same applies to electric 
retinal implants such as Angus III as the glial scarring may have a significant impact on 
these devices especially when implanted subretinally limiting their contact with the host 
neuroretina (Stingl et al., 2013). This study may therefore help to optimise or even 
ease some of the therapies for patients suffering from advanced retinopathies. 
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Chapter 5 
CSPGs modulation in the mouse 
model of retinitis pigmentosa 
  
197"
5.1 Overview 
In the central nervous system (CNS), the majority of damaged axons fail to regenerate 
following injury. This failure is due in part to the response by glial cells, including the 
upregulation of inhibitory molecules in the extracellular matrix (ECM), which may 
present a potent barrier to neuronal regeneration (Yiu and He, 2006).  
An important class of inhibitory ECM molecules are the chondroitin sulphate 
proteoglycans (CSPGs), a diverse group of glycoproteins, which also represent one of 
the most abundant groups of ECM proteins. The inhibitory action of CSPGs has been 
attributed to the abundance of negatively charged glycosaminoglycan (GAG) chains 
that decorate the core protein (Galtrey and Fawcett, 2007). These GAG chains vary in 
length, number and sulphation pattern and were shown to determine the unique 
functions of different proteoglycans (PGs). Several types of CSPGs, including 
Aggrecan, Versican, Neurocan, Brevican and Phosphacan, are found in adult CNS 
tissue and are variously expressed throughout the brain, spinal cord and eye, where 
they are condensed into perineuronal nets surrounding CNS neurons (Brückner et al., 
2000). By interacting with other components of the ECM environment, these PGs 
regulate a wide range of different cellular processes including cell adhesion and 
growth, receptor binding, cell migration and synaptic plasticity. Following CNS injury, 
CSPGs are upregulated (McKeon et al., 1995; Fitch et al., 1999; Jones et al., 2002; 
Morgenstern et al., 2002; Jones et al., 2003a) and appear to inhibit neurite outgrowth 
from adult neurons (Snow et al., 1990; Davies et al., 1999). Digestion of the GAG side 
chains using a bacterial chondroitinase ABC (ChABC) enzyme abrogates CSPG-
dependent neurite outgrowth inhibition in vitro and improves neurite sprouting and 
functional recovery after spinal cord injury (SCI) (McKeon et al., 1995; Zuo et al., 1998; 
Bradbury et al., 2002; Grimpe et al., 2005). Interestingly, the upregulation of CSPGs 
has also been linked to some psychiatric conditions including bipolar disorder, 
schizophrenia and ADHD (reviewed in (De Luca and Papa, 2016)). In recent years, 
Protein tyrosine phosphatase sigma (PTPsigma), Leukocyte common antigen related 
phosphatase (LAR) and Nogo R have been identified as neuronal receptors that 
functionally interact with and mediate CSPG-dependent inhibition of axonal growth 
(Shen et al., 2009; Fisher et al., 2011; Dickendesher et al., 2012).  
In adult retina, CSPGs are found in several regions including the optic nerve, inner 
(IPL) and outer plexiform layer (OPL) and the photoreceptor inner/outer segment 
(IS/OS) region (Zhang et al., 2003b; 2007; Hippert et al., 2015). Numerous studies 
have reported that CSPG levels are increased in a wide spectrum of retinopathies, 
including optic nerve damage and transient retinal ischemia (Inatani et al., 2000; 2001; 
Zhang et al., 2007; Singhal et al., 2008). Recently, a comprehensive assessment by 
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our group showed spatio-temporal differences in the expression of CSPGs between 
different models of inherited retinopathy (see Chapter 3; (Hippert et al., 2015)). Such 
changes have also been linked to poorer therapeutic outcome. Findings from studies of 
cell replacement strategies have indicated that increased CSPGs deposition in the 
diseased retina is correlated with poor cell transplantation outcome, while enzymatic 
reduction of CS GAGs results in increased numbers of donor-labelled cells in the host 
retinae (Suzuki et al., 2007; Singhal et al., 2008; Barber et al., 2013). For example, 
Rho-/- animals, where the number of GFP+ cells in the recipient retina after 
transplantation was very low (Barber et al., 2013) presented high levels of CSPGs from 
the onset of degeneration, and this continued to rise throughout the course of disease 
(see Chapter 3, and (Barber et al., 2013; Hippert et al., 2015)). In contrast, in 
PDE6brd1/rd1 recipients, where the number of observable donor-labelled cells in the host 
retina was higher (Barber et al., 2013), there was a marked decrease in global CSPGs 
expression over time (see Chapter 3 and (Hippert et al., 2015)).  
While it has been generally accepted that CSPGs exert a largely inhibitory impact to 
the regenerative process, this may be an oversimplification. For example, growth-
promoting features have been attributed to several CSPGs in their soluble (Brittis and 
Silver, 1994; Greenfield et al., 1999) and over-sulphated form (Bicknese et al., 1994; 
Nakanishi et al., 2006; Sato et al., 2008). Moreover, CSPG distribution may not be 
uniform at the lesion site, with different CSPGs having unique patterns of expression 
(Tang et al., 2003). This suggests that different PGs may have different roles in 
modulating the spread of the injury. In keeping with this idea, a reduction in Neurocan 
and Versican have both been reported to be beneficial to cell transplantation outcome 
(Zhang et al., 2007; Singhal et al., 2008); however as both PGs were shown to be 
expressed in the wild-type retina in the IS/OS region (Zhang et al., 2003b), it is 
possible that upregulation of other PGs may be detrimental to therapeutic 
interventions.  
Aggrecan is one of the major CSPGs expressed in the central and peripheral nervous 
system of embryos and adults (Oakley and Tosney, 1991; Schwartz et al., 1996). In the 
normal CNS, this PG is produced by glial precursor cells and strongly influences 
neurite outgrowth (Domowicz et al., 2008; Afshari et al., 2010a). It is also required for 
normal astrocyte differentiation (Smith and Strunz, 2005). In the eye, Aggrecan has 
been proposed to be involved in the maintenance of the normal laminar structure of the 
adult retina (Lemons et al., 1999; Ali et al., 2011; Chen et al., 2012a). Findings from the 
injured CNS showed that Aggrecan has a negative impact on Schwan cell migration 
following transplantation after SCI by inhibiting integrin mediated cell adhesion (Afshari 
et al., 2010b). Later, Chen et al. reported that Aggrecan is markedly upregulated in a 
rat model of retinal dystrophy, particularly around the IPL (Chen et al., 2012b). To date, 
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no reports on Aggrecan expression in mouse models of retinitis pigmentosa (RP) have 
been published. Given the negative role of Aggrecan on neuronal regeneration in other 
systems, this study sought to establish whether changes in the levels of Aggrecan 
could, either wholly or partially, account for the reported differences in cell 
transplantation outcome by Barber et al. (Barber et al., 2013). In this chapter, two 
models of RP, Rho-/- and Pde6brd1/rd1, were chosen to study the expression patterns of 
Aggrecan as disease progressed, compared against wild-type controls. The expression 
pattern of the CSPG receptor LAR in the wild-type and diseased mouse retina was also 
assessed. Finally, an alternative enzymatic treatment to ChABC was also made and 
tested in vivo.   
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5.2 Results 
5.2.1 Müller glia primary culture to study effects of elevated CSPGs  
Following CNS injury, there is a marked upregulation of CSPGs, which are believed to 
contribute to reactivity of the glial cells and development of the glial scar (reviewed in 
(Properzi et al., 2003)). To test whether CSPGs can directly influence Müller glial cell 
reactivity, Rlbp.GFP+/+ cells were cultured on CSPGs substrate and compared against 
untreated controls. 
Two different concentrations (10 and 20 µg/ml of a commercially prepared mix of 
CSPGs (Millipore, UK) were chosen to coat cell plates, according to previously 
published reports (Siebert and Osterhout, 2011; Tan et al., 2011), before adding FACS 
sorted Rlbp.GFP+/+ cells. A full description of the protocol is provided in Chapter 2, 
Section 2.2. Cells that grew on laminin-only substrate were used as a negative control. 
After 2 weeks in culture, ICC analysis was performed to look for changes in Müller glia 
reactivity, resulting from the presence of high levels of CSPGs. 
Cultured Müller glial express a variety of typical glial markers, including the 
intermediate filament (IF) proteins, Vimentin and Glial fibrillary acidic protein (GFAP) 
(see Chapter 3). These two IFs have been shown to be markedly upregulated by 
activated Müller glial cells in both injured and diseased retina models (Ekström et al., 
1988; Sheedlo et al., 1995; Fan et al., 1996; Inatani et al., 2001; Escher et al., 2008; 
Hippert et al., 2015). As already demonstrated in Chapter 4, Vimentin is highly 
expressed by Müller glial cells in vitro with no major differences between individual 
cells (Figure 5.1A'). In contrast, GFAP staining was found to be very sparse in Müller 
glia grown in the absence of CSPGs (Figure 5.1A'), which is in line with previous 
reports (Chapter 4; Abrahan et al., 2009). Interestingly, there was a notable increase in 
the number of cells expressing GFAP in the wells coated with CSPG mix (Figure 5.1B'-
C'), compared to untreated controls. A closer examination of the morphology of the 
cells grown on CSPGs substrate revealed changes that were concentration dependent. 
Those that were cultured on CSPGs had smaller nuclei and were thinner, with a more 
elongated profile, compared to cells grown on laminin only coated plates. Interestingly, 
in the presence of high concentrations of CSPGs, the glial processes appeared 
increasingly tangled and formed aggregates, which were not observed in the control 
cultures. These morphologies were particularly evident in the wells with higher 
concentration of CSPGs (Figure 5.1A). 
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Figure 5.1 Müller glia morphology is altered in the presence of high CSPGs levels in vitro 
A) After 2 weeks in culture on laminin-coated plates, Müller cells showed a robust expression of A) 
Vimentin (red), but only a very sparse staining for A') GFAP (green), with no visible changes to cell 
morphology. B - C) Cells that grew in the presence of high levels of CSPGs visibly changed appearance, 
with smaller nuclei and a more condensed morphology, in a concentration-dependant manner. Moreover, 
high levels of CSPGs resulted in Müller glial cells forming aggregates 20 µg/mL of CSPGs substrate. All of 
these morphological changes were accompanied by a visible upregulation in GFAP. Cells were 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar: 50 µm. 
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To test whether the observed changes in Müller glia were caused by high levels of 
CSPGs, rather than a lack of adhesion, Müller glial were first cultured for 2 weeks on 
laminin-only coated plates, and pre-assessed under a white-light microscope before 
the addition of CSPGs mix. Two concentrations were used and added to cultures at 
intervals of 2 days for one week to account for any intrinsic degradation mechanisms 
(Figure 5.2). Cells were assessed for morphological changes 1 week post-treatment 
with ICC analysis. 
In the absence of CSPGs (Figure 5.2A), cultured Müller glia showed flattened 
morphology similar to that observed in the control wells presented in Figure 5.1A. 
Following the addition of the CSPG mix at 2 weeks in culture, there were visible 
changes in glial morphology, although these were not as marked as when the cells had 
been grown on the CSPG substrate from the start of culturing (Figure 5.1B-C). 
Although cells appeared to be more sparsely distributed at first, closer examination 
showed that, in the presence of CSPGs, Müller glia were more likely to form numerous 
cell clusters. These aggregates were very prominent in the wells with the highest 
concentration of CSPGs (Figure 5.2C). The nuclei of the cells also appeared to be 
smaller in comparison to the nuclei in the control wells with the glial processes being 
thinner and more elongated. Together, these findings suggest that CSPGs may have 
an impact on Müller glia behaviour, which could be linked to development of the glial 
scar. 
CSPGs have been reported to have an inhibitory role on neurite extension after SCI 
(reviewed in (Fawcett and Asher, 1999; Sharma et al., 2012a)). In other work carried 
out in the lab, Nrl.GFP+/+ photoreceptor precursor cells were shown to extend their 
processes as early as few hours after being added to cultured Müller glial cells (Warre-
Cornish, PhD thesis, 2013). To test whether the presence of CSPGs has any inhibitory 
effect on the outgrowth of Nrl.GFP+/+ processes, on average 10,000 Nrl.GFP+/+ cells 
were added per well 24 hours after the first dose of CSPGs mix and cultured for 7 days 
before plates were fixed and analysed.  
Qualitative assessment showed no observable differences in the number of GFP+ve 
cells between the three (control, low CSPG and high CSPG addition) experimental 
conditions, suggesting that the presence of CSPGs does not have any significant 
impact on photoreceptor precursor survival in vitro (Figure 5.2B i-iii). Closer inspection 
of the cells revealed that in the control wells, numerous GFP+ve cells were observed 
extending long processes out from the cell body (on average 2.7±0.77 processes with 
the average length of 15.84±1.42 µm) and apparently forming contacts with other cells 
(Figure 5.2B i). The presence of high levels of CSPGs did not have a significant impact 
on the measurable length of extended Nrl.GFP+/+ processes (11.48±2.97 in 50 µg/mL 
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of CSPGs; and 12.05±3.1 µm in 100 µg/mL of CSPGs respectively; Figure 5.3C i, 
P=0.083), but the average number of outgrown processes was markedly decreased 
(1.49±0.61 in 50 µg/mL of CSPGs; and 1.33±0.26 µm in 100 µg/mL of CSPGs 
respectively; Figure 5.3C ii, P<0.05). This suggests that in the presence of high 
concentrations of CSPGs, Nrl.GFP+/+ cells are less likely to extend a process, which 
may be of particular importance for cell transplantation where cells are expected to 
grow their processes to make a contact with the host retina. 
Of note, a similar experiment was also performed with Müller glial cells cultured on 
CSPG substrate from the outset (as opposed to adding CSPGs after 2 weeks in 
culture). Unfortunately, no Nrl.GFP+/+ cells were observed at 2 days post-addition in 
any of the wells that had the CSPGs mix used as a substrate (n = 4 independent 
cultures examined; data not shown). This may indicate an unfavourable environment, 
preventing the survival of these cells. Although the composition of the medium that 
cells grew in was not tested, post-culturing, it is possible that in such conditions 
reactive Müller glia release cytokines, which are detrimental to photoreceptor precursor 
cell survival (Fernández-Sánchez et al., 2015).  
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Figure 5.2 CSPGs alter Müller glia morphology and inhibit extension of Nrl.GFP+/+ 
processes in vitro. 
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Ai-iii) ICC analysis of Müller glia stained with Vimentin antibody (grey). Ai) After 3 weeks in culture, Müller 
glia in control wells typically showed a flattened morphology with cell processes covering majority of the 
area. Aii). Cells that grew in the presence of 50 µg CSPGs demonstrated visible changes in their 
appearance with smaller nuclei with Müller glia aggregating into small clumps, Aiii) with more clusters 
being formed at higher levels of CSPGs.  
Bi-iii) Low magnification images showing a good number of Nrl.GFP+/+ (green) after 1 week in culture in 
both control and CSPGs treated wells. Bi’-I’’) In control wells, Nrl.GFP+/+ extended long processes to 
establish a contact with other Nrl.GFP+/+ cells and Müller glia (white arrows). Bii’-ii’’) The length of 
Nrl.GFP+/+ outgrowths (white arrows) appeared to be shorter in the presence of 50 µg CSPGs. Biii’-iii’’) 
with more clusters being formed at higher levels of CSPGs. Cells were counterstained with nuclei marker 
Hoechst 33342 (blue). Scale bars: Ai-iii) and Bi-iii); 50 µm; Ai-iii), 25 µm. Ci-ii) Quantitative analysis of the 
extended Nrl.GFP+/+ processes showed that Ci) although there was no significant decrease in the length 
of the processes in the presence of CSPGs, Cii) the number of extended processes was. *P < 0.05 with a 
one-way ANOVA. Error bars: SD; n=3 independent cultures examined. Scale bar: 25 µm.  
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5.2.2 Aggrecan expression undergoes disease-specific changes in 
different models of retinal degeneration  
As shown in Chapter 3, the Rho-/- mutant exhibits marked upregulation in CSPGs levels 
with degeneration, whereas in the Pde6brd1/rd1 mice CSPGs were found to decrease 
(Hippert et al., 2015). These differences between these two models may explain why 
cell transplantation outcome differed between the two models, with very low numbers 
of donor-labelled cells reported in the Rho-/- recipients (Barber et al., 2013). Above, it 
has been demonstrated that photoreceptor process outgrowth is altered in the 
presence of CSPGs in vitro. One of the main components of the CSPG mix used in 
section 5.2.1 is Aggrecan, which has been shown to similarly influence process 
outgrowth of brain-derived neuronal cells (Snow and Letourneau, 1992; Challacombe 
et al., 1997). To examine whether there are any differences in Aggrecan expression 
between the two models of inherited retinal degeneration, semi-quantitative Western 
blot (WB) analysis was performed and results were compared to age-matched wild-
type controls.  
As previously reported, in a mouse retina, levels of Aggrecan are elevated during 
development but decrease during adulthood (Ali et al., 2011). In wild-type retina, 
Aggrecan was detectable as early as P10 (Figure 5.3A) with levels decreasing with 
age. In the P10 Rho-/- mutant, levels of Aggrecan were high, but decreased by 3 weeks 
of age, after this time they have started to increase again (Figure 5.3B). Statistical 
analysis showed that there was a marked difference between 3 weeks and 10 weeks of 
age, indicating that there is a significant upregulation of Aggrecan in this model of RP 
(P<0.05; Figure 5.3B). Interestingly, in the Pde6brd1/rd1 mice, the pattern of Aggrecan 
expression was reversed, with global levels of Aggrecan significantly decreasing with 
disease progression (between P10 and 6-8 weeks of age; P<0.05; Figure 5.3C). These 
findings are in line with the findings presented in Chapter 3, where global levels of 
CSPGs, as assessed with CS-56, were shown to decrease between early and late 
stages of disease progression in the same model. 
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Figure 5.3 Aggrecan levels are elevated in Rho-/- mice.  
Semi-quantitative assessments of Aggrecan levels in whole neural retina of A) a wild-type; B) Rho-/- and 
C) Pde6brd1/rd1 mutants. Semi-quantitative assessments of CSPG levels in whole neural retina were 
determined by Western blot. Aggrecan levels were normalized against H2B. Statistical significance was 
assessed with a one-way ANOVA test with Tukey’s correction for multiple comparisons; *P < 0.05. Error 
bars: SEM, n=3 animals examined per time point.  
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5.2.3 Injection of ADAMTS-4 enzyme into subretinal space digests some 
but not all CSPG sugar chains  
Application of ChABC is the predominant strategy used to digest CSPGs. Although 
ChABC has been shown to effectively remove GAG chains and resulted in an increase 
in axonal sprouting following CNS insult in rodents ((Bradbury et al., 2002; Caggiano et 
al., 2005), also reviewed in (Bradbury and Carter, 2011)), there are several 
disadvantages of using it clinically, including a potential risk of immune response due 
to ChABC's bacterial origin. Moreover, given the complexities of the roles of CSPGs in 
promoting and inhibiting regeneration, it may be of greater benefit to target specific 
CSPGs, rather than relying on broad spectrum digestion. Upregulation of the proteases 
that are involved in the turnover of the proteoglycans could be an alternative method to 
reduce levels of CSPGs in the ECM environment. For example, treatment with 
naturally occurring catabolic protein, Aggrecanase, also known as ADAMTS-4 (‘A 
Disintegrin and Metalloproteinase with ThromboSpondin Motifs’), could be one 
alternative (Lemke et al., 2010). In humans, this protease is naturally expressed in the 
CNS, including the brain and retina (Tortorella, 1999; Tang, 2001) and was found to be 
capable of cleaving all the large CSPGs, including Aggrecan. As Aggrecan levels 
increase in the Rho-/- mutants with degeneration, the aim of this experiment was to 
determine whether ADAMTS-4 enzyme is capable of reducing its levels in vivo.  
To assess the effectiveness of Aggrecanase in removing CSPGs in the in vivo retina, 
Rho-/- mutants and wild-type animals received a subretinal injection of a recommended 
dose (100 ng/µL per eye) of ADMATS-4 enzyme to either superior or inferior retina at 6 
weeks of age and were analysed 48 hrs later. In parallel, some animals were injected 
with ChABC and were used as a positive control for CSPG degradation. Earle's 
Balanced Salt Solution (EBSS) injected eyes were used as a negative control, to 
control for the injection itself. All the retinae were analysed with IHC using CS-56 
antibody, which binds to sulphated sugar chains, to assess any alterations in the levels 
of CSPG GAG chains following the enzymatic treatment.  
In wild-type retina, CSPGs are abundant in the IS/OS region (see Chapter 3). Figure 
5.4 shows that subretinal injection of EBSS had little or no effect on CSPG deposition 
within the IS/OS region (Figure 5.4A); CS-56 staining was robust even around the site 
of retinal detachment (Figure 5.4A i'; arrow). Similarly, no differences were observed 
between the injected and uninjected regions (Figure 5.4A i''). A similar pattern of CS-56 
staining was observed in Rho-/- animals injected with EBBS (Figure 5.4B i). Although, 
the extent of the retinal detachment following injection in the Rho-/- retina was greater, 
the intensity of CS-56 staining intensity was comparable between the injected (Figure 
5.4B i') and uninjected sites (Figure 5.4B i'').  
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In contrast, injection of ChABC into wild-type led to a marked reduction in CS-56 
staining (Figure 5.4A ii'), compared to the uninjected region (Figure 5.4A ii''). A similar 
pattern was observed in Rho-/- animals, where CS-56 staining was strong in uninjected 
regions (Figure 5.4B ii'), but almost absent in the region injected with ChABC. Injection 
of ADAMTS-4 enzyme into wild-type retinae led to a slight reduction in CS-56 staining, 
in comparison with the uninjected region (Figure 5.4A iii''), and those retinae receiving 
EBSS, although robust staining was still detectable in the IS/OS region (Figure 5.4A 
iii'). In the retina of the Rho-/- mutant, ADAMTS-4 led to a visible reduction in detectable 
CSPGs in the subretinal region (Figure 5.4B iii'), compared to uninjected and EBSS 
treated controls (Figure 5.4B iii''). These results suggest that the enzymatic treatment 
with ADAMTS-4 leads to removal of CSPGs around the segment region that may not 
be present in a healthy retina.  
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Figure 5.4 ADAMTS-4 reduces CSPGs in the photoreceptor segment region of the 
degenerating retina. 
A-B) IHC analysis of CSPGs levels (red) following subretinal injection into a wild-type and Rho-/- retinae at 
6 weeks of age. Ai') In a wild-type retina that was injected with EBBS control solution, CS-56 staining was 
very similar to that observed Ai'') in the uninjected region, even at the site of retinal detachment (arrows). 
Aii') In contrast, treatment with ChABC resulted in almost complete abolishment of CS-56 staining Aii'') in 
comparison to uninjected site of a retina. Aiii') Injection of ADAMTS-4 enzyme into a healthy retina led to 
a visible reduction in CS-56 staining in comparison to Aiii'') the uninjected retina, with some staining still 
being detectable in the IS/OS region.  
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Bi') EBSS injection did not reduce CS-56 staining (red) in the Rho-/- mutants; although the retinal 
detachment was bigger to that seen in a wild-type. Bii') As in a healthy retina, ChABC injection led to 
complete absence of CS-56 staining detectable in the IS/OS region in comparison to Bii'') the uninjected 
region. Biii') ADAMTS-4 enzyme treatment resulted in a noticeable decrease in CS-56 staining (red) Biii'') 
in comparison to uninjected region. n=4 animals examined per each experimental condition. 
Cryosections were counterstained with nuclei marker Hoechst 33342 (blue). GCL, ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 
25 µm. 
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To test whether enzymatic treatment with ADAMTS-4 altered global protein expression 
of CSPGs, and Aggrecan in particular, WB analyses were performed. In the ADAMTS-
4 treated retina, immunoblotting with CS-56 antibody, which detects the GAG portion of 
native CSPGs, showed a small but not significant decrease in wild-type retina eyes 
(P=0.8741; Figure 5.5A). In contrast, a marked decrease in detectable CSPGs in the 
Rho-/- mutant, in comparison to EBSS-injected eyes (P<0.05; Figure 5.5B). 
Surprisingly, despite the observed reduction in CS-56 staining (Figure 5.4A), no 
difference in the global protein levels of Aggrecan was observed in a wild-type controls 
(P=0.9191; Figure 5.5A) or the Rho-/- mutants (P=0.9681; Figure 5.5B), indicating that 
while ADAMTS-4 enzyme cleaves some CSPGs present in the segment region when 
injected into the subretinal space (Figure 5.4B), this may not include Aggrecan. Taken 
together, these results indicate that ADAMTS-4 can robustly digest CSPGs that are 
specific to the IS/OS region and that are abundant in the diseased retina (Figure 5.5A). 
However, it also suggests that Aggrecan, whilst expressed in the retina, is unlikely to 
be present at significant levels in the segment region. 
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Figure 5.5 Global Aggrecan expression was not affected by subretinal administration of 
ADAMTS-4.  
Semi-quantitative assessments of CSPGs and Aggrecan levels in A) a wild-type retina and B) the Rho-/- 
mutant. Semi-quantitative assessments of CSPGs and Aggrecan levels in whole neural retina were 
determined by Western blot. Protein levels were normalized against H2B. Statistical significance was 
assessed with a Student’s t-test. P <0.5; Error bars: SEM, n=4 animals examined per each experimental 
condition.  
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5.2.4 Aggrecan is not a major component of CSPG deposits in the 
photoreceptor segment region  
Given the lack of reduction in global levels of Aggrecan protein following the enzymatic 
treatment, the spatio-temporal distribution of Aggrecan was examined in two models of 
RP and compared to healthy wild-type controls. Ali et al. reported Aggrecan to be 
present throughout all neuronal layers, including the ONL, in the adult wild-type mouse 
retina (Ali et al., 2011). Having developed a working IHC protocol for Aggrecan (using 
the same antibody as the one used for WB analysis), the pattern of Aggrecan 
distribution was examined in the wild-type, Rho-/- and Pde6brd1/rd1 retina.  
In the P10 wild-type retina, Aggrecan was robustly expressed in the IPL and GCL, with 
some weak staining observed in the OPL (Figure 5.6A i). This pattern of distribution 
was maintained throughout adulthood, although the expression in the IPL appeared to 
decrease with age (Figure 5.6A ii-iv). No Aggrecan expression was observed in the 
ONL or segment region, but positive staining was detectable in the choroid (Figure 
5.6A ii-iv).  
In the P10 Rho-/- retina, the distribution of Aggrecan was similar to that observed in a 
wild-type, but staining appeared stronger in the OPL and weak expression was also 
detectable in the IS/OS region (Figure 5.6B i). As degeneration progressed, the 
staining in the OPL decreased (Figure 5.7B ii-iii). At the later examined time points, 6-
12 weeks, Aggrecan staining was restricted to the ONL and INL with an increased 
deposition within the GCL. These increases are in line with the WB findings presented 
in Figure 5.3B, where Aggrecan expression was significantly higher at 10 weeks of 
age, in comparison to P10 retina.   
In the P10 Pde6brd1/rd1 retina, the expression of Aggrecan was quite similar to wild-type 
control (Figure 5.6C i). As degeneration progressed, Aggrecan staining in the IPL 
gradually decreased (Figure 5.6C ii-iv), being quite sparse at the latest examined time 
point (7-8 week old) even within the plexiform layers and the GCL (Figure 5.6C iv). 
Taken together, these data suggest that while Aggrecan is present in the normal wild-
type retina and its expression is increased in degeneration, it is predominantly found in 
the plexiform layers and not at the IS/OS.  
  
215"
 
Figure 5.6 Aggrecan staining is absent from the photoreceptor segment region. 
Ai-iv) C57Bl/6J wild-type; Bi-iv) Rho-/- and Ci-iv) Pde6brd1/rd1. Cryosections were immunostained for 
Aggrecan (green) and counterstained with nuclei marker Hoechst 33342 (blue). 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm. 
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5.2.5 The CSPG receptor LAR is expressed in the murine retina and 
undergoes disease specific changes in expression 
The potent inhibition of neuronal regeneration by CSPGs has been known for more 
than two decades, with the sulphated GAG chains understood to play the major role in 
this inhibition (Snow et al., 1990; McKeon et al., 1995).However, the CSPG binding 
receptors have only been discovered recently (Shen et al., 2009; Fisher et al., 2011; 
Dickendesher et al., 2012). In particular, two members of the LAR subfamily were 
shown to bind CSPGs with high affinity and mediate their suppression of axon 
elongation (Fisher et al., 2011). To date there have been no published reports on their 
expression in a mouse retina. As a first step to examine the potential roles, IHC 
analysis was performed on wild-type and the same two models of RP as described 
above, to assess spatial distribution of LAR in a retina.  
In P10 wild-type retinae, LAR staining was detectable in the IS/OS region with sparser 
distribution in the OPL and in the GCL (Figure 5.7A i). In 3 week old adult retina, LAR 
staining was additionally prominent within the INL and IPL (Figure 5.7A ii-iv), which 
probably reflects maturation of the synaptic processes (Dunah et al., 2005). 
Interestingly, LAR distribution largely mirrored the pattern of CS-56 staining reported in 
Chapter 3. Unfortunately, both antibodies were raised in mouse, so it was not possible 
to perform co-localisation studies of LAR and CPSG expression.  
When assessing the P10 retina of Rho-/- mice by IHC, LAR was located broadly 
throughout the IS/OS, OPL, IPL and GCL regions (Figure 5.7B i). Surprisingly, as the 
retina matured, LAR expression became reduced in the IPL and the GCL regions, but 
was very prominently expressed in the photoreceptor segment region (Figure 5.7B ii-
iv). At the latest examined stage (10 weeks of age), LAR staining was also detectable 
in the ONL (Figure 5.7B iv). 
In P10 Pde6brd1/rd1 retina, LAR expression within the neural retina was initially quite 
similar to wild-type, although levels in the OPL appeared lower (Figure 5.7C i). Staining 
within the segment region was initially high and presented as a thick band. This 
reduced markedly with (Figure 5.7C ii) and by the latest examined stage (6-8 weeks of 
age), LAR became almost undetectable in the Pde6brd1/rd1 retina (Figure 5.7C iv).  
To date, this is the first study that demonstrated the expression of LAR within the 
mouse retina, particularly within the segment region, and the first to examine changes 
in LAR expression in two models of RP. These findings suggest that LAR should be 
considered as a potential candidate for combined therapeutic interventions with cell 
transplants or retinal implants.   
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Figure 5.7 CSPGs receptor LAR is detectable in a mouse retina of a wild-type and two 
models of RP. 
Ai-iv) C57Bl/6J wild-type; Bi-iv) Rho-/- and Ci-iv) Pde6brd1/rd1. Cryosections were immunostained for LAR 
(red) and counterstained with nuclei marker Hoechst 33342 (blue). 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm. 
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5.2.6 Laminin expression in the diseased retina  
Recent studies have shown that CSPGs form non-permissive perineuronal nets, which 
cause attenuation of adhesion molecules such as laminins that also bind to CSPGs 
and LAR (Tan et al., 2011). Laminins are large glycoproteins consisting of α, β, γ 
chains that are found in at least three different genetic variants resulting in a formation 
of a diverse group of heterodimers. These molecules have been reported to be 
differentially expressed, both temporally and spatially, which likely reflects the variety of 
functions these molecules may have. To test whether the expression of Laminins is 
altered in the diseased retina, IHC analysis of the Rho-/- and Pde6brd1/rd1 retinae was 
performed.  
In wild-type retinae, at P10, staining for Laminin αβ chains was detectable in the IS/OS 
region, the OPL, the INL and in the GCL (Figure 5.8A i), which is in line with previously 
published reports (Libby et al., 2000). This pattern of expression continued throughout 
adulthood with no major changes in levels or localisation over time (Figure 5.8A ii-iv). 
At P10 and 3 weeks of age, Rho-/- mutant retinae presented a very similar distribution 
of Laminin αβ chains to that observed in age-matched wild-type retinae, with Laminin 
staining detectable in the IS/OS region, the OPL, the INL and in the GCL (Figure 5.8B 
i-ii). As degeneration progressed, Laminin staining became more prominent in the 
photoreceptor layer (Figure 5.7B iii-iv), especially at 10 weeks of age, the latest 
examined time point (Figure 5.7B iv).  
In the P10 retina of Pde6brd1/rd1 mice, the expression of Laminin αβ chains in the IS/OS 
region differed from that observed in wild-type and Rho-/- mutant (Figure 5.8C i). In a 
wild-type retina, Laminins formed a band at the edge of the ONL, whereas in the 
Pde6brd1/rd1 retina this band appeared more diffuse, extending into the photoreceptor 
layer. As degeneration progressed, Laminins were found throughout almost all retinal 
layers apart from the IPL (Figure 5.8C ii-iii). IHC analysis also revealed labelling of 
blood vessels in the two models of RP, which is in line with previously published report 
showing that Laminins are associated with neovascularisation and growth of new blood 
vessels in the diabetic retina (reviewed in (Edwards and Lefebvre, 2013)).  
219"
 
 
Figure 5.8 Expression of Laminin αβ chains is altered in the mouse model of RP. 
Ai-iv) C57Bl/6J wild-type; Bi-iv) Rho-/- and Ci-iv) Pde6brd1/rd1. Cryosections were immunostained for 
Laminin αβ chains (red) and counterstained with nuclei marker Hoechst 33342 (blue). 
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segment region. Scale bar, 25 µm. 
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5.3 Discussion 
For the past three decades, CSPGs have earned a negative reputation as being one of 
the main driving forces that impede axonal regeneration following CNS injury (Properzi 
et al., 2003; Matsui and Oohira, 2004; Galtrey and Fawcett, 2007). In the retina, 
CSPGs were found to be markedly upregulated in different models of inherited retinal 
degenerations, glaucoma, optic nerve injury or diabetic retinopathy (Inatani et al., 2000; 
Zhang et al., 2003b; Hippert et al., 2015), which has led to the notion of CSPGs being 
potentially detrimental to therapeutic approaches, including electronic grafts, gene 
therapy and cell transplants ((Grüter et al., 2005; Singhal et al., 2008; Tucker et al., 
2008; Barber et al., 2013)). For example, subretinal implant devices and cell 
transplants are typically administered into the subretinal space, but must make 
contacts with the host neuroretina. This may be impeded by CSPGs located within the 
segment region (reviewed in (Johnson et al., 2010; Pearson, 2014; Pearson et al., 
2014; Zarbin, 2016)). It is important to note too, however, that compelling evidence has 
been gathered suggesting that not all CSPGs are inhibitory, with some of them actually 
promoting CNS recovery (Akita et al., 2004). As CSPGs represent a large family of 
proteins and there are a limited number of studies that have looked at their role in the 
injured and/or diseased retina, the assessment for specific CSPGs is needed to better 
understand the underlying pathological mechanisms. As a first step towards this goal, 
the current study examined the expression pattern of one of the major CSPGs, 
Aggrecan, and the CSPG receptor LAR in the murine wild-type and diseased retina as 
both proteins have both been reported to have negative roles in axon regeneration 
(Kuboyama et al., 2010; Afshari et al., 2010b; Fisher et al., 2011; Tan et al., 2011; 
2012; Sharma et al., 2012b). Here, two models of RP were chosen to investigate 
possible alterations in their expression in the diseased retina. Although CS-56 staining 
is robust in the segment region and the administration of Aggrecanase to the subretinal 
space led to a reduction in CS-56 staining, expression of Aggrecan itself appears to be 
largely restricted to the inner retina and the choroid. In contrast, the expression of 
newly discovered CSPG receptor, LAR, was found to be mainly restricted to the IS/OS 
region, suggesting that LAR may be of potential use for future therapeutic strategies.  
During CNS development, CSPGs are expressed in a highly organised manner 
creating gradients and boundaries that help to navigate growing neurons towards their 
correct locations (Letourneau et al., 1994; Laabs et al., 2005). In the injured CNS, 
including the retina, CSPGs were thought to be upregulated by the reactive glia 
(Inatani et al., 2000; Inatani and Tanihara, 2002), which makes them one of the major 
contributors to formation of a barrier for regenerating neurons (McGraw et al., 2001; 
Massey et al., 2008; Fawcett, 2009). Recent research findings suggest that CSPGs 
play a role in the pathology of diseases such as Alzheimer's disease, stroke and 
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epilepsy (reviewed in (Siebert et al., 2014)). Higher expression of Aggrecan, 
Neurocan and Versican was also reported in human brain of patients with multiple 
sclerosis (Sobel and Ahmed, 2001). Several approaches to remove CSPGs after 
injury have been made including the well characterised use of enzymatic treatment 
with locally applied bacterial ChABC. Although very effective, ChABC has many 
disadvantages making it less suitable for therapeutic use in patients (Lee et al., 2010; 
Sharma et al., 2012a). Broad spectrum removal of all CSPGs may not be beneficial to 
the tissue, as CSPGs are important for the maintenance of synaptic plasticity and 
other cellular processes (reviewed in (Vecino et al., 2016)), thus an alternative is 
needed. Here, a naturally occurring enzyme, ADAMTS-4 (Lemke et al., 2010), was 
tested in the retina of wild-type and Rho-/- mutants and found to be effective in 
digesting CSPGs deposited within the subretinal space. This suggests that 
ADAMTS-4 could be of potential interest in the studies on therapeutic interventions 
as the removal of CSPGs has been shown to enhance viral diffusion and transduction 
of photoreceptors, and transplantation (Zhang et al., 2007; Barber et al., 2013).  
CSPGs represent a diverse group of molecules with some undergoing significant 
changes in their expression in the injured and diseased retinae of rodents (Chaitin and 
Brun-Zinkernagel, 1998; Inatani et al., 2000; Zhang et al., 2003b). Microarray analysis 
of individual Müller glial cells from a mouse model of RP identified a significant 
increase in Neuroglycan (Roesch et al., 2012). Zhang and colleagues reported that 
global levels of Neurocan appeared to be increased in the retina of S334ter-line-3 rat, 
which represents a transgenic model of retinal degeneration (Zhang et al., 2003b). 
They also reported that removal of Neurocan using ChABC enzyme from a diseased 
retina of Rho-/- mutant results in a higher number of observable donor-labelled cells in 
the recipient eye (Zhang et al., 2007). Another study demonstrated the presence of 
Neurocan and Versican in the dystrophic retina of the Royal College of Surgeons 
(RCS) rats by comparing it to normal retina of the Lister Hooded rat strain (Singhal et 
al., 2008). The same study reported that treatment with ChABC at the time of 
transplantation of Müller stem cells leads to a dramatic increase in the number of 
reporter-labelled cells in the host retina and these appeared to invade all layers of the 
retina (Singhal et al., 2008). These findings suggested that both Neurocan and 
Versican may be inhibitory to transplanted donor cells. However, despite a reported 
upregulation in the global protein levels of Neurocan, IHC analysis showed that 
Neurocan was abundant in the segment region in wild-type retinae and the overall 
distribution of Neurocan in the S334ter mutant appeared similar to that seen in control 
retinae (Zhang et al., 2003b). Interestingly, the same study showed that as 
degeneration progressed and photoreceptor cells died, the staining for Neurocan 
disappeared from the subretinal space, but increased at the level of the GCL in the 
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S334ter mutant (Zhang et al., 2003b). As mentioned before, Singhal et al. also 
identified Neurocan as having an inhibitory role in the retina, reporting Neurocan 
deposition in the dystrophic rats but not in the control retina (Singhal et al., 2008). 
However, in their study there was no age-matched comparison, with the neonate wild-
type retina being compared to 5 week-old RCS eyes. This age mismatch may over-
represent the actual changes in Neurocan and Versican at the segment region 
between control and diseased eyes. Moreover, in the study by Singhal et al., no cell 
transplants were performed in the control retinae following ChABC treatment. In the 
future, it would be interesting to see whether the treatment with ChABC of the healthy 
retina also leads to a similar increase in a number of observable transplanted cells 
within the recipient retina.   
To the best of my knowledge, the expression of Aggrecan has never been studied in 
models of retinal degenerations, despite clear evidence that Aggrecan has an inhibitory 
role in the CNS on neuronal extension. In the brain, Aggrecan is the main constituent 
of the perineuronal nets (PNN) (Giamanco et al., 2010). In vitro, axonal attachment and 
growth were reported to be blocked in the presence of purified Aggrecan (Domowicz et 
al., 2008; Afshari and Fawcett, 2011). Chen and colleagues reported that Aggrecan is 
upregulated in a rat model of diabetic retinopathy (Chen et al., 2012a). In the data 
reported here, the WB assessments showed an upregulation of Aggrecan over time in 
the Rho-/- animals and marked decrease in the Pde6brd1/rd1mutants. However, no 
deposition in the segment region was found in any of the examined models, including 
wild-type, as assessed by IHC. The observed upregulation in the retina of Rho-/- mice 
could be linked to an increase of Aggrecan expression in the IPL, potentially due to 
synaptic remodelling between the remaining retinal neuronal cells. As Pde6brd1/rd1 is a 
very fast degenerative model, it is possible that there is insufficient time for this PG to 
become aggregated in this mutant retina or there is redundancy in the system and a 
compensatory increase in a different CSPG. These results suggest that, at least in the 
models of inherited retinal degeneration used here, Aggrecan is not a primary 
component of the CSPGs deposited in and around the segment region of the 
neuroretina, where Müller glia build a glial seal. In keeping with this, subretinal 
administration of ADAMTS-4 enzyme did decrease the overall expression of CSPGs, 
but Aggrecan levels remained unchanged. Interestingly, a very recent study by 
Anderson et al. demonstrated that despite previous evidence for an inhibitory role of 
Aggrecan in CNS regeneration, no deposition of this PG was observed at the lesion 
site weeks after SCI in a mouse (Anderson et al., 2016). Moreover, the same study 
reported that scar-forming astrocytes produce two growth-supportive CSPGs, CSPG4 
and CSPG5, and that both astrocytes and non-astrocyte cells in SCI lesions express 
multiple axon-growth-supportive molecules such as Laminins. Surprisingly, Anderson 
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et al. found that CSPGs are upregulated in the absence of the astrocytes, suggesting 
that other cells including neurons may contribute to CSPG deposition following injury. It 
is tempting to speculate whether, in the retina, photoreceptors are involved in CSPG 
production, and if this might explain why in the very rapidly degenerating Pde6brd1/rd1 
model, CSPG reduction correlates with photoreceptor depletion (Landers and 
Hollyfield, 1992; Hippert et al., 2015). Although not examined in this study, future 
studies should investigate in more detail the role of microglia in the upregulation of 
CSPGs in a diseased retina. Activated microglia cells are an important part of the CNS 
response to injury and infection because of the various products they secrete, including 
cytotoxic molecules (free radicals, i.e., superoxides), neurotrophic molecules (nerve 
growth factor, e.g.), and a variety of pro- and anti-inflammatory cytokines and 
chemokines (reviewed in (Rock et al., 2004)). The release of cytokineses is particularly 
important as these molecules can stimulate the expression of CSPGs in a variety of 
cells in and around the lesion side. Most important are the astrocytes, which also 
undergo a reactive gliosis and in response to various cytokines they become 
hypertrophic and begin secreting CSPGs, leading to the formation of a glial scar at the 
vitreous side (reviewed in (Siebert et al., 2014)).  
Although the potent negative role of CSPGs on neuronal regeneration has been 
studied for decades, only in recent years have the CSPG binding receptors been 
discovered (Shen et al., 2009; Fisher et al., 2011; Dickendesher et al., 2012) 
increasing our understanding of CSPG-mediated inhibition. Using a CSPG gradient 
crossing assay, Shen et al. provided evidence that PTPsigma-dependent interactions 
with CSPGs maintain growth cones in a dystrophic state (Shen et al., 2009). A 
regrowth of sensory axons into scar tissues was enhanced in PTPσ deficient adult 
mice (Shen et al., 2009; Dickendesher et al., 2012). Fisher et al. reported that LAR 
receptor can be blocked pharmacologically with small peptides and stimulated 
regrowth of serotonergic axons (Fisher et al., 2011), while a more recent study showed 
that locomotor functional recovery is significantly better in mice deficient in LAR in 
comparison to normal controls following caudal SCI (Xu et al., 2015). However, many 
critical issues regarding CSPG receptor function remain unknown, including their 
expression in the retina. A better understanding of CSPG receptor function may 
facilitate our ability to modulate scar-mediated growth inhibition and developing more 
effective therapies. Here, for the first time, the assessment of LAR receptor in the 
healthy mouse retina was performed and compared to two models of inherited retinal 
degenerations. LAR was found to be highly abundant in the IS/OS region, the IPL and 
the GCL in all three examined models, but its expression gradually decreased in the 
Pde6brd1/rd1 mutant over time. Knowing that LAR is being expressed in a retina, 
pharmacological targeting of this CSPG receptor could be used as a potential 
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intervention as it does not present the risk of undigested GAG chains, as in case of the 
enzymatic treatment. Lemons et al. reported that these partially digested carbohydrate 
sugar chains left on the molecules may still exhibit their inhibitory effects on the 
neuronal outgrowth (Lemons et al., 2003). Secondly, in the injured CNS, the CSPGs 
are constantly released by the cells; therefore single injection of the enzyme would not 
be sufficient to override the CSPGs inhibition. A course of several ChABC injections 
could potentially induce an immune response that could lead to further damage of the 
injured area. Moreover, as CSPGs represent a large family of proteins, which may be 
differentially expressed at the lesion site, targeting CSPGs receptors may be an easier 
way to override CSPG-mediated inhibition.  
In conclusion, understanding the changes in the expression of CSPGs and their 
receptors in the injured or diseased retina may be crucial in designing effective 
therapeutic strategies. In this study, for the first time, the spatio-temporal expression of 
the CSPG, Aggrecan, and the CSPG receptor LAR were assessed in the degenerating 
mouse retina, which opens a door for future experimental work on how to manipulate 
the inhibitory role of CSPGs. 
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CHAPTER 6 
Remodelling of the outer limiting 
membrane in retinal degeneration  
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6.1 Overview 
The retina is a laminar tissue that can be divided into two distinct compartments. Each 
compartment is composed of a monostratified cell layer in which neuronal elements are 
embedded and each is supplied by a different blood supply (Mestrinerr and Haddad, 
1994). The inner compartment extends from inner blood-retina barrier until the outer 
edge of the outer nuclear layer (ONL), and it is sometimes referred to as a glial 
compartment since it lays between the Müller glia basal and apical processes. The 
outer compartment, also referred to as retinal pigmented epithelium (RPE), extends 
from the edge of the neuroretina and Brunch’s membrane. These two compartments 
are separated from each other by a structure comprised of specialised adherens 
junctions (AJs), the outer limiting membrane (OLM). The OLM is considered to play a 
role in the maintenance of photoreceptor orientation through mechanical strength, 
especially in the retinae of birds and teleosts, where photoreceptors are motile (Ali, 
1971; Burnside, 1978; Burnside and Nagle, 1983; Drenckhahn and Wagner, 1985). 
However, the emerging evidence points to the OLM being part of the retinal barrier due 
to its permeability properties. The AJs, mainly formed between photoreceptor inner 
segments (IS) and the Müller glia apical processes, appear to provide a 
semipermeable diffusion for extracellular components with Stokes radii greater than 
30-36A (Bunt-Milam et al., 1985). In recent years, the OLM has also been identified as 
a possible obstacle to transplanted cells, as the number of GFP+ cells within the 
recipient retina is higher in animal models where OLM integrity is compromised (West 
et al., 2008; Pearson et al., 2010; Barber et al., 2013).  
The OLM is an unusual structure for a number of different reasons. First, the AJs are 
usually formed between only one cell type, whereas in the OLM the junctions are 
heterotypic, with three different cell types being involved (Bunt-Milam et al., 1985). 
Secondly, these junctions are referred to as specialised AJs as they consists of a 
mixture of proteins that are usually associated with tight junctions (TJ) and proteins 
found in a typical AJ (Randlett et al., 2011). OLM junctions contain typical TJ proteins, 
such as claudins, occludin and junction adhesion molecules (JAMs), and typical AJ 
markers, including E-cadherins, β-catenin and α-catenin (Tsukita and Furuse, 1999; 
Tsukita et al., 1999; Omri et al., 2010). Cadherin adhesion molecules are the core of 
the OLM junctional component (Takeichi, 1991). All cadherins contain two or more 
extracellular cadherin domains and a highly conserved cytoplasmic tail that interacts 
with a defined set of cytoplasmic proteins, the catenins. P120-catenin and β-catenin 
bind the cytoplasmic tail of cadherins, and β-catenin binds to α-catenin to form the 
cadherin–catenin complex (Perez-Moreno and Fuchs, 2006; Pokutta and Weis, 2007; 
Nishimura and Takeichi, 2009). These catenins in turn associate with a variety of other 
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molecules, including cytoskeletal proteins and their regulators. As in the ear hair cells, 
the junctional plaques are linked to cell’s cytoskeleton via the actin filaments through 
zonule occludens 1 (ZO-1) (Fanning et al., 2002). Within the OLM, there is also a 
specialised apical region (SAR) that contributes to localisation and organisation of the 
AJs. The SAR, which apically localises to the AJs, is comprised of two protein 
complexes, portioning defective (PAR) and the Crumbs homologue (CRB) (Figure 6.1). 
In the mammalian retina, the PAR complex consists of PAR6, PAR3, atypical protein C 
(aPKC) and cell division control 42 (CD42) (reviewed in (Martin-Belmonte and Perez-
Moreno, 2012)). The core CRB complex is composed of CRB family members, which 
interact with the associated cytoplasmic proteins Protein Associated with Lin Seven 1 
(PALS1) also known as Membrane Protein Palmitoylated 5 (MPP5), and PALS1-
associated tight junction protein (PATJ), or the Multi-PDZ Domain Protein 1 (MUPP1) 
(Bulgakova et al., 2008; Assémat et al., 2013). Both of these structures are very 
dynamic as many of their components undergo changes depending on the 
developmental stage. This apical junctional region is especially important in 
establishing proper cell polarity during retinal development, as loss-of-function or a 
defect in any of these complexes leads to detachment of the progenitor cells and 
perturbations in retinal laminations. These spatio-temporal alterations in retinogenesis 
can result in mild to severe impairment of retinal function and retinal degeneration 
(Pujic and Malicki, 2004; van Rossum et al., 2006; Alves et al., 2012; Pellissier et al., 
2013). For example, during retinogenesis, AJs are important for the anchorage of 
newborn progenitor cells to the apical surface of the epithelium (reviewed in (Alves et 
al., 2014b)). These retinal progenitor cells elongate along the apico–basal axis forming 
long processes, which are important for interkinetic cell migration (Baye and Link, 
2007). Later studies showed that the migration of retinal progenitors is strictly 
dependant on the expression of OLM proteins (Pujic and Malicki, 2004; van Rossum et 
al., 2006; Alves et al., 2012; Pellissier et al., 2013). Moreover, it has been shown that 
AJ proteins take part in the regulation of cell proliferation and disruptions in levels of 
any of these molecules cause loss of cell polarity and epithelial adhesion, and 
concomitant detachment from the apical lamina (reviewed in (Alves et al., 2014b)). In 
the mouse retina, β-catenin links AJs to the cytoskeleton as well as acting as an 
effector of canonical wingless (Wnt) signalling pathway, which regulates cell 
differentiation during neurogenesis (Logan and Nusse, 2004). Removal of β-catenin 
during development results in loss of the typical radial spanning of retinal progenitor 
cells, together with loss of cell adhesion, OLM disruption, and a decrease in cell 
survival (Fu et al., 2006). Studies of the chick eye demonstrated that constitutively 
active β-catenin or Wnt2b signalling pathway have an impact on the identity of retinal 
progenitor cells, pushing progenitors towards the peripheral cell fate of the ciliary body 
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or iris (Cho and Cepko, 2006). The removal of another AJ protein, aPKC, from 
postmitotic photoreceptors results in abnormal lamination and photoreceptor cell 
morphology as well as the defects in establishment of proper neuronal connections 
(Koike et al., 2005). Moreover, in the absence of aPKC the photoreceptor 
differentiation is impaired and takes place at different regions in the retina. In 2012, 
Alves et al. study demonstrated that CRB2 protein restricts proliferation of retinal 
progenitors in mouse and that deletion of it leads to severe retinal disorganisation and 
progressive degeneration with concomitant loss of vision (Alves et al., 2012). 
Furthermore, their study demonstrated that CRB2 removal results in reduction of loss 
of other SAR and AJs proteins suggesting destabilisation of the entire junctional 
complexes. Later studies that used different Cre mouse lines and AAV expressing 
vectors targeting Crb2 expression revealed that CRB2 has a cell specific role (Alves et 
al., 2014a). The deletion of CRB2 from photoreceptor cells during retinal development 
leads to loss of cell adhesion, OLM disintegrity, progressive morphological 
deterioration and loss of retinal lamination. In contrast, when CRB2 is removed from 
Müller cells, the phenotype is milder with moderate disruptions to OLM continuity and 
nuclei mislocalisation, mainly observed at the peripheral retina (Alves et al., 2014a). 
Surprisingly, silencing of CRB2 with AAV vectors in adult retinae results in no changes 
to retinal morphology or function suggesting that CRB2 plays no part in the 
maintenance of AJs in the adulthood (Alves et al., 2014a). Interestingly, the developed 
mouse mutant strikingly resembled a human phenotype observed in RP patients linked 
to CRB1 mutation.  
Finally, the junctional proteins have been found to be asymmetrically distributed 
between photoreceptors and Müller cells, with the junctional plaques being much larger 
in Müller cells than in photoreceptors (Williams et al., 1990). The expression of 
junctional proteins also varies between different cell types or different species. For 
example, in a mouse retina CRB1 is restricted to apical processes of Müller glial cells, 
whereas CRB2 is expressed in both Müller cells and photoreceptor inner segments. 
Interestingly this pattern of expression was found to be reversed in humans (reviewed 
in (Alves et al., 2014b). These discrepancies between the typical epithelial AJs and 
OLM are thought to reflect an adaptation of the OLM for the specialised roles it has to 
perform in the retina.  
Given the importance of the OLM in the retina, we sought to determine whether and 
how this structure changes in a diseased state. Previous reports have shown that in 
chronic pathological conditions, including diabetic retinopathy (DR), the OLM is 
compromised with a loss of the typical honeycomb pattern (Omri et al., 2013). Any 
breach to this barrier between photoreceptor segments and the neuroretina may play 
an important role in development of further pathological changes or acceleration of the 
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degeneration. Better understanding of these alterations should provide insight into a 
pathological environment and help to design more efficient therapeutic approaches for 
patients whose retinae deteriorate. 
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Figure 6.1 Schematic representation of the OLM in the mouse retina. 
OLM junctions comprise of the tight junction (TJ) proteins, Claudin, Occludin and JAM, as well as proteins 
associated with typical adherens junctions (AJs), such as β-catenin, α-catenin and E-cadherin (reviewed 
in (Alves et al., 2014b)). Cytoplasmic protein ZO-1 links the AJ proteins to the cell’s cytoskeleton. The 
CRB complexes are located at the subapical region above the adherens junctions at the OLM. The core of 
the CRB complex is formed by CRB1 and CRB2 that connect to PALS1, which links with PATJ and 
MUPP1. The CRB proteins and PALS1 are also able to bind to the PAR complex member PAR6, which 
associates with aPKC, PAR3 and CDC42. In a mouse retina, CRB1 is restricted to Müller glia. The fact 
that OLM shares similar proteins with the TJs within the RPE suggests that it can function as a retinal 
barrier. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform 
layer; ONL, outer nuclear layer; OLM, outer limiting membrane; AJs, adherens junctions; SAR, subapical 
region. 
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6.2 Results 
Here, the OLM integrity was examined at the early and late time points in all models of 
retinal degeneration introduced in Chapter 3. A global overview of OLM contiguity in 
superior and inferior regions was performed using immunohistochemistry (IHC) for ZO-
1 expression, which is associated with AJs. In parallel, IHC analysis for CRB1 was 
performed, to assess possible alterations to the core complex of SAR. To determine 
possible changes in a number and/or types of AJs in a diseased retina, electron 
micrographs (EM) of each mutant model were examined and compared to healthy age-
matched wild-type retinae.  
 
6.2.1 OLM integrity is largely maintained in the majority of the retinal 
degenerations 
Although, a systematic assessment of both superior and inferior retina was conducted, 
no visible differences between the two regions were found. For the purpose of this 
thesis, representative images of both superior and inferior regions of the retina are 
included in the figures presented, but the qualitative description applies globally with no 
distinction between the two regions.  
In the wild-type inferior and superior retina at 6 weeks of age (early) ZO-1 staining 
formed a continuous line at the edge of the ONL with no nuclei intruding into the 
subretinal space, indicating that the OLM was intact (Figure 6.2A i-ii). This pattern was 
preserved over time, with no differences observed in 6 month-old animals, compared to 
6 week-old mice (Figure 6.2A iii-iv). CRB1 staining followed the same pattern as ZO-1 
with no noticeable dissimilarities between superior and inferior regions (Figure 6.2A v-
viii).  
In the next instance the retina of Crb1rd8/rd8 mouse was assessed. This naturally 
occurring mutant has a 1bp deletion in Crb1 gene, which truncates the transmembrane 
and cytoplasmic domain of CRB1 (Mehalow et al., 2003). As a result, focal 
disorganisation in retinal lamination can be observed with characteristic undulations of 
the ONL. Mehalow et al. reported that the OLM disintegrity starts as early as 2 weeks 
after birth, accompanied by the structural alterations in both photoreceptors and Müller 
glial cells (Mehalow et al., 2003). At 6 weeks of age, the staining for ZO-1 appeared 
fragmented across the entire retina indicating that the integrity of the OLM was already 
compromised (Figure 6.2B i-ii) and became even more prominent at later stage 
examined (Figure 6.2B iii-iv). CRB1 staining was, as expected for this model, mostly 
absent or diffused (Figure 6.2B v-viii). A displacement of photoreceptor cells into the 
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subretinal space was also observed (Figure 6.2B i-viii, arrows), providing a further 
evidence for the breakdown of the OLM barrier.  
The Rdsrd2/rd2 mutant lacks photoreceptor OSs and undergoes a mild progressive retinal 
degeneration. At 4 weeks of age, some occasional absences of ZO-1 expression at the 
level of the OLM were observed (Figure 6.2C i-ii, white arrows) with more breaks in 
ZO-1 staining as degeneration progressed (Figure 6.2C iii-iv, white arrows). Further 
IHC assessment showed that CRB1, although not absent, seemed to be more diffused 
into the segment region (Figure 6.2C v-viii) in comparison to wild-type retina. Sporadic 
nuclei intrusions into the subretinal space were also noticeable. These OLM alterations 
were prominent in both superior and inferior regions.  
In the Pde6brd1/rd1 mouse, which is a very fast degenerative model, the majority of rod 
photoreceptor cells are lost by the 4th week of age. At the earliest time point examined, 
staining for ZO-1 formed a uniform line at the edge of the outer retina but some small 
breaches to its continuity were apparent (Figure 6.2D i-ii). These disruptions became 
more noticeable in mid (3 weeks of age) and late ages (Figure 6.D iii-iv) with a marked 
increase in the breaks in ZO-1 staining over time, indicating significant disruptions of 
the OLM in this model. The ectopic presence of ZO-1 at the level of the outer plexiform 
layer (OPL) was also noticeable between the inner nuclear layer (INL) and the 
remaining ONL from 3 weeks onwards, which is probably associated with the growth of 
new blood vessels. Similar to ZO-1, CRB1 expression was preserved at the early time 
point (Figure 6.2D v-vi), but as degeneration progressed the staining was either 
fragmented or as in the Rdsrd2/rd2 mutant diffused into the segment region (Figure 6.2D 
vii-viii).  
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Figure 6.2 IHC assessment of OLM integrity in animal models carrying a spontaneous 
mutation.  
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Ai-viii) C57Bl/6J wild-type; Bi-viii) Crb1rd8/rd8; Ci-viii) Prph2rd2/rd2 and Di-viii) Pde6brd1/rd1. Cryosections were 
immunostained for ZO-1 and CRB1 (red) and counterstained with nuclei marker Hoechst 33342 (blue); 
arrows, indicate displaced photoreceptors.  Scale bar, 25 µm. INL, inner nuclear layer; OPL, outer 
plexiform layer; ONL, outer nuclear layer; OLM, outer limiting membrane. 
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Rho-/- mice do not develop rod photoreceptor OSs and lose their photoreceptor cells 
within the first 3 months (Humphries et al., 1997). In contrast to previous reports 
(Campbell et al., 2007), we found that the OLM appears to be maintained throughout 
the course of photoreceptor degeneration: IHC for ZO-1 staining was strong and 
formed a single continuous line at the edge of the outer neuroretina (Figure 6.3A i-ii) 
with some evidence of disruption at the later stage of degeneration (Figure 6.3A iii-iv). 
Surprisingly, however, despite the OLM preservation, staining for CRB1 appeared to 
be very weak in this model (Figure 6.3A v-viii).  
In Prph2+/Δ307 mice that are heterozygous for the codon 307 mutation of the Peripherin 
gene (McNally et al., 2002) there is a marked, but fairly slow, reduction in rod cell 
number, in comparison to wild-type retina. In this mutant, the remaining photoreceptor 
cells have shorter OSs that are severely disrupted in number and configuration. The 
OLM in both the inferior and superior retina appeared disrupted even at the beginning 
of degeneration (Figure 6.3B i-ii), but became progressively more disrupted with 
disease, as indicated by marked disruptions in ZO-1 (Figure 6.3B iii-iv) and CRB1 
expression (Figure 6.3B v-viii).  
Nrl-/- retina lacks rod cells; therefore, the AJ formation involves only two cell types, 
Müller glia and so–called 'cods' (Mears et al., 2001). Similar to the Crb1rd8/rd8 mutant, 
Nrl-/- retina develops numerous ONL undulations in both superior and inferior regions, 
with the appearance of the first rosettes as early as P8 (Stuck et al., 2012). Stuck et al.  
showed that the formation of AJs is not uniform in the Nrl-/- retina, which leads to 
protrusion of a population of photoreceptors into the subretinal space during retinal 
development. Recently, the rosette morphogenesis was suggested to be linked to the 
presence of functional RPE65 protein as rosette development was prevented only in 
mutants with reduced RPE65 levels (Samardzija et al., 2014). In keeping with these 
results, and similar to Rho-/-, we founded that ZO-1 expression was very robust in this 
model at both early (Figure 6.3C i-ii) and late time points (Figure 6.3C i-ii) examined, 
but with clear signs of OLM discontinuity and nuclei mislocalisation (Figure 6.3C i-iv; 
white arrows). The CRB1 staining followed the ZO-1 pattern with no visible signs of 
protein diffusion into the segment region (Figure 6.3C v-viii).  
As discussed in Chapter 3, the cytoarchitecture of the retina in the R91W; Nrl-/- mouse 
is well preserved, despite the lack of rods. Moreover, unlike the Nrl-/- mutant, 
the R91W;Nrl−/− model lacks rosettes, which was suggested to be due to a reduction 
in levels of visual chromophore (Samardzija et al., 2014). IHC analysis showed that 
ZO-1 expression is strong, with no clear signs of disruption in the OLM at either of the 
examined time points (Figure 6.3D i-iv), and comparable to ZO-1 labelling in the wild-
type. CRB1 expression was also preserved in this model, with clear and strong staining 
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at the apical margin of the retina (Figure 6.3D v-viii), indicating that OLM may be intact 
in this double mutant. The IHC data presented above indicates that the OLM may be 
disturbed to varying degrees in different models of retinal degeneration.  
Although not relevant to this study, it is worth mentioning, that a punctate ZO-1 staining 
was also present in the OPL of all examined models examined but it was most 
prominent in the Nrl−/− and R91W;Nrl−/− mutants. ZO-1 is a well known intracellular 
component of tight and adherens junctions, which also localises to gap junctions 
formed between horizontal and photoreceptor cells (Puller et al., 2009). It has been 
demonstrated that ZO-1 co-localises with connexins at rod spherules and at the cone 
pedicle base (Puller et al., 2009). As both mutants are cone-dominant retinae, it would 
be interesting to investigate in a future whether this increased expression in the OPL is 
linked to a formation of different types of gap junctions. 
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 Figure 6.3 IHC assessment of OLM integrity in animal models carrying a targeted 
mutation.  
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Ai-viii) Rho-/-; Bi-viii) Prph2+/Δ307; Ci-viii) Nrl-/- and Di-viii) R91W;Nrl-/-. Cryosections were immunostained 
for ZO-1 and CRB1 (red) and counterstained with nuclei marker Hoechst 33342 (blue); arrows, indicate 
displaced photoreceptors. Scale bar, 25 µm. INL, inner nuclear layer; OPL, outer plexiform layer; ONL, 
outer nuclear layer; OLM, outer limiting membrane. 
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6.2.2 Adherens junctions undergo significant remodelling during retinal 
degeneration in order to maintain OLM integrity 
As retinal degeneration progresses, the OLM starts to remodel, a phenomenon that 
has been previously reported, individually, for some of the examined mutants 
(Mehalow et al., 2003; Campbell et al., 2006; 2007). Here, qualitative and quantitative 
analysis of the AJs was performed in different models of retinal degenerations using 
EM. Similar to IHC results, EM demonstrated that, in wild-type retinae, the OLM 
appears as a series of highly ordered, regularly spaced AJs at the outer edge of the 
ONL and this appearance remains unbroken throughout the time frame examined 
(Figure 6.4A i-ii, v-vi). Assessment at the ultra-structural level confirmed previous 
reports (reviewed in (Alves et al., 2014b)) that the vast majority of these AJs are 
formed between rod/cone photoreceptor IS and Müller glia apical processes, creating a 
neatly aligned OLM structure (Figure 6.4A iii-iv, vii-viii; red boxes). 
As expected, in the Crb1rd8/rd8 model the OLM did not present a straight line, as seen in 
a wild-type, but instead exhibited visible undulations of the ONL and displacement of 
the photoreceptor nuclei beyond the limits of the AJs, into the segment region (Figure 
6.4B iii-iv; arrows), providing further evidence for a loss of OLM integrity (Figure 6.4B i-
ii, v-vi; arrows). Interestingly, upon closer inspection at the ultrastructural level, the AJs 
were still numerous. Moreover, the IS seemed also abnormal in their length and 
comparatively thinner than those of the wild-type.  
Analysis of semithin retinal sections of the Rdsrd2/rd2 mouse confirmed the OLM 
disruption seen with IHC. This was particularly evident at the late stage, as the OLM 
appeared uneven at the outer edge of the retina (Figure 6.4B i-ii, v-vi). Ultra-structural 
EM revealed that AJs were well-maintained at the early stage of degeneration (Figure 
6.4C iii-iv), but as diseased progressed the junctions seemed to become more 
elongated (Figure 6.4C vii-viii), which could indicate AJ protein mislocalisation or 
diffusion, which has been previously suggested by Williams et al. (Williams et al., 
1990). Moreover, there were also visible signs in the alterations to ONL lamination, 
with photoreceptor nuclei become sparser over time and clear signs of Müller glia 
hypertrophy. 
As might be expected, Pde6brd1/rd1 retina showed significant changes in the laminar 
organisation within both the ONL itself and the OLM between early (Figure 6.4D i-ii) 
and late stages of degeneration (Figure 6.4D v-vi). Analysis at the ultra-structural level 
revealed that the alignment of the AJs at the outer margin of the ONL was relatively 
normal at the early stage examined (Figure 6.4D iii-iv) but was lost by the latest stage 
(Figure 6.4D vii-viii). At P10 (early stage), most junctions were still formed between 
Müller glia end feet and nascent photoreceptor segments. However, as degeneration 
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progressed, and unsurprisingly in the absence of photoreceptors, the vast majority of 
AJs formed were between the apical processes of two Müller glial cells or Müller glia 
and other retinal cells whose identity could not be confirmed with certainty on the basis 
of location and morphology, due to the extensive degeneration. Together, these results 
indicate that the OLM undergoes significant remodelling, including changes in the type 
of junctions formed, in this model in the face of almost complete loss of the 
photoreceptor layer. 
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Figure 6.4 Ultratructural assessment of the adherens junctions in animal models carrying 
a spontaneous mutation.  
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Ai-viii) C57Bl/6J wild-type; Bi-viii) Crb1rd8/rd8; Ci-viii) Prph2rd2/rd2 and Di-viii) Pde6brd1/rd1. OLM integrity was 
assessed at early and late stage of retinal degeneration using semithin sections (Scale bar: 25 µm) and 
ultrathin electron microscopy (Scale bar: 1 µm). Red boxes: AJs; PR, photoreceptor; MG, Müller glia; 
arrows indicate displaced photoreceptors. ONL, outer nuclear layer; OLM, outer limiting membrane; IS, 
inner segment; OS, outer segment.  
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Examination of semithin sections of Rho-/- mouse showed that at early stage of retinal 
degeneration (Figure 6.5A i-ii), the laminar structure is comparable to a wild-type retina 
(Figure 6.5A i-ii).  As degeneration progresses, the photoreceptor morphology changes 
with the nuclei becoming smaller and the ISs becoming shorter (Figure 6.5A v-vi). 
Further EM analysis revealed the presence of numerous AJs at the early time point 
(Figure 6.5A iii-iv), but as photoreceptor death progressed, the distance between 
junctions increased (Figure 6.5A vii-viii). By the latest stage examined, when the vast 
majority of photoreceptors have died, much of the space at the outer retinal margin 
appeared to be occupied by the terminal processes of the Müller glia. This is reflected 
in a shift in the type of AJs; at the ultra-structural level, many more Müller-to-Müller cell 
AJs were observed in the late stage, in comparison with the early stage.  
In the Prph2+/Δ307 retina, there was a moderate disorganization at the margin of the ONL 
including the mislocalisation of photoreceptor cell bodies into the segment region at 
both early (Figure 6.5B i-ii) and late time points (Figure 6.5B v-vi). Ultra-structural 
analysis confirmed that while junctions remained quite neatly aligned at both stages 
examined, they were less numerous in the late stage (Figure 6.5B vii-viii) in 
comparison to 2 months old retina (Figure 6.5B iii-iv). Additional morphological 
changes in the Müller cells were observed at the late stages of degeneration, including 
hypertrophy of the end feet and an increase in a number of Müller to Müller junctions. 
As in the Crb1rd8/rd8 model, the OLM of the Nrl-/- mutant undergoes significant 
fragmentation and displacement of photoreceptor nuclei into the segment region is 
apparent (Figure 6.5C i-ii, v-vi; arrows). Surprisingly though, inspection at the ultra-
structural level showed that the AJs were still numerous, including in the regions where 
rosettes were formed (Figure 6.5C iii-iv; arrows). The photoreceptor segments also 
appeared to be shorter than those of a wild-type. No major alterations were observed 
between early and late stages.  
Similar to wild-type retinae, the OLM is well preserved in the R91W;Nrl-/- retina 
throughout the time frame examined (Figure 6.5D i-ii, v-vi). Assessment at the 
ultrastructural level showed the AJs were neatly aligned with the majority of junctions 
being formed between photoreceptor segments and Müller apical terminals (Figure 
6.5D iii-iv, vii-viii; red boxes). As in the wild-type, no observable changes in the 
alignment of the AJs were observed between early and late time points examined. 
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Figure 6.5 Ultrastructural assessment of the adherens junctions in animal models carrying 
a targeted mutation. 
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Ai-viii) Rho-/-; Bi-viii) Prph2+/Δ307; Ci-viii) Nrl-/- and Di-viii) R91W;Nrl-/-. OLM integrity was assessed at early 
and late stage of retinal degeneration using semithin sections (Scale bar: 25 µm) and ultrathin electron 
microscopy (Scale bar: 1 µm). Red boxes: AJs; PR, photoreceptor; MG, Müller glia; arrows indicate 
displaced photoreceptors. ONL, outer nuclear layer; OLM, outer limiting membrane; IS, inner segment; 
OS, outer segment.  
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Having noted clear differences in the appearance of the AJs between early and late 
stages of retinal degeneration in some of the examined mutants, a quantitative 
assessment of the AJs was performed (Figure 6.6). Using EM micrographs, a number 
of data analyses was performed including the total number of AJs, and a proportion of 
i) AJs formed between photoreceptor IS and Müller glia apical terminals, ii) AJs 
between two Müller glial cells, iii) AJs between two photoreceptor cells and iv) atypical 
AJs that formed between cellular structures whose identity could not be fully defined 
due to advanced retinal degeneration. Unfortunately, the Crb1rd8/rd8 and Prph2+/Δ307 
mutants had to be excluded from these data analysis as the two lines were lost prior to 
sufficient number of samples being collected for each time point. The number of 
junctions counted in the middle superior and inferior regions was combined, and 
expressed as an average number of AJs per retina per 100 µm. Early and late stages 
of degeneration were compared using an unpaired Student’s t-test with Holm-Sidak 
corrections. 
In wild-type retinae, we did not observe any major changes in absolute number of AJs 
between early and late stages examined (early, 158±12; late, 132±14 junctions per 100 
µm; Figure 6.6A). The majority of the AJs counted were formed between photoreceptor 
IS and Müller glia apical processes. There was a small, but non-significant drop in this 
number with age (Figure 6.6B) (early, 141±13; late, 110±17). As predicted, only a very 
small number of the AJs were formed between two Müller glia cells (early, 18±4; late, 
15±2; Figure 6.6C). A few junctions forming directly between two photoreceptor cells 
were also observed at early stages but this did not change with time (early, 7±4; late, 
7±4; Figure 6.6C). No atypical AJs were found in a wild-type. 
In the slowly degenerating Rdsrd2/rd2 mutant, the total number of junctions per 100 µm 
fell markedly, from 107±4 at the early stage to 76±7 at the late age (P<0.002; Figure 
6.6A). A small, but non-significant, drop in a number of AJs between photoreceptors 
and Müller glia was seen between early (70±20) and late (53±9) time points (Figure 
6.6B) and there was a concomitant increase in the number of AJs formed between two 
Müller glial cells (early, 10±4; late, 16±1; P<0.05; Figure 6.6C). No other significant 
changes were found in the Rdsrd2/rd2 model. 
The most dramatic changes to AJ number and type were seen in the rapidly 
degenerating Pde6brd1/rd1 mutant. In this model, the total number of AJs per 100 µm 
dropped from 111±12 in the early stage of disease to 52±4 by the late age (P<0.001; 
Figure 6.6A). There was a dramatic decrease in a number of photoreceptor IS to Müller 
glial type AJs, with 97±9 AJs counted at the early stage but almost none in the late 
stage (P<0.001; Figure 6.6B). As degeneration progressed, the Müller glial processes 
extended along the outer edge of the neuroretina and there was a marked increase in 
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the number of AJs formed between two glial cells (early, 10±1; late, 38±9; P<0.01; 
Figure 6.6C). At the late stages of retinal degeneration, and most likely due to the 
extensive degeneration and morphological reorganisation of the retina, we also 
observed a significant number of AJs that were formed between cellular structures 
whose identities were difficult to define (12±1; P<0.001; Figure 6.6E).  
The rod OSs of Rho-/- mutants do not develop and these animals lose their 
photoreceptor cells within the first 3 months of age (Humphries et al., 1997). 
Nonetheless, as shown by the IHC and ultrastructural analyses, the OLM integrity 
appears largely preserved. Interestingly, the total number of AJs did decrease 
significantly over the course of degeneration, falling from 116±5 counted per 100 µm at 
the early stage to 61±6 at the late time point (P<0.001; Figure 6.6A). The number of 
AJs formed between photoreceptors and Müller glia dropped markedly, between the 
early (98±1) and late (33±9) time points (P<0.001; Figure 6.6B). Surprisingly, despite 
the progressive loss of photoreceptors, there was no significant increase in the number 
of AJs formed between two glial processes (early, 17±4; late, 20±5; Figure 6.6C), 
although a small number of atypical AJs was also observed in the late time point 
examined (4±2; Figure 6.6E), which could be a result of the extended retinal 
remodelling.  
Nrl-/- retina lacks rod cells; therefore the AJ formation involves only two cell types, 
Müller glia and so–called 'cods' (Mears et al., 2001). Moreover, Nrl-/- mice develop 
numerous rosettes, with many photoreceptor cells being mislocalised in the segment 
region (Stuck et al., 2012). Analysis of the EM micrographs revealed that although the 
total number of AJs was typically lower than that seen in wild-type retina, this did not 
change with age; an average of 70±2 AJs per 100 µm were observed at the early, 
compared to 80±30 at the late, time point (Figure 6.6A). No obvious changes in the 
type of AJs were observed with age, although the number of AJs formed between 
photoreceptors and Müller glia cells was notably lower than that seen in wild-type 
(early, 46±2; late, 52±21; Figure 6.6B). Despite extensive gliosis throughout these 
retinae, no major changes in the number of Müller glia to Müller glia AJs was observed 
over time (early, 23±2; late, 28±12; Figure 6.6C). 
The all-cone retina of the R91W; Nrl-/- mouse had a similar number of AJs to the Nrl-/- 
mutant, with no significant changes over time (early, 86±7; late, 83±8 AJs per 100 µm 
Figure 6.6A). Although the total number of AJs was again lower in comparison to wild-
type, including the number of AJs formed directly between photoreceptor IS and Müller 
glia terminals (early, 57±7; late, 56±7; Figure 6.6B), this does not appear to result in 
any obvious breaks to OLM integrity, and the lamination of the ONL remains intact. No 
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change in a number of junctions formed between two Müller glial cells was observed, 
which was expected given the fact that this model does not really degenerate. 
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Figure 6.6 Assessment of the number of adherens junctions between early and late stages 
of retinal degeneration.  
A) Total number of AJs; B) Number of AJs formed between photoreceptors and Müller glial cells; C) 
Number of AJs formed between two Müller glial cells; D) Number of AJs formed between two 
photoreceptor cells and E) Number of the atypical AJs formed. All the counts are expressed per 100 µm. 
Statistical significance was assessed using unpaired Student's t-test with Holm-Sidak corrections. **P < 
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0.01 and ***P < 0.001. Error bars: SD, n=3 animals examined per time point (with ≥2 retinal sections 
assessed per animal in at least two independent ROI).  
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6.3 Discussion 
The OLM is considered by many to be the third retinal barrier. In this study, it has been 
shown that in a number of murine models of inherited retinal degenerations, this barrier 
undergoes significant remodelling during degeneration. As the photoreceptor cells die, 
both the number and the composition of those AJs between the remaining cells 
changes, with a significant shift in favour of junctions formed between two Müller glia 
cells, rather than between Müller glia and photoreceptor cells. Both in the current 
study, and previous reports (Barber et al., 2013; Hippert et al., 2015), these changes 
can be correlated with the rate of photoreceptor death, with the most striking OLM 
remodelling seen in the Pde6brd1/rd1 mutant, which undergoes a very rapid loss of 
photoreceptors. 
In the retina, Müller glia are arranged in a regular pattern. Each individual glial cell 
constitutes the core of a column of retinal neurons, which represents the smallest 
functional unit in the retina. It has been illustrated that for each Müller cell there is one 
cone and a variable number of rods and inner neurons (reviewed in (Bringmann et al., 
2006)). It is possible then that the AJ connections between Müller cells could represent 
the borders of such units. It is tempting to speculate that the protein expression may be 
different at the ‘unit border’ enabling the junctions to specialise and perform some 
specific function or lead to some differences in permeability to ECM molecules. This 
could be of particular importance in diseased conditions where these individual units 
become rearranged due to loss of cell contacts, leading to an increase in OLM 
permeability and/or decrease in the strength of AJs and susceptibility to retinal 
detachment. Various clinical studies have demonstrated that eyes with a continuous IS/ 
OS junctions have a better visual acuity than those in which IS/OS line is disrupted 
prior the surgery making them more prone to increased vascular leakage upon 
mechanical stress (Mitamura et al., 2013). In the majority of the mouse models of 
inherited retinal degeneration examined in the current study, there were clear signs of 
OLM remodelling, although the nature and extent this remodelling varied markedly 
between different mutants. In addition to these changes, a mislocalisation of 
photoreceptor cells into the segment region was observed, particularly in the areas 
where the OLM was clearly compromised. Interestingly, despite severe loss of 
photoreceptor cells, the retina’s attempt to maintain OLM integrity is remarkable. This 
is evident in the increased number of AJs formed between Müller glia processes in a 
number of different models, demonstrating the importance of this structure in the 
maintenance of retinal architecture.  
During retinal development, the SAR complex localises apically in the neuroepithelium, 
where it helps to form an adhesive OLM belt and plays an important role in the 
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maintenance of the AJs (Mehalow et al., 2003; Alves et al., 2014b). These proteins 
have also been implicated in photoreceptor survival and maintenance. For example, 
mutations in CRB1, which is part of the SAR complex, have been associated with a 
variety of autosomal recessive retinal dystrophies, including Leber's congenital 
amaurosis, retinitis pigmentosa type 12, retinitis pigmentosa with Coats-like exudative 
vasculopathy and other early-onset forms of retinitis pigmentosa (Bujakowska et al., 
2011; Pellissier et al., 2014; Zhao et al., 2015). In mouse, the loss of CRB1 protein 
leads to displaced photoreceptors and focal degeneration of all neural layers. This is 
attributed to loss of adhesion between photoreceptors and Müller cells (Mehalow et al., 
2003; van de Pavert et al., 2004), although more recent reports have indicated this 
phenomenon is background-specific (Luhmann et al., 2015). As described by others, in 
this study the OLM integrity was found to be increasingly compromised with 
degeneration in the Crb1rd8/rd8 mouse mutant. This manifests as ONL undulations, 
commonly known as ‘rosettes’. Moreover, expression of ZO-1 appears reduced in 
comparison to wild-type. In contrast, in the Nrl-/- mouse, another model that also 
develops ONL 'rosettes', both ZO-1 and CRB1 were robustly expressed despite 
numerous OLM breaks and visible displacement of photoreceptors into the segment 
region. Interestingly, in this model, the retinal cells still managed to form AJs within the 
'rosettes'; however, these appeared to be abnormal and did not form a continuous line. 
Previous reports have shown that mutations in the Nrl gene results in a number of 
pathological functions, including aberrant photoreceptor packing, abnormal association 
between photoreceptors and RPE, retinal detachment, changed dendritic fields and 
axon terminals in horizontal cells, vascular leakage, and ganglion cell death (Mears et 
al., 2001; DeAngelis et al., 2002). The exact cause of the OLM disruption in the Nrl-/- 
retina still remains unclear, although recent study by Feathers et al. pointed towards 
the involvement of retinoid intermediates, since Nrl-/- mutants with no functional RPE65 
protein failed to develop rosettes (Feathers et al., 2008). Moreover, it still remains 
unclear why disruptions in the OLM in both Nrl-/- and Crb1rd8/rd8 mutants appear as 
localized disruptions, resulting in focal rosettes, instead of a uniform failure of OLM 
formation across the retina. One possible explanation is that there are differences in 
the protein expression between different AJ types, making some of the junctions 
weaker or more susceptible to disruption. For example, Daniele and colleagues 
reported that in the Nrl-/- retina, which is 'cone' dominant, JAM-C protein, a part of the 
AJs complex, is significantly overexpressed compared to wild-type retina. The authors 
propose that JAM proteins play a specific role in cone polarisation and function 
(Daniele et al., 2007), but these could also lead to functional differences in AJs 
between cone photoreceptors, rod photoreceptors and Müller glia. A previous study in 
diabetic patients reported that S-cones, which are absent from the fovea, are the most 
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prone to retinal degeneration (Hollyfield et al., 1999; Cho et al., 2000). Omri et al. 
reported that in a rat animal model of diabetic retinopathy there was a marked drop of 
S-cone photoreceptors (Omri et al., 2013). They also showed that this mutant 
manifests clear signs of OLM discontinuity with both Occludin, which is mainly found in 
the AJs between Müller glia and cones (Omri et al., 2010), and aPKC protein (Omri et 
al., 2013), to be visibly decreased. Of note, the current study shows that there are 
observable differences in the expression of ZO-1 and CRB1 between different models 
of retinal degenerations, as well as differences in the number and type of the remaining 
AJs. These discrepancies may be related to the fact that there are regional differences 
in both quantity and density of surviving photoreceptors (LaVail and Battelle, 1975; 
Carter-Dawson et al., 1978; LaVail et al., 1992; García-Fernández et al., 1995; LaVail 
et al., 1997; Lin et al., 2009), which may depend on preservation of the OLM. In normal 
mice, the majority of the AJs form between photoreceptor ISs and Müller glia apical 
terminals. However, in the Pde6brd1/rd1 mouse model of RP, for example, where the 
majority of rod photoreceptors are gone by P21, there is extensive junctional 
remodelling and the majority of AJs form between two Müller glial apical terminals. At 
this stage, only the cone photoreceptors remain and wrapped tightly by the gliotic 
processes of Müller cells. These findings suggest a robust attempt by the retina to 
preserve the OLM and retinal architecture. Moreover, qualitative analysis at the 
ultrastructural level showed that the newly AJs seem to extend further than the 
junctions observable in a wild-type, which may suggest that the junctions enlarge or the 
junctional proteins mislocalise or diffuse along the junction. The same phenomenon 
was observed in Rho-/- mice especially at the later examined time-point. This 
corresponds with the results presented in Williams et al. study that showed that the 
cytoplasmic plaques of the OLM junctions are larger in Müller cells than the ones in 
photoreceptors (Williams et al., 1990). They speculated that these large aggregates of 
junctional proteins may control the extracellular pore size of the AJ and thus the 
permeability of the OLM. Although the described changes may be due to sectioning 
artefact, it is possible that in reactive glia the expression of the junctional proteins is 
altered which could lead to abnormities in the newly formed AJs. 
Interestingly, in the Rho-/- model where the loss of the ONL occurs moderately quickly, 
the OLM seemed to stay linear and uninterrupted until at least 6 weeks, by which time 
only 2-3 rows of PRs remain (see Chapter 3). It was only at the latest time point 
examined that some disruption in the OLM was evident, and significant preservation 
even as late as 22 weeks of age (Appendix AA; (Hippert et al., 2015)). These 
observations contrast those of Campbell et al. who reported reduced levels of ZO-1 
and catenin proteins in Rho-/- mice as early as 3 weeks of age and no staining of the 
same AJ proteins after 5 weeks (Campbell et al., 2007). In this study, ZO-1 staining 
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was very visible and even appeared stronger than in a wild-type retina. The reasons for 
these discrepancies are unclear. EM analysis showed that the total number of AJs 
significantly drops in Rho-/- mutant between early and late ages; however, IHC analysis 
did not indicate any major changes to OLM continuity. As mentioned before, the AJs 
especially those formed between two glial cells appeared to be elongated as shown at 
the ultrastructural level. This could explain why ZO-1 staining appeared to be 
unbroken. Interestingly, we did not observe any ring formation of cones as has been 
previously reported in rat model of RP, where a mutation in Rhodopsin gene led to the 
loss of rod photoreceptors triggering a reorganisation of cones into an array of rings 
(Lee et al., 2011; Yu et al., 2016). Lee et al. reported that these rings formed around 
the zones of rod cell death, which were then enwrapped by Müller glia processes and 
formed junctional connections with the cones' IS (Lee et al., 2011). IHC analysis 
showed that OLM was also compromised with an alteration in ZO-1 expression and 
clear remodelling of Müller glia processes, but strong ZO-1 expression was observed 
at the ring boundaries. Interestingly, these Müller glia-cone interactions were disrupted 
following the injection of DL- aminoadipic acid (AAA), which is commonly used to 
disrupt Müller glial cell metabolism (Lee et al., 2011), indicating that Müller glia compel 
cones to migrate to specific areas of rod death to form rings. Another study, by Xia et 
al. showed that this ring formation can be prevented by injection of Oncostatin M 
(OSM), which is a member of the IL-6 cytokine family (Xia et al., 2011). In the past, 
cytokinesis have been reported to alter tight junctions (Abe et al., 2003; Villarroel et al., 
2009; Aveleira et al., 2010); hence it has been suggested that OSM may modulate the 
formation or the strength of the cone-glia AJs. This hypothesis was further tested by Yu 
et al. who showed that treatment of the same mutant with high concentrations of siRNA 
against Zo-1 mRNA leads to the homogenous spread of cones within the ONL without 
any reduction in their number (Yu et al., 2016). These findings suggest that AJs 
represent at least one critical component for cone rearrangement in RP retina. ZO-1 is 
known to act as a molecular scaffold that organizes, assembles, and links the TJ 
complexes to the cytoskeleton through a number of protein-protein interactions 
providing structural integrity to the cells (Wittchen et al., 1999; Van Itallie et al., 2009); 
hence any breakages can result in the loss of the cellular structure.  Moreover, any 
inhibition of the ZO-1 expression may result in weakening of the bundles of filament by 
affecting the AJ complexes and, as a consequence, have an impact on the glial scar 
that forms in many diseased conditions at the outer edge of the neuroretina (reviewed 
in (Hippert et al., 2016)). Equally, it is possible that any intervention that inhibits the 
formation of the glial seal, including downregulation of the intermediate filament 
proteins (e.g. Chapter 5), may lead to a disruption of OLM remodelling.  
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Understanding the composition of retinal barriers, including the specific differences that 
may exist between the AJs in normal and diseased conditions, is a prerequisite for 
understanding why certain pathological events are region specific such as oedema that 
localises to the macula. The macula is the only place in the retina where cones out-
number rods. In this region, the AJs between Müller cells and cone photoreceptors 
were reported to be shorter, in comparison to AJs elsewhere within the retina, and to 
have a structure typical of desmosomes, with dense intermediate filament extensions 
(Omri et al., 2010). At this region, Müller glial cell apices are almost in contact with the 
cone OS leading to a decrease in the glial free SAR that surrounds the fovea. 
Moreover, although it has generally been accepted that the OLM is continuous 
throughout the entire retina, one observation reported that in the centre of the fovea of 
the rabbit retina, there might be areas in which the OLM becomes discontinuous, as 
there is a lack of AJs between some cone IS and Müller glial apical terminals (Bunt-
Milam et al., 1985). These findings could explain why this region is more susceptible to 
pathologies, such as the macular oedema that is associated with AMD disease. 
Macular oedema in humans is a result of diffuse capillary leakage and micro-
aneurysms in the macular region. Geiger et al. showed that exposure to toxic levels of 
blue-light of the all-cone retina of the R91W;Nrl−/−  mutant leads to vascular leakage, 
retinal swelling and the appearance of cystoid spaces in both INL and ONL indicating 
oedema (Geiger et al., 2015). In AMD, like RP is a collection of defects where the 
macular area and fovea become compromised leading to retinal remodelling including 
the remodelling of the AJs. Geiger and colleagues reported that the expression levels 
of ZO-1 were markedly reduced in R91W;Nrl−/−  in comparison to wild-type controls 
(Geiger et al., 2015). Interestingly, in the current study, I found ZO-1 expression to be 
robust, as assessed by IHC, however ZO-1 expression was not quantified, either by 
PCR or WB. Nonetheless, in keeping with Geiger et al. study, here the total number of 
AJs was shown to be much lower, in comparison to wild-type controls, including the 
number of AJs formed directly between photoreceptor IS and Müller cell processes, 
although retinal lamination remained normal. Together, these findings suggest that the 
susceptibility of the R91W;Nrl−/−  mutant to develop vascular leakage may be linked to 
the more sparse distribution of AJs. Recent studies in humans showed that OLM 
integrity is viewed as an important prognostic factor in treatment of the epiretinal 
membrane (Cobos et al., 2013). It has been reported that the presence of an intact 
IS/OS junction on the preoperative spectral-domain optical coherence tomography 
scan was an important predictor of better visual recovery after epiretinal membrane 
surgery. Mitamura et al. demonstrated that the IS/OS junction is important in predicting 
postoperative visual acuity and that the improvement of retinal microstructure after 
surgery is better in patients with fewer OLM discontinuities (Mitamura et al., 2013).  
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It is increasingly evident that understanding the diseased retinal environment is of 
paramount importance when designing effective therapeutic strategies for the 
treatment of retinal degeneration. In the past few years, great progress has been made 
in the development of novel ocular therapies such as electronic implants (Stingl and 
Zrenner, 2013)  and in the field of both cell (MacLaren et al., 2006; Gonzalez-Cordero 
et al., 2013; Santos-Ferreira et al., 2014) and gene (Bainbridge et al., 2008; Maguire et 
al., 2008; Jacobson, 2012) therapy. A compromised OLM may promote gene delivery 
or cell transplantation efficiency by increasing accessibility of the virus or the donor cell 
into the target tissue. A number of different studies demonstrated that combining a 
reversible disruption of the OLM with photoreceptor transplantation increases the 
number of donor-reporter labelled cells observable within the recipient retina (West et 
al., 2008; Pearson et al., 2010; Barber et al., 2013). Previously, transplantation of 
donor cells was thought to lead to their migration from the site of transplantation in the 
sub-retinal space, across the OLM and into the recipient retina. Real-time imaging of 
explants of transplanted retina have confirmed these findings (Pearson et al., 2016). 
However, in the same study, Ali and colleagues found that this process accounts for 
only a minority of apparently integrated cells within the host ONL. Instead, donor and 
host photoreceptor cells engage in the exchange of RNA and/or protein, in a process 
termed material transfer. The precise cellular mechanism underlying this process 
remains unclear. What is known is that it does not involve uptake of free protein, RNA 
or DNA nor does it involve classic cell-cell fusion mechanisms or nuclear transfer. At 
the time of writing, the release by donor photoreceptor cells and subsequent uptake by 
host photoreceptors (and to a lesser extent vice versa) of microvesicles is a working 
hypothesis. Whatever the underlying process, material transfer is surprisingly robust, 
resulting in host cells be able to express a wide variety of photoreceptor specific 
proteins with high fidelity; for example, around 85% of GFPve+ cells in the ONL of 
Gnat1-/- hosts also express rod α-transducin, the protein missing for host 
photoreceptors. A number of reports have demonstrated improvements in visual 
function following photoreceptor transplantation (Lamba et al., 2009; Pearson et al., 
2012; Santos-Ferreira et al., 2014; Barnea-Cramer et al., 2016).   
Intriguingly, the number of GFPve+ cells in the host ONL is markedly higher in models 
that show a disrupted OLM than in models where the OLM remained intact. Moreover, 
disruption of OLM in a wild-type mice using pharmacological (West et al., 2008) and 
siRNA techniques (Pearson et al., 2010) led to a significant increase in the number of 
GFP+ cells within the host retina. It is not clear at present whether these improvements 
are due to improving the number of real integration events or the frequency of material 
transfer events, although the frequency of material transfer events versus true 
integration events seen in the normal retina would make the latter more likely. These 
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findings may help us in elucidating the mechanisms underlying material transfer. 
Previous studies have shown that after the lamination of the retina is complete, the 
OLM creates as barrier to limit the diffusion of macromolecules including Retinoid-
binding protein into the neuroretina from the IS/OS region depending on their molecular 
weight (Carter-Dawson and Burroughs, 1992). Although the recent studies on 
photoreceptor transplantation showed that material transfer does not result from the 
uptake of free proteins from the extracellular milieu(Pearson et al., 2016; Santos-
Ferreira et al., 2016), if the OLM is a semipermeable barrier (Bunt-Milam et al., 1985), 
it may restrict the passage of microvesicles from donor to host and/or access to the 
uptake mechanisms. This could explain why in the retina with a compromised OLM, the 
number of GFP+ cells is higher in comparison to healthy retinae. If the underlying 
biological mechanisms of material transfer can be revealed, they may represent a new 
therapeutic strategy for a broad-spectrum of inherited retinal diseases by introducing 
functional proteins into otherwise diseased photoreceptors.  
In conclusion, disruption to the OLM is an expected outcome of photoreceptor loss and 
is predicted to have significant consequences for the overall homeostasis of the retina 
(Omri et al., 2010). Remarkably, however, our data show that while there is 
undoubtedly significant junctional remodelling, depending upon the model, the OLM 
very often remains intact even at advanced stages of degeneration, suggesting a 
significant attempt by the retina to protect itself from further damage. A better 
understanding of the OLM is needed for our understanding of disease progression. 
This is particularly important when designing therapeutic interventions, as any 
disruption to it, particularly in a diseased condition, may result in acceleration of retinal 
degeneration. 
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CHAPTER 7 
Disruption of OLM integrity  
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7.1 Overview 
In the vertebrate retina, the apical processes of Müller cells are attached to each other 
and to the inner segments (IS) of the photoreceptors by continuous heterotypic 
adherens junctions (AJs) that collectively form the outer limiting membrane (OLM). This 
continuous belt of AJs helps to maintain the integrity of the retinal lamination as it 
creates a barrier which seals off the neuroretina from the retinal pigmented epithelium 
(RPE) and choroid. In recent years, a number of different proteins that contribute to 
localisation and organisation of the AJ 'building blocks' have been studied, including 
proteins of the SAR region. The SAR region, which is located apically to the AJs, is 
comprised of the two complexes, PAR and Crumbs, which directly interact with each 
other. The core of the Crumbs/CRB complex (formed by the CRB proteins, PALS1, 
PATJ and MUPP1 (Richard et al., 2006) has received particular attention from the 
scientific and clinical community because thus far only the Crumbs complex member, 
CRB1, has been associated directly with human disease.  
CRB1 is a large (153 kDa) transmembrane protein, which is one of the three homologs 
to Drosophila protein Crumbs found in human genome (Tepass et al., 1990; Pellikka et 
al., 2002). In the mouse retina, CRB1 is expressed from embryonic (E) day 12.5 
onwards at the SAR adjacent to AJs in retinal progenitor cells (Hollander et al., 2002). 
As the retina matures, the CRB1 expression becomes restricted to Müller cells 
(Pellikka et al., 2002; van de Pavert et al., 2004), where it acts as an anchor between 
Müller glia microvilli and photoreceptor IS, ensuring the integrity of the OLM (Gosens et 
al., 2008). In 1999, the CRB1 gene was found to be mutated in a specific group of 
patients with RP (Hollander et al., 1999) and shortly after, mutations in the human 
CRB1 gene were found to be associated with autosomal recessive RP and autosomal 
Leber's congenital amaurosis (LCA) retinopathy (Jacobson et al., 2003; Hollander et 
al., 2004; Bujakowska et al., 2011). To date, several animal models have been studied 
that provided some insight into the pathology of CRB defects. The Crb1rd8/rd8 mouse is 
a naturally occurring mutant, where a single base deletion in the Crb1 gene causes 
discontinuity and fragmentation of the AJ complexes (van de Pavert et al., 2004; 
Hippert et al., 2015; Figure 7.1 B, white arrows), as well as defects in the photoreceptor 
IS and outer segment (OS) (Mehalow et al., 2003). Moreover, it has been reported that 
mutations of Crb1 lead to retinal folding and the formation of so-called rosettes (see 
Chapter 3 and 6), and subsequent photoreceptor cell death (van de Pavert et al., 
2004). Two studies have demonstrated that the number of GFP cells following 
transplantation of Nrl.GFP+/+ photoreceptor precursors was significantly higher in the 
Crb1rd8/rd8 animals compared with co-transplanted wild-type animals (Pearson et al., 
2010; Barber et al., 2013). This contrasts with the very low numbers of GFP cells 
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typically observed in the recipient retina following cell transplantation into other models 
of retinal degeneration, including the Rho−/− mutant (Barber et al., 2013), where the 
OLM integrity is preserved (see Chapter 6). To test the hypothesis that the OLM may 
represent a barrier to cell transplantation, two molecular approaches were developed 
and tested to downregulate Crb1 expression in a C57BL/6J wild-type retina to assess 
whether CRB1 is a suitable target for OLM disruption. 
In 2010, a study by Pearson et al. showed that using siRNAs against a junctional 
adaptor (ZO-1) leads to a discontinuity in OLM integrity. Moreover, when combined 
with photoreceptor precursor cell transplantation, they reported significantly more 
integrated cells within the recipient retina in both wild-type mice and, importantly, in a 
model of retinal degeneration (Pearson et al., 2010). However, ZO-1 is not exclusively 
expressed in the OLM. It has been shown that ZO-1 is also part of the junctional 
complex within the RPE; thus it is possible that a subretinal injection of siRNA against 
Zo-1 will also interfere with junctions in the RPE. Interestingly, recent work by Daniele 
et al. demonstrated that there are some differences in the expression of tight junction 
proteins in the OLM compared with the AJs of the RPE, which may help to find an 
alternative target for OLM disruption (Daniele et al., 2011). One such possible target for 
an RNAi strategy is Crb1, because its expression in the eye is restricted to the OLM 
(Hollander et al., 2002). It is therefore possible that knocking down mouse CRB1 might 
lead to a more specific disruption of the OLM without the risk of associated damage to 
the RPE.  
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Figure 7.1 The OLM integrity in a wild-type and Crb1rd8/rd8 mouse retina.  
Ai) In a wild-type ZO-1 (red) staining forms a uniform, unfragmented line. Aii) Semithin sections 
demonstrate OLM continuity, as indicated by black dashed line. Aiii) Ultrastructural images show the 
continuous formation of AJs at the OLM level (dashed boxes). Bi) In Crb1rd8/rd8 model a clear disruption of 
the OLM can be seen (arrows) as ZO-1 staining (red) appears to be fragmented. Bii) Semithin sections 
show ONL nuclei being displaced as the OLM continuity is being compromised (black dashed line). Biii) 
Assessment of OLM integrity at the ultrastructural level shows missing AJs in the Crb1rd8/rd8 mutant 
(asterisk). Retinal cryosections were co-stained with the nuclear marker Hoechst 33342 (blue). INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner segment; OS, outer segment; 
RPE, retinal pigmented epithelium (see also Hippert et al., 2015). Scale bars: Ai and Bii, 25 µm; Aii and 
Bii, 10 µm; Aiii and Biii, 0.5 µm.  
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7.2 Results 
7.2.1 CRB1 in a C57BL/6J wild-type retina 
It has been previously suggested that CRB1 levels might vary between different retinal 
regions, based on the fact that the inferior quadrant of the retina is structurally more 
impaired in the Crb1 mouse mutant (Mehalow et al., 2003). To assess whether there is 
any variation in the distribution of CRB1 in a wild-type retina, IHC and QRT-PCR 
analysis were performed on the samples from superior and inferior regions.  
A confocal montage of immunostained wild-type retina (Figure 7.2A i) indicates that 
CRB1 expression is uniform across the whole retina, with no noticeable differences 
between the superior (Figure 7.2A ii) and inferior (Figure 7.2A iii) regions. As expected, 
there were no signs of OLM fragmentation or nuclei displacement into the subretinal 
space.   
Further QRT-PCR analysis on laser-captured samples from orientated retinae showed 
that the levels of Crb1 mRNA were similar between the superior (119.9±36.5%) and 
inferior (118.6±44.5%) parts of the retina (P=0.447; Figure 7.2B). In contrary to 
previous reports (Mehalow et al., 2003), no significant variations between the wild-type 
superior and inferior retinae were detected; however the inter-sample variations in 
detected mRNA levels were high in both regions assessed. Having shown that CRB1 is 
homogenously present in the wild-type retina and can be detected using ICH and QRT-
PCR, I then moved to designing tools to knockdown its expression.   
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Figure 7.2 CRB1 expression in the superior and inferior regions of a wild-type retina.  
Ai-iii) Representative images of the CRB1 staining (red) in a wild-type retina. Ai) A montage image 
showing a uniform and continuous belt of CRB1 at the OLM level across the entire retina. Aii-iii) Higher 
magnification images of the superior and inferior OLM regions. Retinal cryosections were counterstained 
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with the nuclei marker, Hoechst 33342 (blue). B) QRT-PCR analysis on the laser captured samples 
revealed no marked differences in the Crb1 mRNA levels between superior and inferior quadrants 
(P<0.447, two-tailed paired Student’s t-test. Error bars: SEM; n≥6 independent retinal samples examined). 
INL, inner nuclear layer; OLM, outer limiting membrane; ONL, outer nuclear layer. Scale bars: Bi, 500 µm; 
Bii-iii, 25 µm.  
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7.2.2 pCMV6.Crb1.GFP vector expression is effectively silenced in 
cultured HEK-293T cells by RNAi  
Two sequences, starting at base pair 672 and 718 (courtesy of Dr Jan Wijnholds, 
Netherlands) were used to generate the RNAi arrays (Thermofisher, UK). Herein, these 
will be referred to as siCrb1.672 and siCrb1.718, respectively. A non-targeting stealth 
RNAi was used as a control (siCon). The effectiveness of silencing the mouse Crb1 
mRNA expression was first tested in vitro using HEK-293T cells that were co-
transfected with commercially available pCMV6.Crb1.GFP vector (OriGene 
Technologies Inc., USA) to induce exogenous mouse Crb1 cDNA. The efficiency of 
transfection and the effectiveness of siRNA in silencing the Crb1 mRNA transcript were 
assessed 72 hrs post-transfection by ICC and QRT-PCR analysis. Cells transfected 
with pCMV6.Crb1.GFP only were used as a positive control.  
To assess the efficiency of RNAi transfection, a non-targeting RNAi control sequence 
with an attached AlexaFluor was used as a positive reporter (Thermo Fisher Scientific, 
UK). First, the RNAi transfection protocol was optimised in HEK-293T cells by testing 
different concentrations of siCon (20, 40, and 100 pM). Transfected cells were 
analysed with IHC for AlexaFluor expression (Appendix AB). The untreated cells were 
used as a negative control. All three concentrations successfully transfected HEK-293T 
cells and little or no cell death was observed at any of the transfected wells. Among the 
three tested concentrations, the 40 pM dose of siCon was determined to be the most 
effective in transfecting HEK-293T cells, thus this dose was used in further 
experiments.  
As HEK-293T cells do not endogenously express CRB1, the cells were first transfected 
with pCMV6.Crb1.GFP vector, to drive expression of CRB1 and GFP reporter. 
Fluorescent microscopy of the transfected cells showed that in wells transfected with 
pCMV6.Crb1.GFP vector ~80% of the cells were GFP+ve (Figure 7.3A i') and that they 
stained for CRB1 protein (Figure 7.3A i''). Having confirmed a successful expression of 
CRB1 in vitro, HEK-293T cells were transfected with pCMV6.Crb1.GFP plasmid in 
conjunction with the generated RNAi sequences.  
As expected, no noticeable differences in CRB1 expression were observed in the wells 
co-transfected with a non-targeting RNAi (Figure 7.3A ii). All the examined siCon wells 
demonstrated a robust expression of GFP (Figure 7.3A ii') and staining for CRB1 
protein (Figure 7.3A ii''). Further QRT-PCR analysis confirmed the ICC results showing 
that the Crb1 mRNA levels were comparable between the RNAi-untreated cells and 
those co-transfected with siCon (Figure 7.3B). In contrast, the expression of both 
CRB1 and GFP from pCMV6.Crb1.GFP was visibly decreased in the cells co-
transfected with siCrb1.672 (Figure 7.3A iii) and siCrb1.718 (Figure 7.3A iv). This 
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silencing of CRB1 was confirmed by further QRT-PCR results which showed a 
significant drop in the expression of Crb1 mRNA transcript in the cells that were 
transfected with pCMV6.Crb1.GFP vector in conjunction with either siCrb1.672 
(33.3±10.0% of the levels in untreated cells, P<0.01) or siCrb1.718 (6.8±2.3% of the 
levels in untreated cells, P<0.001) with the latter producing a more dramatic effect in 
comparison with siCon treated cells (104.4±9.5% of the levels in untreated cells, 
P=0.9999) or untreated controls (Figure 7.3B). Together this data shows that the two 
generated RNAi sequences are capable of silencing CRB1 expression in vitro.  
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Figure 7.3 RNAi targeting sequences mediate robust silencing of exogenous mouse CRB1 
expression in cultured HEK-293T cells.  
Ai-iv) Transfection with pCMV6.Crb1.GFP vector induced CRB1 expression in HEK-293T cells (red), Ai) 
which was preserved in Aii) siCon treated wells. This robust CRB1 expression co-localised with the GFP 
reporter. In contrast, wells treated with either Aiii) siCrb1.672 or Aiv) siCrb1.718 showed a marked 
reduction in both GFP and CRB1 expression with siCrb1.718 leading to a more effective knockdown. Cells 
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were counterstained with the nuclei marker, Hoechst 33342 (blue). Scale bar, 25 µm. B) Histogram shows 
mRNA levels, assessed by QRT-PCR 72hrs post-transfection, for Crb1, following treatment with siCon, 
siCrb1.672 and siCrb1.718. Both targeting RNAi sequences mediated a significant reduction in Crb1 
mRNA expression, compared to siCon transfected cells or RNAi-untreated controls. *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001 with a one-way ANOVA and Tukey’s correction for multiple comparisons. 
Error bars: SEM; n≥3 independent cultures examined.  
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7.2.3 Endogenous CRB1 is effectively decreased in cultured Müller glia by 
RNAi 
Having established that Crb1 mRNA expression can be silenced in HEK-293T cells in 
vitro, the designed RNAi sequences were next tested to determine if they can also 
effectively reduce endogenous CRB1 in cultured Müller glial cells.  
As shown in Chapter 4, Müller glia can be isolated from P7-8 Rlbp.GFP+/+ mouse using 
FACS and subsequently grown in vitro. After two weeks in culture, Crb1 mRNA was 
detectable in untreated Müller cells (Figure 7.4A) and a robust positive staining for 
CRB1 was observed (Figure 7.4B i''). A similar pattern of CRB1 expression was 
manifested by the cells treated with siCon with the attached Alexa Fluor488 that served 
as a reporter for successful transfection (Figure 7.4Bii'). Further ICC analysis showed 
that staining for CRB1 was not affected by RNAi in the wells transfected with siCon 
(Figure 7.4B ii'') with no detectable changes in Crb1 mRNA levels (100.1±6.2 % of the 
untreated cells; P=0.993; Figure 7.4A). In contrast, cells that received Crb1 RNAi 
targeting sequences, siCrb1.672 and siCrb1.718, showed a significant reduction in the 
mRNA expression (to 13.31±2.1% and 5.9±3.3% of the levels seen in untreated cells; 
P<0.001 and P<0.0001, respectively; Figure 7.4A). The application of either siCrb1.672 
(Figure 7.4B iii''-iii''') or siCrb1.718 (Figure 7.4B iv''-iv''') also led to noticeable reduction 
in CRB1 staining in comparison with the untreated cells or cells that were transfected 
with a non-targeting RNAi. In line with the experiments in HEK-293T cells, siCrb1.718 
was found to be more effective in silencing Crb1 expression in Müller glia than si672. 
No changes in the overall morphology of the treated cells were noticed in any of the 
experimental conditions. These results further confirmed the effectiveness of the 
designed RNAi sequences in decreasing CRB1 expression.  
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Figure 7.4 RNAi targeting sequences successfully knockdown endogenous CRB1 in 
cultured Müller cells.  
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A) Histogram shows that Crb1 mRNA levels, as assessed by QRT-PCR, are robust in untreated Müller 
glia in vitro, and are not affected by siCon RNAi treatment. In contrast, administration of siCrb1.672 or 
siCrb1.718 both mediated a marked reduction in mRNA expression with the latter producing a more 
dramatic effect, compared to siCon treated cells. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 with a 
one-way ANOVA and Tukey’s correction for multiple comparisons. Error bars: SEM; n= 3 independent 
cultures examined. Bi-iv) CRB1 protein can be detected in vitro. Bi) ICC analysis show that untreated 
cells stained uniformly for CRB1. Bii) RNAi transfection itself (as assessed by the AlexaFluor signal 
(green)) had no visible effect on Müller glia morphology or CRB1 levels as shown in siCon treated wells. In 
contrast, administration of the two RNAi targeting sequences (Biv) siCrb1.672 and Biv) siCrb1.718) led to 
noticeable reduction in CRB1 staining, which was almost marked in the wells treated with siCrb1.718. 
Cells were counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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7.2.4 RNAi sequences are unsuccessful in downregulating CRB1 in the 
wild-type retina 
Previous reports showed that in the mouse retina, CRB1 is normally localised at the 
apical process of the Müller glia where it is part of the AJ complex at the OLM 
(Mehalow et al., 2003). Loss of CRB1 or its mislocalisation during development leads 
to impairment of OLM integrity, delamination of the photoreceptor layer and eventual 
retinal degeneration in both the mouse and humans (van de Pavert et al., 2004); hence 
any knockdown of CRB1 should only be temporary. Previous studies have shown that 
it is possible to introduce a transient silencing of ZO-1 (also an AJ protein) using RNAi, 
which resulted in a temporary fragmentation of the OLM that resolved itself within one 
week post-injection (Pearson et al., 2010). Having established that the two RNAi 
sequences designed here successfully decrease levels of CRB1 in vitro, their 
effectiveness was then tested in an adult retina of a wild-type mouse. Both eyes 
received a single injection of 2 µL into the subretinal space (see Chapter 2, Section 
2.3.4 for the details on the specific RNAi concentrations), between the neural retina 
and the underlying RPE in the superior hemisphere, as previously described (Pearson 
et al., 2010). This route of injection was favoured over the intravitreal one due to close 
proximity of the injection side to the OLM, which should lower the risk of siRNA 
degradation. Eyes were examined between 48 hrs to 1 week post-injection.  
All the recipient retinae receiving the subretinal injection tolerated the surgery well and 
presented normal retinal structure with no signs of retinal damage at any time point 
examined. PBS injected eyes were used as a control for any unspecific effect of the 
injection itself. The uninjected region (the inferior quadrant) was used as an internal 
control. As predicted, no direct effect on CRB1 localisation was noticed in PBS injected 
eyes (Figure 7.5A i'-i''). Also administration of non-targeting RNAi resulted in no 
alterations to Crb1 mRNA levels (107.0 ±19.3% of the PBS injected, P=0.7821; Figure 
7.5B i) or any visible changes in CRB1 staining (Figure 7.5A ii'-ii''). Unfortunately, 
despite robust knockdown of CRB1 in vitro, no significant modifications were observed 
in the levels of Crb1 mRNA (152.2±33.6% for siCrb1.672 (P=0.074) and 108.7±12.4% 
for siCrb1.718 injected eyes (P=0.998), respectively; Figure 7.5A i) nor any detectable 
disruptions within OLM integrity following siCrb1.672 (Figure 7.5A v-vi) or siCrb1.718 
administration (Figure 7.5A vii-viii). The CRB1 staining looked comparable across all 
experimental conditions, forming a distinct continuous belt with no observable 
fragmentation nor any nuclei drop. Given the close interaction of CRB1 with CRB2, the 
impact of the RNAi injection on Crb2 mRNA levels was also assessed. As shown in 
Figure 7.5B ii, the levels of Crb2 mRNA remained unchanged and were very similar to 
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the levels detected in the PBS treated retinae (102±24.7% for siCon; 111.7±29.16% for 
siCrb1.672 and 147.2±65% for siCrb1.718.  
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Figure 7.5 RNAi does not mediate a successful knockdown of CRB1 in vivo in a wild-type 
adult retina.  
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Ai-viii) IHC analysis showed that injection of RNAi against Crb1 causes no disruption to OLM integrity or 
CRB1 staining, both look comparable across all the experimental conditions. No visible changes were 
detected between Ai-ii) PBS; Aiii-iv) siCont; Av-vi) siCrb1.672 or Avii-viii) siCrb1.718 treated retinae in 
CRB1 staining (red) which formed a nice uniform line at the OLM level. Retinal cryosections were 
counterstained with nuclei marker Hoechst 33342 (blue). INL, inner nuclear layer; ONL, outer nuclear 
layer; OLM, outer limiting membrane. Scale bar, 25 µm. Bi) QRT-PCR histogram shows that Crb1 mRNA 
expression does not change following the administration of RNAi. Bii) Also levels of Crb2 mRNA remained 
unchanged in the RNAi injected retinae. Statistical significance was assessed with one-way ANOVA and 
Tukey’s correction for multiple comparisons. Error bars: SEM; n=3 animals examined per experimental 
condition. 
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As it has been previously shown that RNAi targeting Zo-1 successfully caused 
disruption of the OLM (Pearson et al., 2010) the absence of CRB1 knockdown was 
surprising. To confirm the effectiveness of RNAi in silencing an OLM protein in a wild-
type retina, the ZO-1 experiment was repeated according to previously published 
protocol (Pearson et al., 2010). The wild-type animals received the same doses of 
siRNA against Zo-1 into the adult superior retina and the eyes were examined 72 hrs 
post-injection. The inferior region was used as an internal control. No visible 
differences in ZO-1 staining were detected between uninjected (Figure 7.6A i-ii) and 
PBS-treated retinae (Figure 7.6B i-ii). Unexpectedly, no visible changes in the OLM 
integrity, or ZO-1 expression following the injection of RNAi targeting Zo-1 were found 
at any of the two experimental concentrations, 15 µM (Figure 7.6B iii-iv) and 30 µM 
(Figure 7.6B v-vi). A clear explanation for these discrepancies is not known. Despite 
using the same concentrations of siRNA, carrier agents as well as the same time-
points for the post-injection assessment, it was not possible to replicate the findings 
published by Pearson et al. study. Having failed to successfully decrease CRB1 or ZO-
1 using siRNA method in vivo, an alternative experimental approach to knockdown 
CRB1 was adopted.      
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Figure 7.6 Administration of RNAi targeting Zo-1does not cause any disruption to OLM 
integrity.  
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Ai-ii) In the uninjected retina, ZO-1 forms a continuous band at the OLM level (red). Bi-ii) Administration 
of PBS did not lead to any fragmentation in the ZO-1 staining. Biii-vi) Injection of RNAi to silence ZO-1 
had no effect on the OLM integrity. Neither Biii-iv) 15 µM nor Bv-vi) 30 µM caused any visible differences 
in ZO-1 levels or led to any dislocation of the cell nuclei as previously reported. Retinal cryosections were 
counterstained with nuclei marker Hoechst 33342 (blue). INL, inner nuclear layer; ONL, outer nuclear 
layer; OLM, outer limiting membrane. Scale bar, 25 µm; n=3 animals examined per experimental 
condition. 
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7.3.5 AAV.shCrb1 successfully reduces p.CMV6.Crb1.GFP plasmid 
expression in vitro 
As the aim of this study was to assess whether post-developmental knockdown of 
CRB1 causes any disruption to OLM integrity, an AAV vector was developed to silence 
CRB1 expression in vivo. Having established that the two RNAi sequences are 
successful in knocking down CRB1 in vitro, the more effective one (siCrb1.718) was 
used as the basis of a short hairpin construct to be packaged into and expressed by an 
AAVShH10-Y445F vector. As mentioned in Chapter 4, this AAV serotype exhibits a 
specific tropism for Müller glia (Klimczak et al., 2009; Alves et al., 2014a) and since 
CRB1 is normally expressed at the apical terminals of Müller glia (van Rossum et al., 
2006) it represents a good tool for use in the current study. A non-targeting sequence 
was used as a control. The two generated vectors will be referred to as AAV.shCon 
and AAV.shCrb1. 
First, the two designed vectors were tested in vitro in HEK-293T cells that were 
additionally transfected with pCMV6.Crb1.GFP plasmid, expressing GFP. As both 
AAV.shCon and AAV.Crb1 vectors included RFP as a reporter protein, AAVShH10-
Y445F transduction efficiency was followed by fluorescence microscopy. As in the 
siRNA experiments described earlier, HEK-293T cells were first transfected with 
pCMV6.Crb1.GFP plasmid and checked for GFP expression after 72 hours and then 
cells were infected with the generated viral vectors (Figure 7.7B i', ii', iii'). The 
transduction efficiency was assessed after one week by ICC and QRT-PCR analysis 
(Figure 7.7). As expected, viral transduction with AAV.shCon and AAV.shCrb1 was 
very efficient with more than 90% of the cells expressing RFP (Figure 7.7A ii'' and 
Figure 7.7A iii'', respectively). No RFP signal was observed in the non-transduced wells 
(Figure 7.7A i''). No noticeable differences in GFP signal were noticed between the 
non-transduced wells (Figure 7.7A i''') and wells treated with AAV.shCon (Figure 7.7A 
ii'''). Further QRT-PCR analysis confirmed the ICC results showing that the Crb1 
mRNA levels were comparable between the control cells and that infected with 
AAV.shCon (78.9±14.1% of the levels in non-transduced cells; P=0.287; Figure 7.7B). 
In contrast, the expression of pCMV6.Crb1.GFP vector was visibly decreased in the 
cells that received AAV.shCrb1 vector (Figure 7.7A iii'''). This silencing of CRB1 was 
confirmed by further QRT-PCR results, which showed a significant drop in the 
expression of Crb1 mRNA transcript in the cells that were transduced with AAV.shCrb1 
in comparison to untreated cells (18.1±8.6% of the levels in untreated cells; P<0.001) 
or cells treated with AAV.shCon (P=0.001; Figure 7.7B). Together, these results 
showed that the designed AAV vector is capable of silencing CRB1 in vitro.  
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 Figure 7.7 AAV.shCrb1 mediate robust silencing of Crb1 mRNA expression in cultured 
HEK-293T cells.  
Transfection with pCMV6.Crb1.GFP vector induced Crb1 expression in HEK-293T cells (green) Ai) which 
was preserved in Aii) AAV.shCon treated wells. In contrary, wells treated with Aiii) AAV.shCrb1 had a 
visible reduction in GFP expression. Cells were counterstained with nuclei marker Hoechst 33342 (blue). 
Scale bar, 25 µm. B) Histogram shows mRNA levels, assessed by QRT-PCR 72hrs post-transfection, for 
Crb1, following treatment with AAV.shCon and AAV.shCrb1. Only AAV.shCrb1 mediated a significant 
reduction in Crb1 mRNA expression, compared to RNAi-untreated controls. ***P<0.001 and ****P<0.0001 
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with a one-way ANOVA and Tukey's correction for multiple comparisons. Error bars: SEM; n=3 
independent cultures examined. 
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7.3.6 AAV.shCrb1 mediates effective knockdown of endogenous Crb1 in a 
C57BL/6J wild-type retina 
Having confirmed the efficacy of AAV.shCrb1 in vitro, the ability of this vector to 
suppress Crb1 expression was then tested in vivo. As shown in Chapter 4, intravitreal 
delivery of AAVShH10-Y445F robustly transduces Müller glial cells at an early 
postnatal age and the surgery itself does not have any major impact on the 
neuroretina. Here, recipient C57BL/6J wild-type mice received titre matched 
AAV.shCon and AAV.shCrb1 in contralateral eyes, and were assessed three weeks 
later by QRT-PCR and IHC.  
In a wild-type retina, CRB1 staining forms a uniform line at the outer edge of the ONL 
(Figure 7.8A).  A global view of the AAV.shCon injected retina showed a widespread 
RFP expression in Müller glial with no visible alterations to the retinal architecture 
(Figure 7.8B i). Surprisingly, intravitreal delivery of AAV.shCon at P8 led to significant 
reduction in Crb1 at the RNA level in comparison to uninjected eyes (59±2.9% of the 
levels in untreated retina; P<0.001; Figure 7.8C i), but this did not translate into any 
visible decrease in CRB1 protein as assessed by IHC (Figure 7.8B ii’-ii’’), similar to that 
described for GFAP in Chapter 4 following the administration of AAV.shCon into Rho-/- 
retina. No observable differences in CRB1 staining were noted between transduced 
and non-transduced regions (Figure 7.8B ii’) or between AAV.shCon treated eyes and 
uninjected controls (Figure 7.8A), with the OLM remaining intact and no visible signs of 
nuclei drop into the subretinal space. In contrast, robust transduction of AAV.shCrb1 
resulted in major changes to retinal architecture including retinal folding (asterisks; 
Figure 7.8B iv-v) and nuclei displacement (arrows; Figure 7.8B v’’). These 
morphological changes are typical characteristics reported in Crb1rd8/rd8 mutant 
(Mehalow et al., 2003). Closer inspection of the outer edge of the neuroretina 
demonstrated a marked reduction in CRB1 staining, when compared to transduced 
region (Figure 7.8B v’) or when compared to AAV.shCon injected retina (Figure 7.8B 
ii’). The observed alterations within the AJ 'belt' were also confirmed with staining for 
ZO-1, which showed clear breaks to OLM especially around the rosettes formed in the 
ONL in the retina treated with AAV.shCrb1 (arrows; Figure 7.8 B vi’-vi’’). The reduction 
of CRB1 immunoreactivity was further confirmed by QRT-PCR analysis which showed 
a statistically significant knockdown of Crb1 mRNA when compared to untreated or 
AAV.shCon injected eyes (9.49±2.1% of the levels in untreated retina; P<0.0001; 
Figure 7.8C i).  
Given an intimate relationship between CRB1 and CRB2 in a mouse retina (Pellissier 
et al., 2014) the impact of Crb1 silencing on the Crb2 mRNA expression was also 
examined (Figure 7.8C ii). A small, but non-significant, drop in RNA levels were 
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observed in the eyes treated with AAV.shCon (89.8±9.4% of the levels in untreated 
retina; P=0.186; Figure 7.8C ii) in comparison to untreated controls. Interestingly, 
AAV.shCrb1 administration and Crb1 silencing had an effect on Crb2 expression 
causing a marked decrease (23.3±5.8% of the levels in untreated retina; P<0.001; 
Figure 7.8C ii). Taken together, these results show that it is possible to knockdown 
CRB1 in vivo via this methodology, but also that global removal of CRB1 leads to 
unwanted pathological changes in retinal architecture.  
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Figure 7.8 Knockdown of CRB1 in Müller glia of C57BL/6J wild-type mouse following a 
delivery of AAV.shCrb1 led to OLM disruption and prominent undulations of the ONL.  
Ai) Immuoreactivity for CRB1 (green) in 4.5 week old C57BL/6J wild-type retina shows a continuous, 
uniform line at the OLM level. Bi-ii) The observed knockdown in Crb1 mRNA AAV.shCon eyes was not 
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translated at the protein level as CRB1 immunoreactivity was comparable to that seen in untreated 
controls. No alterations to OLM continuity were observed which was also confirmed with Biii’-iii’’) staining 
for ZO-1 (grey). Biv-v) In contrast, AAV.shCrb1 injection led to a visible reduction in CRB1 
immunoreactivity, formation of so-called rosettes (asterisks), and nuclei drop into the subretinal space 
(arrows). Bvi’-vi’’) The OLM disruption was further confirmed with IHC analysis for ZO-1, which was 
especially compromised in the areas of the retinal folds. Retinal sections were counterstained with nuclei 
marker Hoechst 33342 (blue). Scale bar = 25 µm, all other images at the same magnification except Bi 
and Biv, Scale bar = 100 µm. Ci) Histogram shows mRNA levels for Crb1, assessed by QRT-PCR 3 
weeks after intravitreal injection at P8 of either AAV.shCon or AAV.shCrb1. Both AAV.shCon and 
AAV.shCrb1 mediated a marked reduction in Crb1 mRNA expression, compared to untreated controls. 
Cii) Delivery of AAV.shCrb1 also resulted in a significant drop in Crb2 mRNA levels which was not 
observed in the retinae treated with AAV.shCon. ***P<0.001 and ****P<0.0001 with a one-way ANOVA 
and Tukey's correction for multiple comparisons. Error bars: SEM; n≥3 animals examined per 
experimental condition. 
 
 
 
  
  
286"
In order to avoid the introduction of pathological changes to a wild-type retina, I 
decided to test whether a sparse knockdown of CRB1 was possible. Recent findings 
demonstrated that AAVShH10-Y445F is not very effective in transducing adult retina, 
with only patches of Müller glial cells being infected with the virus (Klimczak et al., 
2009; Alves et al., 2014a). As morphogenesis is complete by P16 (Xu and Tian, 2007), 
the generated vectors were delivered at P18 and assessed the injected eyes 3 weeks 
later against uninjected controls.  
At six weeks of age, a continuous line at the level of the OLM can be seen following a 
staining with CRB1 antibody in the uninjected wild-type retina (Figure 7.9A). No 
changes in CRB1 staining were observed. In agreement with previous reports, the 
transduction of the more mature retina with AAVShH10-Y445F was not as effective in 
comparison with transduction at P8-P10. A sparse expression of RFP in Müller glial 
cells was observed in both AAV.shCon (Figure 7.9B i) and AAV.shCrb1 (Figure 7.9v iv) 
treated eyes. QRT-PCR analysis demonstrated that Crb1 mRNA levels were 
unaffected by AAV.shCon administration and where similar to those seen in the 
uninjected animals (91.51±17.8% of the levels in untreated retina; P=0.12; Figure 7.9C 
i). Similarly, IHC labeling of CRB1 showed no visible differences between AAV.shCon 
treated (Figure 7.9B ii’) and untreated retinae (Figure 7.9A) which was further 
confirmed with staining for ZO-1 (Figure 7.9B iii’). In contrast, Crb1 expression, while 
not completely abolished, was markedly reduced in the eyes treated with AAV.shCrb1 
(61.2±22.9% of the levels in untreated retina; P<0.05; Figure 7.9C i). Additionally, a 
decrease in the level of CRB1 staining was notable in areas transduced by 
AAV.shCrb1 (Figure 7.9B v’). No major abnormalities ether within the integrity of the 
OLM or immunoreactivity for ZO-1 (Figure 7.9B vi’) were observed. Although there was 
a clear reduction in CRB1 levels, no marked changes to cytoarchitecture were detected 
with the gross retinal lamination being preserved.   
Interestingly, delivery of AAVShH10-Y445F vectors at P18 had no indirect effect on 
levels of Crb2 as assessed at the RNA levels by QRT-PCR (123.2±8.4% and 
87.4±12.0% of the levels in untreated retina for AAV.shCon and AAV.shCrb1, 
respectively; P=0.698; Figure 7.9C ii). The injection of AAV.shCrb1 at P18 did not lead 
to a drop in Crb2 expression, as was observed in the eyes injected at P8; this most 
likely explains the concomitant reduction in the occurrence of ONL undulations.  
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 Figure 7.9 Delivery of AAV.shCrb1 at P18 results in a reduction of CRB1 in Müller glia of 
C57BL/6J wild-type mouse but no prominent undulations of the ONL.  
Ai-ii) Immuoreactivity for CRB1 (green) in 6 week old C57BL/6J wild-type retina shows a continuous and 
uniform line at the OLM level. Bi-ii0 The CRB1 immunoreactivity in AAV.shCon injected retinae was 
comparable to that seen in untreated controls. Biii’-iii’’) No alterations to OLM continuity were observed 
which was also confirmed with staining for ZO-1 (grey). Biv-v) Administration of AAV.shCrb1 led to 
reduction in the signal of CRB1 staining in transduced areas (red); however no visible abnormalities within 
the integrity of the OLM were observed. Bvi’-vi’’) IHC analysis of ZO-1 immunoreactivity confirmed the 
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continuity of OLM and preservation of retinal. Retinal sections were counterstained with nuclei marker 
Hoechst 33342 (blue). Scale bar = 25 µm, all other images at the same magnification except Bi and Biv, 
Scale bar = 100 µm. Ci) Histogram shows mRNA levels, assessed by QRT-PCR 3 weeks after intravitreal 
injection at P18, for Crb1, following treatment with AAV.shCon and AAV.shCrb1. Only AAV.shCrb1 
mediated a marked statistically significant reduction in Crb1 mRNA levels, compared to AAV.shCon 
injected eyes or shRNA untreated controls. Cii) Delivery of AAV.shCrb1 did not alter Crb2 mRNA 
expression. *P<0.05 with a one-way ANOVA and Tukey's correction for multiple comparisons. Error bars: 
SEM; n≥3 animals examined per experimental condition. 
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As illustrated in Chapter 3, the Crb1rd8/rd8 mouse manifests clear signs of reactive 
gliosis; therefore it was hypothesised that the ablation of CRB1 in Müller glia may lead 
to their activation. One of the best markers for reactive glia is GFAP upregulation, as in 
a healthy wild-type retina GFAP immunoreactivity is restricted to astrocytes (see Figure 
7.10A and Chapter 3).     
The delivery of AAV.shCrb1 resulted in marked upregulation in IF with visible GFAP+ve 
processes spanning the entire thickness of a retina even after 3 weeks post-injection, 
both in retinae injected at P8 (Figure 7.10i-ii) or at P18 (Figure 7.10iii-iv). The GFAP 
immunoreactivity was especially prominent around the rosettes, which is in agreement 
with the observations reported in Crb1 mutant (reviewed in (Hippert et al., 2016)). 
Moreover, the processes of the Müller glia in the retina injected at P8 appeared (on 
average) to be much thicker than the processes of the glia cells examined in the eyes 
injected at P18. A possible explanation for this could be that reduction of CRB1 in a 
retina that is not fully developed at P8 has greater consequences on retinal 
morphology and homeostasis than its removal when fully formed. It has been shown 
that AJ proteins, including CRB1 and CRB2, take part in the regulation of cell 
proliferation and any mutation or disruption in their levels may lead to loss of cell 
polarity and epithelial adhesion, and concomitant detachment from the apical lamina 
(reviewed in (Alves et  al.,  2014b)). It is worth noting that upregulation in GFAP levels 
was also observed after administration of AAV.shCon, albeit smaller than that following 
administration of AAV.sCrb1, which may indicate the extreme sensitivity of Müller glia 
to any change within the retinal environment, particularly during development. These 
changes further illustrate the effectiveness of the generated vector in silencing Crb1 
but also demonstrate the risk to, and possible consequences for, retinal health when 
manipulating the expression of a junctional protein. 
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Figure 7.10 AAV.shCrb1 administration and reduction in CRB1 levels leads to activation of 
Müller glia in C57BL/6J wild-type.  
Ai-ii) In a normal retina, there are no signs of activated Müller glia when assessed with IHC for GFAP 
immunoreactivity. Bi-iv) After administration of the generated AAVShH10-Y445F vectors at P8 and P18, 
the injected eyes were assessed after 3 weeks. Bii'-ii'') Targeted ablation of CRB1 in postnatal retina 
results in visible upregulation of GFAP especially in areas close to retinal folds which develop after 
AAV.shCrb1 injection at P8. Biv'-iv'') Although delivery of AAV.shCrb1 at P18 did not lead to any visible 
abnormalities within the retina, decrease in Crb1 levels still resulted in activation of Müller cells. Bi'-i''); 
Biii'-iii') Surprisingly, the delivery of AAV.shCon also resulted in glial activation which demonstrates the 
sensitivity of a retina to any retinal insult including the intravitreal surgery. Retinal sections were 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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7.3 Discussion 
Consistent with the idea of the OLM as a barrier to therapeutic interventions, a 
molecular tool to silence Crb1, one of the key regulators of AJs in the mouse retina 
was developed. In this study, the designed AAV-ShH10-Y445F.shCrb1 vector was 
shown to be capable of silencing the expression of Crb1 mRNA in wild-type C57BL/6J 
Müller glia cells when injected into early postnatal eye. The removal of CRB1 led to 
defects in retinal lamination and development of gliosis, which is in line with previous 
findings from studies of Crb1 mutants.  
In adult murine retina, CRB1 has been shown to be involved in retinal lamination and 
the maintenance of AJs between Müller glial cells and photoreceptors ensuring the 
integrity of the OLM (van de Pavert et al., 2004). Loss of CRB1 or its mislocalisation 
leads to impairment of OLM integrity, delamination of the photoreceptor layer and 
eventual retinal degeneration in both mice and humans (van de Pavert et al., 2004). In 
affected retinal areas, staining for typical AJ or SAR markers is usually reduced or lost, 
which indicates disruptions to OLM continuity (van de Pavert et al., 2004; van Rossum 
et al., 2006). This focal loss of adhesion between photoreceptors and Müller glia can 
then result in ONL undulation and formation of so-called rosettes (Mehalow et al., 
2003). Findings from a study on the Crb1 mutant demonstrated that the rosettes 
become bigger with age and in some areas the retinal lamination was completely lost 
(van de Pavert et al., 2004). It has also been reported that loss of Crb1 in Müller glia 
results in irregularities in the number and size of their apical villi (van de Pavert et al., 
2007). However, all these changes were usually more prominent in the inferior 
quadrant with significantly more signs of retinal disorganization in this region. These 
changes were proposed to be due to differing levels of CRB1 expression between 
superior and inferior retina (Mehalow et al., 2003; van de Pavert et al., 2004; van 
Rossum et al., 2006). A recent study by Krol et al. showed that CRB1 is post-
transcriptionally regulated by miR-183/96/182. Moreover, they demonstrated that the 
photoreceptors and not Müller cells represent the main source of CRB1 in the OLM of 
the early postnatal retina (Krol et al., 2015). In early post-mitotic photoreceptors, when 
mature miR-183/96/182 is not present, CRB1 was found to be expressed at a high 
level to ensure the formation of a strong adhesion between Müller glia and 
photoreceptors. During retinogenesis, this adhesion was proposed to help confine 
retinal progenitors within the tight borders created by the inner and outer limiting 
membranes. After the lamination of the retina is complete, these barriers limit the 
diffusion of important molecules including Retinoid-binding protein into the neuroretina 
(Carter-Dawson and Burroughs, 1992). As the retina matures, it has been 
demonstrated that CRB1 expression becomes suppressed by miR-183/96/182, which 
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may lead to a weakening of the OLM barrier. In terms of this hypothesis, one could 
explain the formation of the retinal folds in Crb1 mutants as regions where retinal 
progenitor migration pushes against these flimsy margins, which may result in a breech 
in the AJs and subsequent cellular protrusions into the subretinal space.  
Given the importance of CRB1 in the maintenance of AJs in the mouse retina and the 
fact it was shown be restricted only to OLM region, this study aimed to develop a 
molecular tool to temporarily silence its expression and potentially open a window for 
therapeutic intervention. Despite encouraging results from initial in vitro studies, 
designed siRNA sequences failed to reduce CRB1 levels or cause any transient 
disruption in OLM integrity in a C57BL/6J wild-type retina. Surprisingly, this RNAi 
technique was also unsuccessful in decreasing levels of ZO-1 in vivo, even though the 
group has previously found it to be effective (Pearson et al., 2010). The reason for 
these discrepancies is not fully understood but one could speculate that they result 
from the lack of an efficient system for siRNA delivery in vivo to Müller glia, degradation 
of the siRNA by endogenous RNAses, or instability of the designed siRNAs. Another 
possibility is that 72 hrs post-injection was too late to assess any more rapid effects of 
the RNAi. A recent study by Yu at al. examined the effects of siRNA targeting ZO-1 at 
24 hrs post-injection in a rat model of RP (Yu et al., 2016). In contrast to previously 
published reports (Pearson et al., 2010); Yu, Eom et al. did not observe any changes 
within the OLM after administration of 15 µM siRNA targeting ZO-1. A clear explanation 
for these discrepancies is not known, but RNAi technology has a number of limiting 
factors that could lead to different experimental results.       
As the primary interest was in knowing whether it is possible to knockdown CRB1 in 
the mouse retina, an AAVShH10-Y445F vector was designed to deliver a shRNA 
sequence to Müller glial cells. Here, AAVShH10-Y445F vector was injected intravitrally 
into the eyes of P8 and P18 C57BL/6J mice and the retinae were assessed after 3 
weeks and compared against uninjected and shCon injected controls. Preliminary 
findings showed that AAV.shCrb1 effectively ablated Crb1 mRNA expression which 
then led to a reduction of CRB1 protein level as assessed by ICH analysis. It has been 
demonstrated that following delivery of AAV.shCrb1 at early time-point (P8), these 
reduced levels of CRB1 in Müller glia result in lamination defects giving rise to many 
retinal folds and rosettes suggesting a severe lack of adhesion between these cells 
and photoreceptor IS. The ONL undulations were present in both superior and interior 
regions of the retina, which is contrasts with the previously published reports on 
different mouse Crb1 mutants (Crb1-/-, Crb1c249wl- and Crb1rd8/rd8), which suggested that 
the phenotype is restricted to the inferior quadrant of a retina (Mehalow et al., 2003; 
van de Pavert et al., 2004; van Rossum et al., 2006). This inferior phenotype has been 
explained in terms of differing levels of CRB1 between the superior and inferior areas; 
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however this study on the laser captured tissue showed no such difference. Recently, 
examination of the BN-J rat strain demonstrated that mislocalisation of CRB1 from the 
SAR of Müller glial cells leads to a retinopathy similar to that observed in Crb1 mutant 
mice except that the observed phenotype manifests itself throughout the entire rat 
retina (Zhao et al., 2015). Given that the phenotypic severity of Crb1 mutations 
depends upon the genetic background, different mutations may lead to various retinal 
phenotypes in different species, including humans (Bujakowska et al., 2011). The lack 
of a clear genotype–phenotype correlation suggests that either other Crumbs proteins 
like CRB2 are able to compensate for the loss of CRB1 function or that interactions 
between the members of the CRB complex vary between different species.  
In a mouse retina, CRB1 and CRB2 display an intimate relationship (Alves et al., 
2014b). A delivery of the shRNA vector and consequent downregulation of CRB1 had a 
negative impact upon Crb2 expression, with levels being markedly decreased in 
comparison to AAV.shCon treated retinae. This decrease may have contributed to 
development of the severe phenotype, as CRB2 has roles in restricting proliferation of 
progenitor cells, the number of rod photoreceptor and Müller glia cells (Alves et al., 
2012; 2014a). It has been shown that targeted ablation of CRB2 from retinal progenitor 
cells leads to abnormalities in retinal lamination, which results in a severe and 
progressive retinal degeneration with concomitant loss of retinal function (Alves et al., 
2012; 2014a). Moreover, it has been demonstrated that in Crb1Crb2 conditional 
knockout retinae, silencing of both CRB1 and CRB2 results in an abnormal and 
thickened retina without a proper and separated photoreceptor cell layer due to 
overproliferation of the retinal progenitor cells (Pellissier et al., 2013). Pelissier et al. 
also reported that the Crumbs proteins manifest a dose-dependent effect, as different 
levels of CRB proteins give rise to different phenotypes. CRB1 retinal dystrophies have 
no clear genotype-phenotype correlation in humans (Bujakowska et al., 2011) nor is 
any such correlation apparent in different models of Crb knockout mice (Luhmann et 
al., 2015). This led some researchers to speculate that variation in CRB2 
downregulation may be responsible for creating the range of different phenotypes 
observed in patients with CRB1 mutations such as CRB1-RP and CRB1- LCA (Alves et 
al., 2014a). In this study, the administration of AAVShH10-Y445F vector at P18 was 
demonstrated to lead to very sparse transduction of the mouse wild-type retina as 
assessed by RFP expression, in comparison to injection at P8. Following treatment 
with AAV.shCrb1 vector, only a small knockdown of CRB1 was observed with no 
significant change in Crb2 mRNA levels. No observable pathological changes to retinal 
architecture including ONL undulations or any major breaks in OLM integrity were 
found at 3 weeks post-injection. These results are in line with previously published 
reports where it has been shown that short-term ablation of CRB2 using AAVShH10-
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Y445F-shCrb2 vector in the adult retinae has no major consequences on the 
maintenance of the retinal structure. In contrast, ablation of CRB2 in early 
photoreceptors using the same vector is essential for proper retinal lamination and 
function (Alves et al., 2014a).  
Recent studies of the AJs within the OLM demonstrate that there is emerging evidence 
for heterogeneity of junctional protein expression in different cell types. This 
heterogeneity could explain the appearance of focal disruptions to OLM integrity 
following the knockdown of junctional proteins (Omri et al., 2010). Indeed, retinal folds 
and rosettes were only formed following the loss of CRB2 from photoreceptor cells and 
not Müller glia, suggesting that CRB2 is critical for the maintenance of AJs between 
rods and cones (Alves et al., 2014a). This is of particular importance as in pathological 
conditions AJs undergo significant re-arrangements that may have a substantial impact 
upon retinal function or cell survival. As it was mentioned previously, numerous studies 
reported that some visual function can be reported following cell transplantation 
(Pearson et al., 2012; Santos-Ferreira et al., 2014). It has also been demonstrated that 
there is a significant increase in a number of observable GFP+ cells in a recipient retina 
with a compromised OLM integrity (West et al., 2008; Pearson et al., 2010; Barber et 
al., 2013); although in mice this is mainly due to a novel phenomenon referred to as 
material transfer (Pearson et al., 2016) or cytoplasmic fusion (Singh et al., 2016). If 
OLM acts as a semipermeable barrier (Bunt-Milam et al.,  1985), any discontinuity 
within it may help GFP particles to diffuse through the retina and be uptaken by the 
host cells making OLM a gate for macromolecule transport. If the underlying biological 
mechanisms of material transfer can be revealed, they may represent a new 
therapeutic strategy for a broad-spectrum of inherited retinal diseases by introducing 
functional proteins into otherwise diseased photoreceptors. Moreover, increased 
understanding of the changes to AJs and the expression of junctional proteins in 
different retinopathies may be crucial to developing successful therapeutic strategies 
as it is possible that these changes may influence the outcome of any medical 
intervention. Here, the reduction of CRB1 protein in Müller glia resulted in detrimental 
effects upon retinal structure. As demonstrated in previous chapters, Müller glia 
undergo significant changes in different retinal degenerations, having an important role 
in the remodelling of the retina following the death of photoreceptors. Upregulation of 
IF proteins in Müller cells allows for the extension of their glial processes to fill in the 
gaps left by photoreceptor loss and to create a gliotic seal at the outer edge of the 
neuroretina (Lee et al., 2011). These changes also result in alterations of the AJs, 
which has been illustrated very well in models such as the Pde6brd1/rd1, where during 
the course of degeneration the majority of the AJs were formed between Müller glial 
terminals (Hippert et al., 2015). Removal of the junctional proteins may then lead to 
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impairment in the formation of this glial seal and subsequent consequences upon the 
glial fibres and the retinal architecture itself. Indeed, in a recent study by Yu et al. it has 
been demonstrated that in the S334ter-line 3 rat model of RP, inhibition of ZO-1 
expression results in a disruption of a distal glial seal as assessed by GFAP staining 
(Yu et al., 2016). This may create a potential risk of increasing the speed of retinal 
degeneration in models such as Pde6brd1/rd1, where glial scarring is perceived as an 
attempt to preserve the retinal architecture. Additionally, decreased expression of ZO-1 
was also found in the all-cone retina of the R91W;Nrl−/− mutant where exposure to toxic 
levels of blue light led to vascular leakage, retinal swelling and the appearance of 
cystoid spaces in both INL and ONL indicating edema (Geiger et al., 2015). Together 
this could suggest that a retina with compromised levels of junctional proteins has a 
weaker OLM which as a result may be more prone to any retinal damage.  
In summary, these results show that I have developed a tool for successful CRB1 
knockdown, which may be prove to be useful in future when combined with potential 
therapeutic approaches. However, a thorough assessment of the long-term impact of 
CRB1 silencing upon the OLM function, especially in regard to permeability and the 
overall retinal structure must be done before proceeding with any such therapeutic 
strategy especially in severely degenerated models like Rho-/- mutant.  
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Chapter 8 
Final conclusions 
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8.1 Summary  
The degenerating retina is a complex and ever changing environment, which 
undergoes constant remodelling in order to adapt to the loss of photoreceptor cells. As 
in the CNS, upon a pathological stimuli, the glial cells become activated as a form of 
neuroprotective response (Sahel et al., 1990; Humphrey et al., 1993; Jones et al., 
2003a)(Sahel et al., 1990; Humphrey et al., 1993). This activation leads to proliferation 
of Müller glia, changes in their morphology, alternations in ion transport and secretion 
of extracellular molecules, leading to the formation of a glial scar as the final outcome. 
Although gliosis has been extensively characterised, there is still no uniform view of its 
role and function and the field is beginning to recognise it as a complex system of 
interacting cells and biological processes. Moreover, rather than being a single process 
initiated by injury or disease, it is becoming increasingly clear that gliosis can present in 
many forms, depending upon the initiating insult (Seoane et al., 1999; Hippert et al., 
2015; Martinez-De Luna et al., 2016); also reviewed in (Bringmann and Wiedemann, 
2012)). The overarching aims of this thesis were firstly to characterise a number of 
different aspects of gliosis and provide a comprehensive spatio-temporal comparison 
of this process in different models of inherited retinal degenerations. Secondly, I sought 
to assess ways of modulating these factors with the aim of improving therapeutic 
outcomes, with particular reference to photoreceptor transplantation therapy. The 
results presented in Chapter 3 show marked variations both in the timing and the 
magnitude of the gliotic response in different mouse models of inherited retinal 
degeneration; these result in a unique, disease-specific pattern of alterations in the 
retinal microenvironment. Here, it has been demonstrated that the classic hallmarks of 
gliosis - the upregulation of intermediate filament (IF) proteins and increases in 
chondroitin sulphate proteoglycans (CSPGs) deposition – need not be positively 
correlated with disease severity. A prevailing hypothesis in the regeneration field is that 
the upregulation of IF proteins and the associated glial cell hypertrophy is inhibitory to 
therapeutic interventions, particularly those involving host-graft or host-device 
interactions. In Chapter 4, I sought to modulate this process by using RNAi to reduce 
the levels of GFAP and Vimentin in a mouse model of chronic. Levels of both GFAP 
and Vimentin in the Rho-/- mutant could be effectively reduced using AAV vectors and 
reducing Vimentin led to a marked decrease in degeneration-associated hypertrophy of 
the glial apical terminal processes. However, neither GFAP nor Vimentin 
downregulation had any significant effect on photoreceptor transplantation outcome, in 
contrast to previous reports (Kinouchi et al., 2003). A wide array of extracellular 
signalling molecules that variously support or inhibit neuronal regeneration are present 
at the site of CNS lesions, with CSPGs playing a major inhibitory role. In Chapter 3, I 
described the broad patterns of CSPG distribution in different models of retinal 
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degeneration and again found significant variations between models. In Chapter 5, the 
spatio-temporal expression of a specific CSPG, Aggrecan, together with the CSPG 
receptor LAR were assessed in two mouse models of RP. This showed that, despite 
the ability of exogenously applied Aggrecanase to reduce CSPGs deposited within the 
photoreceptor segment region of the retina, Aggrecan was only found in the inner 
retina. In contrast, a high abundance of LAR was found in the segment region. 
Although the role of LAR in the developing and mature normal and diseased retina are 
yet to be determined, its presence in the photoreceptor segment region offers a 
potential opportunity for future experimental work to manipulate the inhibitory role of 
CSPGs prior any therapeutic interventions.  
Significant loss of photoreceptors and development of gliosis was predicted to have a 
significant impact on the integrity of the outer limiting membrane (OLM), a series of 
adherens junctions that have previously been shown to impair transplantation outcome 
(West et al., 2008; Pearson et al., 2010; Barber et al., 2013). A comprehensive 
examination of a number of different murine models of inherited retinal degenerations 
was performed; findings presented in Chapter 6 suggest that as the photoreceptors 
die, both the number and the nature of adherens junctions between the remaining cells 
undergo significant changes, with a shift in favour of junctions formed between two 
Müller glia cells, rather than between Müller glia and photoreceptor cells, as typically 
seen in the normal retina. These changes can probably be correlated with the rate of 
photoreceptor death and the extent of retinal remodelling, particularly glial hypertrophy 
(Omri et al., 2010; Hippert et al., 2015; Yu et al., 2016). As noted above, the OLM is 
often regarded as a barrier to therapeutic interventions. For this reason, a molecular 
tool to disrupt the connections between AJs was developed. Here, a 
AAV.ShH10.shCrb1 vector was designed and shown to effectively silence the 
expression of Crb1 mRNA in a wild-type retina. Interestingly, findings from these study 
indicated that the removal of CRB1 from Müller glia cells, and the resulting disruption to 
OLM integrity in early postnatal retina, leads to defects in retinal lamination and the 
development of gliosis. In addition to underlying the importance of this protein in 
normal retinal development, it is of particular importance in considering the utility of 
targeted disruptions of the OLM in severely degenerated mutants; removing the 
remaining junctions may result in development of further pathological changes.   
Overall, findings presented in this thesis increase our knowledge of the remodelling 
that happens within the diseased retina, but also challenge some of the commonly held 
views on the impact that these alterations may have on therapeutic strategies, 
including photoreceptor cell transplantation. 
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8.2 The glial scar and neuroregeneration 
In the adult mammalian CNS, many damaged axons are unable to regrow across the 
site of injury. Potential mechanisms for this failure include: a reduction in the intrinsic 
growth capacity of mature neurons; absence of external growth promoting factors and 
the presence of external inhibitory factors associated with glial scarring. The last of 
these has received the greatest attention, with the common belief that the glial scar 
acts as the main impediment to regenerative strategies following CNS injury. However, 
there is increasing evidence, including a number of the findings presented in this study 
that challenge this prevailing dogma. As discussed in this thesis, one of the hallmarks 
of the glial scar in a retina is the upregulation of the IFs, particularly GFAP, and an 
increase in the hypertrophy of Müller glial cell (Jones et al., 2003a). Both factors have 
been argued to represent a major obstacle to retinal grafts and/or cell transplants and 
breaking down the scar has been viewed as a necessary requirement for good graft-
host interactions (reviewed in (Seiler and Aramant, 2012; Veleri et al., 2015)). Here, no 
improvement in photoreceptor transplantation outcome was found following the 
removal of IF proteins. Moreover, removing of both GFAP and Vimentin resulted in 
exacerbated retinal degeneration including the ONL thinning and retinal detachment as 
well as other ocular complications in the model of chronic retinal degeneration, 
indicating that the diseased retina needs the glial hypertrophy to preserve its 
architecture. These findings are in line with a recent paper published by Anderson and 
colleagues who reported that ablation of scar-forming astrocytes or the removal of 
chronic astrocytic scars after severe spinal cord injury (SCI) in adult mice failed to 
result in spontaneous axonal regrowth (Anderson et al., 2016). So what is the role of 
this scar in the system? Previous reports demonstrated that immediately after injury 
reactive astrocytes seal the lesion site with their processes, which helps to modulate 
the immune response and protect the healthy tissue (Panickar and Norenberg, 2005; 
Pekny and Nilsson, 2005; Wilhelmsson, 2008; Anderson et al., 2016). Moreover, as 
also shown in the current study, in chronic diseases, the hypertrophied glial processes 
may be critical for sustaining tissue integrity as the removal of the IFs had detrimental 
effects on the retinal lamination in the Rho-/- mutant. In the damaged retina, activated 
Müller glia produce a number of neurotrophic growth factors (amongst others) including 
FGF, as well as several antioxidants, molecules that are not normally secreted in the 
healthy retina (reviewed in (Bringmann and Wiedemann, 2012)). To further support this 
argument, studies on transgenic Gfap-/-/Vim-/- mice showed that removal of GFAP and 
Vimentin accelerates monocyte infiltration and faster degeneration of photoreceptors 
following retinal trauma (Lundkvist et al., 2004). In the genetic absence of both GFAP 
and Vimentin together, mortality rate drastically increased among Gfap-/-/Vim-/- mice 
following a brain trauma, in comparison to controls (Lundkvist et al., 2004). Rather than 
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being the major impediment to axonal regrowth, as is often assumed, Anderson and 
colleagues reported that ablating chronic glial scars following SCI in mice does not help 
with axonal sprouting, and they argue that this scar is essential for preserving tissue 
integrity a(Anderson et al., 2016). Therefore, the development of the glial scar may be 
viewed as an attempt to restore homeostasis, which is needed for future axonal 
regrowth and re-establishing of the lost connections. 
Further support for reactive glia acting as a ‘sealing tape’ is presented in this thesis, 
where removal of one of the junctional proteins, CRB1, led to disruption of OLM 
integrity and exacerbated gliosis. The OLM mainly forms between photoreceptor inner 
segments (IS) and the Müller glia apical processes, acts as a semipermeable diffusion 
barrier for extracellular components (Bunt-Milam et al., 1985). Removing CRB1 led to 
the activation of Müller glia cells, seen as an increase in the expression of the IFs and 
hypertrophy, possibly in an attempt to minimise the diffusion of extracellular proteins 
from the segment region. In the current study, the OLM was shown to significantly 
remodel over the course of degeneration, with many more junctions being formed 
among Müller glia apical processes. The heterogeneity of the junctions must be taken 
into account while considering any therapeutic strategy to reversibly disrupt OLM 
integrity. Conversely, it is possible that any intervention that inhibits the formation of the 
glial seal, including downregulation of the intermediate filament proteins, may lead to a 
disruption of the OLM remodelling and increased in OLM permeability to ECM 
molecules.  
How is our understanding of the role of proteoglycans in retinal degeneration affected 
in the light of these changing roles for glial hypertrophy? Proteoglycans, especially 
CSPGs, are known for their immune-related activity as proteoglycans increase in order 
to target the immune response to the damaged area (Nandini and Sugahara, 2006). 
However, it has been suggested that the upregulation of CSPGs at the injury site 
may also help to create a diffusion barrier for molecules that are potentially harmful to 
the undamaged neurons (Roitbak and Syková, 1999). Although the digestion of 
CSPGs several weeks after the injury can be beneficial to axonal regeneration, their 
removal immediately after the lesion does not help axons to regrow. This could indicate 
that CSPG-mediated growth inhibition might be beneficial, as it can help to minimise 
the spread of neurotoxicity as well as stopping the neuronal death mediated by the 
immediate inflammatory response (Vorísek et al., 2002).  
As it was already mentioned, any type of insult to the CNS leads to an immune 
response with macrophages and activated microglia starting to infiltrate the lesion site 
and secreting many different proinflammatory cytokine and chemokine molecules 
(Giulian et al., 1988; Balasingam et al., 1994; Liu et al., 2011; Shechter et al., 2011; 
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Smith et al., 2012). CNS-resident microglia cells are directly activated by CSPGs via 
the CD44 receptor (Rolls et al., 2008). Moreover, the elevated expression of 
cytokineses can stimulate the production of CSPGs including the expression of 
chondroitin 6-sulphate proteoglycan in neighbouring cells (Properzi et al., 2005). 
Recent studies demonstrated an important link between the microglia activation and 
the reactivity of astrocytes, where the two cell types are involved in a direct cross-talk 
with each other and modulates each other’s activity and post-injury response (Liu et al., 
2011; Schechter et al., 2011). For example, microglia can regulate the astrocytes 
expression of CSPGs such as Brevican, Neurocan, and Phosphacan which are 
believed to have a negative impact on axonal growth. Interestingly, macrophages 
themselves can also secrete CSPGs and may be a potentially significant source of 
CSPGs in the post-injury environment (Uhlin-Hansen et al., 1993). Overall, these 
studies indicate that different components of the glial scar are essential for regulating 
of the immune response and allowing the system to restore its homeostatic balance.  
Despite the common acceptance of CSPGs being the ‘bad guys’, recent findings 
suggest that not all CSPGs are detrimental to neuronal growth. As already described in 
Chapter 5, there is some inconsistency in the evidence of CSPG-mediated inhibition. 
Although there is no doubt that removal of CSPGs a few weeks after the injury is 
beneficial to CNS regeneration, not all of these molecules may be detrimental to this 
process. For example, Versican, was found not to exhibit the same inhibitory effect, 
with axons not only being able to grow through deposits of Versican but also showed 
no signs of inhibition in the presence of the purified proteoglycan (Braunewell et al., 
1995; Fidler et al., 1999). In a healthy retina, both Neurocan and Versican were 
reported to be expressed in the photoreceptor segment region (Singhal et al., 2008), 
which is a common site used for cell transplants and grafting of the retinal implants. 
Following cell transplantation, a robust number of donor-labelled cells are seen in the 
healthy recipient retina, despite the presence of CSPGs in the subretinal space 
(Singhal et al., 2008; Pearson et al., 2012; Barber et al., 2013; Santos-Ferreira et al., 
2014). Although, the increase in a number of observable donor labelled cell was 
reported after ChABC treatment. Moreover, in non-mammalian species such as 
zebrafish, CSPGs were shown to guide rather than inhibit axon growth and 
regeneration following optic nerve injury (Becker and Becker, 2002). Wang and 
colleagues reported that CSPGs’ receptor LAR helps to guide somatosensory nerves 
towards their location in the skin and its deletion leads to a disruption of the skin 
innervation (Wang et al., 2012).  
The roles that glial scarring may have in the injured or damaged CNS are complex. 
However, despite some seeming contradictions in these roles, as shown in this thesis it 
is important remember that each disease is different and that the underlying 
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pathological mechanisms may result in a very different cellular response. With this in 
mind, only by understanding these changes and cellular processes can we expect to 
develop more effective and safer therapeutic strategies. 
8.3 Future of cell transplantation  
Cell transplantation has been viewed as a potentially powerful therapeutic strategy for 
tissue regeneration and a broad-spectrum treatment for many pathological eye 
conditions. A remarkable effort has been made in order to find the best method to 
replace lost photoreceptor and RPE cells, including transplantation of whole retinal 
sheets, microaggregates of developing neural retina and suspensions of stem cells and 
donor-derived progenitor cells (reviewed in (Pearson, 2014; Pearson et al., 2014). The 
past decade has seen the generation of retinal cells from renewable sources, including 
embryonic (ES) (Meyer et al., 2009) and induced pluripotent stem (IPS) cells (Lamba et 
al., 2006; Osakada et al., 2008). The use of 3D culture systems has further improved 
our ability to generate retinal neuroepithelial-like structures in vitro (Eiraku and Sasai, 
2012; Zhong et al., 2014), and adaptations of these protocols has yielded 
transplantable populations of donor photoreceptor cells (Gonzalez-Cordero et al., 
2013). Importantly, there are now many reports describing improvements in visual 
function following the transplantation of healthy photoreceptors into models of retinal 
degeneration (Lamba et al., 2006; 2009; Tucker et al., 2011; Pearson et al., 2012; 
Santos-Ferreira et al., 2014; Barnea-Cramer et al., 2016). Although undoubtedly 
exciting, recent work from our group (Pearson et al., 2016), the group of Marius Ader 
(Santos-Ferreira et al., 2016) and the lab of Robert MacLaren (Singh et al., 2016) has 
questioned our previously held assumptions about the ability of the transplanted cells 
to migrate into the correct places within the recipient retina from the injection site. 
Previously, it has been hypothesised that donor cells following transplantation extend a 
process towards the neuroretina in order to establish a contact with the host cells 
which then led to their migration from the subretinal space (Warre-Cornish et al., 2014). 
Recently, real-time imaging of explants of transplanted retina have confirmed these 
findings (Pearson et al., 2016). However, in the same study, Pearson and colleagues 
found that this process accounts for only a minority of apparently integrated cells within 
the host ONL.  
The independent studies by Pearson and Ader ruled out the classic process of cell 
fusion, instead suggesting that, following transplantation, donor photoreceptor cells 
engage in the exchange of RNA and/or protein with host photoreceptor cells in a 
process they have termed ‘material transfer’. The precise cellular mechanism 
underlying this process remains unclear. What is known is that it does not involve 
uptake of free protein, RNA or DNA nor does it involve classic nuclear transfer. 
303"
Pearson et al. proposed that the transplanted cells release material in a form of 
microvesicles, which are subsequently taken up by host cells (and to a lesser extent 
vice versa). If true, this mechanism could explain why the number of reported donor-
labelled cells was increased in the animals with a compromised OLM integrity (West et 
al., 2008; Pearson et al., 2010; Barber et al., 2013). If the OLM is a semipermeable 
barrier (Bunt-Milam et al., 1985), it may restrict the passage of microvesicles from 
donor to host and/or access to the uptake mechanisms. Another working hypothesis 
discusses the possibility of the cytoplasmic transfer similar to the one that occurs 
between photoreceptor outer discs and underlying RPE (Singh et al., 2016). Singh et 
al. argued that because host and donor cells are in a direct contact with each other, 
this could allow for the merger of the two lipid bilayer plasma membranes resulting in a 
cytoplasmic fusion. Interestingly, this novel biological phenomenon is specific to 
photoreceptor precursor donor cells, as previous studies reported rather poor 
outcomes of cell transplantation with more mature cells (MacLaren et al., 2006; 
Gonzalez-Cordero et al., 2013). Whatever the underlying process, material transfer is 
surprisingly robust, resulting in host cells be able to express a wide variety of 
photoreceptor specific proteins with high fidelity; for example, around 85% of GFP+ 
cells in the ONL of Gnat1-/- hosts also express rod a-transducin, the protein missing 
from host photoreceptors (Pearson et al., 2016). Given that material transfer or 
cytoplasmic fusion appears to account for between 70-90% of the reporter-labelled 
cells seen in the host retina, it seems likely that this new mechanism is responsible for 
the observed improvements in visual function (Lamba et al., 2009; Tucker et al., 2011; 
Pearson et al., 2012; Santos-Ferreira et al., 2014). Thus, material transfer may still 
represent a potential therapeutic approach for the treatment of many retinopathies.  
Whatever the mechanisms behind material transfer are, they must account for a 
number of intriguing observations. Previous studies indicated IFs as an obstacle to cell 
integration (Kinouchi et al., 2003), whereas in this study no increase in the observable 
donor cells was observed following the removal of GFAP or Vimentin. If Müller glia 
hypertrophy was a barrier to material transfer, one would have expected to see an 
improvement in the Rho-/- mutant after RNAi treatment. As discussed previously, 
CSPGs help to create a diffusion barrier for molecules (Roitbak and Syková, 1999). It 
is therefore interesting to ask whether material transfer is also impeded by it, and if so, 
which CSPGs are involved. Several studies have reported marked increases in the 
number of visible donor-labelled cells in the host retina after enzymatic treatment with 
ChABC, compared to controls, (Zhang et al., 2007; Singhal et al., 2008; Barber et al., 
2013) which must now be considered likely arising from material transfer (although an 
improvement in true integration, again, cannot be ruled out at this time). At the same 
time, in a healthy recipient retina the number of donor-labelled cells is fairly high 
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despite the presence of CSPGs at the site of cell transplantation (Barber et al., 2013). 
Also, it will be important to determine whether material transfer is species-specific or 
whether it is a universal phenomenon and can be also observed in humans. 
Preliminary data from the group indicates that human photoreceptors can undergo true 
integration into the murine recipient retina, although some evidence of material transfer 
was also observed (Gonzalez-Cordero, personal communication). Despite this novel 
biological event, cell therapy is still of potential use especially when gene therapy is not 
possible and when all the photoreceptors are already being lost in severely 
degenerated retina.  
  
305"
References  
 
Abe T, Sugano E, Saigo Y, Tamai M (2003) Interleukin-1beta and barrier function of 
retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex 
molecules. Invest Ophthalmol Vis Sci 44:4097–4104. 
Abrahan CE, Insua MF, Politi LE, German OL, Rotstein NP (2009) Oxidative stress 
promotes proliferation and dedifferentiation of retina glial cells in vitro. J Neurosci 
Res 87:964–977. 
Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling 
SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J 
(2001) Gene therapy restores vision in a canine model of childhood blindness. Nat 
Genet 28:92–95. 
Adamis P, Miller JW, Bernal MT, D'Amico DJ, Folkman J,Yeo TK, Yeo KT (1995) 
Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With 
Proliferative Diabetic Retinopathy. Am J Ophthalmol 118(4):445-50. 
Afshari FT, Fawcett JW (2011) An In Vitro Assay to Examine Oligodendrocyte 
Precursor Cell Migration on Astrocytes. Methods in Molecular Biology, pp 393–399. 
Afshari FT, Kwok JC, Andrews MR, Blits B, Martin KR, Faissner A, ffrench-Constant C, 
Fawcett JW (2010a) Integrin activation or alpha9 expression allows retinal 
pigmented epithelial cell adhesion on Bruch's membrane in wet age-related 
macular degeneration. Brain 133:448–464. 
Afshari FT, Kwok JC, White L, Fawcett JW (2010b) Schwann cell migration is integrin-
dependent and inhibited by astrocyte-produced aggrecan. Glia 58:857–869. 
Agathocleous M, Harris WA (2009) From progenitors to differentiated cells in the 
vertebrate retina. Annu Rev Cell Dev Biol 25:45–69. 
Akagi T, Mandai M, Ooto S, Hirami Y, Osakada F, Kageyama R, Yoshimura N, 
Takahashi M (2004) Otx2Homeobox Gene Induces Photoreceptor-Specific 
Phenotypes in Cells Derived from Adult Iris and Ciliary Tissue. Invest Ophthalmol 
Vis Sci 45:4570–4575. 
Akimoto M, Cheng H, Zhu D, Brzezinski JA, Khanna R, Filippova E, Oh ECT, Jing Y, 
Linares J-L, Brooks M, Zareparsi S, Mears AJ, Hero A, Glaser T, Swaroop A 
(2006) Targeting of GFP to newborn rods by Nrl promoter and temporal expression 
306"
profiling of flow-sorted photoreceptors. Proc Natl Acad Sci 103:3890–3895. 
Akita K, Toda M, Mizue I, Fushiki S, Oohira A, Okayama M, Yamashita YM, Nakada H 
(2004) Heparan sulphate proteoglycans interact with neurocan and promote 
neurite outgrowth from cerebellar granule cells. Biochem J 383:129–138. 
Alexander JJ, Umino Y, Everhart D, Chang B, Min SH, Li Q, Timmers AM, Hawes NL, 
Pang J-J, Barlow RB, Hauswirth WW (2007) Restoration of cone vision in a mouse 
model of achromatopsia. Nat Med 13:685–687. 
Ali MA (1971) Retinomotor response: characteristics and mechanisms. Vis Res 
11:1225–1288. 
Ali RR, Sarra GM, Stephens C, Alwis MD, Bainbridge JW, Munro PM, Fauser S, 
Reichel MB, Kinnon C, Hunt DM, Bhattacharya SS, Thrasher AJ (2000) 
Restoration of photoreceptor ultrastructure and function in retinal degeneration 
slow mice by gene therapy. Nat Genet 25:306–310. 
Ali SAM, Hosaka YZ, Uehara M (2011) Spatiotemporal distribution of chondroitin 
sulfate proteoglycans in the developing mouse retina and optic nerve. J Vet Med 
Sci 73:13–18. 
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, Gerrard B, 
Baird L, Stauffer D, Peiffer A, Rattner A, Smallwood P, Li Y, Anderson KL, Lewis 
RA, Nathans J, Leppert M, Dean M, Lupski JR (1997) A photoreceptor cell-specific 
ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular 
dystrophy. Nat Genet 15:236–246. 
Alves CH, Pellissier LP, Vos RM, Garcia Garrido M, Sothilingam V, Seide C, Beck SC, 
Klooster J, Furukawa T, Flannery JG, Verhaagen J, Seeliger MW, Wijnholds J 
(2014a) Targeted ablation of Crb2 in photoreceptor cells induces retinitis 
pigmentosa. Hum Mol Genet 23:3384–3401. 
Alves CH, Pellissier LP, Wijnholds J (2014b) The CRB1 and adherens junction 
complex proteins in retinal development and maintenance. Prog Retin Eye Res 
40:35–52. 
Alves CH, Sanz Sanz A, Park B, Pellissier LP, Tanimoto N, Beck SC, Huber G, 
Murtaza M, Richard F, Sridevi Gurubaran I, Garcia Garrido M, Levelt CN, 
Rashbass P, Le Bivic A, Seeliger MW, Wijnholds J (2012) Loss of CRB2 in the 
mouse retina mimics human retinitis pigmentosa due to mutations in the CRB1 
gene. Hum Mol Genet 22:35–50. 
307"
Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW (1997) Vascular 
endothelial growth factor is present in glial cells of the retina and optic nerve of 
human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis 
Sci 38:36–47. 
Anchan RM, Reh TA, Angello J, Balliet A, Walker M (1991) EGF and TGF-alpha 
stimulate retinal neuroepithelial cell proliferation in vitro. Neuron 6:923–936. 
Anderson DH, Guérin CJ, Erickson PA, Stern WH, Fisher SK (1986) Morphological 
recovery in the reattached retina. Invest Ophthalmol Vis Sci 27:168–183. 
Anderson MA, Burda JE, Ren Y, Ao Y, O'Shea TM, Kawaguchi R, Coppola G, Khakh 
BS, Deming TJ, Sofroniew MV (2016) Astrocyte scar formation aids central 
nervous system axon regeneration. Nat 532:195–200. 
Applebury ML, Antoch MP, Baxter LC, Chun L (2000) The murine cone photoreceptor: 
a single cone type expresses both S and M opsins with retinal spatial patterning. 
Neuron 3:513-523. 
Ardeljan D, Chan CC (2013) Aging is not a disease: distinguishing age-related macular 
degeneration from aging. Prog Retin Eye Res 37: 1-49. 
Asher RA, Morgenstern DA, Fidler PS, Adcock KH, Oohira A, Braistead JE, Levine JM, 
Margolis RU, Rogers JH, Fawcett JW (2000) Neurocan is upregulated in injured 
brain and in cytokine-treated astrocytes. J Neurosci 20:2427–2438. 
Assawachananont J, Mandai M, Okamoto S, Yamada C, Eiraku M, Yonemura S, Sasai 
Y, Takahashi M (2014) Transplantation of embryonic and induced pluripotent stem 
cell-derived 3D retinal sheets into retinal degenerative mice. Stem Cell Reports 
2:662–674. 
Assémat E, Crost E, Ponserre M, Wijnholds J, Le Bivic A, Massey-Harroche D (2013) 
The multi-PDZ domain protein-1 (MUPP-1) expression regulates cellular levels of 
the PALS-1/PATJ polarity complex. Exp Cell Res 319:2514–2525. 
Aveleira CA, Lin CM, Abcouwer SF, Ambrósio AF, Antonetti DA (2010) TNF-  Signals 
Through PKC /NF- B to Alter the Tight Junction Complex and Increase Retinal 
Endothelial Cell Permeability. Diabetes 59:2872–2882. 
Baas D, Bumsted KM, Martinez JA, Vaccarino FM, Wikler KC, Barnstable CJ (2000) 
The subcellular localization of Otx2 is cell-type specific and developmentally 
regulated in the mouse retina. Brain Res Mol Brain Res 78:26–37. 
308"
Baden T, Euler T (2016) Retinal Physiology: Non-Bipolar-Cell Excitatory Drive in the 
Inner Retina. Curr Biol 26:R706–R708. 
Baehr W, Karan S, Maeda T, Luo DG, Li S, Bronson JD, Watt CB, Yau KW, Frederick 
JM, Palczewski K (2007) The Function of Guanylate Cyclase 1 and Guanylate 
Cyclase 2 in Rod and Cone Photoreceptors. J Biol Chem 282:8837–8847. 
Bainbridge JWB et al. (2015) Long-term effect of gene therapy on Leber's congenital 
amaurosis. N Engl J Med 372:1887–1897. 
Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, 
Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya 
SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR (2008) Effect 
of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 
358:2231–2239. 
Banin E, Gootwine E, Obolensky A, Ezra-Elia R, Ejzenberg A, Zelinger L, Honig H, 
Rosov A, Yamin E, Sharon D, Averbukh E, Hauswirth WW, Ofri R (2015) Gene 
Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep 
Model of CNGA3 Achromatopsia. Mol Ther 23:1423–1433. 
Barber AC, Hippert C, Duran Y, West EL, Bainbridge JWB, Warre-Cornish K, Luhmann 
UFO, Lakowski J, Sowden JC, Ali RR, Pearson RA (2013b) Repair of the 
degenerate retina by photoreceptor transplantation. Proc Natl Acad Sci 110:354–
359. 
Bareil C, Hamel C, Delague V, Arnaud B, Demaille J (2001) Segregation of a mutation 
in CNGB1 encoding the β-subunit of the rod cGMP-gated channel in a family with 
autosomal recessive retinitis pigmentosa. Hum Genet 4:328-34. 
Barhoum R, Martinez-Navarrete G, Corrochano S, Germain F, Fernandez-Sanchez L, 
la Rosa de EJ, la Villa de P, Cuenca N (2008) Functional and structural 
modifications during retinal degeneration in the rd10 mouse. Neurosci 155:698–
713. 
Barnea-Cramer AO, Wang W, Lu S-J, Singh MS, Luo C, Huo H, McClements ME, 
Barnard AR, MacLaren RE, Lanza R (2016) Function of human pluripotent stem 
cell-derived photoreceptor progenitors in blind mice. Sci Rep 6:29784. 
Barnett NL, Pow DV (2000) Antisense knockdown of GLAST, a glial glutamate 
transporter, compromises retinal function. Invest Ophthalmol Vis Sci 41:585–591. 
309"
Barnett NL, Pow DV, Bull ND (2001) Differential perturbation of neuronal and glial 
glutamate transport systems in retinal ischaemia. Neurochem Int 39(4): 291–299. 
Bartsch U, Oriyakhel W, Kenna PF, Linke S, Richard G, Petrowitz B, Humphries P, 
Farrar GJ, Ader M (2008) Retinal cells integrate into the outer nuclear layer and 
differentiate into mature photoreceptors after subretinal transplantation into adult 
mice. Exp Eye Res 86:691–700. 
Baye LM, Link BA (2007) Interkinetic Nuclear Migration and the Selection of 
Neurogenic Cell Divisions during Vertebrate Retinogenesis. J Neurosci 27:10143–
10152. 
Beattie MS, Hermann GE, Rogers RC, Bresnahan JC (2002) Cell death in models of 
spinal cord injury. Prog Brain Res 137:37–47. 
Becker CG, Becker T (2002) Repellent guidance of regenerating optic axons by 
chondroitin sulfate glycosaminoglycans in zebrafish. J Neurosci 22:842–853. 
Berger W, Kloeckener-Gruissem B, Neidhardt J (2010) The molecular basis of human 
retinal and vitreoretinal diseases. Prog Retin Eye Res 29:335–375. 
Bernardos RL, Barthel LK, Meyers JR, Raymond PA (2007) Late-Stage Neuronal 
Progenitors in the Retina Are Radial Muller Glia That Function as Retinal Stem 
Cells. J Neurosci 27:7028–7040. 
Berta ÁI, Boesze-Battaglia K, Genini S, Goldstein O, O'Brien PJ, Szél Á, Acland GM, 
Beltran WA, Aguirre GD (2011) Photoreceptor cell death, proliferation and 
formation of hybrid rod/S-cone photoreceptors in the degenerating STK38L mutant 
retina. PLoS ONE 6:e24074. 
Bicknese AR, Sheppard AM, O'Leary DD, Pearlman AL (1994) Thalamocortical axons 
extend along a chondroitin sulfate proteoglycan-enriched pathway coincident with 
the neocortical subplate and distinct from the efferent path. J Neurosci 14:3500–
3510. 
Biel M, Seeliger M, Pfeifer A, Kohler K, Gerstner A, Ludwig A, Jaissle G, Fauser S, 
Zrenner E, Hofmann F (1999) Selective loss of cone function in mice lacking the 
cyclic nucleotide-gated channel CNG3. Proc Natl Acad Sci 96:7553–7557. 
Blackshaw S, Harpavat S, Trimarchi J, Cai L, Huang H, Kuo WP, Weber G, Lee K, 
Fraioli RE, Cho S-H, Yung R, Asch E, Ohno-Machado L, Wong WH, Cepko CL 
(2004) Genomic analysis of mouse retinal development. PLoS Biol 2:E247. 
310"
Blanquicett C, Johnson MR, Heslin M, Diasio RB (2002) Housekeeping gene variability 
in normal and carcinomatous colorectal and liver tissues: applications in 
pharmacogenomic gene expression studies. Anal Biochem 303:209–214. 
Boon CJF, Hollander den AI, Hoyng CB, Cremers FPM, Klevering BJ, Keunen JEE 
(2008) The spectrum of retinal dystrophies caused by mutations in the 
peripherin/RDS gene. Prog Retin Eye Res 27:213–235. 
Bovolenta P, Mallamaci A, Briata P, Corte G, Boncinelli E (1997) Implication of OTX2 
in pigment epithelium determination and neural retina differentiation. J Neurosci 
17:4243–4252. 
Bradbury EJ, Carter LM (2011) Manipulating the glial scar: Chondroitinase ABC as a 
therapy for spinal cord injury. Brain Res Bull 84:306–316. 
Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, 
McMahon SB (2002) Chondroitinase ABC promotes functional recovery after spinal 
cord injury. Nat 416:636–640. 
Braunewell KH, Pesheva P, McCarthy JB, Furcht LT, Schmitz B, Schachner M (1995) 
Functional Involvement of Sciatic Nerve‐derived Versicanand Decorin‐like 
Molecules and other Chondroitin Sulphate Proteoglycans in ECM‐mediated Cell 
Adhesion and Neurite Outgrowth. Eur J Neurosci 7:805–814. 
Brenner M (1994) Structure and transcriptional regulation of the GFAP gene. Brain 
Pathol 4:245–257. 
Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A (1994) GFAP promoter 
directs astrocyte-specific expression in transgenic mice. J Neurosci 14:1030–1037. 
Bridges CD (1985) The interphotoreceptor matrix--functions and possible role in 
hereditary retinal degenerations. Prog Clin Biol Res 190:195–212. 
Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P, Osborne NN, 
Reichenbach A (2009a) Cellular signaling and factors involved in Muller cell gliosis: 
Neuroprotective and detrimental effects. Prog Retin Eye Res 28:423–451. 
Bringmann A, Pannicke T, Biedermann B, Francke M, Iandiev I, Grosche J, 
Wiedemann P, Albrecht J, Reichenbach A (2009b) Role of retinal glial cells in 
neurotransmitter uptake and metabolism. Neurochem Int 54:143–160. 
Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, 
311"
Osborne NN, Reichenbach A (2006) Müller cells in the healthy and diseased 
retina. Prog Retin Eye Res 25:397–424. 
Bringmann A, Wiedemann P (2012) Müller Glial Cells in Retinal Disease. 
Ophthalmologica 227:1–19. 
Brittis PA, Silver J (1994) Exogenous glycosaminoglycans induce complete inversion of 
retinal ganglion cell bodies and their axons within the retinal neuroepithelium. Proc 
Natl Acad Sci 91:7539–7542. 
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S 
(2006) Ranibizumab versus Verteporfin for Neovascular Age-Related Macular 
Degeneration. N Engl J Med 355:1432–1444. 
Brückner G, GROSCHE J, Schmidt S, Härtig W, Margolis RU, Delpech B, 
Seidenbecher CI, Czaniera R, Schachner M (2000) Postnatal development of 
perineuronal nets in wild-type mice and in a mutant deficient in tenascin-R. J Comp 
Neurol 428:616–629. 
Bujakowska K, Audo I, Mohand-Saïd S, Lancelot M-E, Antonio A, Germain A, 
Léveillard T, Letexier M, Saraiva J-P, Lonjou C, Carpentier W, Sahel J-A, 
Bhattacharya SS, Zeitz C (2011) CRB1 mutations in inherited retinal dystrophies. 
Hum Mutat 33:306–315. 
Bulgakova NA, Kempkens O, Knust E (2008) Multiple domains of Stardust differentially 
mediate localisation of the Crumbs-Stardust complex during photoreceptor 
development in Drosophila. J Cell Sci 121:2018–2026. 
Bull ND, Limb GA, Martin KR (2008) Human Muller Stem Cell (MIO-M1) 
Transplantation in a Rat Model of Glaucoma: Survival, Differentiation, and 
Integration. Invest Ophthalmol Vis Sci 49:3449–3456. 
Bunt-Milam AHA, Saari JCJ, Klock IBI, Garwin GGG (1985) Zonulae adherentes pore 
size in the external limiting membrane of the rabbit retina. Invest Ophthalmol Vis 
Sci 26:1377–1380. 
Burnside B (1978) Thin (actin) and thick (myosinlike) filaments in cone contraction in 
the teleost retina. J Cell Biol 78:227–246. 
Burnside B, Nagle B (1983) Retinomotor movements of photoreceptors and retinal 
pigment epithelium: mechanisms and regulation. Prog Retin Res 2:67-109. 
312"
Busch SA, Silver J (2007) The role of extracellular matrix in CNS regeneration. Curr 
Opin Neurobiol 17:120–127. 
Caggiano AO, Zimber MP, Ganguly A, Blight AR, Gruskin EA (2005) Chondroitinase 
ABCI Improves Locomotion and Bladder Function following Contusion Injury of the 
Rat Spinal Cord. J Neurotraum 22:226–239. 
Cai X, McGinnis JF (2016) Diabetic Retinopathy: Animal Models, Therapies, and 
Perspectives. J Diabetes Res 2016:1–9. 
Calame M, Cachafeiro M, Philippe S, Schouwey K, Tekaya M, Wanner D, Sarkis C, 
Kostic C, Arsenijevic Y (2011) Retinal Degeneration Progression Changes 
Lentiviral Vector Cell Targeting in the Retina Chédotal A, ed. PLoS ONE 6:e23782. 
Caley DW, Johnson C, Liebelt RA (1972) The postnatal development of the retina in 
the normal and rodless CBA mouse: A light and electron microscopic study. Dev 
Dynam 133:179–211. 
Calvert PD, Krasnoperova NV, Lyubarsky AL, Isayama T, Nicolò M, Kosaras B, Wong 
G, Gannon KS, Margolskee RF, Sidman RL, Pugh EN, Makino CL, Lem J (2000) 
Phototransduction in transgenic mice after targeted deletion of the rod transducin 
alpha -subunit. Proc Natl Acad Sci 97:13913–13918. 
Campbell M, Humphries M, Kenna P, Humphries P, Brankin B (2007) Altered 
expression and interaction of adherens junction proteins in the developing OLM of 
the Rho(-/-) mouse. Exp Eye Res 85:714–720. 
Campbell M, Humphries M, Kennan A, Kenna P, Humphries P, Brankin B (2006) 
Aberrant retinal tight junction and adherens junction protein expression in an 
animal model of autosomal dominant Retinitis pigmentosa: the Rho(-/-) mouse. 
Exp Eye Res 83:484–492. 
Cao W, Li F, Steinberg RH, LaVail MM (2001) Development of normal and injury-
induced gene expression of aFGF, bFGF, CNTF, BDNF, GFAP and IGF-I in the rat 
retina. Exp Eye Res 72:591–604. 
Carter-Dawson L, Burroughs M (1992) Interphotoreceptor retinoid-binding protein in 
the cone matrix sheath. Electron microscopic immunocytochemical localization. 
Invest Ophthalmol Vis Sci 33:1584–1588. 
Carter-Dawson LD, LaVail MM, Sidman RL (1978) Differential effect of the rd mutation 
on rods and cones in the mouse retina. Invest Ophthalmol Vis Sci 17:489–498. 
313"
Carulli D, Laabs T, Geller HM, Fawcett JW (2005) Chondroitin sulfate proteoglycans in 
neural development and regeneration. Curr Opin Neurobiol 15:252. 
Centanin L, Hoeckendorf B, Wittbrodt J (2011) Fate Restriction and Multipotency in 
Retinal Stem Cells. Cell Stem Cell 9:553–562. 
Chacon-Camacho OF, Zenteno JC (2015) Review and update on the molecular basis 
of Leber congenital amaurosis. World J Clin Cases 3:112–124. 
Chaitin MH, Brun-Zinkernagel AM (1998) Immunolocalization of CD44 in the dystrophic 
rat retina. Exp Eye Res 67:283–292. 
Challacombe JF, Snow DM, Letourneau PC (1997) Dynamic microtubule ends are 
required for growth cone turning to avoid an inhibitory guidance cue. J Neurosci 
17:3085–3095. 
Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR (2002) 
Retinal degeneration mutants in the mouse. Vis Res 42:517–525. 
Chaum E (2002) Retinal neuroprotection by growth factors: A mechanistic perspective. 
J Cell Biochem 88:57–75. 
Chen H, Weber AJ (2002) Expression of glial fibrillary acidic protein and glutamine 
synthetase by Müller cells after optic nerve damage and intravitreal application of 
brain-derived neurotrophic factor. Glia 38:115–125. 
Chen H-J, Ma Z-Z (2007) N-cadherin expression in a rat model of retinal detachment 
and reattachment. Invest Ophthalmol Vis Sci 48:1832–1838. 
Chen L-F, FitzGibbon T, He J-R, Yin ZQ (2012a) Localization and developmental 
expression patterns of CSPG-cs56 (aggrecan) in normal and dystrophic retinas in 
two rat strains. Exp Neuro 234:488–498. 
Chen Y, Okano K, Maeda T, Chauhan V, Golczak M, Maeda A, Palczewski K (2012b) 
Mechanism of all-trans-retinal toxicity with implications for stargardt disease and 
age-related macular degeneration. J Biol Chem 287:5059–5069. 
Chen Y, Palczewska G, Mustafi D, Golczak M, Dong Z, Sawada O, Maeda T, Maeda 
A, Palczewski K (2013) Systems pharmacology identifies drug targets for Stargardt 
disease-associated retinal degeneration. J Clin Invest 123:5119–5134. 
Chen YJ, Tsai RK, Wu WC, He MS, Kao YH, Wu WS (2012c) Enhanced PKCδ and 
ERK signaling mediate cell migration of retinal pigment epithelial cells 
314"
synergistically induced by HGF and EGF. PLoS ONE  7(9): e44937. 
Cheng H, Aleman TS, Cideciyan AV, Khanna R, Jacobson SG, Swaroop A (2006) In 
vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor 
identity during mammalian retinal development. Hum Mol Genet 15:2588–2602. 
Cho K-S, Yang L, Lu B, Feng Ma H, Huang X, Pekny M, Chen DF (2005) Re-
establishing the regenerative potential of central nervous system axons in 
postnatal mice. J Cell Sci 118:863–872. 
Cho NC, Poulsen GL, Ver Hoeve JN, Nork TM (2000) Selective loss of S-cones in 
diabetic retinopathy. Arch Ophthalmol 118:1393–1400. 
Cho S-H, Cepko CL (2006) Wnt2b/beta-catenin-mediated canonical Wnt signaling 
determines the peripheral fates of the chick eye. Development 133:3167–3177. 
Chrysostomou V, Rezania F, Trounce IA, Crowston JG (2013) Oxidative stress and 
mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 13:12–15. 
Cideciyan AV (2010) Leber congenital amaurosis due to RPE65 mutations and its 
treatment with gene therapy. Prog Retin Eye Res 29:398–427. 
Clark SJ (2006) His-384 Allotypic Variant of Factor H Associated with Age-related 
Macular Degeneration Has Different Heparin Binding Properties from the Non-
disease-associated Form. J Biol Chem 281:24713–24720. 
Clark SJ, Bishop PN, Day AJ (2010a) Complement factor H and age-related macular 
degeneration: the role of glycosaminoglycan recognition in disease pathology. 
Biochem Soc Trans 38:1342–1348. 
Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, Day AJ (2010b) 
Impaired Binding of the Age-related Macular Degeneration-associated 
Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. J Biol 
Chem 285:30192–30202. 
Close JL, Gumuscu B, Reh TA (2005) Retinal neurons regulate proliferation of 
postnatal progenitors and Müller glia in the rat retina via TGF beta signaling. 
Dev132:3015–3026. 
Cobos E, Arias L, Ruiz-Moreno J, Rubio M, Garcia-Bru P, Caminal J, Catala-Mora J, 
Arruga J (2013) Preoperative study of the inner segment/outer segment junction of 
photoreceptors by spectral-domain optical coherence tomography as a prognostic 
315"
factor in patients with epiretinal membranes. Clin Ophthalmol 7:1467–1470. 
Cochard P, Paulin D (1984) Initial expression of neurofilaments and vimentin in the 
central and peripheral nervous system of the mouse embryo in vivo. J Neurosci 
4:2080–2094. 
Colella P, Auricchio A (2012) Gene therapy of inherited retinopathies: a long and 
successful road from viral vectors to patients. Hum Gene Ther 23:796–807. 
Cornish EE, Hendrickson AE, Provis JM (2004) Distribution of short-wavelength-
sensitive cones in human fetal and postnatal retina: early development of spatial 
order and density profiles. Vis Res 44:2019–2026. 
Coulombe PA, Wong P (2004) Cytoplasmic intermediate filaments revealed as 
dynamic and multipurpose scaffolds. Nat Cell Biol 6:699–706. 
Crespo D, Asher RA, Lin R, Rhodes KE, Fawcett JW (2007) How does chondroitinase 
promote functional recovery in the damaged CNS? Exp Neuro 206:159–171. 
Cuenca N, Fernández-Sánchez L, Campello L, Maneu V, la Villa De P, Lax P, Pinilla I 
(2014) Cellular responses following retinal injuries and therapeutic approaches for 
neurodegenerative diseases. Prog Retin Eye Res 43:17–75. 
Cuenca N, Fernández-Sánchez L, McGill TJ, Lu B, Wang S, Lund R, Huhn S, Capela 
A (2013) Phagocytosis of photoreceptor outer segments by transplanted human 
neural stem cells as a neuroprotective mechanism in retinal degeneration. Invest 
Ophthalmol Vis Sci 54:6745–6756. 
Cuenca N, Pinilla I, Sauvé Y, Lu B, Wang S, Lund RD (2004) Regressive and reactive 
changes in the connectivity patterns of rod and cone pathways of P23H transgenic 
rat retina. Neurosci127:301–317. 
Cuenca N, Pinilla I, Sauvé Y, Lund R (2005) Early changes in synaptic connectivity 
following progressive photoreceptor degeneration in RCS rats. Eur J Neurosci 
22:1057–1072. 
Curcio CA, Sloan KR, Kalina RE, Hendrickson AE (1990) Human photoreceptor 
topography. J Comp Neurol 292:497–523. 
da Cruz L, Chen FK, Ahmado A, Greenwood J, Coffey P (2007) RPE transplantation 
and its role in retinal disease. Prog Retin Eye Res 26:598–635. 
Damiani D, Novelli E, Mazzoni F, Strettoi E (2012) Undersized dendritic arborizations 
316"
in retinal ganglion cells of the rd1 mutant mouse: A paradigm of early onset 
photoreceptor degeneration. J Comp Neurol 520:1406–1423. 
Danciger M, Blaney J, Gao YQ, Zhao DY, Heckenlively JR, Jacobson SG, Farber DB 
(1995) Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa. 
Genomics 30:1–7. 
Daniele LL, Adams RH, Durante DE, Pugh EN, Philp NJ (2007) Novel distribution of 
junctional adhesion molecule-C in the neural retina and retinal pigment epithelium. 
J Comp Neurol 505:166–176. 
Daniele LL, Insinna C, Chance R, Wang J, Nikonov SS, Pugh EN Jr (2011) A mouse 
M-opsin monochromat: Retinal cone photoreceptors have increased M-opsin 
expression when S-opsin is knocked out. Vis Res 51:447–458. 
Das AV, Mallya KB, Zhao X, Ahmad F, Bhattacharya S, Thoreson WB, Hegde GV, 
Ahmad I (2006) Neural stem cell properties of Müller glia in the mammalian retina: 
regulation by Notch and Wnt signaling. Dev Biol 299:283–302. 
Davies SJ, Goucher DR, Doller C, Silver J (1999) Robust regeneration of adult sensory 
axons in degenerating white matter of the adult rat spinal cord. J Neurosci 
19:5810–5822. 
Day AJ, Clark SJ, Bishop PN (2011) Understanding the molecular basis of age-related 
macular degeneration and how the identification of new mechanisms may aid the 
development of novel therapies. Exper Rev Ophthalmol 6:123–128. 
DeAngelis MM, Grimsby JL, Sandberg MA, Berson EL, Dryja TP (2002) Novel 
mutations in the NRL gene and associated clinical findings in patients with 
dominant retinitis pigmentosa. Arch Ophthalmol 120:369–375. 
Desclaux M, Perrin FE, Do-Thi A, Prieto-Cappellini M, Gimenez Y Ribotta M, Mallet J, 
Privat A (2015) Lentiviral-mediated silencing of glial fibrillary acidic protein and 
vimentin promotes anatomical plasticity and functional recovery after spinal cord 
injury. J Neurosci Res 93:43–55. 
Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL, Wood 
A, Geoffroy CG, Zheng B, Liepmann CD, Katagiri Y, Benowitz LI, Geller HM, Giger 
RJ (2012) NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat 
15:703–712. 
Dinet V, Bruban J, Chalour N, Maoui A, An N, Jonet L, Buret A, Behar-Cohen F, Klein 
317"
C, Tréton J, Mascarelli F (2012) Distinct effects of inflammation on gliosis, 
osmohomeostasis, and vascular integrity during amyloid beta-induced retinal 
degeneration. Aging Cell 11:683–693. 
Domowicz MS, Sanders TA, Ragsdale CW, Schwartz NB (2008) Aggrecan is 
expressed by embryonic brain glia and regulates astrocyte development. Dev Biol 
315:114–124. 
Dou CL, Levine JM (1994) Inhibition of neurite growth by the NG2 chondroitin sulfate 
proteoglycan. J Neurosci 14:7616–7628. 
Dowling JE, Boycott BB (1966) Organization of the Primate Retina: Electron 
Microscopy. Proc Biol Sci 166:80–111. 
Dreher Z, Robinson SR, Distler C (1992) Müller cells in vascular and avascular retinae: 
a survey of seven mammals. J Comp Neurol 323:59–80. 
Drenckhahn D, Wagner HJ (1985) Relation of retinomotor responses and contractile 
proteins in vertebrate retinas. Eur J Cell Biol 37:156–168. 
Dryja TP, Finn JT, Peng YW, McGee TL, Berson EL, Yau KW (1995) Mutations in the 
gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal 
recessive retinitis pigmentosa. Proc Natl Acad Sci 92:10177–10181. 
Dryja TP, Hahn LB, Reboul T, Arnaud B (1996) Missense mutation in the gene 
encoding the alpha subunit of rod transducin in the Nougaret form of congenital 
stationary night blindness. Nat Genet 13:358–360. 
Dryja TP, Rucinski DE, Chen SH, Berson EL (1999) Frequency of mutations in the 
gene encoding the alpha subunit of rod cGMP-phosphodiesterase in autosomal 
recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 40:1859–1865. 
Du Y, Miller CM, Kern TS (2003) Hyperglycemia increases mitochondrial superoxide in 
retina and retinal cells. Free Radic Biol Med 35:1491–1499. 
Dunah AW, Hueske E, Wyszynski M (2005) LAR receptor protein tyrosine 
phosphatases in the development and maintenance of excitatory synapses. Nat 
4:458-67. 
Eberle D, Kurth T, Santos-Ferreira T, Wilson J, Corbeil D, Ader M (2012) Outer 
segment formation of transplanted photoreceptor precursor cells. PLoS ONE 
7:e46305. 
318"
Eckes B, Colucci-Guyon E, Smola H, Nodder S, Babinet C, Krieg T, Martin P (2000) 
Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 
113 (13):2455–2462. 
Edwards MM, Lefebvre O (2013) Laminins and retinal vascular development. Cell Adh 
Migr 7:82–89. 
Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Black GC, 
Webster AR, Lotery AJ, Holder GE, Xue K, Downes SM, Simunovic MP, Seabra 
MC, MacLaren RE (2016) Visual Acuity after Retinal Gene Therapy for 
Choroideremia. N Engl J Med 374:1996–1998. 
Eiraku M, Sasai Y (2012) Mouse embryonic stem cell culture for generation of three-
dimensional retinal and cortical tissues. Nat Protoc 7:69–79. 
Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, Sekiguchi K, 
Adachi T, Sasai Y (2011) Self-organizing optic-cup morphogenesis in three-
dimensional culture. Nat 472:51–56. 
Ekström P, Sanyal S, Narfström K, Chader GJ, VANVEEN T (1988) Accumulation of 
Glial Fibrillary Acidic Protein in Muller Radial Glia During Retinal Degeneration. 
Invest Ophthalmol Vis Sci 29:1363–1371. 
El-Bab MF, Zaki NS, Mojaddidi MA, Al-Barry M, El-Beshbishy HA (2013) Diabetic 
retinopathy is associated with oxidative stress and mitigation of gene expression of 
antioxidant enzymes. Int J Gen Med 6:799–806. 
Eliasson C, Sahlgren C, Berthold CH, Stakeberg J, Celis JE, Betsholtz C, Eriksson JE, 
Pekny M (1999) Intermediate filament protein partnership in astrocytes. J Biol 
Chem 274:23996–24006. 
Emerling DE, Lander AD (1996) Inhibitors and Promoters of Thalamic Neuron 
Adhesion and Outgrowth in Embryonic Neocortex: Functional Association with 
Chondroitin Sulfate. Neuron 17:1089–1100. 
Eng LF, Ghirnikar RS (1994) GFAP and astrogliosis. Brain Pathol 4:229–237. 
Eng LF, Lee YL, Kwan H, Brenner M, Messing A (1998) Astrocytes cultured from 
transgenic mice carrying the added human glial fibrillary acidic protein gene 
contain Rosenthal fibers. J Neurosci Res 53:353–360. 
Escher P, Cottet S, Aono S, Oohira A, Schorderet DF (2008) Differential neuroglycan C 
319"
expression during retinal degeneration in Rpe65(-/-) mice. Mol Vis 14:2126–2135. 
Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA (2006) The Proteome of Central 
and Peripheral Retina with Progression of Age-Related Macular Degeneration. 
Invest Ophthalmol Vis Sci 47:2280. 
Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM (1990) 
Photoreceptor degeneration in inherited retinal dystrophy delayed by basic 
fibroblast growth factor. Nat 347:83–86. 
Fan W, Lin N, Sheedlo HJ, Turner JE (1996) Müller and RPE cell response to 
photoreceptor cell degeneration in aging Fischer rats. Exp Eye Res 63:9–18. 
Fanning AS, Ma TY, Anderson JM (2002) Isolation and functional characterization of 
the actin binding region in the tight junction protein ZO-1. FASEB J16:1835–1837. 
Fariss RN, Li ZY, H MA (2000) Abnormalities in rod photoreceptors, amacrine cells, 
and horizontal cells in human retinas with retinitis pigmentosa. J Ophthalmol 
129:215–223. 
Fariss RN, Molday RS, Fisher SK, Matsumoto B (1997) Evidence from normal and 
degenerating photoreceptors that two outer segment integral membrane proteins 
have separate transport pathways. J Comp Neurol 387:148–156. 
Faulkner JR (2004) Reactive Astrocytes Protect Tissue and Preserve Function after 
Spinal Cord Injury. J Neurosci 24:2143–2155. 
Fawcett J (2009) Molecular control of brain plasticity and repair. Prog Brain Res 
175:501–509. 
Fawcett JW, Asher RA (1999) The glial scar and central nervous system repair. Brain 
Res Bull 49:377–391. 
Feathers KL, Lyubarsky AL, Khan NW, Teofilo K, Swaroop A, Williams DS, Pugh EN, 
Thompson DA (2008) Nrl-knockout mice deficient in Rpe65 fail to synthesize 11-cis 
retinal and cone outer segments. Invest Ophthalmol Vis Sci 49:1126–1135. 
Fei Y (2002) Cone neurite sprouting: an early onset abnormality of the cone 
photoreceptors in the retinal degeneration mouse. Mol Vis 8:306–314. 
Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE (2005) 
Housekeeping proteins: a preliminary study illustrating some limitations as useful 
references in protein expression studies. Proteomics 5:566–571. 
320"
Fernández-Sánchez L, Lax P, Campello L, Pinilla I, Cuenca N (2015) Astrocytes and 
Müller Cell Alterations During Retinal Degeneration in a Transgenic Rat Model of 
Retinitis Pigmentosa. Front Cell Neurosci 9:801. 
Fernández-Sánchez L, Lax P, Pinilla I, Martín-Nieto J, Cuenca N (2011) 
Tauroursodeoxycholic acid prevents retinal degeneration in transgenic P23H rats. 
Invest Ophthalmol Vis Sci 52:4998–5008. 
Ferrara N, Adamis AP (2016) Ten years of anti-vascular endothelial growth factor 
therapy. Nat Rev Drug Discov 15:385–403. 
Fidler PS, Schuette K, Asher RA, Dobbertin A, Thornton SR, Calle-Patino Y, Muir E, 
Levine JM, Geller HM, Rogers JH, Faissner A, Fawcett JW (1999) Comparing 
astrocytic cell lines that are inhibitory or permissive for axon growth: the major 
axon-inhibitory proteoglycan is NG2. J Neurosci 19:8778–8788. 
Fimbel SM, Montgomery JE, Burket CT, Hyde DR (2007) Regeneration of inner retinal 
neurons after intravitreal injection of ouabain in zebrafish. J Neurosci 27:1712–
1724. 
Fisher D, Xing B, Dill J, Li H, Hoang HH, Zhao Z, Yang X-L, Bachoo R, Cannon S, 
Longo FM, Sheng M, Silver J, Li S (2011) Leukocyte common antigen-related 
phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon 
growth inhibitors. J Neurosci 31:14051–14066. 
Fisher SK, Lewis GP (2003) Müller cell and neuronal remodeling in retinal detachment 
and reattachment and their potential consequences for visual recovery: a review 
and reconsideration of recent data. Vis Res 43:887–897. 
Fisher SK, Lewis GP, Linberg KA, Verardo MR (2005) Cellular Effects of Detachment 
and Reattachment on the Neural Retina and the Retinal Pigment Epithelium. Prog 
Retin Eye Res 24:1991–2012. 
Fitch MT, Doller C, Combs CK, Landreth GE, Silver J (1999) Cellular and molecular 
mechanisms of glial scarring and progressive cavitation: in vivo and in vitro 
analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 
19:8182–8198. 
Forrester JV (2003) Macrophages eyed in macular degeneration. Nat Med 9:1350–
1351. 
Friedlander DRD, Milev PP, Karthikeyan LL, Margolis RKR, Margolis RUR, Grumet MM 
321"
(1994) The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural 
cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal 
adhesion and neurite outgrowth. J Cell Biol 125:669–680. 
Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A (2014) 
Age-related macular degeneration: genetics and biology coming together. Annu 
Rev Genomics Hum Genet 15:151–171. 
Fu X, Sun H, Klein WH, Mu X (2006) Beta-catenin is essential for lamination but not 
neurogenesis in mouse retinal development. Dev Biol 299:424–437. 
Furukawa T, Morrow EM, Cepko CL (1997) Crx, a Novel otx-like Homeobox Gene, 
Shows Photoreceptor-Specific Expression and Regulates Photoreceptor 
Differentiation. Cell 91:531–541. 
Furukawa T, Morrow EM, Li T, Davis FC, Cepko CL (1999) Retinopathy and attenuated 
circadian entrainment in Crx-deficient mice. Nat Genet 23:466–470. 
Gal A, Orth U, Baehr W, Schwinger E, Rosenberg T (1994) Heterozygous missense 
mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal 
dominant stationary night blindness. Nat Genet 7:551. 
Galou M (1996) Disrupted glial fibrillary acidic protein network in astrocytes from 
vimentin knockout mice. J Cell Biol 133:853–863. 
Galtrey CM, Fawcett JW (2007) The role of chondroitin sulfate proteoglycans in 
regeneration and plasticity in the central nervous system. Brain Res Rev 54:1–18. 
Gao G-P, Lu F, Sanmiguel JC, Tran PT, Abbas Z, Lynd KS, Marsh J, Spinner NB, 
Wilson JM (2002) Rep/Cap gene amplification and high-yield production of AAV in 
an A549 cell line expressing Rep/Cap. Mol Ther 5:644–649. 
García-Ayuso D, Ortín-Martínez A (2013) Changes in the Photoreceptor Mosaic of 
P23H-1 Rats During Retinal Degeneration: Implications for Rod-Cone Dependent 
Survival. Invest Ophthalmol Vis Sci 54(8): 5888-5900. 
García-Fernández JM, Jimenez AJ, Foster RG (1995) The persistence of cone 
photoreceptors within the dorsal retina of aged retinally degenerate mice (rd/rd): 
implications for circadian organization. Neurosci Lett 187:33–36. 
Gastinger MJ, Singh RSJ, Barber AJ (2006) Loss of Cholinergic and Dopaminergic 
Amacrine Cells in Streptozotocin-Diabetic Rat and Ins2 Akita-Diabetic Mouse 
322"
Retinas. Invest Ophthalmol Vis Sci 47:3143. 
Geiger P, Barben M, Grimm C, Samardzija M (2015) Blue light-induced retinal lesions, 
intraretinal vascular leakage and edema formation in the all-cone mouse retina. 
Cell Death Dis 6:e1985. 
Giamanco KA, Morawski M, Matthews RT (2010) Perineuronal net formation and 
structure in aggrecan knockout mice. Neurosci 170:1314–1327. 
Giannelli SG, Demontis GC, Pertile G, Rama P, Broccoli V (2011) Adult human Müller 
glia cells are a highly efficient source of rod photoreceptors. Stem Cells 29:344–
356. 
Gilbert RJ, McKeon RJ, Darr A, Calabro A, Hascall VC, Bellamkonda RV (2005) CS-
4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite 
extension. Mol Cell Neurosci 29:545–558. 
Goel M, Dhingra NK (2012) Müller glia express rhodopsin in a mouse model of 
inherited retinal degeneration. Neurosci 225:152–161. 
Goldman RD, Khuon S, Chou YH, Opal P, Steinert PM (1996) The function of 
intermediate filaments in cell shape and cytoskeletal integrity. J Cell Biol 134:971–
983. 
Gonzalez-Cordero A, West EL, Pearson RA, Duran Y, Carvalho LS, Chu CJ, Naeem A, 
Blackford SJI, Georgiadis A, Lakowski J, Hubank M, Smith AJ, Bainbridge JWB, 
Sowden JC, Ali RR (2013) Photoreceptor precursors derived from three-
dimensional embryonic stem cell cultures integrate and mature within adult 
degenerate retina. Nat Biotechnol 31:741–747. 
Goodman DS (1984) Vitamin A and Retinoids in Health and Disease. N Engl J Med 
310:1023–1031. 
Gosens I, Hollander den AI, Cremers FPM, Roepman R (2008) Composition and 
function of the Crumbs protein complex in the mammalian retina. Exp Eye Res 
86:713–726. 
Gouras P, Du J, Kjeldbye H, Yamamoto S, Zack DJ (1994) Long-term photoreceptor 
transplants in dystrophic and normal mouse retina. Invest Ophthalmol Vis Sci 
35:3145–3153. 
Gouras P, Tanabe T (2003) Survival and integration of neural retinal transplants in rd 
323"
mice. Graefes Arch Clin Exp Ophthalmol 241:403–409. 
Greenfield B, Wang WC, Marquardt H, Piepkorn M, Wolff EA, Aruffo A, Bennett KL 
(1999) Characterization of the heparan sulfate and chondroitin sulfate assembly 
sites in CD44. J Biol Chem 274: 2511–2517. 
Grimpe B, Pressman Y, Lupa MD, Horn KP, Bunge MB, Silver J (2005) The role of 
proteoglycans in Schwann cell/astrocyte interactions and in regeneration failure at 
PNS/CNS interfaces. Mol Cell Neurosci 28:18–29. 
Grüter O, Kostic C, Crippa SV, Perez M-TR, Zografos L, Schorderet DF, Munier FL, 
Arsenijevic Y (2005) Lentiviral vector-mediated gene transfer in adult mouse 
photoreceptors is impaired by the presence of a physical barrier. Gene Ther 
12:942–947. 
Guérin CJ, Anderson DH, Fisher SK (1990) Changes in intermediate filament 
immunolabeling occur in response to retinal detachment and reattachment in 
primates. Invest Ophthalmol Vis Sci 31:1474–1482. 
Gupta N, Brown KE, Milam AH (2003) Activated microglia in human retinitis 
pigmentosa, late-onset retinal degeneration, and age-related macular 
degeneration. Exp Eye Res 76:463–471. 
H MA, Li ZY, Fariss RN (1998) Histopathology of the human retina in retinitis 
pigmentosa. Prog Retin Eye Res 17:175–205. 
Haider NB, Mollema N, Gaule M, Yuan Y, Sachs AJ, Nystuen AM, Naggert JK, Nishina 
PM (2009) Nr2e3-directed transcriptional regulation of genes involved in 
photoreceptor development and cell-type specific phototransduction. Exp Eye Res 
89:365–372. 
Haider NB, Naggert JK, Nishina PM (2001) Excess cone cell proliferation due to lack of 
a functional NR2E3 causes retinal dysplasia and degeneration in rd7/rd7 mice. 
Hum Mol Genet 10:1619–1626. 
Hamel CP (2007) Cone-Rod Dystrophies. Orphanet J Rare Dis 2:7. 
Hanein S, Perrault I, Gerber S, Tanguy G, Rozet JM, Kaplan J (2004) Leber congenital 
amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the 
clinical definition and phenotype–genotype correlations as a strategy for molecular 
diagnosis. Invest Ophthalmol Vis Sci 45:4729–4729. 
324"
Hayashi R, Ishikawa Y, Sasamoto Y, Katori R, Nomura N, Ichikawa T, Araki S, Soma 
T, Kawasaki S, Sekiguchi K, Quantock AJ, Tsujikawa M, Nishida K (2016) Co-
ordinated ocular development from human iPS cells and recovery of corneal 
function. Nat 531:376–380. 
Hicks D, Courtois Y (1990) The growth and behaviour of rat retinal Müller cells in vitro. 
1. An improved method for isolation and culture. Exp Eye Res 51:119–129. 
Himori N, Yamamoto K, Maruyama K, Ryu M, Taguchi K, Yamamoto M, Nakazawa T 
(2013) Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death. J 
Neurochem 127:669–680. 
Hippert C, Graca AB, Barber AC, West EL, Smith AJ, Ali RR, Pearson RA (2015) 
Müller glia activation in response to inherited retinal degeneration is highly varied 
and disease-specific. PLoS ONE 10:e0120415. 
Hippert C, Graca AB, Pearson RA (2016) Gliosis Can Impede Integration Following 
Photoreceptor Transplantation into the Diseased Retina. Adv Exp Med Biol 
854:579–585. 
Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, Yoshimura N, 
Takahashi M (2009) Generation of retinal cells from mouse and human induced 
pluripotent stem cells. Neurosci Lett 458:126–131. 
Ho AC et al. (2015) Long-Term Results from an Epiretinal Prosthesis to Restore Sight 
to the Blind. Ophthalmol 122:1547–1554. 
Holcombe DJ, Lengefeld N, Gole GA, Barnett NL (2008) The effects of acute 
intraocular pressure elevation on rat retinal glutamate transport. Acta Ophthalmol 
86:408–414. 
Hollander den AI, Davis J, van der Velde-Visser SD, Zonneveld MN, Pierrottet CO, 
Koenekoop RK, Kellner U, van den Born LI, Heckenlively JR, Hoyng CB, Handford 
PA, Roepman R, Cremers FPM (2004) CRB1 mutation spectrum in inherited retinal 
dystrophies. Hum Mutat 24:355–369. 
Hollander den AI, Ghiani M, de Kok Y (2002) Isolation of Crb1, a mouse homologue of 
Drosophila crumbs, and analysis of its expression pattern in eye and brain. Mech 
Dev 110(1-2):203-7. 
Hollander den AIA, Brink ten JBJ, de Kok YJY, van Soest SS, van den Born LIL, van 
Driel MAM, van de Pol DJD, Payne AMA, Bhattacharya SSS, Kellner UU, Hoyng 
325"
CBC, Westerveld AA, Brunner HGH, Bleeker-Wagemakers EME, Deutman AFA, 
Heckenlively JRJ, Cremers FPF, Bergen AAA (1999) Mutations in a human 
homologue of Drosophila crumbs cause retinitis pigmentosa (RP12). Nat Genet 
23:217–221. 
Hollyfield JG, Rayborn ME, Midura RJ, Shadrach KG, Acharya S (1999) Chondroitin 
sulfate proteoglycan core proteins in the interphotoreceptor matrix: a comparative 
study using biochemical and immunohistochemical analysis. Exp Eye Res 69:311–
322. 
Holz FG, Tadayoni R, Beatty S, Berger AR, Cereda MG, Hykin P, Staurenghi G, 
Wittrup-Jensen K, Nilsson J, Kim K, Sivaprasad S (2016) Determinants of visual 
acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an 
instrumental variable analysis of the AURA study. Eye 30:1063–1071. 
Huang L, Zhang Q, Li S, Guan L, Xiao X, Zhang J, Jia X, Sun W, Zhu Z, Gao Y, Yin Y, 
Wang P, Guo X, Wang J, Zhang Q (2013) Exome sequencing of 47 chinese 
families with cone-rod dystrophy: mutations in 25 known causative genes. PLoS 
ONE 8:e65546. 
Humphrey MF, Chu Y, Mann K, Rakoczy P (1997) Retinal GFAP and bFGF expression 
after multiple argon laser photocoagulation injuries assessed by both 
immunoreactivity and mRNA levels. Exp Eye Res 64:361–369. 
Humphrey MF, Constable IJ, Chu Y, Wiffen S (1993) A quantitative study of the lateral 
spread of Müller cell responses to retinal lesions in the rabbit. J Comp Neurol 
334:545–558. 
Humphries MM, Rancourt D, Farrar GJ, Kenna P, Hazel M, Bush RA, Sieving PA, 
Sheils DM, McNally N, Creighton P, Erven A, Boros A, Gulya K, Capecchi MR, 
Humphries P (1997) Retinopathy induced in mice by targeted disruption of the 
rhodopsin gene. Nat Genet 15:216–219. 
Hüttl S, Michalakis S, Seeliger M, Luo D-G, Acar N, Geiger H, Hudl K, Mader R, 
Haverkamp S, Moser M, Pfeifer A, Gerstner A, Yau K-W, Biel M (2005) Impaired 
channel targeting and retinal degeneration in mice lacking the cyclic nucleotide-
gated channel subunit CNGB1. J Neurosci 25:130–138. 
Ichijo H (2004) Proteoglycans as cues for axonal guidance in formation of retinotectal 
or retinocollicular projections. Mol Neurobiol 30:23–33. 
Iezzi R (2016) Regenerative ophthalmology: Technologic and pharmacologic 
326"
approaches to restoring sight via retinal prosthesis. Clin Pharmacol Ther 99:33–35. 
Inatani M, Honjo M, Otori Y, Oohira A, Kido N, Tano Y, Honda Y, Tanihara H (2001) 
Inhibitory effects of neurocan and phosphacan on neurite outgrowth from retinal 
ganglion cells in culture. Invest Ophthalmol Vis Sci 42:1930–1938. 
Inatani M, Tanihara H (2002) Proteoglycans in retina. Prog Retin Eye Res 21:429–447. 
Inatani M, Tanihara H, Oohira A, Honjo M, Kido N, Honda Y (2000) Upregulated 
expression of neurocan, a nervous tissue specific proteoglycan, in transient retinal 
ischemia. Invest Ophthalmol Vis Sci 41:2748–2754. 
Inman DM, Horner PJ (2007) Reactive nonproliferative gliosis predominates in a 
chronic mouse model of glaucoma. Glia 55:942–953. 
Ishikawa M, Sawada Y, Yoshitomi T (2015) Structure and function of the 
interphotoreceptor matrix surrounding retinal photoreceptor cells. Exp Eye Res 
133:3–18. 
Ivaska J, Pallari H-M, Nevo J, Eriksson JE (2007) Novel functions of vimentin in cell 
adhesion, migration, and signaling. Exp Cell Res 313:2050–2062. 
Jacobson SG (2012) Gene Therapy for Leber Congenital Amaurosis Caused by 
RPE65 Mutations. Arch Ophthalmol 130:9. 
Jacobson SG, Cideciyan AV, Aleman TS, Pianta MJ, Sumaroka A, Schwartz SB, 
Smilko EE, Milam AH, Sheffield VC, Stone EM (2003) Crumbs homolog 1 (CRB1) 
mutations result in a thick human retina with abnormal lamination. Hum Mol Genet 
12(9):1073-8. 
Jacobson SG, Cideciyan AV, Regunath G, Rodriguez FJ, Vandenburgh K, Sheffield 
VC, Stone EM (1995) Night blindness in Sorsby's fundus dystrophy reversed by 
vitamin A. Nat Genet 11:27–32. 
Jadhav AP, Mason HA, Cepko CL (2006) Notch 1 inhibits photoreceptor production in 
the developing mammalian retina. Development 133:913–923. 
Jayakody SA, Gonzalez-Cordero A, Ali RR, Pearson RA (2015) Progress in Retinal 
and Eye Research. Prog Retin Eye Res 46:31–66. 
Jayaram H, Jones MF, Eastlake K, Cottrill PB, Becker S, Wiseman J, Khaw PT, Limb 
GA (2014) Transplantation of photoreceptors derived from human Muller glia 
restore rod function in the P23H rat. Stem Cells Transl Med 3:323–333. 
327"
Jeon C-J, Strettoi E, Masland RH (1998). The major cell populations of the mouse 
retina. J Neurosci 18(21):8936-46. 
Jing R, Wilhelmsson U, Goodwill W, Li L, Pan Y, Pekny M, Skalli O (2007) Synemin is 
expressed in reactive astrocytes in neurotrauma and interacts differentially with 
vimentin and GFAP intermediate filament networks. J Cell Sci 120:1267–1277. 
Jobling AI, Vessey KA, Waugh M, Mills SA, Fletcher EL (2013) A Naturally Occurring 
Mouse Model of Achromatopsia: Characterization of the Mutation in Cone 
Transducin and Subsequent Retinal Phenotype. Invest Ophthalmol Vis Sci 
54:3350. 
John SK, Smith JE, Aguirre GD, H MA (2000) Loss of cone molecular markers in 
rhodopsin-mutant human retinas with retinitis pigmentosa. Mol Vis 6:204–215. 
Johns PR (1977) Growth of the adult goldfish eye. III. Source of the new retinal cells. J 
Comp Neurol 176:343–357. 
Johns PR, Fernald RD (1981) Genesis of rods in teleost fish retina. Nat 293:141–142. 
Johnson TV, Bull ND, Martin KR (2010) Identification of barriers to retinal engraftment 
of transplanted stem cells. Invest Ophthalmol Vis Sci 51:960–970. 
Jones BW, Kondo M, Terasaki H, Lin Y, McCall M, Marc RE (2012) Retinal remodeling. 
Jpn J Ophthalmol 56:289–306. 
Jones BW, Marc RE (2005) Retinal remodeling during retinal degeneration. Exp Eye 
Res 81:123–137. 
Jones BW, Watt CB, Frederick JM, Baehr W, Chen C-K, Levine EM, Milam AH, LaVail 
MM, Marc RE (2003a) Retinal remodeling triggered by photoreceptor 
degenerations. J Comp Neurol 464:1–16. 
Jones LL, Margolis RU, Tuszynski MH (2003b) The chondroitin sulfate proteoglycans 
neurocan, brevican, phosphacan, and versican are differentially regulated following 
spinal cord injury. Exp Neuro 182 :399–411. 
Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH (2002) NG2 is a major 
chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed 
by macrophages and oligodendrocyte progenitors. J Neurosci 22:2792–2803. 
Jonnal RS, Besecker JR, Derby JC, Kocaoglu OP, Cense B, Gao W, Wang Q, Miller 
DT (2010) Imaging outer segment renewal in living human cone photoreceptors. 
328"
Opt Express 18:5257–5270. 
Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S, Kiryu J, Takahashi M 
(2014) Characterization of human induced pluripotent stem cell-derived retinal 
pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep 2:205–
218. 
Kaupp UB, Seifert R (2002) Cyclic nucleotide-gated ion channels. Physiol Rev 82:769–
824. 
Kaur C, Sivakumar V, Yong Z, Lu J, Foulds WS, Ling EA (2007) Blood-retinal barrier 
disruption and ultrastructural changes in the hypoxic retina in adult rats: the 
beneficial effect of melatonin administration. J Pathol 212:429–439. 
Kedzierski W, Lloyd M, Birch DG, Bok D, Travis GH (1997) Generation and analysis of 
transgenic mice expressing P216L-substituted rds/peripherin in rod 
photoreceptors. Invest Ophthalmol Vis Sci 38:498–509. 
Keen TJ, Inglehearn CF (1996) Mutations and polymorphisms in the human peripherin-
RDS gene and their involvement in inherited retinal degeneration. Hum Mutat 
8:297–303. 
Keenan TDL, Clark SJ, Unwin RD, Ridge LA, Day AJ, Bishop PN (2012) Mapping the 
differential distribution of proteoglycan core proteins in the adult human retina, 
choroid, and sclera. Invest Ophthalmol Vis Sci 53:7528–7538. 
Kevany BM, Palczewski K (2010) Phagocytosis of retinal rod and cone photoreceptors. 
Physiology (Bethesda) 25:8–15. 
Khateb S, Hanany M, Khalaileh A, Beryozkin A, Meyer S, Abu-Diab A, Abu Turky F, 
Mizrahi-Meissonnier L, Lieberman S, Ben-Yosef T, Banin E, Sharon D (2016) 
Identification of genomic deletions causing inherited retinal degenerations by 
coverage analysis of whole exome sequencing data. J Med Genet 53:600–607. 
Kim BG, Dai H-N, Lynskey JV, Mcatee M, Bregman BS (2006) Degradation of 
chondroitin sulfate proteoglycans potentiates transplant-mediated axonal 
remodeling and functional recovery after spinal cord injury in adult rats. J Comp 
Neurol 497:182–198. 
Kim IB, Kim KY, Joo CK, Lee MY, Oh SJ, Chung JW, Chun MH (1998) Reaction of 
Müller cells after increased intraocular pressure in the rat retina. Exp Brain Res 
121:419–424. 
329"
Kim K-Y, Ju W-K, Neufeld AH (2004) Neuronal susceptibility to damage: comparison of 
the retinas of young, old and old/caloric restricted rats before and after transient 
ischemia. Neurobiol Aging 25:491–500. 
Kinouchi R, Takeda M, Yang L, Wilhelmsson U, Lundkvist A, Pekny M, Chen DF 
(2003) Robust neural integration from retinal transplants in mice deficient in GFAP 
and vimentin. Nat Neurosci 6:863–868. 
Kiser PD, Golczak M, Maeda A, Palczewski K (2012) Key enzymes of the retinoid 
(visual) cycle in vertebrate retina. Biochim Biophys Acta 1821(1):137-51. 
Kivelä T, Tarkkanen A, Virtanen I (1986) Intermediate filaments in the human retina 
and retinoblastoma. An immunohistochemical study of vimentin, glial fibrillary 
acidic protein, and neurofilaments. Invest Ophthalmol Vis Sci 27:1075–1084. 
Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV (2009) A novel adeno-
associated viral variant for efficient and selective intravitreal transduction of rat 
Müller cells. PLoS ONE 4:e7467. 
Kljavin IJ, Reh TA (1991) Müller cells are a preferred substrate for in vitro neurite 
extension by rod photoreceptor cells. J Neurosci 11:2985–2994. 
Kohl S, Baumann B, Rosenberg T, Kellner U, Lorenz B, Vadalà M, Jacobson SG, 
Wissinger B (2002) Mutations in the Cone Photoreceptor G-Protein α-Subunit 
Gene GNAT2 in Patients with Achromatopsia. J Hum Genet 71:422–425. 
Kohl S, Marx T, Giddings I, Jägle H, Jacobson SG, Apfelstedt-Sylla E, Zrenner E, 
Sharpe LT, Wissinger B (1998) Total colourblindness is caused by mutations in the 
gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation 
channel. Nat Genet 19:257–259. 
Koike C, Nishida A, Akimoto K, Nakaya M-A, Noda T, Ohno S, Furukawa T (2005) 
Function of atypical protein kinase C lambda in differentiating photoreceptors is 
required for proper lamination of mouse retina. J Neurosci 25:10290–10298. 
Kolb H, Nelson R, Ahnelt P, Cuenca N (2001) Cellular organization of the vertebrate 
retina. Prog Brain Res. 
Kostic C, Chiodini F, Salmon P, Wiznerowicz M, Deglon N, Hornfeld D, Trono D, 
Aebischer P, Schorderet DF, Munier FL, Arsenijevic Y (2003) Activity analysis of 
housekeeping promoters using self-inactivating lentiviral vector delivery into the 
mouse retina. Gene Ther 10:818–821. 
330"
Kowluru RA, Kanwar M (2007) Effects of curcumin on retinal oxidative stress and 
inflammation in diabetes. Nutr Metab (Lond) 4:8. 
Krol J, Krol I, Alvarez CPP, Fiscella M, Hierlemann A, Roska B, Filipowicz W (2015) A 
network comprising short and long noncoding RNAs and RNA helicase controls 
mouse retina architecture. Nat Commun 6:7305. 
Kuboyama T, Luo X, Park K, Blackmore MG, Tojima T, Tohda C, Bixby JL, Lemmon 
VP, Kamiguchi H (2010) Paxillin phosphorylation counteracts proteoglycan-
mediated inhibition of axon regeneration.Exp Neuro 248:1–13. 
Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular 
membranes in age-related macular degeneration express vascular endothelial 
growth factor. Invest Ophthalmol Vis Sci 37:1929–1934. 
Kwan A, Wang S, Lund RD (1999) Photoreceptor layer reconstruction in a rodent 
model of retinal degeneration. Exp Neuro 159:21–33. 
Laabs T, Carulli D, Geller HM, Fawcett JW (2005) Chondroitin sulfate proteoglycans in 
neural development and regeneration. Curr Opin Neurobiol 15:116–120. 
Lai C-M, Shen W-Y, Brankov M, Lai YKY, Barnett NL, Lee S-Y, Yeo IYS, Mathur R, Ho 
JES, Pineda P, Barathi A, Ang C-L, Constable IJ, Rakoczy EP (2005) Long-term 
evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in 
mice and monkeys. Mol Ther 12:659–668. 
Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, 
Barathi A, Villano J, Ang C-L, van der Most RG, Constable IJ, Dismuke D, 
Samulski RJ, Degli-Esposti MA, Rakoczy EP (2011) Preclinical safety evaluation of 
subretinal AAV2.sFlt-1 in non-human primates. Gene Ther 19:999–1009. 
Lakowski J, Baron M, Bainbridge J, Barber AC, Pearson RA, Ali RR, Sowden JC 
(2010) Cone and rod photoreceptor transplantation in models of the childhood 
retinopathy Leber congenital amaurosis using flow-sorted Crx-positive donor cells. 
Hum Mol Genet 19:4545–4559. 
Lamba DA, Gust J, Reh TA (2009) Transplantation of human embryonic stem cell-
derived photoreceptors restores some visual function in Crx-deficient mice. Stem 
Cell 4:73–79. 
Lamba DA, Karl MO, Ware CB, Reh TA (2006) Efficient generation of retinal progenitor 
cells from human embryonic stem cells. Proc Natl Acad Sci 103:12769–12774. 
331"
Landers RA, Hollyfield JG (1992) Proteoglycans in the mouse interphotoreceptor 
matrix. VI. Evidence for photoreceptor synthesis of chondroitin sulfate proteoglycan 
using genetically fractionated retinas. Exp Eye Res 55:345–356. 
Landschulz WH, Johnson PF, McKnight SL (1988) The leucine zipper: a hypothetical 
structure common to a new class of DNA binding proteins. Sci 240:1759–1764. 
Lauritzen JS, Sigulinsky CL, Anderson JR, Kalloniatis M, Nelson NT, Emrich DP, Rapp 
C, McCarthy N, Kerzner E, Meyer M, Jones BW, Marc RE (2016) Rod-cone 
crossover connectome of mammalian bipolar cells. J Comp Neurol, cne.24084. 
LaVail MM, Battelle BA (1975) Influence of eye pigmentation and light deprivation on 
inherited retinal dystrophy in the rat. Exp Eye Res 21:167–192. 
LaVail MM, Matthes MT, Yasumura D, Steinberg RH (1997) Variability in rate of cone 
degeneration in the retinal degeneration (rd/rd) mouse. Exp Eye Res 65:45–50. 
LaVail MM, Pinto LH, Yasumura D (1981) The interphotoreceptor matrix in rats with 
inherited retinal dystrophy. Invest Ophthalmol Vis Sci 21:658–668. 
LaVail MM, Unoki K, Yasumura D, Matthes MT, Yancopoulos GD, Steinberg RH (1992) 
Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from 
the damaging effects of constant light. Proc Natl Acad Sci 89:11249–11253. 
Lawrence JM, Singhal S, Bhatia B, Keegan DJ, Reh TA, Luthert PJ, Khaw PT, Limb 
GA (2007) MIO‐M1 Cells and Similar Müller Glial Cell Lines Derived from Adult 
Human Retina Exhibit Neural Stem Cell Characteristics. Stem Cells 25:2033–2043. 
Lebrun-Julien F, Duplan L, Pernet V, Osswald I, Sapieha P, Bourgeois P, Dickson K, 
Bowie D, Barker PA, Di Polo A (2009) Excitotoxic Death of Retinal Neurons In Vivo 
Occurs via a Non-Cell-Autonomous Mechanism. J Neurosci 29:5536–5545. 
Lee E-J, Ji Y, Zhu CL, Grzywacz NM (2011) Role of Müller cells in cone mosaic 
rearrangement in a rat model of retinitis pigmentosa. Glia 59:1107–1117. 
Lee H, McKeon RJ, Bellamkonda RV (2010) Sustained delivery of thermostabilized 
chABC enhances axonal sprouting and functional recovery after spinal cord injury. 
Proc Natl Acad Sci 107:3340–3345. 
Lemke AK, Sandy JD, Voigt H, Dreier R, Lee JH, Grodzinsky AJ, Mentlein R, Fay J, 
Schünke M, Kurz B (2010) Interleukin-1alpha treatment of meniscal explants 
stimulates the production and release of aggrecanase-generated, GAG-substituted 
332"
aggrecan products and also the release of pre-formed, aggrecanase-generated G1 
and m-calpain-generated G1-G2. Cell Tissue Res 340:179–188. 
Lemons ML, Howland DR, Anderson DK (1999) Chondroitin sulfate proteoglycan 
immunoreactivity increases following spinal cord injury and transplantation.Exp 
Neuro 160:51–65. 
Lemons ML, Sandy JD, Anderson DK, Howland DR (2003) Intact aggrecan and 
chondroitin sulfate-depleted aggrecan core glycoprotein inhibit axon growth in the 
adult rat spinal cord. Exp Neuro 184:981–990. 
Letourneau PC, Condic ML, Snow DM (1994) Interactions of developing neurons with 
the extracellular matrix. J Neurosci 14:915–928. 
Lewis G, Mervin K, Valter K, Maslim J, Kappel PJ, Stone J, Fisher S (1999) Limiting 
the proliferation and reactivity of retinal Müller cells during experimental retinal 
detachment: the value of oxygen supplementation. J Ophthalmol 128:165–172. 
Lewis GP, Chapin EA, Luna G, Linberg KA, Fisher SK (2010) The fate of Müller's glia 
following experimental retinal detachment: nuclear migration, cell division, and 
subretinal glial scar formation. Mol Vis 16:1361–1372. 
Lewis GP, Erickson PA, Guérin CJ, Anderson DH, Fisher SK (1989) Changes in the 
expression of specific Müller cell proteins during long-term retinal detachment. Exp 
Eye Res 49:93–111. 
Lewis GP, Fisher SK (2000) Müller cell outgrowth after retinal detachment: association 
with cone photoreceptors. Invest Ophthalmol Vis Sci 41:1542–1545. 
Lewis GP, Fisher SK (2003) Up-regulation of glial fibrillary acidic protein in response to 
retinal injury: its potential role in glial remodeling and a comparison to vimentin 
expression. Int Rev Cytol 230:263–290. 
Lewis GP, Sethi CS, Carter KM, Charteris DG, Fisher SK (2005) Microglial cell 
activation following retinal detachment: a comparison between species. Mol Vis 
11:491–500. 
Lewis PM, Ackland HM, Lowery AJ, Rosenfeld JV (2015) Restoration of vision in blind 
individuals using bionic devices: a review with a focus on cortical visual 
prostheses. Brain Res 1595:51–73. 
Léveillard T, Mohand-Saïd S, Lorentz O, Hicks D, Fintz A-C, Clérin E, Simonutti M, 
333"
Forster V, Cavusoglu N, Chalmel F, Dollé P, Poch O, Lambrou G, Sahel J-A (2004) 
Identification and characterization of rod-derived cone viability factor. Nat Genet 
36:755–759. 
Li H, Leung TC, Hoffman S, Balsamo J, Lilien J (2000) Coordinate regulation of 
cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. J 
Cell Biol 149:1275–1288. 
Libby RT, Champliaud MF, Claudepierre T, Xu Y, Gibbons EP, Koch M, Burgeson RE, 
Hunter DD, Brunken WJ (2000) Laminin expression in adult and developing 
retinae: evidence of two novel CNS laminins. J Neurosci 20:6517–6528. 
Lin B, Masland RH, Strettoi E (2009) Remodeling of cone photoreceptor cells after rod 
degeneration in rd mice. Exp Eye Res 88:589–599. 
Lin H et al. (2016) Lens regeneration using endogenous stem cells with gain of visual 
function. Nat 531:323–328. 
Linberg KA, Sakai T, Lewis GP, Fisher SK (2002) Experimental retinal detachment in 
the cone-dominant ground squirrel retina: morphology and basic 
immunocytochemistry. Vis Neurosci 19:603–619. 
Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. 
Annu Rev Cell Dev Biol 20:781–810. 
Lu L, Nyalakonda K, Kam L, Bizios R, Göpferich A, Mikos AG (2001) Retinal pigment 
epithelial cell adhesion on novel micropatterned surfaces fabricated from synthetic 
biodegradable polymers. Biomaterials 22:291–297. 
Lu Y-B, Franze K, Seifert G, Steinhäuser C, Kirchhoff F, Wolburg H, Guck J, Janmey 
P, Wei E-Q, Käs J, Reichenbach A (2006) Viscoelastic properties of individual glial 
cells and neurons in the CNS. Proc Natl Acad Sci 103:17759–17764. 
Lu Y-B, Iandiev I, Hollborn M, Körber N, Ulbricht E, Hirrlinger PG, Pannicke T, Wei E-
Q, Bringmann A, Wolburg H, Wilhelmsson U, Pekny M, Wiedemann P, 
Reichenbach A, Käs JA (2011) Reactive glial cells: increased stiffness correlates 
with increased intermediate filament expression. FASEB J 25:624–631. 
Lu Y-B, Pannicke T, Wei E-Q, Bringmann A, Wiedemann P, Habermann G, Buse E, 
Käs JA, Reichenbach A (2013) Biomechanical properties of retinal glial cells: 
comparative and developmental data. Exp Eye Res 113:60–65. 
334"
Luhmann UFO, Carvalho LS, Holthaus S-MK, Cowing JA, Greenaway S, Chu CJ, 
Herrmann P, Smith AJ, Munro PMG, Potter P, Bainbridge JWB, Ali RR (2015) The 
severity of retinal pathology in homozygous Crb1rd8/rd8 mice is dependent on 
additional genetic factors. Hum Mol Genet 24:128–141. 
Lui JH, Hansen DV, Kriegstein AR (2011) Development and Evolution of the Human 
Neocortex. Cell 146:18–36. 
Luna G, Lewis GP, Banna CD, Skalli O, Fisher SK (2010) Expression profiles of nestin 
and synemin in reactive astrocytes and Müller cells following retinal injury: a 
comparison with glial fibrillar acidic protein and vimentin. Mol Vis 16:2511–2523. 
Lundkvist A, Reichenbach A, Betsholtz C, Carmeliet P, Wolburg H, Pekny M (2004) 
Under stress, the absence of intermediate filaments from Müller cells in the retina 
has structural and functional consequences. J Cell Sci 117:3481–3488. 
MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, Swaroop A, 
Sowden JC, Ali RR (2006) Retinal repair by transplantation of photoreceptor 
precursors. Nat 444:203–207. 
Maeda A, Maeda T, Golczak M, Chou S, Desai A, Hoppel CL, Matsuyama S, 
Palczewski K (2009) Involvement of all-trans-retinal in acute light-induced 
retinopathy of mice. J Biol Chem 284:15173–15183. 
Maguire AM et al. (2008) Safety and efficacy of gene transfer for Leber's congenital 
amaurosis. N Engl J Med 358:2240–2248. 
Mansergh FC, Carrigan M, Hokamp K, Farrar GJ (2015) Gene expression changes 
during retinal development and rod specification. Mol Vis 21:61–87. 
Martin-Belmonte F, Perez-Moreno M (2012) Epithelial cell polarity, stem cells and 
cancer. Nat Rev Cancer 12:23–38. 
Martinez-De Luna RI, Ku RY, Aruck AM, Santiago F, Viczian AS, San Mauro D, Zuber 
ME (2016) Müller glia reactivity follows retinal injury despite the absence of the glial 
fibrillary acidic protein gene in Xenopus. Dev Biol pii: S0012-1606(15)30360-2. 
Martinez-Navarrete G, Seiler MJ, Aramant RB, Fernandez-Sanchez L, Pinilla I, Cuenca 
N (2011) Retinal degeneration in two lines of transgenic S334ter rats. Exp Eye Res 
92:227–237. 
Massey JM, Amps J, Viapiano MS, Matthews RT, Wagoner MR, Whitaker CM, Alilain 
335"
W, Yonkof AL, Khalyfa A, Cooper NGF, Silver J, Onifer SM (2008) Increased 
chondroitin sulfate proteoglycan expression in denervated brainstem targets 
following spinal cord injury creates a barrier to axonal regeneration overcome by 
chondroitinase ABC and neurotrophin-3.Exp Neuro 209:426–445. 
Matsui F, Oohira A (2004) Proteoglycans and injury of the central nervous system. 
Congenit Anom 44:181–188. 
Mazzoni F, Novelli E, Strettoi E (2008) Retinal Ganglion Cells Survive and Maintain 
Normal Dendritic Morphology in a Mouse Model of Inherited Photoreceptor 
Degeneration. J Neurosci 28:14282–14292. 
McGraw J, Hiebert GW, Steeves JD (2001) Modulating astrogliosis after neurotrauma. 
J Neurosci Res 63:109–115. 
McKeon RJ, Höke A, Silver J (1995) Injury-induced proteoglycans inhibit the potential 
for laminin-mediated axon growth on astrocytic scars. Exp Neuro 136:32–43. 
McKeon RJ, Schreiber RC, Rudge JS, Silver J (1991) Reduction of neurite outgrowth 
in a model of glial scarring following CNS injury is correlated with the expression of 
inhibitory molecules on reactive astrocytes. J Neurosci 11:3398–3411. 
McLaughlin ME, Sandberg MA, Berson EL, Dryja TP (1993) Recessive mutations in 
the gene encoding the beta-subunit of rod phosphodiesterase in patients with 
retinitis pigmentosa. Nat 4:130–134. 
McNally N, Kenna PF, Rancourt D, Ahmed T, Stitt A, Colledge WH, Lloyd DG, Palfi A, 
O'Neill B, Humphries MM, Humphries P, Farrar GJ (2002) Murine model of 
autosomal dominant retinitis pigmentosa generated by targeted deletion at codon 
307 of the rds-peripherin gene. Hum Mol Genet 11:1005–1016. 
Mears AJ, Kondo M, Swain PK, Takada Y, Bush RA, Saunders TL, Sieving PA, 
Swaroop A (2001b) Nrl is required for rod photoreceptor development. Nat Genet 
29:447–452. 
Mehalow AK, Kameya S, Smith RS, Hawes NL, Denegre JM, Young JA, Bechtold L, 
Haider NB, Tepass U, Heckenlively JR, Chang B, Naggert JK, Nishina PM (2003) 
CRB1 is essential for external limiting membrane integrity and photoreceptor 
morphogenesis in the mammalian retina. Hum Mol Genet 12:2179–2189. 
Mellough CB, Cui Q, Harvey AR (2007) Treatment of adult neural progenitor cells prior 
to transplantation affects graft survival and integration in a neonatal and adult rat 
336"
model of selective retinal ganglion cell depletion. Restor Neurol Neurosci 25:177–
190. 
Menet V, Prieto M, Privat A, Ribotta MGY (2011) Axonal plasticity and functional 
recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein 
and vimentin genes. Proc Natl Acad Sci 100:8999–9004. 
Merriman DK, Sajdak BS, Li W, Jones BW (2016) Seasonal and post-trauma 
remodeling in cone-dominant ground squirrel retina. Exp Eye Res:1–16. 
Mestrinerr ACD, Haddad A (1994) Serum albumin enters the posterior chamber of the 
eye permeating the blood-aqueous barrier. Graefes Arch Clin Exp Ophthalmol 
232:242–251. 
Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, McMillan EL, Zhang S-
C, Gamm DM (2009) Modeling early retinal development with human embryonic 
and induced pluripotent stem cells. Proc Natl Acad Sci 106:16698–16703. 
Mieziewska K, van Veen T, Aguirre GD (1993) Structural changes of the 
interphotoreceptor matrix in an inherited retinal degeneration: a lectin cytochemical 
study of progressive rod-cone degeneration. Invest Ophthalmol Vis Sci 34:3056–
3067. 
Minassian DC, Reidy A, Lightstone A, Desai P (2011) Modelling the prevalence of age-
related macular degeneration (2010-2020) in the UK: expected impact of anti-
vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol 95:1433–
1436. 
Mitamura Y, Mitamura-Aizawa S, Katome T, Naito T, Hagiwara A, Kumagai K, 
Yamamoto S (2013) Photoreceptor impairment and restoration on optical 
coherence tomographic image. J Ophthalmol 2013:518170. 
Mitashov VI (2001) Multipotential stem cells and progenitors in the vertebrate retina. 
Biol Bull Russ Acad Sci 28:606–615. 
Miyoshi H, Takahashi M, Gage FH, Verma IM (1997) Stable and efficient gene transfer 
into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci 94:10319–
10323. 
Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma J-X (2005) RPE65 is the 
isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci 102:12413–
12418. 
337"
Montana CL, Lawrence KA, Williams NL, Tran NM, Peng G-H, Chen S, Corbo JC 
(2011) Transcriptional regulation of neural retina leucine zipper (Nrl), a 
photoreceptor cell fate determinant. J Biol Chem 286:36921–36931. 
Mookherjee S, Hiriyanna S, Kaneshiro K, Li L, Li Y, Li W, Qian H, Li T, Khanna H, 
Colosi P, Swaroop A, Wu Z (2015) Long-term rescue of cone photoreceptor 
degeneration in retinitis pigmentosa 2 ( RP2)-knockout mice by gene replacement 
therapy. Hum Mol Genet 24:6446–6458. 
Moon LD, Asher RA, Rhodes KE, Fawcett JW (2001) Regeneration of CNS axons back 
to their target following treatment of adult rat brain with chondroitinase ABC. Nat 
Neurosci 4:465–466. 
Morgenstern DA, Asher RA, Fawcett JW (2002) Chondroitin sulphate proteoglycans in 
the CNS injury response. Prog Brain Res 137:313–332. 
Morris TA, Fong SL (1993) Characterization of the gene encoding human cone 
transducin alpha-subunit (GNAT2). Genomics 17:442–448. 
Moussaif M, Rubin WW, Kerov V, Reh R, Chen D, Lem J, Chen C-K, Hurley JB, Burns 
ME, Artemyev NO (2006) Phototransduction in a transgenic mouse model of 
Nougaret night blindness. J Neurosci 26:6863–6872. 
Muir D, Engvall E, Varon S, Manthorpe M (1989) Schwannoma cell-derived inhibitor of 
the neurite-promoting activity of laminin. J Cell Biol 109:2353–2362. 
Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniew MV (2006) Essential protective 
roles of reactive astrocytes in traumatic brain injury. Brain 129:2761–2772. 
Naeem MA, Chavali VRM, Ali S, Iqbal M, Riazuddin S, Khan SN, Husnain T, Sieving 
PA, Ayyagari R, Riazuddin S, Hejtmancik JF, Riazuddin SA (2012) GNAT1 
associated with autosomal recessive congenital stationary night blindness. Invest 
Ophthalmol Vis Sci 53:1353–1361. 
Nakanishi K, Aono S, Hirano K, Kuroda Y, Ida M, Tokita Y, Matsui F, Oohira A (2006) 
Identification of neurite outgrowth-promoting domains of neuroglycan C, a brain-
specific chondroitin sulfate proteoglycan, and involvement of phosphatidylinositol 
3-kinase and protein kinase C signaling pathways in neuritogenesis. J Biol Chem 
281:24970–24978. 
Nakazawa M, Naoi N, Wada Y, Nakazaki S, Maruiwa F, Sawada A, Tamai M (1996) 
Autosomal dominant cone-rod dystrophy associated with a Val200Glu mutation of 
338"
the peripherin/RDS gene. Retin 16:405–410. 
Nakazawa T, Takeda M, Lewis GP, Cho K-S, Jiao J, Wilhelmsson U, Fisher SK, Pekny 
M, Chen DF, Miller JW (2007) Attenuated glial reactions and photoreceptor 
degeneration after retinal detachment in mice deficient in glial fibrillary acidic 
protein and vimentin. Invest Ophthalmol Vis Sci 48:2760–2768. 
Nandini CD, Sugahara K (2006) Role of the sulfation pattern of chondroitin sulfate in its 
biological activities and in the binding of growth factors. Adv Pharmacol 53:253–
279. 
Naskar R, Vorwerk CK, Dreyer EB (2000) Concurrent Downregulation of a Glutamate 
Transporter and Receptor in Glaucoma. Invest Ophthalmol Vis Sci 41:1940–1944. 
Nishida A, Furukawa A, Koike C, Tano Y, Aizawa S, Matsuo I, Furukawa T (2003) Otx2 
homeobox gene controls retinal photoreceptor cell fate and pineal gland 
development. Nat Neurosci 6:1255–1263. 
Nishida A, Takahashi M, Tanihara H, Nakano I, Takahashi JB, Mizoguchi A, Ide C, 
Honda Y (2000) Incorporation and differentiation of hippocampus-derived neural 
stem cells transplanted in injured adult rat retina. Invest Ophthalmol Vis Sci 
41:4268–4274. 
Nishiguchi KM, Carvalho LS, Rizzi M, Powell K, Holthaus S-MK, Azam SA, Duran Y, 
Ribeiro J, Luhmann UFO, Bainbridge JWB, Smith AJ, Ali RR (2015) Gene therapy 
restores vision in rd1 mice after removal of a confounding mutation in Gpr179. Nat 
Commun 6:6006. 
Nishiguchi KM, Sandberg MA, Kooijman AC, Martemyanov KA, Pott JWR, Hagstrom 
SA, Arshavsky VY, Berson EL, Dryja TP (2004) Defects in RGS9 or its anchor 
protein R9AP in patients with slow photoreceptor deactivation. Nat 427:75–78. 
Nishimura T, Takeichi M (2009) Remodeling of the adherens junctions during 
morphogenesis. Curr Top Dev Biol 89:33–54. 
Oakley RA, Tosney KW (1991) Peanut agglutinin and chondroitin-6-sulfate are 
molecular markers for tissues that act as barriers to axon advance in the avian 
embryo. Dev Biol 147:187–206. 
Oh ECT, Cheng H, Hao H, Jia L, Khan NW, Swaroop A (2008) Rod differentiation 
factor NRL activates the expression of nuclear receptor NR2E3 to suppress the 
development of cone photoreceptors. Brain Res 1236:16–29. 
339"
Okada M, Matsumura M, Ogino N, Honda Y (1990) Muller Cells in Detached Human 
Retina Express Glial Fibrillary Acidic Protein and Vimentin. Graefes Arch Clin Exp 
Ophthalmol 228:467–474. 
Omri S, Behar-Cohen F, Rothschild P-R, Gélizé E, Jonet L, Jeanny J-C, Omri B, 
Crisanti P (2013) PKCζ Mediates Breakdown of Outer Blood-Retinal Barriers in 
Diabetic Retinopathy. PLoS ONE 8:e81600. 
Omri S, Omri B, Savoldelli M, Jonet L, Thillaye-Goldenberg B, Thuret G, Gain P, 
Jeanny JC, Crisanti P, Behar-Cohen F (2010) The outer limiting membrane (OLM) 
revisited: clinical implications. Clin Ophthalmol 4:183–195. 
Ooto S, Akagi T, Kageyama R, Akita J, Mandai M, Honda Y, Takahashi M (2004) 
Potential for neural regeneration after neurotoxic injury in the adult mammalian 
retina. Proc Natl Acad Sci 101:13654–13659. 
Osakada F, Ikeda H, Mandai M, Wataya T, Watanabe K, Yoshimura N, Akaike A, 
Sasai Y, Takahashi M (2008) Toward the generation of rod and cone 
photoreceptors from mouse, monkey and human embryonic stem cells. Nat 
Biotechnol 26:215–224. 
Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR (2012) The 
estimated prevalence and incidence of late stage age related macular 
degeneration in the UK. Br J Ophthalmol 96:752–756. 
Palfi A, Millington-Ward S, Chadderton N, O'Reilly M, Goldmann T, Humphries MM, Li 
T, Wolfrum U, Humphries P, Kenna PF, Farrar GJ (2010) Adeno-Associated Virus-
Mediated Rhodopsin Replacement Provides Therapeutic Benefit in Mice with a 
Targeted Disruption of the Rhodopsin Gene. Hum Gene Ther 21:311–323. 
Pang J-J, Chang B, Hawes NL, Hurd RE, Davisson MT, Li J, Noorwez SM, Malhotra R, 
McDowell JH, Kaushal S, Hauswirth WW, Nusinowitz S, Thompson DA, 
Heckenlively JR (2005) Retinal degeneration 12 (rd12): a new, spontaneously 
arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis 
11:152–162. 
Pang J-J, Chang B, Kumar A, Nusinowitz S, Noorwez SM, Li J, Rani A, Foster TC, 
Chiodo VA, Doyle T, Li H, Malhotra R, Teusner JT, McDowell JH, Min S-H, Li Q, 
Kaushal S, Hauswirth WW (2006) Gene therapy restores vision-dependent 
behavior as well as retinal structure and function in a mouse model of RPE65 
Leber congenital amaurosis. Mol Ther 13:565–572. 
340"
Panickar KS, Norenberg MD (2005) Astrocytes in cerebral ischemic injury: 
Morphological and general considerations. Glia 50:287–298. 
Pardue MT, Stubbs EB, Perlman JI, Narfström K, Chow AY, Peachey NS (2001) 
Immunohistochemical studies of the retina following long-term implantation with 
subretinal microphotodiode arrays. Exp Eye Res 73:333–343. 
Parmeggiani F (2011) Clinics, epidemiology and genetics of retinitis pigmentosa. Curr 
Genomics 12:236–237. 
Pearson RA (2014) Advances in repairing the degenerate retina by rod photoreceptor 
transplantation. Biotechnol Adv 32:485–491. 
Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, 
Chuang JZ, Azam SA, Luhmann UFO, Benucci A, Sung CH, Bainbridge JW, 
Carandini M, Yau KW, Sowden JC, Ali RR (2012) Restoration of vision after 
transplantation of photoreceptors. Nat 485:99–103. 
Pearson RA, Barber AC, West EL, MacLaren RE, Duran Y, Bainbridge JW, Sowden 
JC, Ali RR (2010) Targeted disruption of outer limiting membrane junctional 
proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor 
precursors into the adult wild-type and degenerating retina. Cell Transplant 
19:487–503. 
Pearson RA, Hippert C, Graca AB, Barber AC (2014) Photoreceptor replacement 
therapy: challenges presented by the diseased recipient retinal environment. Vis 
Neurosci 31:333–344. 
Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y, Klein RL, Hauswirth 
WW, Quigley HA (2009) Effect of CNTF on retinal ganglion cell survival in 
experimental glaucoma. Invest Ophthalmol Vis Sci 50:2194–2200. 
Pekny M, Levéen P, Pekna M, Eliasson C, Berthold CH, Westermark B, Betsholtz C 
(1995) Mice lacking glial fibrillary acidic protein display astrocytes devoid of 
intermediate filaments but develop and reproduce normally. EMBO J 14:1590–
1598. 
Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427–434. 
Pellikka M, Tanentzapf G, Pinto M, Smith C, McGlade CJ, Ready DF, Tepass U (2002) 
Crumbs, the Drosophila homologue of human CRB1/RP12, is essential for 
photoreceptor morphogenesis. Nat 416:143–149. 
341"
Pellissier LP, Alves CH, Quinn PM, Vos RM (2013) Targeted ablation of crb1 and crb2 
in retinal progenitor cells mimics leber congenital amaurosis. PLoS Genet 
9(12):e1003976. 
Pellissier LP, Lundvig DMS, Tanimoto N, Klooster J, Vos RM, Richard F, Sothilingam 
V, Garcia Garrido M, Le Bivic A, Seeliger MW, Wijnholds J (2014) CRB2 acts as a 
modifying factor of CRB1-related retinal dystrophies in mice. Hum Mol Genet 
23:3759–3771. 
Peng Y-W, Zallocchi M, Meehan DT, Delimont D, Chang B, Hawes N, Wang W, 
Cosgrove D (2008) Progressive morphological and functional defects in retinas 
from alpha1 integrin-null mice. Invest Ophthalmol Vis Sci 49:4647–4654. 
Perez-Moreno M, Fuchs E (2006) Catenins: Keeping Cells from Getting Their Signals 
Crossed. Dev Cell 11(5): 1–612. 
Perron M, Harris WA (2000) Retinal stem cells in vertebrates. Bioessays 22:685–688. 
Petito CK, Morgello S, Felix JC, Lesser ML (1990) The two patterns of reactive 
astrocytosis in postischemic rat brain. J Cereb Blood Flow Metab 10:850–859. 
Pokutta S, Weis WI (2007) Structure and Mechanism of Cadherins and Catenins in 
Cell-Cell Contacts. Annu Rev Cell Dev Biol 23:237–261. 
Popp S, Maurel P, Andersen JS, Margolis RU (2004) Developmental changes of 
aggrecan, versican and neurocan in the retina and optic nerve. Exp Eye Res 
79:351–356. 
Properzi F, Asher RA, Fawcett JW (2003) Chondroitin sulphate proteoglycans in the 
central nervous system: changes and synthesis after injury. Biochem Soc Trans 
31:335–336. 
Pujic Z, Malicki J (2004) Retinal pattern and the genetic basis of its formation in 
zebrafish. Semin Cell Dev Biol 15:105–114. 
Punzo C, Cepko C (2007) Cellular responses to photoreceptor death in the rd1 mouse 
model of retinal degeneration. Invest Ophthalmol Vis Sci 48:849–857. 
Qiu G, Seiler MJ, Mui C, Arai S, Aramant RB (2005) Photoreceptor differentiation and 
integration of retinal progenitor cells transplanted into transgenic rats. Exp Eye Res 
80:515–525. 
Rachel RA, Li T, Swaroop A (2012) Photoreceptor sensory cilia and ciliopathies: focus 
342"
on CEP290, RPGR and their interacting proteins. Cilia 1:22. 
Radtke ND, Aramant RB, Petry HM, Green PT, Pidwell DJ, Seiler MJ (2008) Vision 
Improvement in Retinal Degeneration Patients by Implantation of Retina Together 
with Retinal Pigment Epithelium. J Ophthalmol 146:172–182.e1. 
Radtke ND, Aramant RB, Seiler M, Petry HM (1999) Preliminary report: indications of 
improved visual function after retinal sheet transplantation in retinitis pigmentosa 
patients. J Ophthalmol 128:384–387. 
Ramachandran R, Fausett BV, Goldman D (2010) Ascl1a regulates Müller glia 
dedifferentiation and retinal regeneration through a Lin-28-dependent, let-7 
microRNA signalling pathway. Nat Cell Biol 12:1101–1107. 
Randlett O, Norden C, Harris WA (2011) The vertebrate retina: A model for neuronal 
polarization in vivo. Dev Neurobio 71:567–583. 
Redmond TM, Poliakov E, Yu S, Tsai J-Y, Lu Z, Gentleman S (2005) Mutation of key 
residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual 
cycle. Proc Natl Acad Sci 102:13658–13663. 
Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, Goletz P, Ma J-X, Crouch 
RK, Pfeifer K (1998) Rpe65 is necessary for production of 11-cis-vitamin A in the 
retinal visual cycle. Nat Genet 20:344–350. 
Reese BE (2011) Development of the retina and optic pathway. Vis Res 51:613–632. 
Rehemtulla A, Warwar R, Kumar R, Ji X, Zack DJ, Swaroop A (1996) The basic motif-
leucine zipper transcription factor Nrl can positively regulate rhodopsin gene 
expression. Proc Natl Acad Sci 93:191–195. 
Reicher S, Seroussi E, Gootwine E (2010) A mutation in gene CNGA3 is associated 
with day blindness in sheep. Genomics 95:101–104. 
Richard M, Roepman R, Aartsen WM, van Rossum AGSH, Hollander den AI, Knust E, 
Wijnholds J, Cremers FPM (2006) Towards understanding CRUMBS function in 
retinal dystrophies. Hum Mol Genet 15 Spec No 2:R235–R243. 
Ridet JL, Malhotra SK, Privat A, Gage FH (1997) Reactive astrocytes: cellular and 
molecular cues to biological function. Trends Neurosci 20:570–577. 
Roesch K, Jadhav AP, Trimarchi JM, Stadler MB, Roska B, Ben B Sun, Cepko CL 
(2008) The transcriptome of retinal Müller glial cells. J Comp Neurol 509:225–238. 
343"
Roesch K, Stadler MB, Cepko CL (2012) Gene expression changes within Müller glial 
cells in retinitis pigmentosa. Mol Vis 18:1197–1214. 
Roitbak T, Syková E (1999) Diffusion barriers evoked in the rat cortex by reactive 
astrogliosis. Glia 28:40–48. 
Roof DJ, Adamian M, Hayes A (1994) Rhodopsin accumulation at abnormal sites in 
retinas of mice with a human P23H rhodopsin transgene. Invest Ophthalmol Vis 
Sci 35:4049–4062. 
Ruoslahti E (1989) Proteoglycans in cell regulation. J Biol Chem 264:13369–13372. 
Sabel BA (2008) Plasticity and restoration of vision after visual system damage: an 
update. Restor Neurol Neurosci 26:243–247. 
Sahel JA, Albert DM, Lessell S (1990) Proliferation of retinal glia and excitatory amino 
acids. Ophtalmologie 4:13–16. 
Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA (2009) An 
essential role for RPE-derived soluble VEGF in the maintenance of the 
choriocapillaris. Proc Natl Acad Sci 106:18751–18756. 
Saint-Geniez M, Maharaj ASR, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, 
Darland DC, Young MJ, D'Amore PA (2008) Endogenous VEGF Is Required for 
Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors. 
PLoS ONE 3:e3554. 
Sakaguchi DS, Van Hoffelen SJ, Grozdanic SD, Kwon YH, Kardon RH, Young MJ 
(2005) Neural progenitor cell transplants into the developing and mature central 
nervous system. Ann N Y Acad Sci 1049:118–134. 
Sakaguchi DS, Van Hoffelen SJ, Theusch E, Parker E, Orasky J, Harper MM, 
Benediktsson A, Young MJ (2004) Transplantation of neural progenitor cells into 
the developing retina of the Brazilian opossum: an in vivo system for studying 
stem/progenitor cell plasticity. Dev Neurosci 26:336–345. 
Samardzija M, Caprara C, Heynen SR, Willcox DeParis S, Meneau I, Traber G, Agca 
C, Lintig von J, Grimm C (2014) A mouse model for studying cone photoreceptor 
pathologies. Invest Ophthalmol Vis Sci 55:5304–5313. 
Samardzija M, Lintig von J, Tanimoto N, Oberhauser V, Thiersch M, Reme CE, 
Seeliger M, Grimm C, Wenzel A (2007) R91W mutation in Rpe65 leads to milder 
344"
early-onset retinal dystrophy due to the generation of low levels of 11-cis-retinal. 
Hum Mol Genet 17:281–292. 
Sanes JR, Masland RH (2015) The types of retinal ganglion cells: current status and 
implications for neuronal classification. Annu Rev Neurosci 38:221–246. 
Santos-Ferreira T, Postel K, Stutzki H, Kurth T, Zeck G, Ader M (2014) Daylight Vision 
Repair by Cell Transplantation. Stem Cells 33:79–90. 
Sanyal S, Bal AK (1973) Comparative light and electron microscopic study of retinal 
histogenesis in normal and rd mutant mice. Z Anat Entwicklungsgesch 142:219–
238. 
Sarra GM, Stephens C, de Alwis M, Bainbridge JW, Smith AJ, Thrasher AJ, Ali RR 
(2001) Gene replacement therapy in the retinal degeneration slow (rds) mouse: the 
effect on retinal degeneration following partial transduction of the retina. Hum Mol 
Genet 10:2353–2361. 
Sarthy PV (1985) Establishment of Muller cell cultures from adult rat retina. Brain Res 
337:138–141. 
Sarthy V, Egal H (1995) Transient induction of the glial intermediate filament protein 
gene in Müller cells in the mouse retina. DNA Cell Biol 14:313–320. 
Sato Y, Nakanishi K, Tokita Y, Kakizawa H, Ida M, Maeda H, Matsui F, Aono S, Saito 
A, Kuroda Y, Hayakawa M, Kojima S, Oohira A (2008) A highly sulfated chondroitin 
sulfate preparation, CS-E, prevents excitatory amino acid-induced neuronal cell 
death. J Neurochem 104:1565–1576. 
Sawides L, de Castro A, Burns SA (2016) The organization of the cone photoreceptor 
mosaic measured in the living human retina. Vision Res pii: S0042-6989(16)30049-
9. 
Schmidt-Kastner R, Szymas J, Hossmann K-A (1990) Immunohistochemical study of 
glial reaction and serum-protein extravasation in relation to neuronal damage in rat 
hippocampus after ischemia. Neurosci 38:527–540. 
Schumer RA, Podos SM (1994) The nerve of glaucoma! Arch Ophthalmol 112:37–44. 
Schwartz NB, Domowicz M, Krueger RC, Li H, Mangoura D (1996) Brain aggrecan. 
Perspect Dev Neurobiol 3:291–306. 
Schwartz SD, Hubschman J-P, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, 
345"
Mickunas E, Gay R, Klimanskaya I, Lanza R (2012) Embryonic stem cell trials for 
macular degeneration: a preliminary report. Lancet 379:713–720. 
Seiler MJ, Aramant RB (2012) Cell replacement and visual restoration by retinal sheet 
transplants. Prog Retin Eye Res 31:661–687. 
Seiler MJ, Aramant RB, Seeliger MW, Bragadottir R, Mahoney M, Narfstrom K (2009) 
Functional and structural assessment of retinal sheet allograft transplantation in 
feline hereditary retinal degeneration. Vet Ophthalmol 12:158–169. 
Seoane A, Espejo M, Pallàs M, Rodríguez-Farré E, Ambrosio S, Llorens J (1999) 
Degeneration and gliosis in rat retina and central nervous system following 3,3'-
iminodipropionitrile exposure. Brain Res 833:258–271. 
Sernagor E (2005) Retinal development: second sight comes first. Curr Biol 15:R556–
R559. 
Sethi CS, Lewis GP, Fisher SK, Leitner WP, Mann DL, Luthert PJ, Charteris DG (2005) 
Glial remodeling and neural plasticity in human retinal detachment with proliferative 
vitreoretinopathy. Invest Ophthalmol Vis Sci 46:329–342. 
Sharma K, Selzer ME, Li S (2012) Scar-mediated inhibition and CSPG receptors in the 
CNS.Exp Neuro 237:370–378. 
Sheedlo HJ, Jaynes D, Bolan AL, Turner JE (1995) Mullerian glia in dystrophic rodent 
retinas: an immimocytochemical analysis. Brain Res Dev Brain Res 85:171–180. 
Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, He Z, Silver J, Flanagan 
JG (2009) PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor 
of neural regeneration. Sci 326:592–596. 
Siebert JR, Conta Steencken A, Osterhout DJ (2014) Chondroitin sulfate proteoglycans 
in the nervous system: inhibitors to repair. Biomed Res Int 2014:845323. 
Siebert JR, Osterhout DJ (2011) The inhibitory effects of chondroitin sulfate 
proteoglycans on oligodendrocytes. J Neurochem 119:176–188. 
Silver J, Miller JH (2004) Regeneration beyond the glial scar. Nat Rev Neurosci 5:146–
156. 
Simó R, Hernández C (2015) Novel approaches for treating diabetic retinopathy based 
on recent pathogenic evidence. Prog Retin Eye Res 48:160–180. 
346"
Singhal S, Bhatia B, Jayaram H, Becker S, Jones MF, Cottrill PB, Khaw PT, Salt TE, 
Limb GA (2012) Human Muller Glia with Stem Cell Characteristics Differentiate into 
Retinal Ganglion Cell (RGC) Precursors In Vitro and Partially Restore RGC 
Function In Vivo Following Transplantation. Stem Cells Transl Med 1:188–199. 
Singhal S, Lawrence JM, Bhatia B, Ellis JS, Kwan AS, MacNeil A, Luthert PJ, Fawcett 
JW, Perez M-T, Khaw PT, Limb GA (2008) Chondroitin sulfate proteoglycans and 
microglia prevent migration and integration of grafted Müller stem cells into 
degenerating retina. Stem Cells 26:1074–1082. 
Smith GM, Strunz C (2005) Growth factor and cytokine regulation of chondroitin sulfate 
proteoglycans by astrocytes. Glia 52:209–218. 
Snow DM, Lemmon V, Carrino DA, Caplan AI, Silver J (1990) Sulfated proteoglycans 
in astroglial barriers inhibit neurite outgrowth in vitro. Exp Neuro 109:111–130. 
Snow DM, Letourneau PC (1992) Neurite outgrowth on a step gradient of chondroitin 
sulfate proteoglycan (CS-PG). J Neurobiol 23:322–336. 
Sobel RA, Ahmed AS (2001) White matter extracellular matrix chondroitin 
sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J Neuropathol Exp 
Neurol 60:1198–1207. 
Sofroniew MV (2005) Reactive astrocytes in neural repair and protection. The 
Neuroscientist 11:400–407. 
Stacy RC (2005) Disruption and Recovery of Patterned Retinal Activity in the Absence 
of Acetylcholine. J Neurosci 25:9347–9357. 
Stingl K, Bartz-Schmidt K-U, Gekeler F, Kusnyerik A, Sachs H, Zrenner E (2013) 
Functional outcome in subretinal electronic implants depends on foveal 
eccentricity. Invest Ophthalmol Vis Sci 54:7658–7665. 
Stingl K, Zrenner E (2013) Electronic approaches to restitute vision in patients with 
neurodegenerative diseases of the retina. Ophthalmic Res 50:215–220. 
Stone J, van Driel D, Valter K, Rees S, Provis J (2008) The locations of mitochondria in 
mammalian photoreceptors: relation to retinal vasculature. Brain Res 1189:58–69. 
Strettoi E, Pignatelli V, Rossi C, Porciatti V, Falsini B (2003) Remodeling of second-
order neurons in the retina of rd/rd mutant mice. Vis Res 43:867–877. 
Strettoi E, Porciatti V, Falsini B, Pignatelli V, Rossi C (2002) Morphological and 
347"
functional abnormalities in the inner retina of the rd/rd mouse. J Neurosci 22:5492–
5504. 
Strom TM, Nyakatura G, Apfelstedt-Sylla E, Hellebrand H, Lorenz B, Weber BH, Wutz 
K, Gutwillinger N, Rüther K, Drescher B, Sauer C, Zrenner E, Meitinger T, 
Rosenthal A, Meindl A (1998) An L-type calcium-channel gene mutated in 
incomplete X-linked congenital stationary night blindness. Nat Genet 19:260–263. 
Stuck MW, Conley SM, Naash MI (2012) Defects in the Outer Limiting Membrane Are 
Associated with Rosette Development in the Nrl−/− Retina Lewin A, ed. PLoS ONE 
7:e32484. 
Sullivan RKP, Woldemussie E, Pow DV (2007) Dendritic and synaptic plasticity of 
neurons in the human age-related macular degeneration retina. Invest Ophthalmol 
Vis Sci 48:2782–2791. 
Suzuki T, Akimoto M, Imai H, Ueda Y, Mandai M, Yoshimura N, Swaroop A, Takahashi 
M (2007) Chondroitinase ABC treatment enhances synaptogenesis between 
transplant and host neurons in model of retinal degeneration. cell transplant 
16:493–503. 
Swaroop A, Kim D, Forrest D (2010) Transcriptional regulation of photoreceptor 
development and homeostasis in the mammalian retina. Nat Rev Neurosci 11:563–
576. 
Swaroop A, Xu JZ, Pawar H, Jackson A, Skolnick C, Agarwal N (1992) A conserved 
retina-specific gene encodes a basic motif/leucine zipper domain. Proc Natl Acad 
Sci USA 89:266–270. 
Takahashi M, Miyoshi H, Verma IM, Gage FH (1999) Rescue from Photoreceptor 
Degeneration in therd Mouse by Human Immunodeficiency Virus Vector-Mediated 
Gene Transfer. J Virol 73:7812–7816. 
Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Sci 
251:1451–1455. 
Tan CL, Andrews MR, Kwok JCF, Heintz TGP, Gumy LF, Fässler R, Fawcett JW 
(2012) Kindlin-1 Enhances Axon Growth on Inhibitory Chondroitin Sulfate 
Proteoglycans and Promotes Sensory Axon Regeneration. J Neurosci 32:7325–
7335. 
Tan CL, Kwok JCF, Patani R, ffrench-Constant C, Chandran S, Fawcett JW (2011) 
348"
Integrin Activation Promotes Axon Growth on Inhibitory Chondroitin Sulfate 
Proteoglycans by Enhancing Integrin Signaling. J Neurosci 31:6289–6295. 
Tang BL (2001) ADAMTS: a novel family of extracellular matrix proteases. Int J 
Biochem Cell Biol 33:33–44. 
Tang X, Davies JE, Davies SJA (2003) Changes in distribution, cell associations, and 
protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, 
and tenascin-C during acute to chronic maturation of spinal cord scar tissue. J 
Neurosci Res 71:427–444. 
Tatzelt J, Maeda N, Pekny M, Yang SL, Betsholtz C, Eliasson C, Cayetano J, 
Camerino AP, DeArmond SJ, Prusiner SB (1996) Scrapie in mice deficient in 
apolipoprotein E or glial fibrillary acidic protein. Neurology 47:449–453. 
Taylor KR (2006) Glycosaminoglycans and their proteoglycans: host-associated 
molecular patterns for initiation and modulation of inflammation. FASEB J 20:9–22. 
Tepass U, Theres C, Knust E (1990) crumbsencodes an EGF-like protein expressed 
on apical membranes of Drosophila epithelial cells and required for organization of 
epithelia. Cell 61:787–799. 
Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K, Banfi S, Surace EM, 
Sun J, Acerra C, Wright JF, Wellman J, High KA, Auricchio A, Bennett J, Simonelli 
F (2013) Three-year follow-up after unilateral subretinal delivery of adeno-
associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmol 
120:1283–1291. 
Tortorella MD (1999) Purification and Cloning of Aggrecanase-1: A Member of the 
ADAMTS Family of Proteins. Sci 284:1664–1666. 
Travis GH, Golczak M, Moise AR, Palczewski K (2007) Diseases Caused by Defects in 
the Visual Cycle: Retinoids as Potential Therapeutic Agents. Annu Rev Pharmacol 
Toxicol 47:469–512. 
Travis GH, Sutcliffe JG, Bok D (1991) The retinal degeneration slow (rds) gene product 
is a photoreceptor disc membrane-associated glycoprotein. Neuron 6:61–70. 
Tsang KY, Cheung MCH, Chan D, Cheah KSE (2009) The developmental roles of the 
extracellular matrix: beyond structure to regulation. Cell Tissue Res 339:93–110. 
Tsukita S, Furuse M (1999) Occludin and claudins in tight-junction strands: leading or 
349"
supporting players? Trends Cell Biol 9:268–273. 
Tsukita S, Furuse M, Itoh M (1999) Structural and signalling molecules come together 
at tight junctions. Curr Opin Cell Biol 11:628–633. 
Tucker B, Klassen H, Yang L, Chen DF, Young MJ (2008) Elevated MMP Expression 
in the MRL Mouse Retina Creates a Permissive Environment for Retinal 
Regeneration. Invest Ophthalmol Vis Sci 49:1686–1695. 
Tucker BA, Park I-H, Qi SD, Klassen HJ, Jiang C, Yao J, Redenti S, Daley GQ, Young 
MJ (2011) Transplantation of adult mouse iPS cell-derived photoreceptor 
precursors restores retinal structure and function in degenerative mice. PLoS ONE 
6:e18992. 
Turner DL, Cepko CL (1987) A common progenitor for neurons and glia persists in rat 
retina late in development. Nat 328:131–136. 
Usuelli V, La Rocca E (2015) Novel therapeutic approaches for diabetic nephropathy 
and retinopathy. Pharmacol Res 98:39–44. 
van de Pavert SA, Kantardzhieva A, Malysheva A, Meuleman J, Versteeg I, Levelt C, 
Klooster J, Geiger S, Seeliger MW, Rashbass P, Le Bivic A, Wijnholds J (2004) 
Crumbs homologue 1 is required for maintenance of photoreceptor cell polarization 
and adhesion during light exposure. J Cell Sci 117:4169–4177. 
van de Pavert SA, Sanz AS, Aartsen WM, Vos RM, Versteeg I, Beck SC, Klooster J, 
Seeliger MW, Wijnholds J (2007) Crb1 is a determinant of retinal apical Müller glia 
cell features. Glia 55:1486–1497. 
Van Itallie CM, Fanning AS, Bridges A, Anderson JM (2009) ZO-1 Stabilizes the Tight 
Junction Solute Barrier through Coupling to the Perijunctional Cytoskeleton. Mol 
Biol Cell 20:3930–3940. 
van Rossum AGSH, Aartsen WM, Meuleman J, Klooster J, Malysheva A, Versteeg I, 
Arsanto J-P, Le Bivic A, Wijnholds J (2006) Pals1/Mpp5 is required for correct 
localization of Crb1 at the subapical region in polarized Muller glia cells. Hum Mol 
Genet 15:2659–2672. 
Vázquez-Chona FR, Clark AM, Levine EM (2009) Rlbp1 promoter drives robust Müller 
glial GFP expression in transgenic mice. Invest Ophthalmol Vis Sci 50:3996–4003. 
Vázquez-Chona FR, Swan A, Ferrell WD, Jiang L, Baehr W, Chien W-M, Fero M, Marc 
350"
RE, Levine EM (2011) Proliferative reactive gliosis is compatible with glial 
metabolic support and neuronal function. BMC Neurosci 12:98. 
Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC (2016) Glia-neuron 
interactions in the mammalian retina. Prog Retin Eye Res 51:1–40. 
Veleri S, Lazar CH, Chang B, Sieving PA, Banin E, Swaroop A (2015) Biology and 
therapy of inherited retinal degenerative disease: insights from mouse models. Dis 
Model Mech 8:109–129. 
Verardo MR, Lewis GP, Takeda M, Linberg KA, Byun J, Luna G, Wilhelmsson U, 
Pekny M, Chen DF, Fisher SK (2008) Abnormal reactivity of muller cells after 
retinal detachment in mice deficient in GFAP and vimentin. Invest Ophthalmol Vis 
Sci 49:3659–3665. 
Verderber L, Johnson W, Mucke L, Sarthy V (1995) Differential regulation of a glial 
fibrillary acidic protein-LacZ transgene in retinal astrocytes and Müller cells. Invest 
Ophthalmol Vis Sci 36:1137–1143. 
Villarroel M, García-Ramírez M, Corraliza L (2009) Effects of high glucose 
concentration on the barrier function and the expression of tight junction proteins in 
human retinal pigment epithelial cells. Exp Eye Res 89:913–920. 
Vorísek I, Hájek M, Tintera J, Nicolay K, Syková E (2002) Water ADC, extracellular 
space volume, and tortuosity in the rat cortex after traumatic injury. Magn Reson 
Med 48:994–1003. 
Vugler AA (2010) Progress toward the maintenance and repair of degenerating retinal 
circuitry. Retina 30:983–1001. 
Wald G (1934) Carotenoids and the vitamin A cycle in vision. Nat 134. 
Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu ZX, Tan F, Santiago L, 
Mills EM, Wang Y, Symes AJ, Geller HM (2008) Chondroitin-4-sulfation negatively 
regulates axonal guidance and growth. J Cell Sci 121:3083–3091. 
Wang M, Ma W, Zhao L, Fariss RN, Wong WT (2011) Adaptive Müller cell responses 
to microglial activation mediate neuroprotection and coordinate inflammation in the 
retina. J Neuroinflammation 8:173. 
Wanner IB, Anderson MA, Song B, Levine J, Fernandez A, Gray-Thompson Z, Ao Y, 
Sofroniew MV (2013) Glial scar borders are formed by newly proliferated, 
351"
elongated astrocytes that interact to corral inflammatory and fibrotic cells via 
STAT3-dependent mechanisms after spinal cord injury. J Neurosci 33:12870–
12886. 
Wehman AM, Staub W, Meyers JR, Raymond PA, Baier H (2005) Genetic dissection of 
the zebrafish retinal stem-cell compartment. Dev Biol 281:53–65. 
Weil D, Levy G, Sahly I, Levi-Acobas F, Blanchard S, El-Amraoui A, Crozet F, Philippe 
H, Abitbol M, Petit C (1996) Human myosin VIIA responsible for the Usher 1B 
syndrome: a predicted membrane-associated motor protein expressed in 
developing sensory epithelia. Proc Natl Acad Sci 93:3232–3237. 
West EL, Pearson RA, Barber A, Duran Y, Sowden JC, Ali RR (2010) Immune 
responses affect the survival of integrated photoreceptor precursors transplanted 
to the adult murine retina. Invest Ophthalmol Vis Sci 51:5242–5242. 
West EL, Pearson RA, Tschernutter M, Sowden JC, MacLaren RE, Ali RR (2008) 
Pharmacological disruption of the outer limiting membrane leads to increased 
retinal integration of transplanted photoreceptor precursors. Exp Eye Res 86:601–
611. 
Westenskow PD, Kurihara T, Aguilar E, Scheppke EL, Moreno SK, Wittgrove C, 
Marchetti V, Michael IP, Anand S, Nagy A, Cheresh D, Friedlander M (2013) Ras 
pathway inhibition prevents neovascularization by repressing endothelial cell 
sprouting. J Clin Invest 123:4900–4908. 
Wetts R, Fraser SE (1988) Multipotent precursors can give rise to all major cell types of 
the frog retina. Sci 239:1142–1145. 
Wilhelmsson U1 (2008) Astrocytes, reactive gliosis and CNS regeneration. 
Williams DS, Arikawa K, Paallysaho T (1990) Cytoskeletal components of the 
adherens junctions between the photoreceptors and the supportive Müller cells. J 
Comp Neurol 295:155–164. 
Wittchen ES, Haskins J, Stevenson BR (1999) Protein interactions at the tight junction. 
Actin has multiple binding partners, and ZO-1 forms independent complexes with 
ZO-2 and ZO-3. J Biol Chem 274:35179–35185. 
Wycisk KA, Budde B, Feil S, Skosyrski S, Buzzi F, Neidhardt J, Glaus E, Nürnberg P, 
Ruether K, Berger W (2006a) Structural and functional abnormalities of retinal 
ribbon synapses due to Cacna2d4 mutation. Invest Ophthalmol Vis Sci 47:3523–
352"
3530. 
Wycisk KA, Zeitz C, Feil S, Wittmer M, Forster U, Neidhardt J, Wissinger B, Zrenner E, 
Wilke R, Kohl S, Berger W (2006b) Mutation in the auxiliary calcium-channel 
subunit CACNA2D4 causes autosomal recessive cone dystrophy. Am J Hum 
Genet 79:973–977. 
Xia X, Li Y, Huang D, Wang Z, Luo L, Song Y, Zhao L, Wen R (2011) Oncostatin M 
protects rod and cone photoreceptors and promotes regeneration of cone outer 
segment in a rat model of retinal degeneration. PLoS ONE 6:e18282. 
Xu B, Park D, Ohtake Y, Li H, Hayat U, Liu J, Selzer ME, Longo FM, Li S (2015) Role 
of CSPG receptor LAR phosphatase in restricting axon regeneration after CNS 
injury. Neurobiol Dis 73:36–48. 
Xu H-P, Tian N (2007) Retinal ganglion cell dendrites undergo a visual activity-
dependent redistribution after eye opening. J Comp Neurol 503:244–259. 
Xue LP, Lu J, Cao Q, Hu S, Ding P, Ling EA (2006) Müller glial cells express nestin 
coupled with glial fibrillary acidic protein in experimentally induced glaucoma in the 
rat retina. Neurosci 139:723–732. 
Yang P, Seiler MJ, Aramant RB, Whittemore SR (2002) Differential lineage restriction 
of rat retinal progenitor cells in vitro and in vivo. J Neurosci Res 69:466–476. 
Yao J, Ko CW, Baranov PY, Regatieri CV, Redenti S, Tucker BA, Mighty J, Tao SL, 
Young MJ (2015) Enhanced Differentiation and Delivery of Mouse Retinal 
Progenitor Cells Using a Micropatterned Biodegradable Thin-Film 
Polycaprolactone Scaffold. Tissue Eng 21:1247–1260. 
Yaron O, Farhy C, Marquardt T, Applebury M, Ashery-Padan R (2006) Notch1 
functions to suppress cone-photoreceptor fate specification in the developing 
mouse retina. Dev133:1367–1378. 
Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617–
627. 
Young M (2000) Neuronal Differentiation and Morphological Integration of 
Hippocampal Progenitor Cells Transplanted to the Retina of Immature and Mature 
Dystrophic Rats. Mol Cell Neurosci 16:197–205. 
Young RW (1985) Cell differentiation in the retina of the mouse. Anat Rec 212:199–
353"
205. 
Young RW, Bok D (1969) Participation of the retinal pigment epithelium in the rod outer 
segment renewal process. J Cell Biol 42:392–403. 
Yu W-Q, Eom YS, Shin J-A, Nair D, Grzywacz SXZ, Grzywacz NM, Craft CM, Lee E-J 
(2016) Reshaping the Cone-Mosaic in a Rat Model of Retinitis Pigmentosa: 
Modulatory Role of ZO-1 Expression in DL-Alpha-Aminoadipic Acid Reshaping. 
PLoS ONE 11:e0151668. 
Zarbin M (2016) Cell-Based Therapy for Degenerative Retinal Disease. Trends Mol 
Med 22:115–134. 
Zencak D, Schouwey K, Chen D, Ekström P, Tanger E, Bremner R, van Lohuizen M, 
Arsenijevic Y (2013) Retinal degeneration depends on Bmi1 function and 
reactivation of cell cycle proteins. Proc Natl Acad Sci 110:E593–E601. 
Zhang Y, Caffé AR, Azadi S, van Veen T, Ehinger B, Perez M-TR (2003a) Neuronal 
integration in an abutting-retinas culture system. Invest Ophthalmol Vis Sci 
44:4936–4946. 
Zhang Y, Kardaszewska AK, van Veen T, Rauch U, Perez M-TR (2004) Integration 
between abutting retinas: role of glial structures and associated molecules at the 
interface. Invest Ophthalmol Vis Sci 45:4440–4449. 
Zhang Y, Klassen HJ, Tucker BA, Perez M-TR, Young MJ (2007) CNS Progenitor Cells 
Promote a Permissive Environment for Neurite Outgrowth via a Matrix 
Metalloproteinase-2-Dependent Mechanism. J Neurosci 27:4499–4506. 
Zhang Y, Rauch U, Perez M-TR (2003b) Accumulation of neurocan, a brain chondroitin 
sulfate proteoglycan, in association with the retinal vasculature in RCS rats. Invest 
Ophthalmol Vis Sci 44:1252–1261. 
Zhao M et al. (2015) A new CRB1 rat mutation links Müller glial cells to retinal 
telangiectasia. J Neurosci 35:6093–6106. 
Zhao X-F, Wan J, Powell C, Ramachandran R, Myers MG, Goldman D (2014) Leptin 
and IL-6 family cytokines synergize to stimulate Müller glia reprogramming and 
retina regeneration. Cell Rep 9:272–284. 
Zhong X, Gutierrez C, Xue T, Hampton C, Vergara MN, Cao L-H, Peters A, Park TS, 
Zambidis ET, Meyer JS, Gamm DM, Yau K-W, Canto-Soler MV (2014) Generation 
354"
of three-dimensional retinal tissue with functional photoreceptors from human 
iPSCs. Nat Commun 5: 4047. 
Zhou FQ (2006) Neurotrophins support regenerative axon assembly over CSPGs by 
an ECM-integrin-independent mechanism. J Cell Sci 119:2787–2796. 
Zuo J, Neubauer D, Dyess K, Ferguson TA, Muir D (1998) Degradation of chondroitin 
sulfate proteoglycan enhances the neurite-promoting potential of spinal cord 
tissue.Exp Neuro 154:654–662. 
  
355"
Appendix  
 
Appendix A. Assessment of intermediate filament protein GFAP at early (6 weeks), middle (6 months) 
and late (12 months) time points in wild-type mice. Cryosections were immunostained for glial cell marker 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix B. Assessment of intermediate filament protein Vimentin at early (6 weeks), middle (6 months) 
and late (12 months) time points in wild-type mice. Cryosections were immunostained for glial cell marker 
Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix C. Assessment of CSPGs deposition at early (6 weeks), middle (6 months) and late (12 
months) time points in wild-type mice. Cryosections were immunostained for CSPGs marker (CS-56; red) 
and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix D. Assessment of intermediate filament protein GFAP at early (3 weeks), middle (6 weeks) and 
late (12 weeks) time points in the Crb1rd8/rd8 mice. Cryosections were immunostained for glial cell marker 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix E. Assessment of intermediate filament protein Vimentin at early (3 weeks), middle (6 weeks) 
and late (12 weeks) time points in the Crb1rd8/rd8 mice. Cryosections were immunostained for glial cell 
marker Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix F. Assessment of CSPGs deposition at early (3 weeks), middle (6 weeks) and late (12 weeks) 
time points in the Crb1rd8/rd8 mice. Cryosections were immunostained for CSPGs marker (CS-56; red) and 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix G. Assessment of intermediate filament protein GFAP at early (4 weeks), middle (6 weeks) and 
late (12 weeks) time points in the Rdsrd1/rd1 mice. Cryosections were immunostained for glial cell marker 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix H. Assessment of intermediate filament protein Vimentin at early (4 weeks), middle (6 weeks) 
and late (12 weeks) time points in the Rdsrd1/rd1 mice. Cryosections were immunostained for glial cell 
marker Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix J. Assessment of intermediate filament protein GFAP at early(P10), middle (3 weeks) and late 
(6-7 weeks) time points in the Pde6brd1/rd mice. Cryosections were immunostained for glial cell marker 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix K. Assessment of intermediate filament protein Vimentin at early(P10), middle (3 weeks) and 
late (6-7 weeks)  time points in the Pde6brd1/rd mice. Cryosections were immunostained for glial cell marker 
Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix L. Assessment of gliosis at P15 in the Pde6brd1/rd1 mice. Cryosections were immunostained for 
glial cell marker GFAP (green) or Vimentin (green) or CSPGs (red) and co-stained with nuclei marker 
Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix M. Assessment of CSPGs deposition at early (P10), middle (3 weeks) and late (6-7 weeks) 
time points in the Pde6brd1/rd mice. Cryosections were immunostained for CSPGs marker (CS-56; red) and 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix N. Assessment of intermediate filament protein GFAP at early (4 weeks), middle (6 weeks) and 
late (10 weeks) time points in the Rho-/- mice. Cryosections were immunostained for glial cell marker 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix O. Assessment of intermediate filament protein Vimentin at early  (4 weeks), middle (6 weeks) 
and late (10 weeks) time points in the Rho-/- mice. Cryosections were immunostained for glial cell marker 
Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix P. Assessment of CSPGs deposition at early  (4 weeks), middle (6 weeks) and late (10 weeks) 
time points in the Rho-/- mice. Cryosections were immunostained for CSPGs marker (CS-56; red) and 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix Q. Assessment of intermediate filament protein GFAP at early (2 months), middle (4 months) 
and late (6 months) time points in the Prph2+/Δ 307 mice. Cryosections were immunostained for glial cell 
marker GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix R. Assessment of intermediate filament protein Vimentin at early (2 months), middle (4 months) 
and late (6 months) time points in the Prph2+/Δ 307 mice. Cryosections were immunostained for glial cell 
marker Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix S. Assessment of CSPGs deposition at early (2 months), middle (4 months) and late (6 
months) time points in the Prph2+/Δ 307 mice. Cryosections were immunostained for CSPGs marker (CS-56; 
red) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix T. Assessment of intermediate filament protein GFAP at early (3 weeks), middle (6 weeks) and 
late (12 weeks) time points in the Nrl-/- mice. Cryosections were immunostained for glial cell marker GFAP 
(green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix U. Assessment of intermediate filament protein Vimentin at early (3 weeks), middle (6 weeks) 
and late (12 weeks) time points in the Nrl-/- mice. Cryosections were immunostained for glial cell marker 
Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix V. Assessment of CSPGs deposition at early (3 weeks), middle (6 weeks) and late (12 weeks) 
time points in the Nrl-/- mice. Cryosections were immunostained for CSPGs marker (CS-56; red) and 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix W. Assessment of intermediate filament protein GFAP at early (3 weeks), middle (6 weeks) and 
late (12 weeks) time points in the RW1;Nrl-/- mice. Cryosections were immunostained for glial cell marker 
GFAP (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix X. Assessment of intermediate filament protein Vimentin at early (3 weeks), middle (6 weeks) 
and late (12 weeks) time points in the RW1;Nrl-/- mice. Cryosections were immunostained for glial cell 
marker Vimentin (green) and counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix Y. Assessment of CSPGs deposition at early (3 weeks), middle (6 weeks) and late (12 weeks) 
time points in the RW1;Nrl-/- mice. Cryosections were immunostained for CSPGs marker (CS-56; red) and 
counterstained with nuclei marker Hoechst 33342 (blue). Scale bar, 25 µm. 
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Appendix Z. RNAi-mediated knockdown of Gfap and Vimentin mRNA in vitro.  (A, C) Histograms show 
RNA levels, assessed by qRT-PCR, for Gfap and (B, D) Vimentin following co-transfection of the 
respective expression cassettes, together with (A) pshGfap, (C) pshVimentin or (C, D) pLsh in 293T cells. 
Results are shown normalised against average values obtained following co-transfection with pshCont. *P 
< 0.05, **P < 0.01 and ***P < 0.001 with a one-way ANOVA (n=3 independent cultures). Error bars: SEM. 
 
  
380"
Appendix AA. Assessment of OLM integrity at 22 weeks old in Rho-/-. Cryosections were immunostained 
for ZO-1 (red) and co-stained with nuclei marker Hoechst 33342 (blue). Scale bar, 50 µm. 
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Appendix AB. Transfection of HEK-293T cells with different concentrations (20, 40, and 100 pM) of a 
non-targeting RNAi control sequence with an attached AlexaFluor633. Cells were co-stained with nuclei 
marker Hoechst 33342 (blue). Scale bar, 25 µm. 
 
 
 
 
 
